Cover Page for Statistical Analysis Plan

Sponsor name:	Novo Nordisk A/S
NCT number	NCT02501161
Sponsor trial ID:	NN9068-4228
Official title of study:	A 104 week clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus (DUAL™ VIII)
Document date:	07 March 2019

16.1.9 Documentation of statistical methods

List of contents

Statistical Analysis Plan ..... Link

Statistical Documentation ..... Link

Redacted statistical analysis plan
Includes redaction of personal identifiable information only.

.

Statistical Analysis Plan

Trial ID: NN9068-4228

DUAL™ VIII – Durability

A 104 week clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus

Author

[redacted]

This ~~confidential~~ document is the property of Novo Nordisk. ~~No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.~~

Table of contents Page

Table of contents **2**

List of abbreviations **3**

1 Introduction **4**
1.1 Trial information 4
1.2 Scope of the statistical analysis plan 4

2 Statistical considerations **4**
2.1 Sample size calculation 6
2.2 Definition of analysis sets 6
2.3 Primary endpoint 6
2.4 Secondary endpoints 8
2.4.1 Supportive secondary endpoints 8
2.4.1.1 Efficacy endpoints 8
2.4.1.2 Safety endpoints 10
2.5 Health economics endpoints 12

3 Changes to the statistical analyses planned in the protocol **12**

4 References **13**

List of abbreviations

ADA	American Diabetes Association
AE	adverse event
BG	blood glucose
DPP-4	Dipeptidyl peptidase-4
ECG	electrocardiogram
FAS	full analysis set
FPG	fasting plasma glucose
HbA1c	glycated haemoglobin
HDL	high density lipoprotein
IDegLira	insulin degludec/liraglutide
IGlar	insulin glargine
LDL	low density lipoprotein
LLOQ	lower limit of quantification
MMRM	mixed model for repeated measurement
OAD	oral antidiabetic drugs
PRO	patient reported outcome
QD	quaque die (once daily)
SAE	serious adverse event
SAP	statistical analysis plan
SAS	safety analysis set
SF-36V2	Medical outcomes study 36-item short form version 2
SMPG	self-measured plasma glucose
T2DM	type 2 diabetes mellitus
TEAEs	treatment emergent adverse events
TRIM-D	Treatment related impact measure
UTN	Universal Trial Number
VLDL	very low density lipoprotein

1 Introduction

1.1 Trial information

This is a 2-year, multinational, open-label, two-arm parallel, randomised trial with glycaemic target in subjects with T2DM inadequately controlled with OAD(s).
Inadequately controlled T2DM will be defined as an HbA1c level of 7.0-11.0% (53-97 mmol/mol), both inclusive. A total of 1000 subjects will be randomised in a 1:1 manner using a centralised allocation via interactive web response system.

Subjects will be randomised to receive either once daily (QD) IDegLira or IGlar in combination with OAD(s) at randomisation. Dipeptidyl peptidase-4 (DPP-4) inhibitors and glinides must be discontinued at randomisation.

1.2 Scope of the statistical analysis plan

This Statistical Analysis Plan (SAP) is based on Final Protocol version 4.0 (16-Dec-2016).

The scope of this SAP is to update the sensitivity analyses for the primary endpoint. Furthermore, some errors have been corrected and descriptive statistics that did not address the scientific objectives have been omitted. For further details on the changes see section 3.

2 Statistical considerations

Novo Nordisk will analyse and report data from all sites together.

All analyses of efficacy and safety endpoints will be based on the full analysis set (FAS).

All efficacy endpoints and PRO endpoints will be summarised using the FAS and safety endpoints will be summarised using the safety analysis set (SAS).

The impact of protocol deviations and outliers may be investigated further in sensitivity analyses if deemed relevant.

Unless otherwise specified, all continuous measurements will be summarised descriptively at each visit by treatment using observed data. Endpoints that are analysed untransformed and endpoints that are not formally analysed are summarised by the arithmetic mean, standard deviation, median, and minimum and maximum value. Endpoints that are analysed log-transformed are summarized with the geometric mean and coefficient of variation. For measurements over time, mean values will be plotted to explore the trajectory over time. Observed data will be used as the basis for plotting data if not otherwise specified. Change from baseline plots will be based on Least Square Means and SEs estimated from the mixed model for repeated measurement (MMRM). For

endpoints that are analysed log-transformed, the geometric mean values will be plotted. All descriptive summaries and plots will be based on on-treatment data unless otherwise specified.

Only endpoints derived after 26 and 104 weeks of treatment will be analysed statistically.

Subjects withdrawing from the trial or discontinuing treatment will contribute to the primary analysis as needing rescue therapy from the time of withdrawal/discontinuation.

For secondary endpoints, the expected percentage of missing data after 26 weeks of treatment is around 5%. Due to the nature of the trial design, the expected percentage of missing data after 104 weeks of treatment is 45% and 55% for IDegLira and IGlar respectively.

If an assessment has been made both at screening and randomisation, and if not otherwise specified, the value from the randomisation visit will be used as the baseline value. If the value measured at the randomisation visit is missing and the assessment also has been made at screening, then the screening value will be used as the baseline value.

Laboratory values below the lower limit of quantification (LLOQ) will be set to ½LLOQ.

A MMRM with an unstructured covariance matrix, with testing performed at week 26 and 104 will be applied for secondary continuous endpoints. The model includes treatment, visit, HbA_{1c} group, pre-trial diabetes medication and region as fixed factors and the corresponding baseline value as a covariate. Interactions between visit and all factors and the covariate are also to be included in the model.

The factor "baseline HbA_{1c} group" is a dichotomised baseline HbA_{1c} variable with 2 categories: HbA_{1c} <8.5% or HbA_{1c} ≥8.5%.

The factor "previous OAD treatment" has 2 levels: OAD(s) + sulphonylurea or OAD(s).

The factor "region" has 5 levels: Europe (Norway, Israel, Russia, Turkey, Italy, UK, Slovakia, Hungary, Czech Republic and Poland), North America (US), South America (Mexico, Brazil and Argentina), Africa (South Africa), and Asia (India).

In the following, this model will be referred to as the standard MMRM model. This analysis will estimate the difference in change from baseline in the endpoint between IDegLira and IGlar assuming that subjects remain on trial product until week 26 and 104, respectively. In this model it is assumed that data are missing at random which is a reasonable assumption since most missing data will arise from subjects withdrawing due to inadequate glucose control as observed at the time of withdrawal.

Presentation of results from a statistical analysis will include the estimated mean treatment effects (Least Square Means) for absolute values and change from baseline. In addition, estimated mean

treatment difference (or ratio) will be presented together with the two-sided 95% confidence interval and corresponding two-sided p-value.

2.1 Sample size calculation

Sample size calculations are described in the protocol section 17.1 and will not further be described here.

2.2 Definition of analysis sets

The following analysis sets are defined in accordance with the ICH-E9 guidance:

Full Analysis Set (FAS): includes all randomised subjects. In exceptional cases, subjects may be eliminated from the FAS. In such cases the elimination will be justified and documented.

The statistical evaluation of the FAS will follow the intention-to-treat principle and subjects will contribute to the evaluation "as randomised".

Safety Analysis Set (SAS): includes all subjects receiving at least 1 dose of the investigational product or comparator. Subjects in the safety set will contribute to the evaluation "as treated".

Randomised subjects who are lost to follow up and where no exposure information of the investigational product or comparators is available after randomisation will be handled as unexposed.

Before data are released for statistical analysis, a review of all data will take place to identify protocol deviations that could potentially affect the results. Any decision to exclude any subject or observation from the statistical analysis is the joint responsibility of the members of the study group. The subjects or observations to be excluded and the reason(s) for their exclusion will be documented and signed by all parties. The documentation will be stored together with the remaining trial documentation.

2.3 Primary endpoint

The following endpoint will be assessed up to 104 weeks. Time from randomisation to inadequate glycaemic control and need for treatment intensification defined as an HbA_{1c} ≥7% at 2 consecutive visits from week 26 (including week 26, if HbA_{1c} was ≥ to 7% at week 12).

Subjects withdrawing from the trial or discontinuing treatment will contribute to the primary analysis as needing rescue therapy from the time of withdrawal/discontinuation. The data will inherently be interval censored, since HbA_{1c} is only measured at the scheduled visits while subjects may reach an HbA_{1c} ≥7.0% at any time between 2 visits (including week 26 if HbA1c was ≥ to 7% at week 12).

The primary endpoint will be analysed using a stratified log-rank test where treatment, baseline HbA_{1c} group and previous OAD treatment will be included as strata in the model.

The variable "baseline HbA_{1c} group" is a dichotomised baseline HbA_{1c} variable with 2 categories: $HbA_{1c} < 8.5\%$ or $HbA_{1c} \geq 8.5\%$.

The variable "previous OAD treatment" is a categorical variable with 2 categories: OAD(s) + sulphonylurea or OAD(s).

Formally, let D be the hazard ratio for time to treatment intensification. The null-hypothesis of no treatment difference will be tested against the alternative hypothesis as given by

H0: D =1 against HA: D ≠1

Kaplan-Meier curves by treatment arm and strata from the model will be presented.

Sensitivity analysis

Two sensitivity analyses will be carried out taking the interval censored nature of the data into account.

The possible failure times will be viewed as continuous variables which can only be observed to lie in the interval between the visit when treatment failure is established and the previous scheduled visit.

The first sensitivity analysis will take the interval censored nature of the data into account by using a proportional hazards regression model for interval censored data with piecewise constant baseline hazard. Baseline HbA_{1c} group and previous OAD treatment will be included in the model by stratification, while treatment and region will be included as factors in the model. The estimated treatment hazard ratio (IDegLira vs. IGlar) will be presented together with the two-sided 95% confidence interval and corresponding two-sided p-value.

In the second sensitivity analysis, the time to inadequate glycaemic control and need for treatment intensification will be compared between the IDegLira arm and the IGlar arm using a two-sided nonparametric test at a 5% significance level. The test will be a generalised log rank test for interval censored failure time data. The analysis will not be based on any model assumptions such as proportional hazards.

2.4 Secondary endpoints

2.4.1 Supportive secondary endpoints

2.4.1.1 Efficacy endpoints

Time from randomisation to HbA_{1c} > 6.5% at 2 consecutive visits from week 26.
Time from randomisation to HbA_{1c} > 6.5% at 2 consecutive visits from week 26 (including week 26 if HbA_{1c} was > 6.5% at week 12) will be analysed and presented in the same way as the primary endpoint.

HbA_{1c}
Change from baseline in HbA_{1c} after 26 weeks of treatment will be analysed using the standard MMRM model. Mean curves by time of treatment discontinuation will be plotted.

Body weight
Change from baseline in body weight after 26 and 104 weeks of treatment will be analysed using the standard MMRM model.

Insulin dose after 26 and 104 weeks of treatment
The actual insulin dose will be summarised descriptively according to regimen as dose in units, and units/kg. The actual daily insulin dose will be analysed using the standard MMRM model.

HbA_{1c} responder after 26 and 104 weeks of treatment (yes/no)
Two dichotomous endpoints (responder/non-responder) will be defined based on whether a subject has met a specific target level after 26 and 104 weeks of treatment:

- HbA_{1c} target < 7.0%
- HbA_{1c} target ≤ 6.5%

Analysis of each of the four responder endpoints will be based on a logistic regression model with treatment, HbA_{1c} group, previous OAD treatment and region as fixed factors and baseline HbA_{1c} value as a covariate. Subjects withdrawing from the trial or discontinuing treatment will be imputed as being non-responder from time of withdrawal/discontinuation in line with the evaluation of the primary endpoint.

HbA_{1c} responder endpoints without weight gain
Responder for HbA_{1c} without weight gain after 26 and 104 weeks of treatment will be defined as HbA_{1c}<7.0% or ≤6.5% and change in body weight from baseline ≤ 0. Analysis of each of the 2 responder endpoints will be based on a logistic regression model with treatment, HbA_{1c} group, previous OAD treatment and region as fixed factors and baseline HbA_{1c} and baseline body weight as covariates. Subjects withdrawing from the trial or discontinuing treatment will be imputed as being non-responder from time of withdrawal/discontinuation in line with the evaluation of the primary endpoint.

HbA_{1c} responder endpoints without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes

Responder for HbA_{1c} without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 26 and 104 weeks of treatment will be defined as $HbA_{1c} < 7.0\%$ or $\leq 6.5\%$ and without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of each treatment period. Analysis of each of the 2 responder endpoints will be based on a logistic regression model with treatment, HbA_{1c} group, previous OAD treatment and region as fixed factors and baseline HbA_{1c} values as a covariate. Subjects withdrawing from the trial or discontinuing treatment will be imputed as being non-responder from time of withdrawal/discontinuation in line with the evaluation of the primary endpoint.

HbA_{1c} responder endpoints without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes and without weight gain

Responder for HbA_{1c} without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes and without weight gain after 26 and 104 weeks of treatment will be defined as $HbA_{1c} < 7.0\%$ or $\leq 6.5\%$ without treatment-emergent severe or BG confirmed symptomatic during the last 12 weeks of each treatment period, and change in body weight from baseline ≤ 0. Analysis of each of the 2 responder endpoints will be based on a logistic regression model with treatment, HbA_{1c} group, previous OAD treatment and region as fixed factors and baseline HbA_{1c} values and baseline body weight as covariates. Subjects withdrawing from the trial or discontinuing treatment will be imputed as being non-responder from time of withdrawal/discontinuation in line with the evaluation of the primary endpoint.

Fasting plasma glucose

Change from baseline in FPG after 26 and 104 weeks of treatment will be analysed using the standard MMRM model.

9-point profile

The following 6 endpoints from the 9-point SMPG profile will be defined:

- 9-point profile (individual points in the profile)
- Mean of the 9-point profile, defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time
- Prandial plasma glucose increments (from before meal to 90 min after for breakfast, lunch and dinner). The mean increment over all meals will be derived as the mean of all available meal increments

A linear mixed effect model will be fitted to the 9-point profile data at week 26 and week 104. The model will include treatment, region, time (within 9-point profile), the interaction between treatment and time, the interaction between region and time as fixed factors, and subject as random

effect, where measurements within subjects will be assumed correlated using a compound symmetry covariance matrix.

Change from baseline in mean of the 9-point profile and prandial increment endpoints will be analysed separately using the standard MMRM model.

Blood pressure (systolic and diastolic)
Change from baseline in systolic and diastolic blood pressure will be analysed separately using the standard MMRM model.

Fasting C-peptide and fasting human insulin
These endpoints will be analysed separately using the standard MMRM model. In these statistical analyses, the endpoint will be log-transformed and so will the corresponding baseline covariate.

Fasting lipid profile
Cholesterol, LDL cholesterol, HDL cholesterol, VLDL cholesterol, triglycerides and free fatty acids will be analysed separately using the standard MMRM model. In these statistical analyses, the endpoint will be log-transformed and so will the corresponding baseline covariate.

2.4.1.2 Safety endpoints

Adverse events
AEs will be coded using the most recent version of the Medical Dictionary for Regulatory Activities.

A TEAE is defined as an event that has onset date on or after the 1st day of exposure to trial product and no later than 7 days after the last day of trial product. If the event has onset date before the 1st day of exposure on trial product and increases in severity during the treatment period and until 7 days after the last drug date, then this event should also be considered as a TEAE. MACEs are considered treatment-emergent until 30 calendar days after the last day of trial product.

TEAEs are summarised descriptively, whereas non-TEAEs are presented in listings. TEAE data will be displayed in terms of the number of subjects with at least 1 event (N), the percentage of subjects with at least 1 event (%), the number of events (E) and the event rate per 100 years of exposure (R).

Summaries of TEAEs and of serious TEAEs will be presented as an overview including all AEs, serious AEs, number of deaths, AEs by severity, AEs by relation to treatment and AEs of special interest including AEs leading to treatment discontinuation or withdrawal.

Furthermore summary tables based on system organ class and preferred terms are made for:
- All TEAEs
- Serious TEAEs

- TEAEs possibly or probably related to trial product
- Severe, moderate and mild TEAEs
- TEAEs reported by safety areas of interest
- TEAEs with preferred term that are experienced by at least 5% (1%) of the subjects in any treatment arm or by at least 5% (1%) of all subjects

A listing for non-TEAEs with onset date before the first day of exposure to trial product will be presented. A listing will also be presented for non-TEAEs collected after the treatment-emergent period according to the definition of TEAE. All summaries will be prepared for TEAEs during 26 and 104 weeks of treatment separately.

Additional summaries will be displayed for MACEs collected between visit 13 and visit 13A for subjects who discontinue trial product prematurely.

Hypoglycaemic events
Data on treatment-emergent hypoglycaemic episodes are presented in terms of the number of subjects with at least 1 event (N), the percentage of subjects with at least 1 event (%), the number of events (E) and the event rate per 100 years (R).

Separate summaries are made by severity considering all severe or BG confirmed symptomatic hypoglycaemic episodes, nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes and the ADA classification of hypoglycaemia. All summaries will be prepared for episodes during 26 and 104 weeks of treatment separately.

A negative binomial model with a log-link function and the logarithm of the time period in which a hypoglycaemic episode is considered treatment-emergent as offset will be used to analyse the number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during 26 and 104 weeks of treatment. The model will further include treatment, HbA_{1c} group, previous OAD treatment and region as fixed factors.

Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes during 26 and 104 weeks of treatment will be analysed using the same model as used for the treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes.

Clinical evaluation (eye examination, ECG and urine albumin/creatinine ratio)
Eye examination, ECG findings and urine albumin/creatinine ratio will be summarised descriptively, including:

- Summaries for each visit
- Change from baseline after 104 weeks of treatment

Pulse
Change from baseline in pulse will be analysed using the standard MMRM model.

Laboratory assessments (Biochemistry, Haematology and Calcitonin)
All laboratory parameters will be summarised descriptively.

The following tables will be presented:
- Shift tables from baseline to after 26 and 104 weeks of treatment
- Proportion of subjects with measurements outside reference range by treatment and week

For each laboratory parameter, individual values outside the reference ranges (abnormal values) will be listed. Summaries by visit will be based on data from scheduled visits. If a blood re-sample related to a specific visit is made, the first value will be used.

For lipase and amylase the following rule applies in the evaluation of the result:
- If the amylase or lipase baseline (at screening) value is > 3x upper normal range the information will be regarded as medical history for that subject

2.5 Health economics endpoints

The following questionnaires will be used to compare PROs between treatments:
- SF-36v2
- TRIM-D

For each questionnaire, the summary scores will be summarised descriptively by visit and the change from baseline in score will be analysed separately using the standard MMRM model.

3 Changes to the statistical analyses planned in the protocol

Corrections have been made to the parameterization of the baseline hazard in the first sensitivity analyses for the primary analysis.

Models for fasting C-peptide and fasting human insulin have been updated to be analysed as log-transformed endpoints as this was erroneously left out in the protocol.

The model fitted to the 9-point profile data has been simplified so that profile data from previous visits are disregarded in the modelling of the week 26 and week 104 measurements. The simplified model is considered adequate since the predictive value of profile data from previous visits several weeks earlier is regarded as minimal due to day-to-day variability.

Box plots have been left out and mean curves by time of treatment discontinuation have been clarified only to be done for change from baseline in HbA1c.

4 References

Table of contents

Page

1: Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set 3
2: Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) – primary statistical analysis – full analysis set 114
3: Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) – statistical sensitivity analysis – accounting for interval censoring – proportional hazards regression model – full analysis set 138
4: Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) – statistical sensitivity analysis – accounting for interval censoring – generalized log rank test – full analysis set 140
5: Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set 145
6: HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set 167
7: Responder for HbA1c treatment target after 26 weeks – supportive statistical analysis – full analysis set 467
8: Responder for HbA1c treatment target after 104 weeks – supportive statistical analysis – full analysis set 471
9: Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 26 weeks – supportive statistical analysis – full analysis set 475
10: Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 104 weeks – supportive statistical analysis – full analysis set 479
11: Responder for HbA1c treatment target without weight gain after 26 weeks – supportive statistical analysis – full analysis set 483
12: Responder for HbA1c treatment target without weight gain after 104 weeks – supportive statistical analysis – full analysis set 487
13: Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes and weight gain after 26 weeks – supportive statistical analysis – full analysis set 491
14: Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes and weight gain after 104 weeks – supportive statistical analysis – full analysis set 495
15: Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set 499
16: Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set 710
17: 9-point self-measured plasma glucose profile after 26 weeks – supportive statistical analysis – full analysis set 918

18: 9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set....970
19: Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set....1022
20: Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set....1121
21: Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set....1520
22: Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set....1571
23: Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set....1674
24: Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set....1761
25: HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set....1848
26: Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set....2219
27: Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set....2719
28: Hypoglycaemic episodes during 26 weeks of treatment – treatment emergent – supportive statistical analysis – full analysis set....3019
29: Hypoglycaemic episodes during 104 weeks of treatment – treatment emergent – supportive statistical analysis – full analysis set....3021
30: Nocturnal hypoglycaemic episodes during 26 weeks of treatment – treatment emergent – supportive statistical analysis – full analysis set....3023
31: Nocturnal hypoglycaemic episodes during 104 weeks of treatment – treatment emergent – supportive statistical analysis – full analysis set....3025
32: Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set....3027

Statistical documentation

1: Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

```
TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

                  Model Information

Data Set                      WORK.INSDOS_MMRM
Dependent Variable            AVAL
Covariance Structure          Compound Symmetry
Subject Effect                USUBJID
Estimation Method             REML
Residual Variance Method      Profile
Fixed Effects SE Method       Kenward-Roger
Degrees of Freedom Method     Kenward-Roger


               Class Level Information

Class        Levels    Values

TREATMENT         2    IDegLira IGlar
REGION            5    Africa Asia Europe North
                       America South America
AVISITN          11    30 40 50 60 70 80 90 100 110
                       120 130
```

Actual daily total insulin dose after 26 and 104 weeks - supportive statistical analysis - full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks - supportive statistical analysis - full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks - supportive statistical analysis - full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	2
Columns in X	122
Columns in Z	0
Subjects	1012
Max Obs per Subject	11

Number of Observations

Number of Observations Read	11132
Number of Observations Used	8520
Number of Observations Not Used	2612

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	71227.83069321	
1	2	66718.92798804	0.00022347
2	1	66712.57042805	0.00000827
3	1	66712.35312938	0.00000001
4	1	66712.35278106	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
CS	USUBJID	132.91
Residual		115.53

Fit Statistics

-2 Res Log Likelihood	66712.4
AIC (Smaller is Better)	66716.4

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Fit Statistics

AICC (Smaller is Better)	66716.4
BIC (Smaller is Better)	66726.2

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
1	4515.48	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
TREATMENT(AVISITN)	11	7508	69.87	<.0001
REGION(AVISITN)	44	8101	9.40	<.0001
PREOAD(AVISITN)	11	7499	2.83	0.0011
HBA1CG1(AVISITN)	11	7509	9.85	<.0001

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	1
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	0.0879
REGION(AVISITN)		Asia			30	0.0909
REGION(AVISITN)		Europe			30	0.4911
REGION(AVISITN)		North America			30	0.1502
REGION(AVISITN)		South America			30	0.1798

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	0.3538
PREOAD(AVISITN)			SU users		30	0.6462

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	0.5306
HBA1CG1(AVISITN)				>=8.5	30	0.4694
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V030 IDegLira	WORK.INSDOS_MMRM	12.2506	0.7072	2691	17.32

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V030 IDegLira	<.0001	0.05	10.8639	13.6373

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	1
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	0.0879
REGION(AVISITN)		Asia			30	0.0909
REGION(AVISITN)		Europe			30	0.4911
REGION(AVISITN)		North America			30	0.1502
REGION(AVISITN)		South America			30	0.1798
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	0.3538
PREOAD(AVISITN)			SU users		30	0.6462
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	0.5306
HBA1CG1(AVISITN)				>=8.5	30	0.4694
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V030 IGlar	WORK.INSDOS_MMRM	12.3394	0.7081	2708	17.43

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V030 IGlar	<.0001	0.05	10.9510	13.7278

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	1
TREATMENT(AVISITN)	IGlar				30	-1
TREATMENT(AVISITN)	IDegLira				40	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V030 IDegLira - IGlar	WORK.INSDOS_MMRM	-0.08887	1.0053	2700

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V030 IDegLira - IGlar	-0.09	0.9296	0.05	-2.0601	1.8824

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	1
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	0.0879
REGION(AVISITN)		Asia			40	0.0909
REGION(AVISITN)		Europe			40	0.4911
REGION(AVISITN)		North America			40	0.1502
REGION(AVISITN)		South America			40	0.1798
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	0.3538
PREOAD(AVISITN)			SU users		40	0.6462
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	0.5306
HBA1CG1(AVISITN)				>=8.5	40	0.4694
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V040 IDegLira	WORK.INSDOS_MMRM	15.3502	0.7081	2700	21.68

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V040 IDegLira	<.0001	0.05	13.9618	16.7386

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	1
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	0.0879
REGION(AVISITN)		Asia			40	0.0909
REGION(AVISITN)		Europe			40	0.4911
REGION(AVISITN)		North America			40	0.1502
REGION(AVISITN)		South America			40	0.1798
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	0.3538
PREOAD(AVISITN)			SU users		40	0.6462
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	0.5306
HBA1CG1(AVISITN)				>=8.5	40	0.4694
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V040 IGlar	WORK.INSDOS_MMRM	15.7489	0.7105	2729	22.17

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V040 IGlar	<.0001	0.05	14.3558	17.1420

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	1
TREATMENT(AVISITN)	IGlar				40	-1
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V040 IDegLira - IGlar	WORK.INSDOS_MMRM	-0.3987	1.0078	2716

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V040 IDegLira - IGlar	-0.40	0.6924	0.05	-2.3749	1.5774

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	1
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	0.0879
REGION(AVISITN)		Asia			50	0.0909
REGION(AVISITN)		Europe			50	0.4911
REGION(AVISITN)		North America			50	0.1502
REGION(AVISITN)		South America			50	0.1798
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	0.3538
PREOAD(AVISITN)			SU users		50	0.6462
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				<8.5	50	0.5306
HBA1CG1(AVISITN)				>=8.5	50	0.4694
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V050 IDegLira	WORK.INSDOS_MMRM	20.6784	0.7095	2715	29.15

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V050 IDegLira	<.0001	0.05	19.2871	22.0696

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	0.0879
REGION(AVISITN)		Asia			50	0.0909
REGION(AVISITN)		Europe			50	0.4911
REGION(AVISITN)		North America			50	0.1502
REGION(AVISITN)		South America			50	0.1798
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	0.3538
PREOAD(AVISITN)			SU users		50	0.6462
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	0.5306
HBA1CG1(AVISITN)				>=8.5	50	0.4694
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V050 IGlar	WORK.INSDOS_MMRM	22.0085	0.7104	2727	30.98

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V050 IGlar	<.0001	0.05	20.6154	23.4015

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	1
TREATMENT(AVISITN)	IGlar				50	-1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V050 IDegLira - IGlar	WORK.INSDOS_MMRM	-1.3301	1.0086	2721

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V050 IDegLira - IGlar	-1.32	0.1874	0.05	-3.3079	0.6477

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	1
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			60	0.0879
REGION(AVISITN)		Asia			60	0.0909
REGION(AVISITN)		Europe			60	0.4911
REGION(AVISITN)		North America			60	0.1502
REGION(AVISITN)		South America			60	0.1798
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	0.3538
PREOAD(AVISITN)			SU users		60	0.6462
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	0.5306
HBA1CG1(AVISITN)				>=8.5	60	0.4694
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V060 IDegLira	WORK.INSDOS_MMRM	32.4690	0.7160	2793	45.35

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IDegLira	<.0001	0.05	31.0651	33.8729

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	1
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	0.0879
REGION(AVISITN)		Asia			60	0.0909
REGION(AVISITN)		Europe			60	0.4911
REGION(AVISITN)		North America			60	0.1502
REGION(AVISITN)		South America			60	0.1798
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	0.3538
PREOAD(AVISITN)			SU users		60	0.6462
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	0.5306
HBA1CG1(AVISITN)				>=8.5	60	0.4694
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V060 IGlar	WORK.INSDOS_MMRM	38.2698	0.7206	2849	53.11

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IGlar	<.0001	0.05	36.8569	39.6827

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	1
TREATMENT(AVISITN)	IGlar				60	-1
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V060 IDegLira - IGlar	WORK.INSDOS_MMRM	-5.8008	1.0202	2819

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IDegLira - IGlar	-5.69	<.0001	0.05	-7.8013	-3.8003

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	1
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	0.0879
REGION(AVISITN)		Asia			70	0.0909
REGION(AVISITN)		Europe			70	0.4911
REGION(AVISITN)		North America			70	0.1502
REGION(AVISITN)		South America			70	0.1798
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	0.3538
PREOAD(AVISITN)			SU users		70	0.6462
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	0.5306
HBA1CG1(AVISITN)				>=8.5	70	0.4694
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V070 IDegLira	WORK.INSDOS_MMRM	35.4096	0.7186	2825	49.28

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IDegLira	<.0001	0.05	34.0005	36.8186

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	0.0879
REGION(AVISITN)		Asia			70	0.0909
REGION(AVISITN)		Europe			70	0.4911
REGION(AVISITN)		North America			70	0.1502
REGION(AVISITN)		South America			70	0.1798
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	0.3538
PREOAD(AVISITN)			SU users		70	0.6462
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	0.5306
HBA1CG1(AVISITN)				>=8.5	70	0.4694
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V070 IGlar	WORK.INSDOS_MMRM	48.4182	0.7298	2966	66.35

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IGlar	<.0001	0.05	46.9872	49.8491

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	1
TREATMENT(AVISITN)	IGlar				70	-1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V070 IDegLira - IGlar	WORK.INSDOS_MMRM	-13.0086	1.0286	2893

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IDegLira - IGlar	-12.65	<.0001	0.05	-15.0254	-10.9918

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IDegLira				80	1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	0.0879
REGION(AVISITN)		Asia			80	0.0909
REGION(AVISITN)		Europe			80	0.4911
REGION(AVISITN)		North America			80	0.1502
REGION(AVISITN)		South America			80	0.1798
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	0.3538
PREOAD(AVISITN)			SU users		80	0.6462
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	0.5306
HBA1CG1(AVISITN)				>=8.5	80	0.4694
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V080 IDegLira	WORK.INSDOS_MMRM	35.8502	0.7544	3286	47.52

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IDegLira	<.0001	0.05	34.3710	37.3295

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	1
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	0.0879
REGION(AVISITN)		Asia			80	0.0909
REGION(AVISITN)		Europe			80	0.4911
REGION(AVISITN)		North America			80	0.1502
REGION(AVISITN)		South America			80	0.1798
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	0.3538
PREOAD(AVISITN)			SU users		80	0.6462
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	0.5306
HBA1CG1(AVISITN)				>=8.5	80	0.4694
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V080 IGlar	WORK.INSDOS_MMRM	49.7157	0.8285	4261	60.00

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IGlar	<.0001	0.05	48.0913	51.3401

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	1
TREATMENT(AVISITN)	IGlar				80	-1
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V080 IDegLira - IGlar	WORK.INSDOS_MMRM	-13.8655	1.1190	3722

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IDegLira - IGlar	-12.39	<.0001	0.05	-16.0593	-11.6716

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	1
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	0.0879
REGION(AVISITN)		Asia			90	0.0909
REGION(AVISITN)		Europe			90	0.4911
REGION(AVISITN)		North America			90	0.1502
REGION(AVISITN)		South America			90	0.1798
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	0.3538
PREOAD(AVISITN)			SU users		90	0.6462
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	0.5306
HBA1CG1(AVISITN)				>=8.5	90	0.4694
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V090 IDegLira	WORK.INSDOS_MMRM	36.5250	0.7626	3393	47.90

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IDegLira	<.0001	0.05	35.0299	38.0202

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	0.0879
REGION(AVISITN)		Asia			90	0.0909
REGION(AVISITN)		Europe			90	0.4911
REGION(AVISITN)		North America			90	0.1502
REGION(AVISITN)		South America			90	0.1798
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	0.3538
PREOAD(AVISITN)			SU users		90	0.6462
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	0.5306
HBA1CG1(AVISITN)				>=8.5	90	0.4694
HBA1CG1(AVISITN)				<8.5	100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V090 IGlar	WORK.INSDOS_MMRM	51.7973	0.8434	4458	61.41

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IGlar	<.0001	0.05	50.1437	53.4508

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	1
TREATMENT(AVISITN)	IGlar				90	-1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V090 IDegLira - IGlar	WORK.INSDOS_MMRM	-15.2722	1.1356	3878

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IDegLira - IGlar	-13.45	<.0001	0.05	-17.4987	-13.0458

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	1
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	0.0879
REGION(AVISITN)		Asia			100	0.0909
REGION(AVISITN)		Europe			100	0.4911
REGION(AVISITN)		North America			100	0.1502
REGION(AVISITN)		South America			100	0.1798
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	0.3538
PREOAD(AVISITN)			SU users		100	0.6462
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	0.5306
HBA1CG1(AVISITN)				>=8.5	100	0.4694
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V100 IDegLira	WORK.INSDOS_MMRM	36.6638	0.7801	3629	47.00

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IDegLira	<.0001	0.05	35.1343	38.1933

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	1
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	0.0879
REGION(AVISITN)		Asia			100	0.0909
REGION(AVISITN)		Europe			100	0.4911
REGION(AVISITN)		North America			100	0.1502
REGION(AVISITN)		South America			100	0.1798
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	0.3538
PREOAD(AVISITN)			SU users		100	0.6462
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	0.5306
HBA1CG1(AVISITN)				>=8.5	100	0.4694
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V100 IGlar	WORK.INSDOS_MMRM	51.9556	0.8794	4927	59.08

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IGlar	<.0001	0.05	50.2316	53.6795

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	1
TREATMENT(AVISITN)	IGlar				100	-1
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V100 IDegLira - IGlar	WORK.INSDOS_MMRM	-15.2918	1.1715	4220

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IDegLira - IGlar	-13.05	<.0001	0.05	-17.5886	-12.9949

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	1
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	0.0879
REGION(AVISITN)		Asia			110	0.0909
REGION(AVISITN)		Europe			110	0.4911
REGION(AVISITN)		North America			110	0.1502
REGION(AVISITN)		South America			110	0.1798
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	0.3538
PREOAD(AVISITN)			SU users		110	0.6462
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	0.5306
HBA1CG1(AVISITN)				>=8.5	110	0.4694
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V110 IDegLira	WORK.INSDOS_MMRM	36.6929	0.7933	3809	46.25

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IDegLira	<.0001	0.05	35.1376	38.2482

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	1
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	0.0879
REGION(AVISITN)		Asia			110	0.0909
REGION(AVISITN)		Europe			110	0.4911
REGION(AVISITN)		North America			110	0.1502
REGION(AVISITN)		South America			110	0.1798
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	0.3538
PREOAD(AVISITN)			SU users		110	0.6462
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	0.5306
HBA1CG1(AVISITN)				>=8.5	110	0.4694
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V110 IGlar	WORK.INSDOS_MMRM	51.6286	0.9158	5385	56.38

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IGlar	<.0001	0.05	49.8332	53.4239

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	1
TREATMENT(AVISITN)	IGlar				110	-1
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V110 IDegLira - IGlar	WORK.INSDOS_MMRM	-14.9356	1.2038	4526

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IDegLira - IGlar	-12.41	<.0001	0.05	-17.2956	-12.5757

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	1
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	0.0879
REGION(AVISITN)		Asia			120	0.0909
REGION(AVISITN)		Europe			120	0.4911
REGION(AVISITN)		North America			120	0.1502
REGION(AVISITN)		South America			120	0.1798
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	0.3538
PREOAD(AVISITN)			SU users		120	0.6462
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	0.5306
HBA1CG1(AVISITN)				>=8.5	120	0.4694
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V120 IDegLira	WORK.INSDOS_MMRM	36.5938	0.7988	3884	45.81

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IDegLira	<.0001	0.05	35.0278	38.1599

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	1
TREATMENT(AVISITN)	IDegLira				130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	0.0879
REGION(AVISITN)		Asia			120	0.0909
REGION(AVISITN)		Europe			120	0.4911
REGION(AVISITN)		North America			120	0.1502
REGION(AVISITN)		South America			120	0.1798
REGION(AVISITN)		Africa			130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	0.3538
PREOAD(AVISITN)			SU users		120	0.6462
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	0.5306
HBA1CG1(AVISITN)				>=8.5	120	0.4694
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V120 IGlar	WORK.INSDOS_MMRM	51.7331	0.9371	5641	55.21

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IGlar	<.0001	0.05	49.8960	53.5701

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	1
TREATMENT(AVISITN)	IGlar				120	-1
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V120 IDegLira - IGlar	WORK.INSDOS_MMRM	-15.1392	1.2207	4686

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IDegLira - IGlar	-12.40	<.0001	0.05	-17.5324	-12.7460

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	0.0879
REGION(AVISITN)		Asia			130	0.0909
REGION(AVISITN)		Europe			130	0.4911
REGION(AVISITN)		North America			130	0.1502
REGION(AVISITN)		South America			130	0.1798
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	0.3538
PREOAD(AVISITN)			SU users		130	0.6462
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	0.5306
HBA1CG1(AVISITN)				>=8.5	130	0.4694

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V130 IDegLira	WORK.INSDOS_MMRM	37.1396	0.8130	4080	45.68

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IDegLira	<.0001	0.05	35.5456	38.7336

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	1
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	0.0879
REGION(AVISITN)		Asia			130	0.0909
REGION(AVISITN)		Europe			130	0.4911
REGION(AVISITN)		North America			130	0.1502
REGION(AVISITN)		South America			130	0.1798
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	0.3538
PREOAD(AVISITN)			SU users		130	0.6462
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	0.5306
HBA1CG1(AVISITN)				>=8.5	130	0.4694

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V130 IGlar	WORK.INSDOS_MMRM	52.0818	0.9815	6138	53.06

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IGlar	<.0001	0.05	50.1577	54.0060

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				30	
TREATMENT(AVISITN)	IGlar				30	
TREATMENT(AVISITN)	IDegLira				40	
TREATMENT(AVISITN)	IGlar				40	
TREATMENT(AVISITN)	IDegLira				50	
TREATMENT(AVISITN)	IGlar				50	
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	1

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				130	-1
REGION(AVISITN)		Africa			30	
REGION(AVISITN)		Asia			30	
REGION(AVISITN)		Europe			30	
REGION(AVISITN)		North America			30	
REGION(AVISITN)		South America			30	
REGION(AVISITN)		Africa			40	
REGION(AVISITN)		Asia			40	
REGION(AVISITN)		Europe			40	
REGION(AVISITN)		North America			40	
REGION(AVISITN)		South America			40	
REGION(AVISITN)		Africa			50	
REGION(AVISITN)		Asia			50	
REGION(AVISITN)		Europe			50	
REGION(AVISITN)		North America			50	
REGION(AVISITN)		South America			50	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.INSDOS_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		30	
PREOAD(AVISITN)			SU users		30	
PREOAD(AVISITN)			Non-SU users		40	
PREOAD(AVISITN)			SU users		40	
PREOAD(AVISITN)			Non-SU users		50	
PREOAD(AVISITN)			SU users		50	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	30	
HBA1CG1(AVISITN)				>=8.5	30	
HBA1CG1(AVISITN)				<8.5	40	
HBA1CG1(AVISITN)				>=8.5	40	
HBA1CG1(AVISITN)				<8.5	50	
HBA1CG1(AVISITN)				>=8.5	50	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	

Actual daily total insulin dose after 26 and 104 weeks – supportive statistical analysis – full analysis set

TOPIC_CD=TOTAL_DOSE_DAILY_ACT_U

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V130 IDegLira - IGlar	WORK.INSDOS_MMRM	-14.9422	1.2597	5046

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IDegLira - IGlar	-11.86	<.0001	0.05	-17.4118	-12.4726

2: Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) – primary statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 1: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	0.000	1.0000	0	0	0	112
1	16.000	0.9911	0.00893	0.00889	1	111
1	28.000	0.9821	0.0179	0.0125	2	110
1	77.000	0.9732	0.0268	0.0153	3	109
1	84.000	0.9643	0.0357	0.0175	4	108
1	183.000				5	107
1	183.000				6	106
1	183.000	0.9375	0.0625	0.0229	7	105
1	184.000	0.9286	0.0714	0.0243	8	104
1	200.000	0.9196	0.0804	0.0257	9	103
1	210.000	0.9107	0.0893	0.0269	10	102
1	224.000	0.9018	0.0982	0.0281	11	101
1	238.000	0.8929	0.1071	0.0292	12	100
1	246.000	0.8839	0.1161	0.0303	13	99
1	266.000	0.8750	0.1250	0.0313	14	98
1	271.000	0.8661	0.1339	0.0322	15	97
1	275.000	0.8571	0.1429	0.0331	16	96
1	365.000				17	95
1	365.000				18	94
1	365.000	0.8304	0.1696	0.0355	19	93
1	456.000	0.8214	0.1786	0.0362	20	92
1	470.000	0.8125	0.1875	0.0369	21	91
1	547.000				22	90
1	547.000	0.7946	0.2054	0.0382	23	89
1	632.000	0.7857	0.2143	0.0388	24	88
1	640.000	0.7768	0.2232	0.0393	25	87
1	714.000*				25	86
1	716.000	0.7678	0.2322	0.0399	26	85
1	720.000*				26	84
1	721.000*				26	83
1	721.000*				26	82
1	721.000*				26	81
1	723.000*				26	80
1	723.000*				26	79
1	725.000*				26	78
1	725.000*				26	77
1	725.000*				26	76
1	726.000*				26	75
1	726.000*				26	74
1	726.000*				26	73
1	726.000*				26	72
1	726.000*				26	71
1	727.000	0.7569	0.2431	0.0408	27	70
1	727.000*				27	69
1	727.000*				27	68
1	727.000*				27	67
1	727.000*				27	66
1	727.000*				27	65
1	727.000*				27	64
1	727.000*				27	63
1	727.000*				27	62
1	727.000*				27	61
1	727.000*				27	60
1	727.000*				27	59
1	727.000*				27	58
1	728.000	0.7439	0.2561	0.0421	28	57
1	728.000*				28	56
1	728.000*				28	55
1	728.000*				28	54
1	728.000*				28	53
1	728.000*				28	52

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 1: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	728.000*				28	51
1	728.000*				28	50
1	728.000*				28	49
1	728.000*				28	48
1	728.000*				28	47
1	728.000*				28	46
1	728.000*				28	45
1	728.000*				28	44
1	728.000*				28	43
1	728.000*				28	42
1	728.000*				28	41
1	728.000*				28	40
1	728.000*				28	39
1	728.000*				28	38
1	728.000*				28	37
1	728.000*				28	36
1	728.000*				28	35
1	728.000*				28	34
1	728.000*				28	33
1	728.000*				28	32
1	728.000*				28	31
1	728.000*				28	30
1	729.000*				28	29
1	729.000*				28	28
1	729.000*				28	27
1	729.000*				28	26
1	729.000*				28	25
1	729.000*				28	24
1	729.000*				28	23
1	729.000*				28	22
1	729.000*				28	21
1	729.000*				28	20
1	729.000*				28	19
1	729.000*				28	18
1	729.000*				28	17
1	729.000*				28	16
1	729.000*				28	15
1	729.000*				28	14
1	730.000*				28	13
1	730.000*				28	12
1	730.000*				28	11
1	730.000*				28	10
1	731.000*				28	9
1	732.000*				28	8
1	732.000*				28	7
1	734.000*				28	6
1	735.000*				28	5
1	737.000*				28	4
1	742.000*				28	3
1	743.000*				28	2
1	752.000*				28	1
1	755.000*				28	0

NOTE: The marked survival times are censored observations.

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 1: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = Non-SU users

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
1	75		LOGLOG		
1	50		LOGLOG		
1	25	728.000	LOGLOG	365.000	

TRTPN	Mean	Standard Error
1	630.158	19.223

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	0.000	1.0000	0	0	0	105
2	29.000	0.9905	0.00952	0.00948	1	104
2	31.000	0.9810	0.0190	0.0133	2	103
2	38.000	0.9714	0.0286	0.0163	3	102
2	51.000	0.9619	0.0381	0.0187	4	101
2	147.000	0.9524	0.0476	0.0208	5	100
2	176.000	0.9429	0.0571	0.0227	6	99
2	180.000	0.9333	0.0667	0.0243	7	98
2	181.000	0.9238	0.0762	0.0259	8	97
2	182.000				9	96
2	182.000	0.9048	0.0952	0.0286	10	95
2	183.000				11	94
2	183.000				12	93
2	183.000				13	92
2	183.000				14	91
2	183.000				15	90
2	183.000				16	89
2	183.000	0.8381	0.1619	0.0359	17	88
2	184.000				18	87
2	184.000	0.8190	0.1810	0.0376	19	86
2	186.000	0.8095	0.1905	0.0383	20	85
2	188.000	0.8000	0.2000	0.0390	21	84
2	196.000	0.7905	0.2095	0.0397	22	83
2	198.000	0.7810	0.2190	0.0404	23	82
2	212.000	0.7714	0.2286	0.0410	24	81
2	222.000	0.7619	0.2381	0.0416	25	80
2	266.000	0.7524	0.2476	0.0421	26	79
2	267.000	0.7429	0.2571	0.0427	27	78
2	269.000	0.7333	0.2667	0.0432	28	77
2	275.000	0.7238	0.2762	0.0436	29	76
2	364.000				30	75
2	364.000				31	74
2	364.000	0.6952	0.3048	0.0449	32	73
2	365.000				33	72
2	365.000	0.6762	0.3238	0.0457	34	71
2	366.000	0.6667	0.3333	0.0460	35	70
2	372.000	0.6571	0.3429	0.0463	36	69
2	442.000	0.6476	0.3524	0.0466	37	68
2	449.000				38	67
2	449.000				39	66

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 1: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	449.000	0.6190	0.3810	0.0474	40	65
2	451.000	0.6095	0.3905	0.0476	41	64
2	540.000	0.6000	0.4000	0.0478	42	63
2	547.000	0.5905	0.4095	0.0480	43	62
2	548.000	0.5810	0.4190	0.0482	44	61
2	629.000	0.5714	0.4286	0.0483	45	60
2	632.000	0.5619	0.4381	0.0484	46	59
2	697.000	0.5524	0.4476	0.0485	47	58
2	719.000*				47	57
2	721.000*				47	56
2	722.000*				47	55
2	723.000*				47	54
2	723.000*				47	53
2	724.000*				47	52
2	725.000*				47	51
2	725.000*				47	50
2	725.000*				47	49
2	725.000*				47	48
2	725.000*				47	47
2	726.000*				47	46
2	726.000*				47	45
2	727.000*				47	44
2	727.000*				47	43
2	727.000*				47	42
2	728.000*				47	41
2	728.000*				47	40
2	728.000*				47	39
2	728.000*				47	38
2	728.000*				47	37
2	728.000*				47	36
2	728.000*				47	35
2	728.000*				47	34
2	728.000*				47	33
2	728.000*				47	32
2	728.000*				47	31
2	728.000*				47	30
2	728.000*				47	29
2	728.000*				47	28
2	728.000*				47	27
2	729.000*				47	26
2	729.000*				47	25
2	729.000*				47	24
2	729.000*				47	23
2	729.000*				47	22
2	729.000*				47	21
2	729.000*				47	20
2	729.000*				47	19
2	729.000*				47	18
2	729.000*				47	17
2	730.000				48	16
2	730.000	0.4874	0.5126	0.0608	49	15
2	730.000*				49	14
2	730.000*				49	13
2	730.000*				49	12
2	730.000*				49	11
2	730.000*				49	10
2	730.000*				49	9
2	731.000	0.4332	0.5668	0.0743	50	8
2	731.000*				50	7
2	731.000*				50	6
2	731.000*				50	5

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 1: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	732.000*				50	4
2	732.000*				50	3
2	733.000*				50	2
2	733.000*				50	1
2	736.000*				50	0

NOTE: The marked survival times are censored observations.

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
2	75		LOGLOG		
2	50	730.000	LOGLOG	540.000	
2	25	267.000	LOGLOG	184.000	366.000

TRTPN	Mean	Standard Error
2	532.468	24.241

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	0.000	1.0000	0	0	0	185
1	15.000	0.9946	0.00541	0.00539	1	184
1	22.000	0.9892	0.0108	0.00760	2	183
1	36.000	0.9838	0.0162	0.00929	3	182
1	143.000	0.9784	0.0216	0.0107	4	181
1	158.000	0.9730	0.0270	0.0119	5	180
1	179.000	0.9676	0.0324	0.0130	6	179
1	181.000				7	178
1	181.000	0.9568	0.0432	0.0150	8	177
1	183.000				9	176
1	183.000				10	175
1	183.000	0.9405	0.0595	0.0174	11	174
1	184.000				12	173
1	184.000	0.9297	0.0703	0.0188	13	172
1	190.000	0.9243	0.0757	0.0194	14	171
1	203.000	0.9189	0.0811	0.0201	15	170
1	204.000	0.9135	0.0865	0.0207	16	169
1	264.000	0.9081	0.0919	0.0212	17	168
1	266.000	0.9027	0.0973	0.0218	18	167
1	267.000				19	166
1	267.000	0.8919	0.1081	0.0228	20	165
1	269.000				21	164
1	269.000	0.8811	0.1189	0.0238	22	163
1	274.000	0.8757	0.1243	0.0243	23	162
1	276.000	0.8703	0.1297	0.0247	24	161
1	277.000	0.8649	0.1351	0.0251	25	160
1	362.000	0.8595	0.1405	0.0256	26	159
1	363.000	0.8541	0.1459	0.0260	27	158
1	365.000	0.8486	0.1514	0.0263	28	157
1	372.000				29	156
1	372.000	0.8378	0.1622	0.0271	30	155
1	385.000	0.8324	0.1676	0.0275	31	154
1	388.000	0.8270	0.1730	0.0278	32	153
1	404.000	0.8216	0.1784	0.0281	33	152
1	446.000	0.8162	0.1838	0.0285	34	151
1	447.000	0.8108	0.1892	0.0288	35	150
1	448.000	0.8054	0.1946	0.0291	36	149
1	449.000				37	148
1	449.000	0.7946	0.2054	0.0297	38	147
1	450.000				39	146
1	450.000	0.7838	0.2162	0.0303	40	145
1	451.000	0.7784	0.2216	0.0305	41	144
1	453.000	0.7730	0.2270	0.0308	42	143
1	455.000	0.7676	0.2324	0.0311	43	142
1	545.000	0.7622	0.2378	0.0313	44	141
1	552.000	0.7568	0.2432	0.0315	45	140
1	584.000	0.7514	0.2486	0.0318	46	139
1	629.000	0.7459	0.2541	0.0320	47	138
1	631.000	0.7405	0.2595	0.0322	48	137
1	632.000				49	136
1	632.000	0.7297	0.2703	0.0327	50	135
1	635.000	0.7243	0.2757	0.0329	51	134
1	643.000	0.7189	0.2811	0.0330	52	133
1	718.000*				52	132
1	721.000*				52	131
1	721.000*				52	130
1	721.000*				52	129
1	724.000*				52	128
1	724.000*				52	127
1	725.000	0.7133	0.2867	0.0333	53	126
1	725.000*				53	125

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	725.000*				53	124
1	725.000*				53	123
1	725.000*				53	122
1	725.000*				53	121
1	725.000*				53	120
1	725.000*				53	119
1	725.000*				53	118
1	726.000	0.7072	0.2928	0.0335	54	117
1	726.000*				54	116
1	726.000*				54	115
1	726.000*				54	114
1	726.000*				54	113
1	726.000*				54	112
1	726.000*				54	111
1	726.000*				54	110
1	726.000*				54	109
1	726.000*				54	108
1	726.000*				54	107
1	726.000*				54	106
1	726.000*				54	105
1	726.000*				54	104
1	727.000*				54	103
1	727.000*				54	102
1	727.000*				54	101
1	727.000*				54	100
1	727.000*				54	99
1	727.000*				54	98
1	727.000*				54	97
1	727.000*				54	96
1	727.000*				54	95
1	727.000*				54	94
1	727.000*				54	93
1	727.000*				54	92
1	728.000*				54	91
1	728.000*				54	90
1	728.000*				54	89
1	728.000*				54	88
1	728.000*				54	87
1	728.000*				54	86
1	728.000*				54	85
1	728.000*				54	84
1	728.000*				54	83
1	728.000*				54	82
1	728.000*				54	81
1	728.000*				54	80
1	728.000*				54	79
1	728.000*				54	78
1	728.000*				54	77
1	728.000*				54	76
1	728.000*				54	75
1	728.000*				54	74
1	728.000*				54	73
1	728.000*				54	72
1	728.000*				54	71
1	728.000*				54	70
1	728.000*				54	69
1	728.000*				54	68
1	728.000*				54	67
1	728.000*				54	66
1	728.000*				54	65
1	728.000*				54	64

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	728.000*				54	63
1	728.000*				54	62
1	728.000*				54	61
1	728.000*				54	60
1	728.000*				54	59
1	728.000*				54	58
1	728.000*				54	57
1	728.000*				54	56
1	728.000*				54	55
1	728.000*				54	54
1	728.000*				54	53
1	728.000*				54	52
1	728.000*				54	51
1	729.000				55	50
1	729.000	0.6795	0.3205	0.0375	56	49
1	729.000*				56	48
1	729.000*				56	47
1	729.000*				56	46
1	729.000*				56	45
1	729.000*				56	44
1	729.000*				56	43
1	729.000*				56	42
1	729.000*				56	41
1	729.000*				56	40
1	729.000*				56	39
1	729.000*				56	38
1	729.000*				56	37
1	729.000*				56	36
1	729.000*				56	35
1	729.000*				56	34
1	729.000*				56	33
1	729.000*				56	32
1	729.000*				56	31
1	729.000*				56	30
1	729.000*				56	29
1	729.000*				56	28
1	729.000*				56	27
1	730.000	0.6543	0.3457	0.0438	57	26
1	730.000*				57	25
1	730.000*				57	24
1	730.000*				57	23
1	730.000*				57	22
1	730.000*				57	21
1	730.000*				57	20
1	731.000	0.6216	0.3784	0.0524	58	19
1	731.000*				58	18
1	731.000*				58	17
1	731.000*				58	16
1	731.000*				58	15
1	732.000	0.5802	0.4198	0.0632	59	14
1	732.000*				59	13
1	732.000*				59	12
1	732.000*				59	11
1	733.000*				59	10
1	733.000*				59	9
1	738.000*				59	8
1	742.000*				59	7
1	742.000*				59	6
1	742.000*				59	5
1	743.000*				59	4
1	747.000	0.4351	0.5649	0.1343	60	3

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	750.000*				60	2
1	754.000*				60	1
1	756.000*				60	0

NOTE: The marked survival times are censored observations.

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
1	75		LOGLOG	747.000	
1	50	747.000	LOGLOG	732.000	
1	25	629.000	LOGLOG	447.000	729.000

TRTPN	Mean	Standard Error
1	631.195	14.924

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	0.000	1.0000	0	0	0	135
2	8.000	0.9926	0.00741	0.00738	1	134
2	9.000	0.9852	0.0148	0.0104	2	133
2	18.000	0.9778	0.0222	0.0127	3	132
2	35.000	0.9704	0.0296	0.0146	4	131
2	37.000				5	130
2	37.000	0.9556	0.0444	0.0177	6	129
2	55.000	0.9481	0.0519	0.0191	7	128
2	84.000	0.9407	0.0593	0.0203	8	127
2	85.000	0.9333	0.0667	0.0215	9	126
2	125.000	0.9259	0.0741	0.0225	10	125
2	159.000	0.9185	0.0815	0.0235	11	124
2	172.000	0.9111	0.0889	0.0245	12	123
2	179.000	0.9037	0.0963	0.0254	13	122
2	180.000	0.8963	0.1037	0.0262	14	121
2	182.000				15	120
2	182.000				16	119
2	182.000	0.8741	0.1259	0.0286	17	118
2	183.000				18	117
2	183.000				19	116
2	183.000				20	115
2	183.000				21	114
2	183.000				22	113
2	183.000				23	112
2	183.000				24	111
2	183.000				25	110
2	183.000				26	109

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	183.000				27	108
2	183.000				28	107
2	183.000	0.7852	0.2148	0.0353	29	106
2	184.000				30	105
2	184.000	0.7704	0.2296	0.0362	31	104
2	185.000				32	103
2	185.000				33	102
2	185.000	0.7481	0.2519	0.0374	34	101
2	186.000				35	100
2	186.000				36	99
2	186.000				37	98
2	186.000	0.7185	0.2815	0.0387	38	97
2	187.000				39	96
2	187.000	0.7037	0.2963	0.0393	40	95
2	188.000	0.6963	0.3037	0.0396	41	94
2	205.000	0.6889	0.3111	0.0398	42	93
2	226.000	0.6815	0.3185	0.0401	43	92
2	260.000	0.6741	0.3259	0.0403	44	91
2	266.000	0.6667	0.3333	0.0406	45	90
2	267.000				46	89
2	267.000	0.6519	0.3481	0.0410	47	88
2	268.000	0.6444	0.3556	0.0412	48	87
2	269.000				49	86
2	269.000	0.6296	0.3704	0.0416	50	85
2	329.000	0.6222	0.3778	0.0417	51	84
2	364.000				52	83
2	364.000	0.6074	0.3926	0.0420	53	82
2	365.000				54	81
2	365.000	0.5926	0.4074	0.0423	55	80
2	368.000	0.5852	0.4148	0.0424	56	79
2	372.000	0.5778	0.4222	0.0425	57	78
2	378.000	0.5704	0.4296	0.0426	58	77
2	448.000	0.5630	0.4370	0.0427	59	76
2	449.000				60	75
2	449.000	0.5481	0.4519	0.0428	61	74
2	450.000	0.5407	0.4593	0.0429	62	73
2	463.000	0.5333	0.4667	0.0429	63	72
2	547.000				64	71
2	547.000	0.5185	0.4815	0.0430	65	70
2	631.000				66	69
2	631.000	0.5037	0.4963	0.0430	67	68
2	632.000	0.4963	0.5037	0.0430	68	67
2	634.000	0.4889	0.5111	0.0430	69	66
2	645.000	0.4815	0.5185	0.0430	70	65
2	672.000	0.4741	0.5259	0.0430	71	64
2	695.000*				71	63
2	718.000*				71	62
2	721.000*				71	61
2	725.000*				71	60
2	725.000*				71	59
2	725.000*				71	58
2	726.000*				71	57
2	726.000*				71	56
2	726.000*				71	55
2	726.000*				71	54
2	727.000*				71	53
2	727.000*				71	52
2	727.000*				71	51
2	727.000*				71	50
2	727.000*				71	49
2	727.000*				71	48

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	727.000*				71	47
2	727.000*				71	46
2	727.000*				71	45
2	728.000				72	44
2	728.000	0.4530	0.5470	0.0436	73	43
2	728.000*				73	42
2	728.000*				73	41
2	728.000*				73	40
2	728.000*				73	39
2	728.000*				73	38
2	728.000*				73	37
2	728.000*				73	36
2	728.000*				73	35
2	728.000*				73	34
2	728.000*				73	33
2	728.000*				73	32
2	728.000*				73	31
2	728.000*				73	30
2	728.000*				73	29
2	728.000*				73	28
2	729.000				74	27
2	729.000				75	26
2	729.000				76	25
2	729.000	0.3883	0.6117	0.0479	77	24
2	729.000*				77	23
2	729.000*				77	22
2	729.000*				77	21
2	729.000*				77	20
2	729.000*				77	19
2	729.000*				77	18
2	729.000*				77	17
2	729.000*				77	16
2	729.000*				77	15
2	730.000	0.3624	0.6376	0.0512	78	14
2	730.000*				78	13
2	730.000*				78	12
2	730.000*				78	11
2	731.000	0.3295	0.6705	0.0562	79	10
2	731.000*				79	9
2	731.000*				79	8
2	731.000*				79	7
2	732.000*				79	6
2	733.000*				79	5
2	735.000*				79	4
2	735.000*				79	3
2	736.000	0.2196	0.7804	0.0972	80	2
2	736.000*				80	1
2	768.000*				80	0

NOTE: The marked survival times are censored observations.

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) – primary statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
2	75	736.000	LOGLOG	731.000	
2	50	632.000	LOGLOG	368.000	729.000
2	25	185.000	LOGLOG	183.000	260.000

TRTPN	Mean	Standard Error
2	485.414	22.947

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 3: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	0.000	1.0000	0	0	0	74
1	5.000	0.9865	0.0135	0.0134	1	73
1	16.000	0.9730	0.0270	0.0189	2	72
1	40.000	0.9595	0.0405	0.0229	3	71
1	58.000	0.9459	0.0541	0.0263	4	70
1	101.000	0.9324	0.0676	0.0292	5	69
1	176.000	0.9189	0.0811	0.0317	6	68
1	182.000				7	67
1	182.000	0.8919	0.1081	0.0361	8	66
1	183.000				9	65
1	183.000				10	64
1	183.000				11	63
1	183.000				12	62
1	183.000	0.8243	0.1757	0.0442	13	61
1	185.000	0.8108	0.1892	0.0455	14	60
1	192.000	0.7973	0.2027	0.0467	15	59
1	193.000	0.7838	0.2162	0.0479	16	58
1	194.000	0.7703	0.2297	0.0489	17	57
1	268.000	0.7568	0.2432	0.0499	18	56
1	278.000	0.7432	0.2568	0.0508	19	55
1	309.000	0.7297	0.2703	0.0516	20	54
1	354.000	0.7162	0.2838	0.0524	21	53
1	364.000	0.7027	0.2973	0.0531	22	52
1	365.000	0.6892	0.3108	0.0538	23	51
1	373.000	0.6757	0.3243	0.0544	24	50
1	456.000	0.6622	0.3378	0.0550	25	49
1	633.000	0.6486	0.3514	0.0555	26	48
1	700.000	0.6351	0.3649	0.0560	27	47
1	712.000*				27	46
1	722.000*				27	45
1	725.000*				27	44
1	726.000*				27	43
1	726.000*				27	42
1	726.000*				27	41
1	727.000*				27	40
1	727.000*				27	39
1	727.000*				27	38
1	728.000*				27	37
1	728.000*				27	36
1	728.000*				27	35
1	728.000*				27	34
1	728.000*				27	33
1	728.000*				27	32
1	728.000*				27	31
1	728.000*				27	30
1	728.000*				27	29
1	728.000*				27	28
1	728.000*				27	27
1	728.000*				27	26
1	728.000*				27	25
1	728.000*				27	24
1	728.000*				27	23
1	728.000*				27	22
1	728.000*				27	21
1	728.000*				27	20
1	728.000*				27	19
1	728.000*				27	18
1	729.000*				27	17
1	729.000*				27	16
1	729.000*				27	15
1	729.000*				27	14

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 3: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	729.000*				27	13
1	729.000*				27	12
1	729.000*				27	11
1	730.000*				27	10
1	730.000*				27	9
1	730.000*				27	8
1	731.000*				27	7
1	731.000*				27	6
1	731.000*				27	5
1	732.000	0.5081	0.4919	0.1221	28	4
1	733.000*				28	3
1	736.000*				28	2
1	749.000*				28	1
1	754.000*				28	0

NOTE: The marked survival times are censored observations.

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
1	75		LOGLOG		
1	50		LOGLOG	732.000	
1	25	278.000	LOGLOG	183.000	633.000

TRTPN	Mean	Standard Error
1	553.284	30.244

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	0.000	1.0000	0	0	0	67
2	10.000	0.9851	0.0149	0.0148	1	66
2	19.000	0.9701	0.0299	0.0208	2	65
2	128.000	0.9552	0.0448	0.0253	3	64
2	180.000	0.9403	0.0597	0.0289	4	63
2	181.000				5	62
2	181.000	0.9104	0.0896	0.0349	6	61
2	182.000				7	60
2	182.000				8	59
2	182.000				9	58
2	182.000				10	57
2	182.000				11	56
2	182.000	0.8209	0.1791	0.0468	12	55
2	183.000				13	54
2	183.000				14	53
2	183.000				15	52

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 3: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	183.000				16	51
2	183.000				17	50
2	183.000				18	49
2	183.000	0.7164	0.2836	0.0551	19	48
2	184.000	0.7015	0.2985	0.0559	20	47
2	186.000	0.6866	0.3134	0.0567	21	46
2	187.000				22	45
2	187.000	0.6567	0.3433	0.0580	23	44
2	191.000	0.6418	0.3582	0.0586	24	43
2	204.000	0.6269	0.3731	0.0591	25	42
2	217.000	0.6119	0.3881	0.0595	26	41
2	364.000	0.5970	0.4030	0.0599	27	40
2	365.000				28	39
2	365.000				29	38
2	365.000				30	37
2	365.000	0.5373	0.4627	0.0609	31	36
2	372.000	0.5224	0.4776	0.0610	32	35
2	452.000				33	34
2	452.000	0.4925	0.5075	0.0611	34	33
2	543.000	0.4776	0.5224	0.0610	35	32
2	547.000	0.4627	0.5373	0.0609	36	31
2	554.000	0.4478	0.5522	0.0608	37	30
2	597.000	0.4328	0.5672	0.0605	38	29
2	633.000	0.4179	0.5821	0.0603	39	28
2	638.000				40	27
2	638.000	0.3881	0.6119	0.0595	41	26
2	655.000	0.3731	0.6269	0.0591	42	25
2	714.000	0.3582	0.6418	0.0586	43	24
2	721.000*				43	23
2	726.000*				43	22
2	726.000*				43	21
2	726.000*				43	20
2	727.000*				43	19
2	728.000*				43	18
2	728.000*				43	17
2	728.000*				43	16
2	728.000*				43	15
2	728.000*				43	14
2	728.000*				43	13
2	728.000*				43	12
2	728.000*				43	11
2	729.000				44	10
2	729.000	0.2931	0.7069	0.0635	45	9
2	729.000*				45	8
2	729.000*				45	7
2	729.000*				45	6
2	729.000*				45	5
2	729.000*				45	4
2	729.000*				45	3
2	730.000*				45	2
2	736.000	0.1465	0.8535	0.1084	46	1
2	777.000*				46	0

NOTE: The marked survival times are censored observations.

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) – primary statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 3: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = Non-SU users

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
2	75	736.000	LOGLOG	714.000	
2	50	452.000	LOGLOG	204.000	655.000
2	25	183.000	LOGLOG	182.000	191.000

TRTPN	Mean	Standard Error
2	457.917	31.444

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	0.000	1.0000	0	0	0	135
1	2.000	0.9926	0.00741	0.00738	1	134
1	4.000	0.9852	0.0148	0.0104	2	133
1	19.000	0.9778	0.0222	0.0127	3	132
1	85.000	0.9704	0.0296	0.0146	4	131
1	93.000	0.9630	0.0370	0.0163	5	130
1	94.000	0.9556	0.0444	0.0177	6	129
1	134.000	0.9481	0.0519	0.0191	7	128
1	176.000	0.9407	0.0593	0.0203	8	127
1	180.000	0.9333	0.0667	0.0215	9	126
1	181.000				10	125
1	181.000				11	124
1	181.000	0.9111	0.0889	0.0245	12	123
1	182.000				13	122
1	182.000				14	121
1	182.000	0.8889	0.1111	0.0270	15	120
1	183.000				16	119
1	183.000				17	118
1	183.000				18	117
1	183.000				19	116
1	183.000				20	115
1	183.000				21	114
1	183.000				22	113
1	183.000				23	112
1	183.000				24	111
1	183.000				25	110
1	183.000				26	109
1	183.000	0.8000	0.2000	0.0344	27	108
1	184.000				28	107
1	184.000				29	106
1	184.000	0.7778	0.2222	0.0358	30	105
1	185.000				31	104
1	185.000				32	103
1	185.000				33	102
1	185.000	0.7481	0.2519	0.0374	34	101
1	186.000				35	100
1	186.000	0.7333	0.2667	0.0381	36	99
1	189.000	0.7259	0.2741	0.0384	37	98
1	190.000	0.7185	0.2815	0.0387	38	97
1	198.000	0.7111	0.2889	0.0390	39	96
1	260.000	0.7037	0.2963	0.0393	40	95
1	273.000	0.6963	0.3037	0.0396	41	94
1	363.000	0.6889	0.3111	0.0398	42	93
1	365.000				43	92
1	365.000				44	91
1	365.000				45	90
1	365.000				46	89
1	365.000	0.6519	0.3481	0.0410	47	88
1	366.000				48	87
1	366.000	0.6370	0.3630	0.0414	49	86
1	376.000	0.6296	0.3704	0.0416	50	85
1	449.000				51	84
1	449.000	0.6148	0.3852	0.0419	52	83
1	451.000	0.6074	0.3926	0.0420	53	82
1	452.000	0.6000	0.4000	0.0422	54	81
1	482.000	0.5926	0.4074	0.0423	55	80
1	529.000	0.5852	0.4148	0.0424	56	79
1	546.000	0.5778	0.4222	0.0425	57	78
1	549.000	0.5704	0.4296	0.0426	58	77
1	561.000	0.5630	0.4370	0.0427	59	76
1	578.000	0.5556	0.4444	0.0428	60	75

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	630.000	0.5481	0.4519	0.0428	61	74
1	631.000				62	73
1	631.000				63	72
1	631.000	0.5259	0.4741	0.0430	64	71
1	632.000	0.5185	0.4815	0.0430	65	70
1	633.000	0.5111	0.4889	0.0430	66	69
1	714.000*				66	68
1	714.000*				66	67
1	721.000*				66	66
1	721.000*				66	65
1	723.000	0.5032	0.4968	0.0431	67	64
1	725.000*				67	63
1	725.000*				67	62
1	725.000*				67	61
1	725.000*				67	60
1	726.000*				67	59
1	726.000*				67	58
1	726.000*				67	57
1	726.000*				67	56
1	727.000*				67	55
1	727.000*				67	54
1	727.000*				67	53
1	727.000*				67	52
1	727.000*				67	51
1	727.000*				67	50
1	727.000*				67	49
1	727.000*				67	48
1	727.000*				67	47
1	727.000*				67	46
1	728.000	0.4923	0.5077	0.0435	68	45
1	728.000*				68	44
1	728.000*				68	43
1	728.000*				68	42
1	728.000*				68	41
1	728.000*				68	40
1	728.000*				68	39
1	728.000*				68	38
1	728.000*				68	37
1	728.000*				68	36
1	728.000*				68	35
1	728.000*				68	34
1	728.000*				68	33
1	728.000*				68	32
1	728.000*				68	31
1	728.000*				68	30
1	728.000*				68	29
1	729.000				69	28
1	729.000	0.4584	0.5416	0.0467	70	27
1	729.000*				70	26
1	729.000*				70	25
1	729.000*				70	24
1	729.000*				70	23
1	729.000*				70	22
1	729.000*				70	21
1	729.000*				70	20
1	729.000*				70	19
1	729.000*				70	18
1	730.000	0.4329	0.5671	0.0505	71	17
1	730.000*				71	16
1	730.000*				71	15
1	730.000*				71	14

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	730.000*				71	13
1	730.000*				71	12
1	730.000*				71	11
1	730.000*				71	10
1	731.000	0.3896	0.6104	0.0613	72	9
1	731.000*				72	8
1	731.000*				72	7
1	732.000*				72	6
1	735.000*				72	5
1	735.000*				72	4
1	737.000	0.2922	0.7078	0.0961	73	3
1	737.000*				73	2
1	744.000*				73	1
1	750.000*				73	0

NOTE: The marked survival times are censored observations.

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
1	75		LOGLOG	737.000	
1	50	728.000	LOGLOG	529.000	737.000
1	25	185.000	LOGLOG	183.000	365.000

TRTPN	Mean	Standard Error
1	516.334	22.056

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	0.000	1.0000	0	0	0	199
2	2.000	0.9950	0.00503	0.00501	1	198
2	6.000	0.9899	0.0101	0.00707	2	197
2	29.000	0.9849	0.0151	0.00864	3	196
2	35.000	0.9799	0.0201	0.00995	4	195
2	36.000	0.9749	0.0251	0.0111	5	194
2	48.000	0.9698	0.0302	0.0121	6	193
2	50.000	0.9648	0.0352	0.0131	7	192
2	77.000	0.9598	0.0402	0.0139	8	191
2	85.000	0.9548	0.0452	0.0147	9	190
2	93.000	0.9497	0.0503	0.0155	10	189
2	106.000	0.9447	0.0553	0.0162	11	188
2	110.000	0.9397	0.0603	0.0169	12	187
2	125.000	0.9347	0.0653	0.0175	13	186
2	138.000	0.9296	0.0704	0.0181	14	185
2	169.000	0.9246	0.0754	0.0187	15	184

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	175.000	0.9196	0.0804	0.0193	16	183
2	176.000	0.9146	0.0854	0.0198	17	182
2	178.000	0.9095	0.0905	0.0203	18	181
2	179.000	0.9045	0.0955	0.0208	19	180
2	180.000				20	179
2	180.000				21	178
2	180.000				22	177
2	180.000				23	176
2	180.000	0.8794	0.1206	0.0231	24	175
2	181.000				25	174
2	181.000				26	173
2	181.000				27	172
2	181.000				28	171
2	181.000				29	170
2	181.000				30	169
2	181.000	0.8442	0.1558	0.0257	31	168
2	182.000				32	167
2	182.000				33	166
2	182.000				34	165
2	182.000				35	164
2	182.000				36	163
2	182.000				37	162
2	182.000				38	161
2	182.000	0.8040	0.1960	0.0281	39	160
2	183.000				40	159
2	183.000				41	158
2	183.000				42	157
2	183.000				43	156
2	183.000				44	155
2	183.000				45	154
2	183.000				46	153
2	183.000				47	152
2	183.000				48	151
2	183.000				49	150
2	183.000				50	149
2	183.000				51	148
2	183.000				52	147
2	183.000				53	146
2	183.000				54	145
2	183.000				55	144
2	183.000				56	143
2	183.000				57	142
2	183.000				58	141
2	183.000				59	140
2	183.000				60	139
2	183.000				61	138
2	183.000				62	137
2	183.000				63	136
2	183.000				64	135
2	183.000				65	134
2	183.000				66	133
2	183.000				67	132
2	183.000				68	131
2	183.000				69	130
2	183.000				70	129
2	183.000				71	128
2	183.000				72	127
2	183.000				73	126
2	183.000				74	125
2	183.000				75	124
2	183.000				76	123

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	183.000				77	122
2	183.000				78	121
2	183.000				79	120
2	183.000				80	119
2	183.000	0.5930	0.4070	0.0348	81	118
2	184.000				82	117
2	184.000				83	116
2	184.000				84	115
2	184.000				85	114
2	184.000	0.5678	0.4322	0.0351	86	113
2	185.000				87	112
2	185.000				88	111
2	185.000				89	110
2	185.000				90	109
2	185.000				91	108
2	185.000				92	107
2	185.000				93	106
2	185.000				94	105
2	185.000				95	104
2	185.000	0.5176	0.4824	0.0354	96	103
2	186.000				97	102
2	186.000				98	101
2	186.000				99	100
2	186.000	0.4975	0.5025	0.0354	100	99
2	187.000	0.4925	0.5075	0.0354	101	98
2	188.000	0.4874	0.5126	0.0354	102	97
2	189.000				103	96
2	189.000	0.4774	0.5226	0.0354	104	95
2	191.000				105	94
2	191.000	0.4673	0.5327	0.0354	106	93
2	195.000	0.4623	0.5377	0.0353	107	92
2	220.000	0.4573	0.5427	0.0353	108	91
2	225.000	0.4523	0.5477	0.0353	109	90
2	267.000				110	89
2	267.000	0.4422	0.5578	0.0352	111	88
2	313.000	0.4372	0.5628	0.0352	112	87
2	355.000	0.4322	0.5678	0.0351	113	86
2	362.000	0.4271	0.5729	0.0351	114	85
2	364.000	0.4221	0.5779	0.0350	115	84
2	365.000				116	83
2	365.000				117	82
2	365.000				118	81
2	365.000	0.4020	0.5980	0.0348	119	80
2	367.000				120	79
2	367.000	0.3920	0.6080	0.0346	121	78
2	368.000	0.3869	0.6131	0.0345	122	77
2	370.000	0.3819	0.6181	0.0344	123	76
2	376.000				124	75
2	376.000	0.3719	0.6281	0.0343	125	74
2	413.000	0.3668	0.6332	0.0342	126	73
2	446.000	0.3618	0.6382	0.0341	127	72
2	448.000				128	71
2	448.000	0.3518	0.6482	0.0339	129	70
2	449.000				130	69
2	449.000	0.3417	0.6583	0.0336	131	68
2	450.000	0.3367	0.6633	0.0335	132	67
2	456.000				133	66
2	456.000	0.3266	0.6734	0.0332	134	65
2	462.000	0.3216	0.6784	0.0331	135	64
2	545.000	0.3166	0.6834	0.0330	136	63
2	546.000				137	62

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	546.000	0.3065	0.6935	0.0327	138	61
2	547.000				139	60
2	547.000				140	59
2	547.000				141	58
2	547.000	0.2864	0.7136	0.0320	142	57
2	560.000	0.2814	0.7186	0.0319	143	56
2	562.000	0.2764	0.7236	0.0317	144	55
2	563.000	0.2714	0.7286	0.0315	145	54
2	622.000	0.2663	0.7337	0.0313	146	53
2	631.000	0.2613	0.7387	0.0311	147	52
2	632.000	0.2563	0.7437	0.0309	148	51
2	636.000	0.2513	0.7487	0.0307	149	50
2	638.000	0.2462	0.7538	0.0305	150	49
2	684.000	0.2412	0.7588	0.0303	151	48
2	687.000	0.2362	0.7638	0.0301	152	47
2	699.000*				152	46
2	721.000	0.2310	0.7690	0.0299	153	45
2	723.000*				153	44
2	724.000*				153	43
2	725.000	0.2257	0.7743	0.0297	154	42
2	725.000*				154	41
2	725.000*				154	40
2	726.000	0.2200	0.7800	0.0295	155	39
2	727.000*				155	38
2	727.000*				155	37
2	727.000*				155	36
2	727.000*				155	35
2	727.000*				155	34
2	727.000*				155	33
2	727.000*				155	32
2	727.000*				155	31
2	727.000*				155	30
2	728.000*				155	29
2	728.000*				155	28
2	728.000*				155	27
2	728.000*				155	26
2	728.000*				155	25
2	728.000*				155	24
2	728.000*				155	23
2	728.000*				155	22
2	728.000*				155	21
2	728.000*				155	20
2	728.000*				155	19
2	728.000*				155	18
2	728.000*				155	17
2	728.000*				155	16
2	728.000*				155	15
2	729.000				156	14
2	729.000	0.1907	0.8093	0.0320	157	13
2	729.000*				157	12
2	729.000*				157	11
2	729.000*				157	10
2	730.000*				157	9
2	730.000*				157	8
2	730.000*				157	7
2	731.000*				157	6
2	732.000*				157	5
2	735.000*				157	4
2	736.000	0.1430	0.8570	0.0478	158	3
2	736.000*				158	2
2	744.000*				158	1

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - primary statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	762.000	0	1.0000		159	0

NOTE: The marked survival times are censored observations.

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
2	75	638.000	LOGLOG	546.000	736.000
2	50	186.000	LOGLOG	184.000	355.000
2	25	183.000	LOGLOG	182.000	183.000

TRTPN	Mean	Standard Error
2	370.838	17.755

Summary of the Number of Censored and Uncensored Values

Stratum	HBA1CG1	PREOAD	TRTPN	Total	Failed	Censored	Percent Censored
1	<8.5	Non-SU users	1	112	28	84	75.00
1	<8.5	Non-SU users	2	105	50	55	52.38
Subtotal				217	78	139	64.06
2	<8.5	SU users	1	185	60	125	67.57
2	<8.5	SU users	2	135	80	55	40.74
Subtotal				320	140	180	56.25
3	>=8.5	Non-SU users	1	74	28	46	62.16
3	>=8.5	Non-SU users	2	67	46	21	31.34
Subtotal				141	74	67	47.52
4	>=8.5	SU users	1	135	73	62	45.93
4	>=8.5	SU users	2	199	159	40	20.10
Subtotal				334	232	102	30.54
Total				1012	524	488	48.22

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) – primary statistical analysis – full analysis set

The LIFETEST Procedure

Stratified Comparison of Survival Curves for AVAL over Group

Rank Statistics

TRTPN	Log-Rank
1	-96.914
2	96.914

Covariance Matrix for the Log-Rank Statistics

TRTPN	1	2
1	121.675	-121.675
2	-121.675	121.675

Stratified Test of Equality over Group

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	77.1923	1	<.0001

3: Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) – statistical sensitivity analysis – accounting for interval censoring – proportional hazards regression model – full analysis set

The ICPHREG Procedure

Model Information

Data Set	WORK.ADTTE
Left Boundary	ALBNDDY
Right Boundary	ARBNDDY
Strata Variable	STRAT1
Baseline Hazard	Piecewise Constant

Number of Observations Read	1012
Number of Observations Used	1009
Noncensored Observations	102
Right Censored Observations	488
Interval Censored Observations	419
Incorrectly Specified Response Observations	3

Class Level Information

Name	Levels	Values
TRTP	2	IDegLira IGlar
REGION1	5	Africa Asia Europe North America South America
STRAT1	4	<8.5Non-SU users <8.5SU users >=8.5Non-SU users >=8.5SU users

Constant Hazard Time Intervals

Strata
<8.5Non-SU users
<8.5Non-SU users
<8.5Non-SU users
<8.5Non-SU users
<8.5Non-SU users
<8.5SU users
<8.5SU users
<8.5SU users
<8.5SU users
<8.5SU users
>=8.5Non-SU users
>=8.5Non-SU users
>=8.5Non-SU users
>=8.5Non-SU users
>=8.5Non-SU users

Constant Hazard Time Intervals

Interval [Lower	Interval Upper)	Hazard Parameter
0	136.25	Haz1
136.25	233.5	Haz2
233.5	366.5	Haz3
366.5	547.5	Haz4
547.5	Infty	Haz5
0	136	Haz6
136	230.5	Haz7
230.5	405.5	Haz8
405.5	628	Haz9
628	Infty	Haz10
0	130	Haz11
130	184.5	Haz12
184.5	317.5	Haz13
317.5	527	Haz14
527	Infty	Haz15

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - statistical sensitivity analysis - accounting for interval censoring - proportional hazards regression model - full analysis set

The ICPHREG Procedure

Constant Hazard Time Intervals

Strata

>=8.5SU users
>=8.5SU users
>=8.5SU users
>=8.5SU users
>=8.5SU users

Constant Hazard Time Intervals

Interval [Lower	Upper)	Hazard Parameter
0	132.5	Haz16
132.5	220	Haz17
220	407	Haz18
407	585	Haz19
585	Infty	Haz20

Optimization Information

Optimization Technique	Newton-Raphson
Parameters in Optimization	25

Convergence criterion (GCONV=1E-8) satisfied.

Fit Statistics

-2 Log Likelihood	4044.524
AIC (Smaller is Better)	4094.524
AICC (Smaller is Better)	4095.846
BIC (Smaller is Better)	4217.442

Analysis of Maximum Likelihood Parameter Estimates

Effect	Planned Treatment	Geographic Region 1	DF	Estimate	Standard Error	95% Confidence Limits		Chi-Square	Pr > ChiSq
Haz1			1	0.0006	0.0002	0.0002	0.0010		
Haz2			1	0.0017	0.0004	0.0008	0.0025		
Haz3			1	0.0009	0.0002	0.0004	0.0014		
Haz4			1	0.0005	0.0002	0.0002	0.0009		
Haz5			1	0.0005	0.0002	0.0002	0.0009		
Haz6			1	0.0007	0.0002	0.0003	0.0010		
Haz7			1	0.0025	0.0005	0.0015	0.0035		
Haz8			1	0.0009	0.0002	0.0005	0.0013		
Haz9			1	0.0005	0.0002	0.0002	0.0008		
Haz10			1	0.0015	0.0004	0.0008	0.0023		
Haz11			1	0.0008	0.0003	0.0002	0.0014		
Haz12			1	0.0056	0.0013	0.0030	0.0081		
Haz13			1	0.0012	0.0004	0.0004	0.0020		
Haz14			1	0.0006	0.0003	0.0000	0.0011		
Haz15			1	0.0011	0.0003	0.0004	0.0017		
Haz16			1	0.0009	0.0002	0.0005	0.0013		
Haz17			1	0.0072	0.0010	0.0053	0.0091		
Haz18			1	0.0011	0.0002	0.0006	0.0015		
Haz19			1	0.0014	0.0003	0.0008	0.0021		
Haz20			1	0.0018	0.0004	0.0009	0.0026		
TRTP	IDegLira		1	-0.7985	0.0925	-0.9797	-0.6173	74.61	<.0001
TRTP	IGlar		0	0.0000					
REGION1		Africa	1	0.2731	0.1769	-0.0736	0.6198	2.38	0.1226
REGION1		Asia	1	0.4002	0.1695	0.0680	0.7325	5.57	0.0182

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - statistical sensitivity analysis - accounting for interval censoring - proportional hazards regression model - full analysis set

The ICPHREG Procedure

Analysis of Maximum Likelihood Parameter Estimates

Effect	Planned Treatment	Geographic Region 1	DF	Estimate	Standard Error	95% Confidence Limits		Chi-Square	Pr > ChiSq
REGION1		Europe	1	0.1260	0.1265	-0.1220	0.3740	0.99	0.3193
REGION1		North America	1	0.2927	0.1526	-0.0064	0.5917	3.68	0.0551
REGION1		South America	0	0.0000					

Hazard Ratios for Planned Treatment

Description	Point Estimate	95% Wald Confidence Limits	
TRTP IDegLira vs IGlar	0.450	0.375	0.539

4: Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) – statistical sensitivity analysis – accounting for interval censoring – generalized log rank test – full analysis set

The ICLIFETEST Procedure

Data and Methods Information

Data Set	WORK.ADTTE
Left Boundary	ALBNDDY
Right Boundary	ARBNDDY
Estimation Method	EMICM
Number of Observations Read	1012
Number of Observations Used	1009
Number of Imputations for Standard Errors	10000
Number of Imputations for Testing	10000
Imputation Seed	1234
Weight Function for Generalized Log-Rank Test	SUN

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - statistical sensitivity analysis - accounting for interval censoring - generalized log rank test - full analysis set

The ICLIFETEST Procedure

Group 1: TRTPN = 1

Nonparametric Survival Estimates

Time	Interval	Probability Estimate Failure	Probability Estimate Survival	Imputation Standard Error
0	2	0.0000	1.0000	0.0000
2	4	0.0020	0.9980	0.0020
4	5	0.0040	0.9960	0.0028
5	15	0.0059	0.9941	0.0034
15	16	0.0079	0.9921	0.0039
16	19	0.0119	0.9881	0.0048
19	22	0.0138	0.9862	0.0052
22	28	0.0158	0.9842	0.0055
28	36	0.0178	0.9822	0.0059
36	40	0.0198	0.9802	0.0062
40	58	0.0217	0.9783	0.0065
58	77	0.0237	0.9763	0.0068
77	84	0.0258	0.9742	0.0070
84	85	0.0281	0.9719	0.0074
85	93	0.0306	0.9694	0.0078
93	94	0.0424	0.9576	0.0100
94	101	0.0573	0.9427	0.0120
101	134	0.0749	0.9251	0.0137
134	143	0.0963	0.9037	0.0151
143	158	0.1177	0.8823	0.0159
158	176	0.1391	0.8609	0.0163
176	192	0.1569	0.8431	0.0162
192	200	0.1657	0.8343	0.0168
200	224	0.1731	0.8269	0.0172
224	238	0.1793	0.8207	0.0174
238	246	0.1856	0.8144	0.0176
246	271	0.1918	0.8082	0.0176
271	275	0.2040	0.7960	0.0183
275	309	0.2238	0.7762	0.0191
309	385	0.2447	0.7553	0.0191
385	404	0.2571	0.7429	0.0197
404	450	0.2732	0.7268	0.0199
450	453	0.2814	0.7186	0.0202
453	470	0.2864	0.7136	0.0202
470	482	0.2899	0.7101	0.0203
482	529	0.2934	0.7066	0.0204
529	578	0.3004	0.6996	0.0204
578	584	0.3090	0.6910	0.0208
584	628	0.3176	0.6824	0.0210
629	632	0.3297	0.6703	0.0210
632	643	0.3347	0.6653	0.0211
643	700	0.3425	0.6575	0.0214
700	716	0.3512	0.6488	0.0216
716	728	0.3603	0.6397	0.0216
729	729	0.3784	0.6216	0.0225
730	730	0.3930	0.6070	0.0237
731	756	0.4170	0.5830	0.0250

NOTE: The estimation algorithm converged.

Quartile Estimates

Percentile	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
75		LOGLOG		
50		LOGLOG		
25	385	LOGLOG	275	470

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - statistical sensitivity analysis - accounting for interval censoring - generalized log rank test - full analysis set

The ICLIFETEST Procedure

Group 2: TRTPN = 2

Nonparametric Survival Estimates

Time	Interval	Probability Estimate Failure	Probability Estimate Survival	Imputation Standard Error
0	2	0.0000	1.0000	0.0000
2	6	0.0020	0.9980	0.0020
6	8	0.0040	0.9960	0.0028
8	9	0.0060	0.9940	0.0034
9	10	0.0080	0.9920	0.0040
10	18	0.0099	0.9901	0.0044
18	19	0.0119	0.9881	0.0048
19	29	0.0139	0.9861	0.0052
29	31	0.0179	0.9821	0.0059
31	35	0.0199	0.9801	0.0062
35	36	0.0239	0.9761	0.0068
36	37	0.0258	0.9742	0.0071
37	38	0.0298	0.9702	0.0076
38	48	0.0318	0.9682	0.0078
48	50	0.0338	0.9662	0.0081
50	51	0.0358	0.9642	0.0083
51	55	0.0378	0.9622	0.0085
55	77	0.0398	0.9602	0.0087
77	84	0.0418	0.9582	0.0089
84	85	0.0440	0.9560	0.0092
85	92	0.0489	0.9511	0.0097
93	106	0.0703	0.9297	0.0130
106	110	0.1163	0.8837	0.0175
110	125	0.1623	0.8377	0.0203
125	128	0.1950	0.8050	0.0216
128	138	0.2278	0.7722	0.0225
138	147	0.2605	0.7395	0.0230
147	159	0.2932	0.7068	0.0232
159	172	0.3259	0.6741	0.0231
172	178	0.3552	0.6448	0.0226
178	184	0.3883	0.6117	0.0218
184	196	0.3933	0.6067	0.0219
196	198	0.3972	0.6028	0.0220
198	204	0.4011	0.5989	0.0221
204	205	0.4050	0.5950	0.0221
205	217	0.4090	0.5910	0.0222
217	222	0.4138	0.5862	0.0222
222	226	0.4186	0.5814	0.0222
226	260	0.4234	0.5766	0.0222
260	267	0.4281	0.5719	0.0221
267	313	0.4310	0.5690	0.0221
313	329	0.4484	0.5516	0.0227
329	355	0.4658	0.5342	0.0229
355	364	0.4832	0.5168	0.0227
364	370	0.5002	0.4998	0.0224
372	413	0.5019	0.4981	0.0224
413	456	0.5376	0.4624	0.0223
456	462	0.5471	0.4529	0.0225
462	545	0.5695	0.4305	0.0222
546	552	0.5707	0.4293	0.0221
554	634	0.6021	0.3979	0.0219
634	655	0.6105	0.3895	0.0219
655	684	0.6163	0.3837	0.0220
684	687	0.6215	0.3785	0.0220
687	697	0.6266	0.3734	0.0220
697	714	0.6319	0.3681	0.0219
714	721	0.6372	0.3628	0.0218
721	728	0.6426	0.3574	0.0217
729	735	0.6755	0.3245	0.0217
736	762	0.7214	0.2786	0.0333

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - statistical sensitivity analysis - accounting for interval censoring - generalized log rank test - full analysis set

The ICLIFETEST Procedure

Group 2: TRTPN = 2

Nonparametric Survival Estimates

Time Interval		Probability Estimate Failure	Survival	Imputation Standard Error
762	777	0.8143	0.1857	0.0248

NOTE: The estimation algorithm converged.

Quartile Estimates

Percentile	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
75	762	LOGLOG	736	762
50	364	LOGLOG	329	456
25	138	LOGLOG	128	147

Time to need for treatment intensification (HbA1c >= 7% at 2 consecutive visits) - statistical sensitivity analysis - accounting for interval censoring - generalized log rank test - full analysis set

The ICLIFETEST Procedure

Generalized Log-Rank Statistics

TRTPN	Log-Rank
1	-106.465
2	106.4648

Covariance Matrix for the Generalized Log-Rank Statistics

TRTPN	1	2
1	125.053	-125.053
2	-125.053	125.053

Test of Equality over Group

Weight	Chi-Square	DF	Pr > Chi-Square
SUN	90.6397	1	<.0001

Number of Censored and Uncensored Values

Group ID	TRTPN	Total	Left	Type of Censoring: Interval	Right	Uncensored
1	1	506	0 (0.0%)	146 (28.9%)	317 (62.6%)	43 (8.5%)
2	2	503	0 (0.0%)	273 (54.3%)	171 (34.0%)	59 (11.7%)
Total		1009	0 (0.0%)	419 (41.5%)	488 (48.4%)	102 (10.1%)

5: Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 1: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	0.000	1.0000	0	0	0	112
1	16.000	0.9911	0.00893	0.00889	1	111
1	28.000	0.9821	0.0179	0.0125	2	110
1	77.000	0.9732	0.0268	0.0153	3	109
1	84.000	0.9643	0.0357	0.0175	4	108
1	181.000	0.9554	0.0446	0.0195	5	107
1	182.000				6	106
1	182.000	0.9375	0.0625	0.0229	7	105
1	183.000				8	104
1	183.000				9	103
1	183.000				10	102
1	183.000				11	101
1	183.000	0.8929	0.1071	0.0292	12	100
1	184.000	0.8839	0.1161	0.0303	13	99
1	185.000	0.8750	0.1250	0.0313	14	98
1	187.000				15	97
1	187.000	0.8571	0.1429	0.0331	16	96
1	200.000	0.8482	0.1518	0.0339	17	95
1	206.000	0.8393	0.1607	0.0347	18	94
1	210.000	0.8304	0.1696	0.0355	19	93
1	224.000	0.8214	0.1786	0.0362	20	92
1	238.000	0.8125	0.1875	0.0369	21	91
1	246.000	0.8036	0.1964	0.0375	22	90
1	267.000	0.7946	0.2054	0.0382	23	89
1	268.000	0.7857	0.2143	0.0388	24	88
1	275.000	0.7768	0.2232	0.0393	25	87
1	364.000				26	86
1	364.000	0.7589	0.2411	0.0404	27	85
1	365.000				28	84
1	365.000				29	83
1	365.000	0.7321	0.2679	0.0418	30	82
1	447.000	0.7232	0.2768	0.0423	31	81
1	449.000	0.7143	0.2857	0.0427	32	80
1	450.000	0.7054	0.2946	0.0431	33	79
1	470.000				34	78
1	470.000	0.6875	0.3125	0.0438	35	77
1	544.000				36	76
1	544.000	0.6696	0.3304	0.0444	37	75
1	545.000	0.6607	0.3393	0.0447	38	74
1	547.000	0.6518	0.3482	0.0450	39	73
1	548.000	0.6429	0.3571	0.0453	40	72
1	555.000	0.6339	0.3661	0.0455	41	71
1	630.000				42	70
1	630.000	0.6161	0.3839	0.0460	43	69
1	637.000	0.6071	0.3929	0.0461	44	68
1	714.000*				44	67
1	716.000	0.5981	0.4019	0.0463	45	66
1	721.000*				45	65
1	721.000*				45	64
1	723.000*				45	63
1	723.000*				45	62
1	725.000*				45	61
1	725.000*				45	60
1	725.000*				45	59
1	726.000*				45	58
1	726.000*				45	57
1	727.000	0.5876	0.4124	0.0467	46	56
1	727.000*				46	55
1	727.000*				46	54
1	727.000*				46	53
1	727.000*				46	52
1	727.000*				46	51

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 1: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	727.000*				46	50
1	727.000*				46	49
1	727.000*				46	48
1	727.000*				46	47
1	728.000				47	46
1	728.000	0.5626	0.4374	0.0479	48	45
1	728.000*				48	44
1	728.000*				48	43
1	728.000*				48	42
1	728.000*				48	41
1	728.000*				48	40
1	728.000*				48	39
1	728.000*				48	38
1	728.000*				48	37
1	728.000*				48	36
1	728.000*				48	35
1	728.000*				48	34
1	728.000*				48	33
1	728.000*				48	32
1	728.000*				48	31
1	728.000*				48	30
1	728.000*				48	29
1	728.000*				48	28
1	728.000*				48	27
1	728.000*				48	26
1	728.000*				48	25
1	728.000*				48	24
1	729.000	0.5391	0.4609	0.0514	49	23
1	729.000*				49	22
1	729.000*				49	21
1	729.000*				49	20
1	729.000*				49	19
1	729.000*				49	18
1	729.000*				49	17
1	729.000*				49	16
1	729.000*				49	15
1	729.000*				49	14
1	729.000*				49	13
1	729.000*				49	12
1	729.000*				49	11
1	729.000*				49	10
1	730.000*				49	9
1	730.000*				49	8
1	730.000*				49	7
1	731.000*				49	6
1	732.000*				49	5
1	734.000*				49	4
1	737.000*				49	3
1	742.000*				49	2
1	743.000*				49	1
1	752.000*				49	0

NOTE: The marked survival times are censored observations.

Time to HbA1c > 6.5% at 2 consecutive visits - supportive statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 1: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = Non-SU users

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
1	75		LOGLOG		
1	50		LOGLOG	727.000	
1	25	365.000	LOGLOG	210.000	544.000

TRTPN	Mean	Standard Error
1	565.934	21.870

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	0.000	1.0000	0	0	0	105
2	29.000	0.9905	0.00952	0.00948	1	104
2	31.000	0.9810	0.0190	0.0133	2	103
2	38.000	0.9714	0.0286	0.0163	3	102
2	51.000	0.9619	0.0381	0.0187	4	101
2	147.000	0.9524	0.0476	0.0208	5	100
2	176.000	0.9429	0.0571	0.0227	6	99
2	180.000	0.9333	0.0667	0.0243	7	98
2	181.000				8	97
2	181.000	0.9143	0.0857	0.0273	9	96
2	182.000				10	95
2	182.000				11	94
2	182.000				12	93
2	182.000				13	92
2	182.000	0.8667	0.1333	0.0332	14	91
2	183.000				15	90
2	183.000				16	89
2	183.000				17	88
2	183.000				18	87
2	183.000				19	86
2	183.000				20	85
2	183.000				21	84
2	183.000				22	83
2	183.000				23	82
2	183.000				24	81
2	183.000				25	80
2	183.000				26	79
2	183.000				27	78
2	183.000				28	77
2	183.000				29	76
2	183.000	0.7143	0.2857	0.0441	30	75
2	184.000				31	74
2	184.000				32	73
2	184.000				33	72
2	184.000	0.6762	0.3238	0.0457	34	71
2	185.000				35	70
2	185.000				36	69
2	185.000	0.6476	0.3524	0.0466	37	68
2	186.000				38	67
2	186.000				39	66
2	186.000	0.6190	0.3810	0.0474	40	65

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 1: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	187.000	0.6095	0.3905	0.0476	41	64
2	188.000	0.6000	0.4000	0.0478	42	63
2	197.000	0.5905	0.4095	0.0480	43	62
2	198.000	0.5810	0.4190	0.0482	44	61
2	212.000	0.5714	0.4286	0.0483	45	60
2	222.000	0.5619	0.4381	0.0484	46	59
2	266.000	0.5524	0.4476	0.0485	47	58
2	363.000	0.5429	0.4571	0.0486	48	57
2	364.000				49	56
2	364.000				50	55
2	364.000	0.5143	0.4857	0.0488	51	54
2	366.000	0.5048	0.4952	0.0488	52	53
2	449.000				53	52
2	449.000				54	51
2	449.000	0.4762	0.5238	0.0487	55	50
2	547.000				56	49
2	547.000				57	48
2	547.000				58	47
2	547.000				59	46
2	547.000	0.4286	0.5714	0.0483	60	45
2	630.000				61	44
2	630.000				62	43
2	630.000	0.4000	0.6000	0.0478	63	42
2	631.000				64	41
2	631.000				65	40
2	631.000	0.3714	0.6286	0.0472	66	39
2	632.000	0.3619	0.6381	0.0469	67	38
2	636.000	0.3524	0.6476	0.0466	68	37
2	697.000	0.3429	0.6571	0.0463	69	36
2	719.000*				69	35
2	721.000*				69	34
2	723.000*				69	33
2	724.000	0.3325	0.6675	0.0461	70	32
2	725.000*				70	31
2	725.000*				70	30
2	725.000*				70	29
2	725.000*				70	28
2	727.000*				70	27
2	727.000*				70	26
2	728.000*				70	25
2	728.000*				70	24
2	728.000*				70	23
2	728.000*				70	22
2	728.000*				70	21
2	728.000*				70	20
2	728.000*				70	19
2	728.000*				70	18
2	728.000*				70	17
2	728.000*				70	16
2	729.000	0.3117	0.6883	0.0476	71	15
2	729.000*				71	14
2	729.000*				71	13
2	729.000*				71	12
2	729.000*				71	11
2	729.000*				71	10
2	729.000*				71	9
2	730.000				72	8
2	730.000	0.2424	0.7576	0.0569	73	7
2	730.000*				73	6
2	730.000*				73	5
2	730.000*				73	4
2	731.000*				73	3

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 1: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	731.000*				73	2
2	732.000*				73	1
2	736.000*				73	0

NOTE: The marked survival times are censored observations.

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
2	75	730.000	LOGLOG	724.000	
2	50	449.000	LOGLOG	188.000	630.000
2	25	183.000	LOGLOG	183.000	185.000

TRTPN	Mean	Standard Error
2	438.984	25.171

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	0.000	1.0000	0	0	0	185
1	15.000	0.9946	0.00541	0.00539	1	184
1	22.000	0.9892	0.0108	0.00760	2	183
1	36.000	0.9838	0.0162	0.00929	3	182
1	143.000	0.9784	0.0216	0.0107	4	181
1	158.000	0.9730	0.0270	0.0119	5	180
1	176.000	0.9676	0.0324	0.0130	6	179
1	179.000	0.9622	0.0378	0.0140	7	178
1	180.000				8	177
1	180.000	0.9514	0.0486	0.0158	9	176
1	181.000				10	175
1	181.000				11	174
1	181.000	0.9351	0.0649	0.0181	12	173
1	182.000				13	172
1	182.000				14	171
1	182.000	0.9189	0.0811	0.0201	15	170
1	183.000				16	169
1	183.000				17	168
1	183.000				18	167
1	183.000				19	166
1	183.000				20	165
1	183.000				21	164
1	183.000				22	163
1	183.000				23	162
1	183.000				24	161
1	183.000				25	160
1	183.000				26	159
1	183.000				27	158
1	183.000				28	157
1	183.000				29	156
1	183.000				30	155
1	183.000				31	154
1	183.000	0.8270	0.1730	0.0278	32	153
1	184.000				33	152
1	184.000				34	151
1	184.000				35	150
1	184.000				36	149
1	184.000				37	148
1	184.000				38	147
1	184.000				39	146
1	184.000				40	145
1	184.000	0.7784	0.2216	0.0305	41	144
1	185.000				42	143
1	185.000				43	142
1	185.000				44	141
1	185.000	0.7568	0.2432	0.0315	45	140
1	189.000				46	139
1	189.000	0.7459	0.2541	0.0320	47	138
1	190.000	0.7405	0.2595	0.0322	48	137
1	191.000	0.7351	0.2649	0.0324	49	136
1	197.000				50	135
1	197.000	0.7243	0.2757	0.0329	51	134
1	203.000	0.7189	0.2811	0.0330	52	133
1	204.000	0.7135	0.2865	0.0332	53	132
1	264.000	0.7081	0.2919	0.0334	54	131
1	267.000				55	130
1	267.000				56	129
1	267.000				57	128
1	267.000	0.6865	0.3135	0.0341	58	127
1	269.000	0.6811	0.3189	0.0343	59	126
1	274.000	0.6757	0.3243	0.0344	60	125
1	275.000	0.6703	0.3297	0.0346	61	124

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	350.000				62	123
1	350.000	0.6595	0.3405	0.0348	63	122
1	358.000	0.6541	0.3459	0.0350	64	121
1	362.000	0.6486	0.3514	0.0351	65	120
1	363.000	0.6432	0.3568	0.0352	66	119
1	365.000				67	118
1	365.000				68	117
1	365.000	0.6270	0.3730	0.0356	69	116
1	366.000	0.6216	0.3784	0.0357	70	115
1	367.000				71	114
1	367.000	0.6108	0.3892	0.0358	72	113
1	368.000	0.6054	0.3946	0.0359	73	112
1	388.000	0.6000	0.4000	0.0360	74	111
1	404.000	0.5946	0.4054	0.0361	75	110
1	445.000	0.5892	0.4108	0.0362	76	109
1	448.000	0.5838	0.4162	0.0362	77	108
1	449.000				78	107
1	449.000				79	106
1	449.000	0.5676	0.4324	0.0364	80	105
1	451.000				81	104
1	451.000				82	103
1	451.000	0.5514	0.4486	0.0366	83	102
1	452.000				84	101
1	452.000	0.5405	0.4595	0.0366	85	100
1	453.000	0.5351	0.4649	0.0367	86	99
1	545.000				87	98
1	545.000	0.5243	0.4757	0.0367	88	97
1	547.000	0.5189	0.4811	0.0367	89	96
1	554.000	0.5135	0.4865	0.0367	90	95
1	584.000	0.5081	0.4919	0.0368	91	94
1	629.000	0.5027	0.4973	0.0368	92	93
1	631.000				93	92
1	631.000				94	91
1	631.000				95	90
1	631.000	0.4811	0.5189	0.0367	96	89
1	632.000	0.4757	0.5243	0.0367	97	88
1	643.000	0.4703	0.5297	0.0367	98	87
1	721.000*				98	86
1	721.000*				98	85
1	724.000*				98	84
1	725.000*				98	83
1	725.000*				98	82
1	725.000*				98	81
1	725.000*				98	80
1	725.000*				98	79
1	726.000*				98	78
1	726.000*				98	77
1	726.000*				98	76
1	726.000*				98	75
1	726.000*				98	74
1	726.000*				98	73
1	726.000*				98	72
1	726.000*				98	71
1	726.000*				98	70
1	726.000*				98	69
1	726.000*				98	68
1	727.000	0.4634	0.5366	0.0368	99	67
1	727.000*				99	66
1	727.000*				99	65
1	727.000*				99	64
1	727.000*				99	63
1	727.000*				99	62

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	727.000*				99	61
1	727.000*				99	60
1	727.000*				99	59
1	727.000*				99	58
1	727.000*				99	57
1	727.000*				99	56
1	728.000	0.4551	0.5449	0.0371	100	55
1	728.000*				100	54
1	728.000*				100	53
1	728.000*				100	52
1	728.000*				100	51
1	728.000*				100	50
1	728.000*				100	49
1	728.000*				100	48
1	728.000*				100	47
1	728.000*				100	46
1	728.000*				100	45
1	728.000*				100	44
1	728.000*				100	43
1	728.000*				100	42
1	728.000*				100	41
1	728.000*				100	40
1	728.000*				100	39
1	728.000*				100	38
1	728.000*				100	37
1	728.000*				100	36
1	728.000*				100	35
1	728.000*				100	34
1	728.000*				100	33
1	728.000*				100	32
1	728.000*				100	31
1	728.000*				100	30
1	728.000*				100	29
1	728.000*				100	28
1	728.000*				100	27
1	729.000				101	26
1	729.000	0.4214	0.5786	0.0413	102	25
1	729.000*				102	24
1	729.000*				102	23
1	729.000*				102	22
1	729.000*				102	21
1	729.000*				102	20
1	729.000*				102	19
1	729.000*				102	18
1	729.000*				102	17
1	729.000*				102	16
1	729.000*				102	15
1	729.000*				102	14
1	729.000*				102	13
1	729.000*				102	12
1	729.000*				102	11
1	730.000	0.3831	0.6169	0.0524	103	10
1	730.000*				103	9
1	730.000*				103	8
1	730.000*				103	7
1	731.000*				103	6
1	732.000				104	5
1	732.000	0.2554	0.7446	0.0816	105	4
1	732.000*				105	3
1	742.000*				105	2
1	743.000*				105	1
1	756.000*				105	0

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

NOTE: The marked survival times are censored observations.

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
1	75		LOGLOG	732.000	
1	50	631.000	LOGLOG	449.000	730.000
1	25	189.000	LOGLOG	184.000	267.000

TRTPN	Mean	Standard Error
1	499.052	18.177

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	0.000	1.0000	0	0	0	135
2	8.000	0.9926	0.00741	0.00738	1	134
2	9.000	0.9852	0.0148	0.0104	2	133
2	18.000	0.9778	0.0222	0.0127	3	132
2	35.000	0.9704	0.0296	0.0146	4	131
2	37.000				5	130
2	37.000	0.9556	0.0444	0.0177	6	129
2	55.000	0.9481	0.0519	0.0191	7	128
2	84.000	0.9407	0.0593	0.0203	8	127
2	85.000	0.9333	0.0667	0.0215	9	126
2	125.000	0.9259	0.0741	0.0225	10	125
2	159.000	0.9185	0.0815	0.0235	11	124
2	172.000	0.9111	0.0889	0.0245	12	123
2	177.000	0.9037	0.0963	0.0254	13	122
2	179.000	0.8963	0.1037	0.0262	14	121
2	180.000				15	120
2	180.000	0.8815	0.1185	0.0278	16	119
2	181.000				17	118
2	181.000	0.8667	0.1333	0.0293	18	117
2	182.000				19	116
2	182.000				20	115
2	182.000				21	114
2	182.000	0.8370	0.1630	0.0318	22	113
2	183.000				23	112
2	183.000				24	111
2	183.000				25	110
2	183.000				26	109
2	183.000				27	108
2	183.000				28	107
2	183.000				29	106
2	183.000				30	105
2	183.000				31	104
2	183.000				32	103
2	183.000				33	102
2	183.000				34	101
2	183.000				35	100
2	183.000				36	99
2	183.000				37	98

Time to HbA1c > 6.5% at 2 consecutive visits - supportive statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	183.000				38	97
2	183.000				39	96
2	183.000				40	95
2	183.000				41	94
2	183.000				42	93
2	183.000				43	92
2	183.000				44	91
2	183.000				45	90
2	183.000				46	89
2	183.000				47	88
2	183.000				48	87
2	183.000				49	86
2	183.000				50	85
2	183.000	0.6222	0.3778	0.0417	51	84
2	184.000				52	83
2	184.000				53	82
2	184.000				54	81
2	184.000				55	80
2	184.000				56	79
2	184.000				57	78
2	184.000	0.5704	0.4296	0.0426	58	77
2	185.000				59	76
2	185.000				60	75
2	185.000				61	74
2	185.000				62	73
2	185.000				63	72
2	185.000	0.5259	0.4741	0.0430	64	71
2	186.000				65	70
2	186.000				66	69
2	186.000				67	68
2	186.000				68	67
2	186.000	0.4889	0.5111	0.0430	69	66
2	187.000				70	65
2	187.000				71	64
2	187.000				72	63
2	187.000	0.4593	0.5407	0.0429	73	62
2	188.000	0.4519	0.5481	0.0428	74	61
2	190.000	0.4444	0.5556	0.0428	75	60
2	204.000	0.4370	0.5630	0.0427	76	59
2	205.000	0.4296	0.5704	0.0426	77	58
2	226.000	0.4222	0.5778	0.0425	78	57
2	267.000				79	56
2	267.000	0.4074	0.5926	0.0423	80	55
2	268.000				81	54
2	268.000	0.3926	0.6074	0.0420	82	53
2	270.000	0.3852	0.6148	0.0419	83	52
2	360.000	0.3778	0.6222	0.0417	84	51
2	363.000	0.3704	0.6296	0.0416	85	50
2	364.000	0.3630	0.6370	0.0414	86	49
2	365.000				87	48
2	365.000				88	47
2	365.000				89	46
2	365.000	0.3333	0.6667	0.0406	90	45
2	372.000	0.3259	0.6741	0.0403	91	44
2	378.000	0.3185	0.6815	0.0401	92	43
2	449.000				93	42
2	449.000	0.3037	0.6963	0.0396	94	41
2	451.000				95	40
2	451.000	0.2889	0.7111	0.0390	96	39
2	547.000				97	38
2	547.000				98	37
2	547.000	0.2667	0.7333	0.0381	99	36

Time to HbA1c > 6.5% at 2 consecutive visits - supportive statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 2: HbA1c at Baseline Group 1 = <8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	548.000	0.2593	0.7407	0.0377	100	35
2	628.000	0.2519	0.7481	0.0374	101	34
2	629.000	0.2444	0.7556	0.0370	102	33
2	631.000				103	32
2	631.000	0.2296	0.7704	0.0362	104	31
2	632.000				105	30
2	632.000	0.2148	0.7852	0.0353	106	29
2	634.000	0.2074	0.7926	0.0349	107	28
2	645.000	0.2000	0.8000	0.0344	108	27
2	721.000*				108	26
2	725.000*				108	25
2	726.000*				108	24
2	726.000*				108	23
2	726.000*				108	22
2	727.000*				108	21
2	727.000*				108	20
2	727.000*				108	19
2	727.000*				108	18
2	727.000*				108	17
2	728.000*				108	16
2	728.000*				108	15
2	728.000*				108	14
2	728.000*				108	13
2	728.000*				108	12
2	728.000*				108	11
2	728.000*				108	10
2	729.000*				108	9
2	729.000*				108	8
2	730.000*				108	7
2	730.000*				108	6
2	731.000	0.1667	0.8333	0.0418	109	5
2	731.000*				109	4
2	735.000*				109	3
2	735.000*				109	2
2	736.000*				109	1
2	768.000*				109	0

NOTE: The marked survival times are censored observations.

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
2	75	629.000	LOGLOG	372.000	
2	50	186.000	LOGLOG	184.000	267.000
2	25	183.000	LOGLOG		

TRTPN	Mean	Standard Error
2	344.081	20.480

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Time to HbA1c > 6.5% at 2 consecutive visits - supportive statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 3: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	0.000	1.0000	0	0	0	74
1	5.000	0.9865	0.0135	0.0134	1	73
1	16.000	0.9730	0.0270	0.0189	2	72
1	40.000	0.9595	0.0405	0.0229	3	71
1	58.000	0.9459	0.0541	0.0263	4	70
1	101.000	0.9324	0.0676	0.0292	5	69
1	176.000	0.9189	0.0811	0.0317	6	68
1	182.000				7	67
1	182.000				8	66
1	182.000	0.8784	0.1216	0.0380	9	65
1	183.000				10	64
1	183.000				11	63
1	183.000				12	62
1	183.000				13	61
1	183.000				14	60
1	183.000				15	59
1	183.000				16	58
1	183.000				17	57
1	183.000				18	56
1	183.000	0.7432	0.2568	0.0508	19	55
1	184.000	0.7297	0.2703	0.0516	20	54
1	185.000				21	53
1	185.000				22	52
1	185.000				23	51
1	185.000	0.6757	0.3243	0.0544	24	50
1	186.000	0.6622	0.3378	0.0550	25	49
1	192.000	0.6486	0.3514	0.0555	26	48
1	193.000	0.6351	0.3649	0.0560	27	47
1	194.000	0.6216	0.3784	0.0564	28	46
1	309.000	0.6081	0.3919	0.0567	29	45
1	363.000	0.5946	0.4054	0.0571	30	44
1	365.000	0.5811	0.4189	0.0574	31	43
1	366.000	0.5676	0.4324	0.0576	32	42
1	367.000	0.5541	0.4459	0.0578	33	41
1	373.000	0.5405	0.4595	0.0579	34	40
1	380.000	0.5270	0.4730	0.0580	35	39
1	449.000				36	38
1	449.000				37	37
1	449.000	0.4865	0.5135	0.0581	38	36
1	551.000	0.4730	0.5270	0.0580	39	35
1	629.000	0.4595	0.5405	0.0579	40	34
1	631.000	0.4459	0.5541	0.0578	41	33
1	700.000	0.4324	0.5676	0.0576	42	32
1	726.000*				42	31
1	726.000*				42	30
1	727.000*				42	29
1	728.000	0.4175	0.5825	0.0575	43	28
1	728.000*				43	27
1	728.000*				43	26
1	728.000*				43	25
1	728.000*				43	24
1	728.000*				43	23
1	728.000*				43	22
1	728.000*				43	21
1	728.000*				43	20
1	728.000*				43	19
1	728.000*				43	18
1	728.000*				43	17
1	728.000*				43	16
1	728.000*				43	15
1	728.000*				43	14
1	729.000				44	13

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 3: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	729.000	0.3579	0.6421	0.0629	45	12
1	729.000*				45	11
1	729.000*				45	10
1	729.000*				45	9
1	729.000*				45	8
1	729.000*				45	7
1	730.000*				45	6
1	730.000*				45	5
1	730.000*				45	4
1	731.000*				45	3
1	731.000*				45	2
1	736.000*				45	1
1	754.000*				45	0

NOTE: The marked survival times are censored observations.

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
1	75		LOGLOG	729.000	
1	50	449.000	LOGLOG	309.000	729.000
1	25	183.000	LOGLOG	183.000	192.000

TRTPN	Mean	Standard Error
1	461.742	30.953

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	0.000	1.0000	0	0	0	67
2	10.000	0.9851	0.0149	0.0148	1	66
2	19.000	0.9701	0.0299	0.0208	2	65
2	128.000	0.9552	0.0448	0.0253	3	64
2	175.000	0.9403	0.0597	0.0289	4	63
2	180.000	0.9254	0.0746	0.0321	5	62
2	181.000				6	61
2	181.000	0.8955	0.1045	0.0374	7	60
2	182.000				8	59
2	182.000				9	58
2	182.000				10	57
2	182.000				11	56
2	182.000				12	55
2	182.000	0.8060	0.1940	0.0483	13	54
2	183.000				14	53
2	183.000				15	52
2	183.000				16	51
2	183.000				17	50

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 3: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = Non-SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	183.000				18	49
2	183.000				19	48
2	183.000				20	47
2	183.000				21	46
2	183.000				22	45
2	183.000				23	44
2	183.000				24	43
2	183.000				25	42
2	183.000				26	41
2	183.000				27	40
2	183.000	0.5821	0.4179	0.0603	28	39
2	184.000				29	38
2	184.000	0.5522	0.4478	0.0608	30	37
2	185.000				31	36
2	185.000	0.5224	0.4776	0.0610	32	35
2	186.000				33	34
2	186.000	0.4925	0.5075	0.0611	34	33
2	187.000				35	32
2	187.000	0.4627	0.5373	0.0609	36	31
2	191.000	0.4478	0.5522	0.0608	37	30
2	217.000	0.4328	0.5672	0.0605	38	29
2	362.000	0.4179	0.5821	0.0603	39	28
2	364.000	0.4030	0.5970	0.0599	40	27
2	365.000				41	26
2	365.000				42	25
2	365.000	0.3582	0.6418	0.0586	43	24
2	366.000	0.3433	0.6567	0.0580	44	23
2	368.000	0.3284	0.6716	0.0574	45	22
2	372.000	0.3134	0.6866	0.0567	46	21
2	377.000	0.2985	0.7015	0.0559	47	20
2	449.000	0.2836	0.7164	0.0551	48	19
2	452.000	0.2687	0.7313	0.0542	49	18
2	597.000	0.2537	0.7463	0.0532	50	17
2	631.000	0.2388	0.7612	0.0521	51	16
2	638.000	0.2239	0.7761	0.0509	52	15
2	721.000*				52	14
2	726.000*				52	13
2	726.000*				52	12
2	727.000*				52	11
2	728.000*				52	10
2	728.000*				52	9
2	728.000*				52	8
2	728.000*				52	7
2	728.000*				52	6
2	729.000	0.1866	0.8134	0.0544	53	5
2	729.000*				53	4
2	729.000*				53	3
2	729.000*				53	2
2	729.000*				53	1
2	777.000*				53	0

NOTE: The marked survival times are censored observations.

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 3: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = Non-SU users

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
2	75	631.000	LOGLOG	365.000	
2	50	186.000	LOGLOG	183.000	365.000
2	25	183.000	LOGLOG	182.000	183.000

TRTPN	Mean	Standard Error
2	352.373	28.742

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	0.000	1.0000	0	0	0	135
1	2.000	0.9926	0.00741	0.00738	1	134
1	4.000	0.9852	0.0148	0.0104	2	133
1	19.000	0.9778	0.0222	0.0127	3	132
1	85.000	0.9704	0.0296	0.0146	4	131
1	93.000	0.9630	0.0370	0.0163	5	130
1	94.000	0.9556	0.0444	0.0177	6	129
1	134.000	0.9481	0.0519	0.0191	7	128
1	176.000	0.9407	0.0593	0.0203	8	127
1	180.000	0.9333	0.0667	0.0215	9	126
1	181.000				10	125
1	181.000				11	124
1	181.000				12	123
1	181.000	0.9037	0.0963	0.0254	13	122
1	182.000				14	121
1	182.000				15	120
1	182.000				16	119
1	182.000				17	118
1	182.000	0.8667	0.1333	0.0293	18	117
1	183.000				19	116
1	183.000				20	115
1	183.000				21	114
1	183.000				22	113
1	183.000				23	112
1	183.000				24	111
1	183.000				25	110
1	183.000				26	109
1	183.000				27	108
1	183.000				28	107
1	183.000				29	106
1	183.000				30	105
1	183.000				31	104
1	183.000				32	103
1	183.000				33	102
1	183.000				34	101
1	183.000				35	100
1	183.000				36	99
1	183.000				37	98
1	183.000				38	97
1	183.000				39	96
1	183.000				40	95
1	183.000				41	94
1	183.000	0.6889	0.3111	0.0398	42	93
1	184.000				43	92
1	184.000				44	91
1	184.000				45	90
1	184.000	0.6593	0.3407	0.0408	46	89
1	185.000				47	88
1	185.000				48	87
1	185.000				49	86
1	185.000				50	85
1	185.000				51	84
1	185.000	0.6148	0.3852	0.0419	52	83
1	186.000				53	82
1	186.000				54	81
1	186.000				55	80
1	186.000	0.5852	0.4148	0.0424	56	79
1	189.000	0.5778	0.4222	0.0425	57	78
1	190.000				58	77
1	190.000				59	76
1	190.000	0.5556	0.4444	0.0428	60	75
1	198.000	0.5481	0.4519	0.0428	61	74

Time to HbA1c > 6.5% at 2 consecutive visits - supportive statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	267.000	0.5407	0.4593	0.0429	62	73
1	268.000	0.5333	0.4667	0.0429	63	72
1	270.000	0.5259	0.4741	0.0430	64	71
1	273.000	0.5185	0.4815	0.0430	65	70
1	357.000	0.5111	0.4889	0.0430	66	69
1	364.000	0.5037	0.4963	0.0430	67	68
1	365.000				68	67
1	365.000				69	66
1	365.000				70	65
1	365.000				71	64
1	365.000				72	63
1	365.000	0.4593	0.5407	0.0429	73	62
1	367.000	0.4519	0.5481	0.0428	74	61
1	368.000	0.4444	0.5556	0.0428	75	60
1	374.000	0.4370	0.5630	0.0427	76	59
1	376.000	0.4296	0.5704	0.0426	77	58
1	448.000	0.4222	0.5778	0.0425	78	57
1	449.000				79	56
1	449.000				80	55
1	449.000	0.4000	0.6000	0.0422	81	54
1	451.000	0.3926	0.6074	0.0420	82	53
1	452.000	0.3852	0.6148	0.0419	83	52
1	461.000	0.3778	0.6222	0.0417	84	51
1	482.000	0.3704	0.6296	0.0416	85	50
1	547.000				86	49
1	547.000				87	48
1	547.000				88	47
1	547.000	0.3407	0.6593	0.0408	89	46
1	548.000	0.3333	0.6667	0.0406	90	45
1	553.000	0.3259	0.6741	0.0403	91	44
1	555.000	0.3185	0.6815	0.0401	92	43
1	578.000	0.3111	0.6889	0.0398	93	42
1	632.000	0.3037	0.6963	0.0396	94	41
1	714.000*				94	40
1	715.000	0.2961	0.7039	0.0393	95	39
1	722.000	0.2885	0.7115	0.0390	96	38
1	725.000*				96	37
1	725.000*				96	36
1	725.000*				96	35
1	726.000*				96	34
1	726.000*				96	33
1	726.000*				96	32
1	726.000*				96	31
1	727.000*				96	30
1	727.000*				96	29
1	727.000*				96	28
1	728.000*				96	27
1	728.000*				96	26
1	728.000*				96	25
1	728.000*				96	24
1	728.000*				96	23
1	728.000*				96	22
1	728.000*				96	21
1	728.000*				96	20
1	728.000*				96	19
1	729.000				97	18
1	729.000				98	17
1	729.000	0.2430	0.7570	0.0408	99	16
1	729.000*				99	15
1	729.000*				99	14
1	729.000*				99	13
1	729.000*				99	12

Time to HbA1c > 6.5% at 2 consecutive visits - supportive statistical analysis - full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
1	729.000*				99	11
1	730.000				100	10
1	730.000	0.1988	0.8012	0.0437	101	9
1	730.000*				101	8
1	730.000*				101	7
1	730.000*				101	6
1	730.000*				101	5
1	730.000*				101	4
1	730.000*				101	3
1	732.000*				101	2
1	737.000*				101	1
1	750.000*				101	0

NOTE: The marked survival times are censored observations.

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
1	75	729.000	LOGLOG	553.000	
1	50	365.000	LOGLOG	186.000	449.000
1	25	183.000	LOGLOG	183.000	184.000

TRTPN	Mean	Standard Error
1	403.180	21.231

NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	0.000	1.0000	0	0	0	199
2	2.000	0.9950	0.00503	0.00501	1	198
2	6.000	0.9899	0.0101	0.00707	2	197
2	29.000	0.9849	0.0151	0.00864	3	196
2	35.000	0.9799	0.0201	0.00995	4	195
2	36.000	0.9749	0.0251	0.0111	5	194
2	48.000	0.9698	0.0302	0.0121	6	193
2	50.000	0.9648	0.0352	0.0131	7	192
2	77.000	0.9598	0.0402	0.0139	8	191
2	85.000	0.9548	0.0452	0.0147	9	190
2	93.000	0.9497	0.0503	0.0155	10	189
2	106.000	0.9447	0.0553	0.0162	11	188
2	110.000	0.9397	0.0603	0.0169	12	187
2	125.000	0.9347	0.0653	0.0175	13	186
2	138.000	0.9296	0.0704	0.0181	14	185
2	169.000	0.9246	0.0754	0.0187	15	184
2	172.000	0.9196	0.0804	0.0193	16	183
2	175.000	0.9146	0.0854	0.0198	17	182
2	176.000	0.9095	0.0905	0.0203	18	181

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	178.000	0.9045	0.0955	0.0208	19	180
2	179.000	0.8995	0.1005	0.0213	20	179
2	180.000				21	178
2	180.000				22	177
2	180.000				23	176
2	180.000				24	175
2	180.000				25	174
2	180.000				26	173
2	180.000	0.8643	0.1357	0.0243	27	172
2	181.000				28	171
2	181.000				29	170
2	181.000				30	169
2	181.000				31	168
2	181.000				32	167
2	181.000				33	166
2	181.000				34	165
2	181.000	0.8241	0.1759	0.0270	35	164
2	182.000				36	163
2	182.000				37	162
2	182.000				38	161
2	182.000				39	160
2	182.000				40	159
2	182.000				41	158
2	182.000				42	157
2	182.000				43	156
2	182.000				44	155
2	182.000				45	154
2	182.000				46	153
2	182.000				47	152
2	182.000	0.7588	0.2412	0.0303	48	151
2	183.000				49	150
2	183.000				50	149
2	183.000				51	148
2	183.000				52	147
2	183.000				53	146
2	183.000				54	145
2	183.000				55	144
2	183.000				56	143
2	183.000				57	142
2	183.000				58	141
2	183.000				59	140
2	183.000				60	139
2	183.000				61	138
2	183.000				62	137
2	183.000				63	136
2	183.000				64	135
2	183.000				65	134
2	183.000				66	133
2	183.000				67	132
2	183.000				68	131
2	183.000				69	130
2	183.000				70	129
2	183.000				71	128
2	183.000				72	127
2	183.000				73	126
2	183.000				74	125
2	183.000				75	124
2	183.000				76	123
2	183.000				77	122
2	183.000				78	121
2	183.000				79	120
2	183.000				80	119

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	183.000				81	118
2	183.000				82	117
2	183.000				83	116
2	183.000				84	115
2	183.000				85	114
2	183.000				86	113
2	183.000				87	112
2	183.000				88	111
2	183.000				89	110
2	183.000				90	109
2	183.000				91	108
2	183.000				92	107
2	183.000				93	106
2	183.000				94	105
2	183.000				95	104
2	183.000				96	103
2	183.000				97	102
2	183.000				98	101
2	183.000				99	100
2	183.000				100	99
2	183.000				101	98
2	183.000				102	97
2	183.000				103	96
2	183.000				104	95
2	183.000				105	94
2	183.000				106	93
2	183.000				107	92
2	183.000	0.4573	0.5427	0.0353	108	91
2	184.000				109	90
2	184.000				110	89
2	184.000				111	88
2	184.000				112	87
2	184.000				113	86
2	184.000				114	85
2	184.000				115	84
2	184.000				116	83
2	184.000				117	82
2	184.000	0.4070	0.5930	0.0348	118	81
2	185.000				119	80
2	185.000				120	79
2	185.000				121	78
2	185.000				122	77
2	185.000				123	76
2	185.000				124	75
2	185.000				125	74
2	185.000				126	73
2	185.000				127	72
2	185.000				128	71
2	185.000				129	70
2	185.000				130	69
2	185.000	0.3417	0.6583	0.0336	131	68
2	186.000				132	67
2	186.000				133	66
2	186.000				134	65
2	186.000				135	64
2	186.000	0.3166	0.6834	0.0330	136	63
2	187.000				137	62
2	187.000	0.3065	0.6935	0.0327	138	61
2	188.000	0.3015	0.6985	0.0325	139	60
2	189.000				140	59
2	189.000	0.2915	0.7085	0.0322	141	58
2	190.000	0.2864	0.7136	0.0320	142	57

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Product-Limit Survival Estimates

TRTPN	AVAL	Survival	Failure	Survival Standard Error	Number Failed	Number Left
2	191.000				143	56
2	191.000	0.2764	0.7236	0.0317	144	55
2	195.000	0.2714	0.7286	0.0315	145	54
2	205.000	0.2663	0.7337	0.0313	146	53
2	220.000	0.2613	0.7387	0.0311	147	52
2	225.000	0.2563	0.7437	0.0309	148	51
2	267.000				149	50
2	267.000	0.2462	0.7538	0.0305	150	49
2	270.000	0.2412	0.7588	0.0303	151	48
2	313.000	0.2362	0.7638	0.0301	152	47
2	355.000	0.2312	0.7688	0.0299	153	46
2	359.000	0.2261	0.7739	0.0297	154	45
2	363.000	0.2211	0.7789	0.0294	155	44
2	364.000	0.2161	0.7839	0.0292	156	43
2	365.000				157	42
2	365.000				158	41
2	365.000				159	40
2	365.000				160	39
2	365.000				161	38
2	365.000				162	37
2	365.000				163	36
2	365.000	0.1759	0.8241	0.0270	164	35
2	366.000	0.1709	0.8291	0.0267	165	34
2	376.000				166	33
2	376.000	0.1608	0.8392	0.0260	167	32
2	448.000				168	31
2	448.000	0.1508	0.8492	0.0254	169	30
2	449.000				170	29
2	449.000				171	28
2	449.000	0.1357	0.8643	0.0243	172	27
2	451.000	0.1307	0.8693	0.0239	173	26
2	456.000	0.1256	0.8744	0.0235	174	25
2	457.000	0.1206	0.8794	0.0231	175	24
2	546.000	0.1156	0.8844	0.0227	176	23
2	547.000				177	22
2	547.000				178	21
2	547.000	0.1005	0.8995	0.0213	179	20
2	630.000				180	19
2	630.000	0.0905	0.9095	0.0203	181	18
2	631.000	0.0854	0.9146	0.0198	182	17
2	638.000	0.0804	0.9196	0.0193	183	16
2	699.000*				183	15
2	725.000	0.0750	0.9250	0.0187	184	14
2	727.000*				184	13
2	727.000*				184	12
2	728.000	0.0688	0.9312	0.0182	185	11
2	728.000*				185	10
2	728.000*				185	9
2	728.000*				185	8
2	728.000*				185	7
2	728.000*				185	6
2	729.000	0.0573	0.9427	0.0184	186	5
2	729.000*				186	4
2	735.000*				186	3
2	736.000	0.0382	0.9618	0.0199	187	2
2	744.000*				187	1
2	762.000	0	1.0000		188	0

NOTE: The marked survival times are censored observations.

Time to HbA1c > 6.5% at 2 consecutive visits – supportive statistical analysis – full analysis set

The LIFETEST Procedure

Stratum 4: HbA1c at Baseline Group 1 = >=8.5 Pre Trial OAD = SU users

Summary Statistics for Time Variable AVAL

Quartile Estimates

TRTPN	Percent	Point Estimate	95% Confidence Interval Transform	[Lower	Upper)
2	75	267.000	LOGLOG	187.000	365.000
2	50	183.000	LOGLOG	183.000	184.000
2	25	183.000	LOGLOG	182.000	183.000

TRTPN	Mean	Standard Error
2	263.468	12.805

Summary of the Number of Censored and Uncensored Values

Stratum	HBA1CG1	PREOAD	TRTPN	Total	Failed	Censored	Percent Censored
1	<8.5	Non-SU users	1	112	49	63	56.25
1	<8.5	Non-SU users	2	105	73	32	30.48
Subtotal				217	122	95	43.78
2	<8.5	SU users	1	185	105	80	43.24
2	<8.5	SU users	2	135	109	26	19.26
Subtotal				320	214	106	33.13
3	>=8.5	Non-SU users	1	74	45	29	39.19
3	>=8.5	Non-SU users	2	67	53	14	20.90
Subtotal				141	98	43	30.50
4	>=8.5	SU users	1	135	101	34	25.19
4	>=8.5	SU users	2	199	188	11	5.53
Subtotal				334	289	45	13.47
Total				1012	723	289	28.56

```
Time to HbA1c > 6.5% at 2 consecutive visits - supportive statistical analysis - full analysis set

The LIFETEST Procedure

Stratified Comparison of Survival Curves for AVAL over Group


    Rank Statistics

TRTPN           Log-Rank

1                -115.94
2                 115.94


Covariance Matrix for the Log-Rank Statistics

TRTPN             1             2

1           155.988      -155.988
2          -155.988       155.988


  Stratified Test of Equality over Group

                                    Pr >
Test      Chi-Square      DF    Chi-Square

Log-Rank     86.1780       1      <.0001
```

6: HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

```
TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

                  Model Information

Data Set                      WORK.HBA1C_MMRM
Dependent Variable            AVAL
Covariance Structure          Unstructured
Subject Effect                USUBJID
Estimation Method             REML
Residual Variance Method      None
Fixed Effects SE Method       Kenward-Roger
Degrees of Freedom Method     Kenward-Roger


               Class Level Information

Class        Levels    Values

TREATMENT         2    IDegLira IGlar
REGION            5    Africa Asia Europe North
                       America South America
AVISITN           8    60 70 80 90 100 110 120 130
```

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228[redacted] NN9068-4228[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/ [redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/ [redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/ [redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users ers
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	36
Columns in X	97
Columns in Z	0
Subjects	1012
Max Obs per Subject	8

Number of Observations

Number of Observations Read	8096
Number of Observations Used	5628
Number of Observations Not Used	2468

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12237.63846590	
1	3	9598.23248044	2.21155466
2	2	9526.79396652	0.60896419
3	2	9443.51778375	0.22608790
4	1	9351.88776293	0.07811941
5	1	9311.40873439	0.01650097
6	1	9302.70248954	0.00183659
7	1	9301.80066679	0.00003417
8	1	9301.78491936	0.00000001
9	1	9301.78491264	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.6193
UN(2,1)	USUBJID	0.4041
UN(2,2)	USUBJID	0.7426

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(3,1)	USUBJID	0.4282
UN(3,2)	USUBJID	0.5400
UN(3,3)	USUBJID	0.7138
UN(4,1)	USUBJID	0.3752
UN(4,2)	USUBJID	0.5570
UN(4,3)	USUBJID	0.5785
UN(4,4)	USUBJID	0.7511
UN(5,1)	USUBJID	0.3842
UN(5,2)	USUBJID	0.5487
UN(5,3)	USUBJID	0.5808
UN(5,4)	USUBJID	0.6331
UN(5,5)	USUBJID	0.7638
UN(6,1)	USUBJID	0.3254
UN(6,2)	USUBJID	0.4881
UN(6,3)	USUBJID	0.5193
UN(6,4)	USUBJID	0.5736
UN(6,5)	USUBJID	0.5823
UN(6,6)	USUBJID	0.6708
UN(7,1)	USUBJID	0.3135
UN(7,2)	USUBJID	0.4572
UN(7,3)	USUBJID	0.4973
UN(7,4)	USUBJID	0.5402
UN(7,5)	USUBJID	0.5762
UN(7,6)	USUBJID	0.5508
UN(7,7)	USUBJID	0.6507
UN(8,1)	USUBJID	0.3682
UN(8,2)	USUBJID	0.5613
UN(8,3)	USUBJID	0.6052
UN(8,4)	USUBJID	0.6669
UN(8,5)	USUBJID	0.7162
UN(8,6)	USUBJID	0.6627
UN(8,7)	USUBJID	0.6986
UN(8,8)	USUBJID	1.0267

Fit Statistics

-2 Res Log Likelihood	9301.8
AIC (Smaller is Better)	9373.8
AICC (Smaller is Better)	9374.3
BIC (Smaller is Better)	9550.9

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
35	2935.85	<.0001

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
TREATMENT(AVISITN)	8	499	20.01	<.0001
REGION(AVISITN)	32	1381	3.01	<.0001
PREOAD(AVISITN)	8	470	3.37	0.0009
HBA1CG1(AVISITN)	8	496	1.32	0.2316
BASE(AVISITN)	8	518	17.77	<.0001

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	1
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	0.0879
REGION(AVISITN)		Asia			60	0.0909
REGION(AVISITN)		Europe			60	0.4911
REGION(AVISITN)		North America			60	0.1502
REGION(AVISITN)		South America			60	0.1798
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	0.3538
PREOAD(AVISITN)			SU users		60	0.6462
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	0.5306
HBA1CG1(AVISITN)				>=8.5	60	0.4694
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	8.3411
BASE(AVISITN)					70	
BASE(AVISITN)					80	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V060 IDegLira	WORK.HBA1C_MMRM	6.5823	0.03627	964.9	181.49

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IDegLira	<.0001	0.05	6.5112	6.6535

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	1
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	0.0879
REGION(AVISITN)		Asia			60	0.0909
REGION(AVISITN)		Europe			60	0.4911
REGION(AVISITN)		North America			60	0.1502
REGION(AVISITN)		South America			60	0.1798
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	0.3538
PREOAD(AVISITN)			SU users		60	0.6462
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	0.5306
HBA1CG1(AVISITN)				>=8.5	60	0.4694
HBA1CG1(AVISITN)				<8.5	70	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	8.3411
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V060 IGlar	WORK.HBA1C_MMRM	7.1850	0.03677	963.7	195.40

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IGlar	<.0001	0.05	7.1129	7.2572

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	1
TREATMENT(AVISITN)	IGlar				60	-1
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V060 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.6027	0.05096	964

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IDegLira - IGlar	-11.83	<.0001	0.05	-0.7027	-0.5027

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	1
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	0.0879
REGION(AVISITN)		Asia			70	0.0909
REGION(AVISITN)		Europe			70	0.4911
REGION(AVISITN)		North America			70	0.1502
REGION(AVISITN)		South America			70	0.1798
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	0.3538
PREOAD(AVISITN)			SU users		70	0.6462
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	0.5306
HBA1CG1(AVISITN)				>=8.5	70	0.4694
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	8.3411
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V070 IDegLira	WORK.HBA1C_MMRM	6.3708	0.03992	928.8	159.60

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IDegLira	<.0001	0.05	6.2924	6.4491

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	0.0879
REGION(AVISITN)		Asia			70	0.0909
REGION(AVISITN)		Europe			70	0.4911
REGION(AVISITN)		North America			70	0.1502
REGION(AVISITN)		South America			70	0.1798
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	0.3538
PREOAD(AVISITN)			SU users		70	0.6462
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	0.5306
HBA1CG1(AVISITN)				>=8.5	70	0.4694
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	8.3411
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V070 IGlar	WORK.HBA1C_MMRM	6.8393	0.04069	934.4	168.09

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IGlar	<.0001	0.05	6.7595	6.9192

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	1
TREATMENT(AVISITN)	IGlar				70	-1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V070 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.4686	0.05628	932.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IDegLira - IGlar	-8.33	<.0001	0.05	-0.5790	-0.3581

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	1

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	0.0879
REGION(AVISITN)		Asia			80	0.0909
REGION(AVISITN)		Europe			80	0.4911
REGION(AVISITN)		North America			80	0.1502
REGION(AVISITN)		South America			80	0.1798
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	0.3538
PREOAD(AVISITN)			SU users		80	0.6462
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	0.5306
HBA1CG1(AVISITN)				>=8.5	80	0.4694
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	8.3411
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V080 IDegLira	WORK.HBA1C_MMRM	6.4329	0.04037	483	159.33

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IDegLira	<.0001	0.05	6.3536	6.5122

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	1
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	0.0879
REGION(AVISITN)		Asia			80	0.0909
REGION(AVISITN)		Europe			80	0.4911
REGION(AVISITN)		North America			80	0.1502
REGION(AVISITN)		South America			80	0.1798
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	0.3538
PREOAD(AVISITN)			SU users		80	0.6462
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	0.5306
HBA1CG1(AVISITN)				>=8.5	80	0.4694
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	8.3411
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V080 IGlar	WORK.HBA1C_MMRM	6.9584	0.04360	564.9	159.61

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IGlar	<.0001	0.05	6.8728	7.0441

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	1
TREATMENT(AVISITN)	IGlar				80	-1
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V080 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.5255	0.05865	525.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IDegLira - IGlar	-8.96	<.0001	0.05	-0.6408	-0.4103

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	1
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	0.0879
REGION(AVISITN)		Asia			90	0.0909
REGION(AVISITN)		Europe			90	0.4911
REGION(AVISITN)		North America			90	0.1502
REGION(AVISITN)		South America			90	0.1798
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	0.3538
PREOAD(AVISITN)			SU users		90	0.6462
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	0.5306
HBA1CG1(AVISITN)				>=8.5	90	0.4694
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	8.3411
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V090 IDegLira	WORK.HBA1C_MMRM	6.4987	0.04185	414.5	155.28

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IDegLira	<.0001	0.05	6.4165	6.5810

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	0.0879
REGION(AVISITN)		Asia			90	0.0909
REGION(AVISITN)		Europe			90	0.4911
REGION(AVISITN)		North America			90	0.1502
REGION(AVISITN)		South America			90	0.1798
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	0.3538
PREOAD(AVISITN)			SU users		90	0.6462
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	0.5306
HBA1CG1(AVISITN)				>=8.5	90	0.4694
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	8.3411
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V090 IGlar	WORK.HBA1C_MMRM	7.0116	0.04567	492.7	153.53

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IGlar	<.0001	0.05	6.9218	7.1013

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	1
TREATMENT(AVISITN)	IGlar				90	-1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V090 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.5128	0.06121	456.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IDegLira - IGlar	-8.38	<.0001	0.05	-0.6331	-0.3925

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	1
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	0.0879

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	0.0909
REGION(AVISITN)		Europe			100	0.4911
REGION(AVISITN)		North America			100	0.1502
REGION(AVISITN)		South America			100	0.1798
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	0.3538
PREOAD(AVISITN)			SU users		100	0.6462
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	0.5306
HBA1CG1(AVISITN)				>=8.5	100	0.4694
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	8.3411
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V100 IDegLira	WORK.HBA1C_MMRM	6.5872	0.04273	362.6	154.16

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IDegLira	<.0001	0.05	6.5031	6.6712

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	1
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	0.0879
REGION(AVISITN)		Asia			100	0.0909
REGION(AVISITN)		Europe			100	0.4911
REGION(AVISITN)		North America			100	0.1502
REGION(AVISITN)		South America			100	0.1798
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	0.3538
PREOAD(AVISITN)			SU users		100	0.6462
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	0.5306
HBA1CG1(AVISITN)				>=8.5	100	0.4694
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	8.3411
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V100 IGlar	WORK.HBA1C_MMRM	7.0799	0.04729	435.3	149.70

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IGlar	<.0001	0.05	6.9869	7.1728

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	1
TREATMENT(AVISITN)	IGlar				100	-1
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V100 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.4927	0.06298	402.4

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IDegLira - IGlar	-7.82	<.0001	0.05	-0.6165	-0.3689

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	1
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	0.0879
REGION(AVISITN)		Asia			110	0.0909
REGION(AVISITN)		Europe			110	0.4911

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	0.1502
REGION(AVISITN)		South America			110	0.1798
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	0.3538
PREOAD(AVISITN)			SU users		110	0.6462
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	0.5306
HBA1CG1(AVISITN)				>=8.5	110	0.4694
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	8.3411
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V110 IDegLira	WORK.HBA1C_MMRM	6.5633	0.04077	301.4	160.97

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IDegLira	<.0001	0.05	6.4830	6.6435

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	1
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	0.0879
REGION(AVISITN)		Asia			110	0.0909
REGION(AVISITN)		Europe			110	0.4911
REGION(AVISITN)		North America			110	0.1502
REGION(AVISITN)		South America			110	0.1798
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	0.3538
PREOAD(AVISITN)			SU users		110	0.6462
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	0.5306
HBA1CG1(AVISITN)				>=8.5	110	0.4694
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	8.3411
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V110 IGlar	WORK.HBA1C_MMRM	7.1002	0.04607	367.9	154.13

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IGlar	<.0001	0.05	7.0096	7.1908

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	1
TREATMENT(AVISITN)	IGlar				110	-1
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V110 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.5369	0.06071	336.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IDegLira - IGlar	-8.84	<.0001	0.05	-0.6563	-0.4175

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	1
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	0.0879
REGION(AVISITN)		Asia			120	0.0909
REGION(AVISITN)		Europe			120	0.4911
REGION(AVISITN)		North America			120	0.1502
REGION(AVISITN)		South America			120	0.1798
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	0.3538
PREOAD(AVISITN)			SU users		120	0.6462
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	0.5306
HBA1CG1(AVISITN)				>=8.5	120	0.4694
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	8.3411
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V120 IDegLira	WORK.HBA1C_MMRM	6.5939	0.04059	286.4	162.44

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IDegLira	<.0001	0.05	6.5140	6.6738

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	1
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	0.0879
REGION(AVISITN)		Asia			120	0.0909
REGION(AVISITN)		Europe			120	0.4911
REGION(AVISITN)		North America			120	0.1502
REGION(AVISITN)		South America			120	0.1798
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	0.3538
PREOAD(AVISITN)			SU users		120	0.6462
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	0.5306
HBA1CG1(AVISITN)				>=8.5	120	0.4694
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	8.3411
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V120 IGlar	WORK.HBA1C_MMRM	7.1234	0.04676	360.6	152.33

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IGlar	<.0001	0.05	7.0315	7.2154

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	1
TREATMENT(AVISITN)	IGlar				120	-1
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V120 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.5295	0.06102	324.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IDegLira - IGlar	-8.68	<.0001	0.05	-0.6496	-0.4095

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	0.0879
REGION(AVISITN)		Asia			130	0.0909
REGION(AVISITN)		Europe			130	0.4911
REGION(AVISITN)		North America			130	0.1502
REGION(AVISITN)		South America			130	0.1798
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	0.3538
PREOAD(AVISITN)			SU users		130	0.6462
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	0.5306
HBA1CG1(AVISITN)				>=8.5	130	0.4694
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	8.3411

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V130 IDegLira	WORK.HBA1C_MMRM	6.7531	0.05165	271.9	130.74

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IDegLira	<.0001	0.05	6.6514	6.8548

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	0.0879
REGION(AVISITN)		Asia			130	0.0909
REGION(AVISITN)		Europe			130	0.4911
REGION(AVISITN)		North America			130	0.1502
REGION(AVISITN)		South America			130	0.1798
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	0.3538
PREOAD(AVISITN)			SU users		130	0.6462
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	0.5306
HBA1CG1(AVISITN)				>=8.5	130	0.4694
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	8.3411

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V130 IGlar	WORK.HBA1C_MMRM	7.2944	0.06055	349.7	120.46

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IGlar	<.0001	0.05	7.1753	7.4135

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	1
TREATMENT(AVISITN)	IGlar				130	-1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V130 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.5412	0.07837	312.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IDegLira - IGlar	-6.91	<.0001	0.05	-0.6954	-0.3870

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Model Information

Data Set	WORK.HBA1C_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
TREATMENT	2	IDegLira IGlar
REGION	5	Africa Asia Europe North America South America
AVISITN	8	60 70 80 90 100 110 120 130

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full
analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]

```
HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full
analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
                              NN9068-4228/[redacted]
```

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	36
Columns in X	97
Columns in Z	0
Subjects	1012
Max Obs per Subject	8

Number of Observations

Number of Observations Read	8096
Number of Observations Used	5628
Number of Observations Not Used	2468

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	38850.37623665	
1	3	36210.97025120	0.05214327
2	2	36139.53173727	0.01607535
3	2	36056.25555450	0.00671595
4	1	35964.62553368	0.00260674
5	1	35924.14650515	0.00057746
6	1	35915.44026029	0.00006492
7	1	35914.53843754	0.00000121
8	1	35914.52269011	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	73.9837
UN(2,1)	USUBJID	48.2695
UN(2,2)	USUBJID	88.7112
UN(3,1)	USUBJID	51.1495

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(3,2)	USUBJID	64.5045
UN(3,3)	USUBJID	85.2742
UN(4,1)	USUBJID	44.8177
UN(4,2)	USUBJID	66.5404
UN(4,3)	USUBJID	69.1036
UN(4,4)	USUBJID	89.7196
UN(5,1)	USUBJID	45.8894
UN(5,2)	USUBJID	65.5445
UN(5,3)	USUBJID	69.3788
UN(5,4)	USUBJID	75.6247
UN(5,5)	USUBJID	91.2385
UN(6,1)	USUBJID	38.8689
UN(6,2)	USUBJID	58.2986
UN(6,3)	USUBJID	62.0304
UN(6,4)	USUBJID	68.5159
UN(6,5)	USUBJID	69.5487
UN(6,6)	USUBJID	80.1226
UN(7,1)	USUBJID	37.4473
UN(7,2)	USUBJID	54.6136
UN(7,3)	USUBJID	59.3970
UN(7,4)	USUBJID	64.5195
UN(7,5)	USUBJID	68.8242
UN(7,6)	USUBJID	65.7831
UN(7,7)	USUBJID	77.7164
UN(8,1)	USUBJID	43.9765
UN(8,2)	USUBJID	67.0468
UN(8,3)	USUBJID	72.2813
UN(8,4)	USUBJID	79.6572
UN(8,5)	USUBJID	85.5477
UN(8,6)	USUBJID	79.1553
UN(8,7)	USUBJID	83.4338
UN(8,8)	USUBJID	122.63

Fit Statistics

-2 Res Log Likelihood	35914.5
AIC (Smaller is Better)	35986.5
AICC (Smaller is Better)	35987.0
BIC (Smaller is Better)	36163.6

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
35	2935.85	<.0001

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
TREATMENT(AVISITN)	8	499	20.01	<.0001
REGION(AVISITN)	32	1381	3.01	<.0001
PREOAD(AVISITN)	8	470	3.37	0.0009
HBA1CG1(AVISITN)	8	496	1.32	0.2315
BASE(AVISITN)	8	518	17.77	<.0001

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	1
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	0.0879
REGION(AVISITN)		Asia			60	0.0909
REGION(AVISITN)		Europe			60	0.4911
REGION(AVISITN)		North America			60	0.1502
REGION(AVISITN)		South America			60	0.1798
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	0.3538
PREOAD(AVISITN)			SU users		60	0.6462
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	0.5306
HBA1CG1(AVISITN)				>=8.5	60	0.4694
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	67.668
BASE(AVISITN)					70	
BASE(AVISITN)					80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V060 IDegLira	WORK.HBA1C_MMRM	48.4450	0.3964	964.9	122.21

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IDegLira	<.0001	0.05	47.6670	49.2229

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	1
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	0.0879
REGION(AVISITN)		Asia			60	0.0909
REGION(AVISITN)		Europe			60	0.4911
REGION(AVISITN)		North America			60	0.1502
REGION(AVISITN)		South America			60	0.1798
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	0.3538
PREOAD(AVISITN)			SU users		60	0.6462
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	0.5306
HBA1CG1(AVISITN)				>=8.5	60	0.4694
HBA1CG1(AVISITN)				<8.5	70	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	67.668
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V060 IGlar	WORK.HBA1C_MMRM	55.0325	0.4019	963.7	136.93

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IGlar	<.0001	0.05	54.2438	55.8212

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	1
TREATMENT(AVISITN)	IGlar				60	-1
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V060 IDegLira - IGlar	WORK.HBA1C_MMRM	-6.5876	0.5570	964

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IDegLira - IGlar	-11.83	<.0001	0.05	-7.6805	-5.4946

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	1
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	0.0879
REGION(AVISITN)		Asia			70	0.0909
REGION(AVISITN)		Europe			70	0.4911
REGION(AVISITN)		North America			70	0.1502
REGION(AVISITN)		South America			70	0.1798
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	0.3538
PREOAD(AVISITN)			SU users		70	0.6462
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	0.5306
HBA1CG1(AVISITN)				>=8.5	70	0.4694
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	67.668
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V070 IDegLira	WORK.HBA1C_MMRM	46.1324	0.4363	928.8	105.74

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IDegLira	<.0001	0.05	45.2762	46.9886

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	0.0879
REGION(AVISITN)		Asia			70	0.0909
REGION(AVISITN)		Europe			70	0.4911
REGION(AVISITN)		North America			70	0.1502
REGION(AVISITN)		South America			70	0.1798
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	0.3538
PREOAD(AVISITN)			SU users		70	0.6462
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	0.5306
HBA1CG1(AVISITN)				>=8.5	70	0.4694
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	67.668
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V070 IGlar	WORK.HBA1C_MMRM	51.2537	0.4447	934.4	115.25

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IGlar	<.0001	0.05	50.3809	52.1265

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	1
TREATMENT(AVISITN)	IGlar				70	-1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V070 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.1213	0.6151	932.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IDegLira - IGlar	-8.33	<.0001	0.05	-6.3284	-3.9142

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	1

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	0.0879
REGION(AVISITN)		Asia			80	0.0909
REGION(AVISITN)		Europe			80	0.4911
REGION(AVISITN)		North America			80	0.1502
REGION(AVISITN)		South America			80	0.1798
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	0.3538
PREOAD(AVISITN)			SU users		80	0.6462
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	0.5306
HBA1CG1(AVISITN)				>=8.5	80	0.4694
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	67.668
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V080 IDegLira	WORK.HBA1C_MMRM	46.8116	0.4413	483.1	106.08

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IDegLira	<.0001	0.05	45.9445	47.6786

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	1
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	0.0879
REGION(AVISITN)		Asia			80	0.0909
REGION(AVISITN)		Europe			80	0.4911
REGION(AVISITN)		North America			80	0.1502
REGION(AVISITN)		South America			80	0.1798
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	0.3538
PREOAD(AVISITN)			SU users		80	0.6462
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	0.5306
HBA1CG1(AVISITN)				>=8.5	80	0.4694
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	67.668
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V080 IGlar	WORK.HBA1C_MMRM	52.5556	0.4765	564.9	110.29

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IGlar	<.0001	0.05	51.6197	53.4916

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	1
TREATMENT(AVISITN)	IGlar				80	-1
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V080 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.7441	0.6410	525.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IDegLira - IGlar	-8.96	<.0001	0.05	-7.0034	-4.4848

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	1
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	0.0879
REGION(AVISITN)		Asia			90	0.0909
REGION(AVISITN)		Europe			90	0.4911
REGION(AVISITN)		North America			90	0.1502
REGION(AVISITN)		South America			90	0.1798
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	0.3538
PREOAD(AVISITN)			SU users		90	0.6462
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	0.5306
HBA1CG1(AVISITN)				>=8.5	90	0.4694
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	67.668
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V090 IDegLira	WORK.HBA1C_MMRM	47.5311	0.4574	414.6	103.91

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IDegLira	<.0001	0.05	46.6319	48.4302

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	0.0879
REGION(AVISITN)		Asia			90	0.0909
REGION(AVISITN)		Europe			90	0.4911
REGION(AVISITN)		North America			90	0.1502
REGION(AVISITN)		South America			90	0.1798
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	0.3538
PREOAD(AVISITN)			SU users		90	0.6462
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	0.5306
HBA1CG1(AVISITN)				>=8.5	90	0.4694
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	67.668
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V090 IGlar	WORK.HBA1C_MMRM	53.1362	0.4991	492.8	106.45

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IGlar	<.0001	0.05	52.1554	54.1169

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	1
TREATMENT(AVISITN)	IGlar				90	-1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V090 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.6051	0.6690	457

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IDegLira - IGlar	-8.38	<.0001	0.05	-6.9198	-4.2904

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	1
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	0.0879

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	0.0909
REGION(AVISITN)		Europe			100	0.4911
REGION(AVISITN)		North America			100	0.1502
REGION(AVISITN)		South America			100	0.1798
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	0.3538
PREOAD(AVISITN)			SU users		100	0.6462
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	0.5306
HBA1CG1(AVISITN)				>=8.5	100	0.4694
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	67.668
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V100 IDegLira	WORK.HBA1C_MMRM	48.4975	0.4670	362.7	103.85

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IDegLira	<.0001	0.05	47.5791	49.4158

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	1
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	0.0879
REGION(AVISITN)		Asia			100	0.0909
REGION(AVISITN)		Europe			100	0.4911
REGION(AVISITN)		North America			100	0.1502
REGION(AVISITN)		South America			100	0.1798
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	0.3538
PREOAD(AVISITN)			SU users		100	0.6462
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	0.5306
HBA1CG1(AVISITN)				>=8.5	100	0.4694
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	67.668
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V100 IGlar	WORK.HBA1C_MMRM	53.8828	0.5169	435.4	104.24

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IGlar	<.0001	0.05	52.8669	54.8988

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	1
TREATMENT(AVISITN)	IGlar				100	-1
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V100 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.3853	0.6884	402.5

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IDegLira - IGlar	-7.82	<.0001	0.05	-6.7386	-4.0321

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	1
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	0.0879
REGION(AVISITN)		Asia			110	0.0909
REGION(AVISITN)		Europe			110	0.4911

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	0.1502
REGION(AVISITN)		South America			110	0.1798
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	0.3538
PREOAD(AVISITN)			SU users		110	0.6462
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	0.5306
HBA1CG1(AVISITN)				>=8.5	110	0.4694
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	67.668
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V110 IDegLira	WORK.HBA1C_MMRM	48.2362	0.4456	301.5	108.25

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IDegLira	<.0001	0.05	47.3593	49.1131

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	1
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	0.0879
REGION(AVISITN)		Asia			110	0.0909
REGION(AVISITN)		Europe			110	0.4911
REGION(AVISITN)		North America			110	0.1502
REGION(AVISITN)		South America			110	0.1798
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	0.3538
PREOAD(AVISITN)			SU users		110	0.6462
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	0.5306
HBA1CG1(AVISITN)				>=8.5	110	0.4694
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	67.668
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V110 IGlar	WORK.HBA1C_MMRM	54.1046	0.5035	368	107.46

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IGlar	<.0001	0.05	53.1145	55.0946

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	1
TREATMENT(AVISITN)	IGlar				110	-1
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V110 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.8683	0.6635	336.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IDegLira - IGlar	-8.84	<.0001	0.05	-7.1735	-4.5632

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	1
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	0.0879
REGION(AVISITN)		Asia			120	0.0909
REGION(AVISITN)		Europe			120	0.4911
REGION(AVISITN)		North America			120	0.1502
REGION(AVISITN)		South America			120	0.1798
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	0.3538
PREOAD(AVISITN)			SU users		120	0.6462
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	0.5306
HBA1CG1(AVISITN)				>=8.5	120	0.4694
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	67.668
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V120 IDegLira	WORK.HBA1C_MMRM	48.5713	0.4436	286.5	109.48

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IDegLira	<.0001	0.05	47.6981	49.4445

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	1
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	0.0879
REGION(AVISITN)		Asia			120	0.0909
REGION(AVISITN)		Europe			120	0.4911
REGION(AVISITN)		North America			120	0.1502
REGION(AVISITN)		South America			120	0.1798
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	0.3538
PREOAD(AVISITN)			SU users		120	0.6462
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	0.5306
HBA1CG1(AVISITN)				>=8.5	120	0.4694
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	67.668
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V120 IGlar	WORK.HBA1C_MMRM	54.3585	0.5111	360.7	106.36

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IGlar	<.0001	0.05	53.3534	55.3636

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	1
TREATMENT(AVISITN)	IGlar				120	-1
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V120 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.7872	0.6669	324.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IDegLira - IGlar	-8.68	<.0001	0.05	-7.0993	-4.4751

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	0.0879
REGION(AVISITN)		Asia			130	0.0909
REGION(AVISITN)		Europe			130	0.4911
REGION(AVISITN)		North America			130	0.1502
REGION(AVISITN)		South America			130	0.1798
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	0.3538
PREOAD(AVISITN)			SU users		130	0.6462
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	0.5306
HBA1CG1(AVISITN)				>=8.5	130	0.4694
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	67.668

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V130 IDegLira	WORK.HBA1C_MMRM	50.3114	0.5645	272	89.12

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IDegLira	<.0001	0.05	49.2000	51.4227

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	0.0879
REGION(AVISITN)		Asia			130	0.0909
REGION(AVISITN)		Europe			130	0.4911
REGION(AVISITN)		North America			130	0.1502
REGION(AVISITN)		South America			130	0.1798
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	0.3538
PREOAD(AVISITN)			SU users		130	0.6462
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	0.5306
HBA1CG1(AVISITN)				>=8.5	130	0.4694
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	67.668

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V130 IGlar	WORK.HBA1C_MMRM	56.2264	0.6618	349.8	84.96

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IGlar	<.0001	0.05	54.9249	57.5280

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	1
TREATMENT(AVISITN)	IGlar				130	-1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V130 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.9151	0.8565	312.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IDegLira - IGlar	-6.91	<.0001	0.05	-7.6004	-4.2298

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Model Information

Data Set	WORK.HBA1C_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
TREATMENT	2	IDegLira IGlar
REGION	5	Africa Asia Europe North America South America
AVISITN	8	60 70 80 90 100 110 120 130

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

[redacted]

NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	36
Columns in X	97
Columns in Z	0
Subjects	1012
Max Obs per Subject	8

Number of Observations

Number of Observations Read	8096
Number of Observations Used	5628
Number of Observations Not Used	2468

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12237.63846590	
1	3	9598.23248044	2.21155466
2	2	9526.79396652	0.60896419
3	2	9443.51778375	0.22608790
4	1	9351.88776293	0.07811941
5	1	9311.40873439	0.01650097
6	1	9302.70248954	0.00183659
7	1	9301.80066679	0.00003417
8	1	9301.78491936	0.00000001
9	1	9301.78491264	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.6193
UN(2,1)	USUBJID	0.4041
UN(2,2)	USUBJID	0.7426

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(3,1)	USUBJID	0.4282
UN(3,2)	USUBJID	0.5400
UN(3,3)	USUBJID	0.7138
UN(4,1)	USUBJID	0.3752
UN(4,2)	USUBJID	0.5570
UN(4,3)	USUBJID	0.5785
UN(4,4)	USUBJID	0.7511
UN(5,1)	USUBJID	0.3842
UN(5,2)	USUBJID	0.5487
UN(5,3)	USUBJID	0.5808
UN(5,4)	USUBJID	0.6331
UN(5,5)	USUBJID	0.7638
UN(6,1)	USUBJID	0.3254
UN(6,2)	USUBJID	0.4881
UN(6,3)	USUBJID	0.5193
UN(6,4)	USUBJID	0.5736
UN(6,5)	USUBJID	0.5823
UN(6,6)	USUBJID	0.6708
UN(7,1)	USUBJID	0.3135
UN(7,2)	USUBJID	0.4572
UN(7,3)	USUBJID	0.4973
UN(7,4)	USUBJID	0.5402
UN(7,5)	USUBJID	0.5762
UN(7,6)	USUBJID	0.5508
UN(7,7)	USUBJID	0.6507
UN(8,1)	USUBJID	0.3682
UN(8,2)	USUBJID	0.5613
UN(8,3)	USUBJID	0.6052
UN(8,4)	USUBJID	0.6669
UN(8,5)	USUBJID	0.7162
UN(8,6)	USUBJID	0.6627
UN(8,7)	USUBJID	0.6986
UN(8,8)	USUBJID	1.0267

Fit Statistics

-2 Res Log Likelihood	9301.8
AIC (Smaller is Better)	9373.8
AICC (Smaller is Better)	9374.3
BIC (Smaller is Better)	9550.9

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
35	2935.85	<.0001

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
TREATMENT(AVISITN)	8	499	20.01	<.0001
REGION(AVISITN)	32	1381	3.01	<.0001
PREOAD(AVISITN)	8	470	3.37	0.0009
HBA1CG1(AVISITN)	8	496	1.32	0.2316
BASE(AVISITN)	8	518	26.33	<.0001

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	1
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	0.0879
REGION(AVISITN)		Asia			60	0.0909
REGION(AVISITN)		Europe			60	0.4911
REGION(AVISITN)		North America			60	0.1502
REGION(AVISITN)		South America			60	0.1798
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	0.3538
PREOAD(AVISITN)			SU users		60	0.6462
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	0.5306
HBA1CG1(AVISITN)				>=8.5	60	0.4694
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	8.3411
BASE(AVISITN)					70	
BASE(AVISITN)					80	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V060 IDegLira	WORK.HBA1C_MMRM	-1.7588	0.03627	964.9	-48.49

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IDegLira	<.0001	0.05	-1.8300	-1.6876

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	1
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	0.0879
REGION(AVISITN)		Asia			60	0.0909
REGION(AVISITN)		Europe			60	0.4911
REGION(AVISITN)		North America			60	0.1502
REGION(AVISITN)		South America			60	0.1798
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	0.3538
PREOAD(AVISITN)			SU users		60	0.6462
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	0.5306
HBA1CG1(AVISITN)				>=8.5	60	0.4694
HBA1CG1(AVISITN)				<8.5	70	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	8.3411
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V060 IGlar	WORK.HBA1C_MMRM	-1.1561	0.03677	963.7	-31.44

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IGlar	<.0001	0.05	-1.2282	-1.0839

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	1
TREATMENT(AVISITN)	IGlar				60	-1
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V060 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.6027	0.05096	964

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IDegLira - IGlar	-11.83	<.0001	0.05	-0.7027	-0.5027

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	1
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	0.0879
REGION(AVISITN)		Asia			70	0.0909
REGION(AVISITN)		Europe			70	0.4911
REGION(AVISITN)		North America			70	0.1502
REGION(AVISITN)		South America			70	0.1798
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	0.3538
PREOAD(AVISITN)			SU users		70	0.6462
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	0.5306
HBA1CG1(AVISITN)				>=8.5	70	0.4694
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	8.3411
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V070 IDegLira	WORK.HBA1C_MMRM	-1.9704	0.03992	928.8	-49.36

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IDegLira	<.0001	0.05	-2.0487	-1.8920

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	0.0879
REGION(AVISITN)		Asia			70	0.0909
REGION(AVISITN)		Europe			70	0.4911
REGION(AVISITN)		North America			70	0.1502
REGION(AVISITN)		South America			70	0.1798
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	0.3538
PREOAD(AVISITN)			SU users		70	0.6462
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	0.5306
HBA1CG1(AVISITN)				>=8.5	70	0.4694
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	8.3411
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V070 IGlar	WORK.HBA1C_MMRM	-1.5018	0.04069	934.4	-36.91

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IGlar	<.0001	0.05	-1.5817	-1.4220

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	1
TREATMENT(AVISITN)	IGlar				70	-1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V070 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.4686	0.05628	932.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IDegLira - IGlar	-8.33	<.0001	0.05	-0.5790	-0.3581

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	1

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	0.0879
REGION(AVISITN)		Asia			80	0.0909
REGION(AVISITN)		Europe			80	0.4911
REGION(AVISITN)		North America			80	0.1502
REGION(AVISITN)		South America			80	0.1798
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	0.3538
PREOAD(AVISITN)			SU users		80	0.6462
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	0.5306
HBA1CG1(AVISITN)				>=8.5	80	0.4694
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	8.3411
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V080 IDegLira	WORK.HBA1C_MMRM	-1.9082	0.04037	483	-47.26

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IDegLira	<.0001	0.05	-1.9875	-1.8289

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	1
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	0.0879
REGION(AVISITN)		Asia			80	0.0909
REGION(AVISITN)		Europe			80	0.4911
REGION(AVISITN)		North America			80	0.1502
REGION(AVISITN)		South America			80	0.1798
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	0.3538
PREOAD(AVISITN)			SU users		80	0.6462
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	0.5306
HBA1CG1(AVISITN)				>=8.5	80	0.4694
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	8.3411
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V080 IGlar	WORK.HBA1C_MMRM	-1.3827	0.04360	564.9	-31.71

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IGlar	<.0001	0.05	-1.4683	-1.2970

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	1
TREATMENT(AVISITN)	IGlar				80	-1
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V080 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.5255	0.05865	525.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IDegLira - IGlar	-8.96	<.0001	0.05	-0.6408	-0.4103

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	1
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	0.0879
REGION(AVISITN)		Asia			90	0.0909
REGION(AVISITN)		Europe			90	0.4911
REGION(AVISITN)		North America			90	0.1502
REGION(AVISITN)		South America			90	0.1798
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	0.3538
PREOAD(AVISITN)			SU users		90	0.6462
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	0.5306
HBA1CG1(AVISITN)				>=8.5	90	0.4694
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	8.3411
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V090 IDegLira	WORK.HBA1C_MMRM	-1.8424	0.04185	414.5	-44.02

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IDegLira	<.0001	0.05	-1.9246	-1.7601

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	0.0879
REGION(AVISITN)		Asia			90	0.0909
REGION(AVISITN)		Europe			90	0.4911
REGION(AVISITN)		North America			90	0.1502
REGION(AVISITN)		South America			90	0.1798
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	0.3538
PREOAD(AVISITN)			SU users		90	0.6462
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	0.5306
HBA1CG1(AVISITN)				>=8.5	90	0.4694
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	8.3411
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V090 IGlar	WORK.HBA1C_MMRM	-1.3295	0.04567	492.7	-29.11

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IGlar	<.0001	0.05	-1.4193	-1.2398

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	1
TREATMENT(AVISITN)	IGlar				90	-1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V090 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.5128	0.06121	456.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IDegLira - IGlar	-8.38	<.0001	0.05	-0.6331	-0.3925

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	1
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	0.0879

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	0.0909
REGION(AVISITN)		Europe			100	0.4911
REGION(AVISITN)		North America			100	0.1502
REGION(AVISITN)		South America			100	0.1798
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	0.3538
PREOAD(AVISITN)			SU users		100	0.6462
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	0.5306
HBA1CG1(AVISITN)				>=8.5	100	0.4694
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	8.3411
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V100 IDegLira	WORK.HBA1C_MMRM	-1.7540	0.04273	362.6	-41.05

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IDegLira	<.0001	0.05	-1.8380	-1.6699

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	1
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	0.0879
REGION(AVISITN)		Asia			100	0.0909
REGION(AVISITN)		Europe			100	0.4911
REGION(AVISITN)		North America			100	0.1502
REGION(AVISITN)		South America			100	0.1798
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	0.3538
PREOAD(AVISITN)			SU users		100	0.6462
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	0.5306
HBA1CG1(AVISITN)				>=8.5	100	0.4694
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	8.3411
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V100 IGlar	WORK.HBA1C_MMRM	-1.2612	0.04729	435.3	-26.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IGlar	<.0001	0.05	-1.3542	-1.1683

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	1
TREATMENT(AVISITN)	IGlar				100	-1
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V100 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.4927	0.06298	402.4

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IDegLira - IGlar	-7.82	<.0001	0.05	-0.6165	-0.3689

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	1
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	0.0879
REGION(AVISITN)		Asia			110	0.0909
REGION(AVISITN)		Europe			110	0.4911

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	0.1502
REGION(AVISITN)		South America			110	0.1798
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	0.3538
PREOAD(AVISITN)			SU users		110	0.6462
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	0.5306
HBA1CG1(AVISITN)				>=8.5	110	0.4694
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	8.3411
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V110 IDegLira	WORK.HBA1C_MMRM	-1.7779	0.04077	301.4	-43.60

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IDegLira	<.0001	0.05	-1.8581	-1.6976

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	1
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	0.0879
REGION(AVISITN)		Asia			110	0.0909
REGION(AVISITN)		Europe			110	0.4911
REGION(AVISITN)		North America			110	0.1502
REGION(AVISITN)		South America			110	0.1798
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	0.3538
PREOAD(AVISITN)			SU users		110	0.6462
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	0.5306
HBA1CG1(AVISITN)				>=8.5	110	0.4694
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	8.3411
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V110 IGlar	WORK.HBA1C_MMRM	-1.2409	0.04607	367.9	-26.94

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IGlar	<.0001	0.05	-1.3315	-1.1503

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	1
TREATMENT(AVISITN)	IGlar				110	-1
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V110 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.5369	0.06071	336.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IDegLira - IGlar	-8.84	<.0001	0.05	-0.6563	-0.4175

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	1
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	0.0879
REGION(AVISITN)		Asia			120	0.0909
REGION(AVISITN)		Europe			120	0.4911
REGION(AVISITN)		North America			120	0.1502
REGION(AVISITN)		South America			120	0.1798
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	0.3538
PREOAD(AVISITN)			SU users		120	0.6462
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	0.5306
HBA1CG1(AVISITN)				>=8.5	120	0.4694
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	8.3411
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V120 IDegLira	WORK.HBA1C_MMRM	-1.7472	0.04059	286.4	-43.04

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IDegLira	<.0001	0.05	-1.8271	-1.6673

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	1
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	0.0879
REGION(AVISITN)		Asia			120	0.0909
REGION(AVISITN)		Europe			120	0.4911
REGION(AVISITN)		North America			120	0.1502
REGION(AVISITN)		South America			120	0.1798
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	0.3538
PREOAD(AVISITN)			SU users		120	0.6462
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	0.5306
HBA1CG1(AVISITN)				>=8.5	120	0.4694
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	8.3411
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V120 IGlar	WORK.HBA1C_MMRM	-1.2177	0.04676	360.6	-26.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IGlar	<.0001	0.05	-1.3096	-1.1257

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	1
TREATMENT(AVISITN)	IGlar				120	-1
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V120 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.5295	0.06102	324.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IDegLira - IGlar	-8.68	<.0001	0.05	-0.6496	-0.4095

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	0.0879
REGION(AVISITN)		Asia			130	0.0909
REGION(AVISITN)		Europe			130	0.4911
REGION(AVISITN)		North America			130	0.1502
REGION(AVISITN)		South America			130	0.1798
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	0.3538
PREOAD(AVISITN)			SU users		130	0.6462
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	0.5306
HBA1CG1(AVISITN)				>=8.5	130	0.4694
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	8.3411

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V130 IDegLira	WORK.HBA1C_MMRM	-1.5880	0.05165	271.9	-30.74

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IDegLira	<.0001	0.05	-1.6897	-1.4863

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	0.0879
REGION(AVISITN)		Asia			130	0.0909
REGION(AVISITN)		Europe			130	0.4911
REGION(AVISITN)		North America			130	0.1502
REGION(AVISITN)		South America			130	0.1798
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	0.3538
PREOAD(AVISITN)			SU users		130	0.6462
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	0.5306
HBA1CG1(AVISITN)				>=8.5	130	0.4694
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	8.3411

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V130 IGlar	WORK.HBA1C_MMRM	-1.0468	0.06055	349.7	-17.29

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IGlar	<.0001	0.05	-1.1658	-0.9277

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	1
TREATMENT(AVISITN)	IGlar				130	-1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V130 IDegLira - IGlar	WORK.HBA1C_MMRM	-0.5412	0.07837	312.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IDegLira - IGlar	-6.91	<.0001	0.05	-0.6954	-0.3870

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Model Information

Data Set	WORK.HBA1C_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
TREATMENT	2	IDegLira IGlar
REGION	5	Africa Asia Europe North America South America
AVISITN	8	60 70 80 90 100 110 120 130

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228/[redacted] NN9068-4228/[redacted]

```
HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full
analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	36
Columns in X	97
Columns in Z	0
Subjects	1012
Max Obs per Subject	8

Number of Observations

Number of Observations Read	8096
Number of Observations Used	5628
Number of Observations Not Used	2468

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	38850.37623665	
1	3	36210.97025120	0.05214327
2	2	36139.53173727	0.01607535
3	2	36056.25555450	0.00671595
4	1	35964.62553368	0.00260674
5	1	35924.14650515	0.00057746
6	1	35915.44026029	0.00006492
7	1	35914.53843754	0.00000121
8	1	35914.52269011	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	73.9837
UN(2,1)	USUBJID	48.2695
UN(2,2)	USUBJID	88.7112
UN(3,1)	USUBJID	51.1495

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(3,2)	USUBJID	64.5045
UN(3,3)	USUBJID	85.2742
UN(4,1)	USUBJID	44.8177
UN(4,2)	USUBJID	66.5404
UN(4,3)	USUBJID	69.1036
UN(4,4)	USUBJID	89.7196
UN(5,1)	USUBJID	45.8894
UN(5,2)	USUBJID	65.5445
UN(5,3)	USUBJID	69.3788
UN(5,4)	USUBJID	75.6247
UN(5,5)	USUBJID	91.2385
UN(6,1)	USUBJID	38.8689
UN(6,2)	USUBJID	58.2986
UN(6,3)	USUBJID	62.0304
UN(6,4)	USUBJID	68.5159
UN(6,5)	USUBJID	69.5487
UN(6,6)	USUBJID	80.1226
UN(7,1)	USUBJID	37.4473
UN(7,2)	USUBJID	54.6136
UN(7,3)	USUBJID	59.3970
UN(7,4)	USUBJID	64.5195
UN(7,5)	USUBJID	68.8242
UN(7,6)	USUBJID	65.7831
UN(7,7)	USUBJID	77.7164
UN(8,1)	USUBJID	43.9765
UN(8,2)	USUBJID	67.0468
UN(8,3)	USUBJID	72.2813
UN(8,4)	USUBJID	79.6572
UN(8,5)	USUBJID	85.5477
UN(8,6)	USUBJID	79.1553
UN(8,7)	USUBJID	83.4338
UN(8,8)	USUBJID	122.63

Fit Statistics

-2 Res Log Likelihood	35914.5
AIC (Smaller is Better)	35986.5
AICC (Smaller is Better)	35987.0
BIC (Smaller is Better)	36163.6

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
35	2935.85	<.0001

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
TREATMENT(AVISITN)	8	499	20.01	<.0001
REGION(AVISITN)	32	1381	3.01	<.0001
PREOAD(AVISITN)	8	470	3.37	0.0009
HBA1CG1(AVISITN)	8	496	1.32	0.2315
BASE(AVISITN)	8	518	26.33	<.0001

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	1
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	0.0879
REGION(AVISITN)		Asia			60	0.0909
REGION(AVISITN)		Europe			60	0.4911
REGION(AVISITN)		North America			60	0.1502
REGION(AVISITN)		South America			60	0.1798
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	0.3538
PREOAD(AVISITN)			SU users		60	0.6462
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	0.5306
HBA1CG1(AVISITN)				>=8.5	60	0.4694
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	67.668
BASE(AVISITN)					70	
BASE(AVISITN)					80	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V060 IDegLira	WORK.HBA1C_MMRM	-19.2234	0.3964	964.9	-48.49

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IDegLira	<.0001	0.05	-20.0014	-18.4455

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	1
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	0.0879
REGION(AVISITN)		Asia			60	0.0909
REGION(AVISITN)		Europe			60	0.4911
REGION(AVISITN)		North America			60	0.1502
REGION(AVISITN)		South America			60	0.1798
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	0.3538
PREOAD(AVISITN)			SU users		60	0.6462
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	0.5306
HBA1CG1(AVISITN)				>=8.5	60	0.4694
HBA1CG1(AVISITN)				<8.5	70	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	67.668
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V060 IGlar	WORK.HBA1C_MMRM	-12.6359	0.4019	963.7	-31.44

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IGlar	<.0001	0.05	-13.4246	-11.8472

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	1
TREATMENT(AVISITN)	IGlar				60	-1
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V060 IDegLira - IGlar	WORK.HBA1C_MMRM	-6.5876	0.5570	964

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V060 IDegLira - IGlar	-11.83	<.0001	0.05	-7.6805	-5.4946

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	1
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	0.0879
REGION(AVISITN)		Asia			70	0.0909
REGION(AVISITN)		Europe			70	0.4911
REGION(AVISITN)		North America			70	0.1502
REGION(AVISITN)		South America			70	0.1798
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	0.3538
PREOAD(AVISITN)			SU users		70	0.6462
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	0.5306
HBA1CG1(AVISITN)				>=8.5	70	0.4694
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	67.668
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V070 IDegLira	WORK.HBA1C_MMRM	-21.5360	0.4363	928.8	-49.36

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IDegLira	<.0001	0.05	-22.3922	-20.6798

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	0.0879
REGION(AVISITN)		Asia			70	0.0909
REGION(AVISITN)		Europe			70	0.4911
REGION(AVISITN)		North America			70	0.1502
REGION(AVISITN)		South America			70	0.1798
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	0.3538
PREOAD(AVISITN)			SU users		70	0.6462
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	0.5306
HBA1CG1(AVISITN)				>=8.5	70	0.4694
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	67.668
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V070 IGlar	WORK.HBA1C_MMRM	-16.4147	0.4447	934.4	-36.91

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IGlar	<.0001	0.05	-17.2875	-15.5419

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	1
TREATMENT(AVISITN)	IGlar				70	-1
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V070 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.1213	0.6151	932.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V070 IDegLira - IGlar	-8.33	<.0001	0.05	-6.3284	-3.9142

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	1

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	0.0879
REGION(AVISITN)		Asia			80	0.0909
REGION(AVISITN)		Europe			80	0.4911
REGION(AVISITN)		North America			80	0.1502
REGION(AVISITN)		South America			80	0.1798
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	0.3538
PREOAD(AVISITN)			SU users		80	0.6462
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	0.5306
HBA1CG1(AVISITN)				>=8.5	80	0.4694
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	67.668
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V080 IDegLira	WORK.HBA1C_MMRM	-20.8568	0.4413	483.1	-47.27

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IDegLira	<.0001	0.05	-21.7239	-19.9898

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	1
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	0.0879
REGION(AVISITN)		Asia			80	0.0909
REGION(AVISITN)		Europe			80	0.4911
REGION(AVISITN)		North America			80	0.1502
REGION(AVISITN)		South America			80	0.1798
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	0.3538
PREOAD(AVISITN)			SU users		80	0.6462
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	0.5306
HBA1CG1(AVISITN)				>=8.5	80	0.4694
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	67.668
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V080 IGlar	WORK.HBA1C_MMRM	-15.1127	0.4765	564.9	-31.72

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IGlar	<.0001	0.05	-16.0487	-14.1768

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	1
TREATMENT(AVISITN)	IGlar				80	-1
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V080 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.7441	0.6410	525.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V080 IDegLira - IGlar	-8.96	<.0001	0.05	-7.0034	-4.4848

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	1
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	0.0879
REGION(AVISITN)		Asia			90	0.0909
REGION(AVISITN)		Europe			90	0.4911
REGION(AVISITN)		North America			90	0.1502
REGION(AVISITN)		South America			90	0.1798
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	0.3538
PREOAD(AVISITN)			SU users		90	0.6462
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	0.5306
HBA1CG1(AVISITN)				>=8.5	90	0.4694
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	67.668
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V090 IDegLira	WORK.HBA1C_MMRM	-20.1373	0.4574	414.6	-44.02

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IDegLira	<.0001	0.05	-21.0365	-19.2382

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	0.0879
REGION(AVISITN)		Asia			90	0.0909
REGION(AVISITN)		Europe			90	0.4911
REGION(AVISITN)		North America			90	0.1502
REGION(AVISITN)		South America			90	0.1798
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	0.3538
PREOAD(AVISITN)			SU users		90	0.6462
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	0.5306
HBA1CG1(AVISITN)				>=8.5	90	0.4694
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	67.668
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V090 IGlar	WORK.HBA1C_MMRM	-14.5322	0.4991	492.8	-29.11

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IGlar	<.0001	0.05	-15.5129	-13.5515

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	1
TREATMENT(AVISITN)	IGlar				90	-1
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V090 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.6051	0.6690	457

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V090 IDegLira - IGlar	-8.38	<.0001	0.05	-6.9198	-4.2904

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	1
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	0.0879

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	0.0909
REGION(AVISITN)		Europe			100	0.4911
REGION(AVISITN)		North America			100	0.1502
REGION(AVISITN)		South America			100	0.1798
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	0.3538
PREOAD(AVISITN)			SU users		100	0.6462
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	0.5306
HBA1CG1(AVISITN)				>=8.5	100	0.4694
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	67.668
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V100 IDegLira	WORK.HBA1C_MMRM	-19.1709	0.4670	362.7	-41.05

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IDegLira	<.0001	0.05	-20.0893	-18.2525

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	1
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	0.0879
REGION(AVISITN)		Asia			100	0.0909
REGION(AVISITN)		Europe			100	0.4911
REGION(AVISITN)		North America			100	0.1502
REGION(AVISITN)		South America			100	0.1798
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	0.3538
PREOAD(AVISITN)			SU users		100	0.6462
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	0.5306
HBA1CG1(AVISITN)				>=8.5	100	0.4694
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	67.668
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V100 IGlar	WORK.HBA1C_MMRM	-13.7856	0.5169	435.4	-26.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IGlar	<.0001	0.05	-14.8015	-12.7696

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	1
TREATMENT(AVISITN)	IGlar				100	-1
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V100 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.3853	0.6884	402.5

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V100 IDegLira - IGlar	-7.82	<.0001	0.05	-6.7386	-4.0321

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	1
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	0.0879
REGION(AVISITN)		Asia			110	0.0909
REGION(AVISITN)		Europe			110	0.4911

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	0.1502
REGION(AVISITN)		South America			110	0.1798
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	0.3538
PREOAD(AVISITN)			SU users		110	0.6462
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	0.5306
HBA1CG1(AVISITN)				>=8.5	110	0.4694
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	67.668
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V110 IDegLira	WORK.HBA1C_MMRM	-19.4322	0.4456	301.5	-43.61

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IDegLira	<.0001	0.05	-20.3091	-18.5553

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	1
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	0.0879
REGION(AVISITN)		Asia			110	0.0909
REGION(AVISITN)		Europe			110	0.4911
REGION(AVISITN)		North America			110	0.1502
REGION(AVISITN)		South America			110	0.1798
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	0.3538
PREOAD(AVISITN)			SU users		110	0.6462
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	0.5306
HBA1CG1(AVISITN)				>=8.5	110	0.4694
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	67.668
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V110 IGlar	WORK.HBA1C_MMRM	-13.5638	0.5035	368	-26.94

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IGlar	<.0001	0.05	-14.5539	-12.5738

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	1
TREATMENT(AVISITN)	IGlar				110	-1
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V110 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.8683	0.6635	336.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V110 IDegLira - IGlar	-8.84	<.0001	0.05	-7.1735	-4.5632

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	1
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	0.0879
REGION(AVISITN)		Asia			120	0.0909
REGION(AVISITN)		Europe			120	0.4911
REGION(AVISITN)		North America			120	0.1502
REGION(AVISITN)		South America			120	0.1798
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	0.3538
PREOAD(AVISITN)			SU users		120	0.6462
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	0.5306
HBA1CG1(AVISITN)				>=8.5	120	0.4694
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	67.668
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V120 IDegLira	WORK.HBA1C_MMRM	-19.0971	0.4436	286.5	-43.05

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IDegLira	<.0001	0.05	-19.9703	-18.2239

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	1
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	0.0879
REGION(AVISITN)		Asia			120	0.0909
REGION(AVISITN)		Europe			120	0.4911
REGION(AVISITN)		North America			120	0.1502
REGION(AVISITN)		South America			120	0.1798
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	0.3538
PREOAD(AVISITN)			SU users		120	0.6462
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	0.5306
HBA1CG1(AVISITN)				>=8.5	120	0.4694
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	67.668
BASE(AVISITN)					130	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V120 IGlar	WORK.HBA1C_MMRM	-13.3099	0.5111	360.7	-26.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IGlar	<.0001	0.05	-14.3150	-12.3048

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	1
TREATMENT(AVISITN)	IGlar				120	-1
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V120 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.7872	0.6669	324.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V120 IDegLira - IGlar	-8.68	<.0001	0.05	-7.0993	-4.4751

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	1
TREATMENT(AVISITN)	IGlar				130	
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	0.0879
REGION(AVISITN)		Asia			130	0.0909
REGION(AVISITN)		Europe			130	0.4911
REGION(AVISITN)		North America			130	0.1502
REGION(AVISITN)		South America			130	0.1798
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	0.3538
PREOAD(AVISITN)			SU users		130	0.6462
HBA1CG1(AVISITN)				<8.5	60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	0.5306
HBA1CG1(AVISITN)				>=8.5	130	0.4694
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	67.668

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V130 IDegLira	WORK.HBA1C_MMRM	-17.3570	0.5645	272	-30.75

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IDegLira	<.0001	0.05	-18.4684	-16.2457

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						1
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	
TREATMENT(AVISITN)	IGlar				130	1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	0.0879
REGION(AVISITN)		Asia			130	0.0909
REGION(AVISITN)		Europe			130	0.4911
REGION(AVISITN)		North America			130	0.1502
REGION(AVISITN)		South America			130	0.1798
PREOAD(AVISITN)			Non-SU users		60	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	0.3538
PREOAD(AVISITN)			SU users		130	0.6462
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	0.5306
HBA1CG1(AVISITN)				>=8.5	130	0.4694
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	67.668

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
TREATMENT(AVISITN)	V130 IGlar	WORK.HBA1C_MMRM	-11.4420	0.6618	349.8	-17.29

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IGlar	<.0001	0.05	-12.7435	-10.1404

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
Intercept						
TREATMENT(AVISITN)	IDegLira				60	
TREATMENT(AVISITN)	IGlar				60	
TREATMENT(AVISITN)	IDegLira				70	
TREATMENT(AVISITN)	IGlar				70	
TREATMENT(AVISITN)	IDegLira				80	
TREATMENT(AVISITN)	IGlar				80	
TREATMENT(AVISITN)	IDegLira				90	
TREATMENT(AVISITN)	IGlar				90	
TREATMENT(AVISITN)	IDegLira				100	
TREATMENT(AVISITN)	IGlar				100	
TREATMENT(AVISITN)	IDegLira				110	
TREATMENT(AVISITN)	IGlar				110	
TREATMENT(AVISITN)	IDegLira				120	
TREATMENT(AVISITN)	IGlar				120	
TREATMENT(AVISITN)	IDegLira				130	1
TREATMENT(AVISITN)	IGlar				130	-1
REGION(AVISITN)		Africa			60	
REGION(AVISITN)		Asia			60	
REGION(AVISITN)		Europe			60	
REGION(AVISITN)		North America			60	
REGION(AVISITN)		South America			60	
REGION(AVISITN)		Africa			70	
REGION(AVISITN)		Asia			70	
REGION(AVISITN)		Europe			70	
REGION(AVISITN)		North America			70	
REGION(AVISITN)		South America			70	
REGION(AVISITN)		Africa			80	
REGION(AVISITN)		Asia			80	
REGION(AVISITN)		Europe			80	
REGION(AVISITN)		North America			80	
REGION(AVISITN)		South America			80	
REGION(AVISITN)		Africa			90	
REGION(AVISITN)		Asia			90	
REGION(AVISITN)		Europe			90	
REGION(AVISITN)		North America			90	
REGION(AVISITN)		South America			90	
REGION(AVISITN)		Africa			100	
REGION(AVISITN)		Asia			100	
REGION(AVISITN)		Europe			100	
REGION(AVISITN)		North America			100	
REGION(AVISITN)		South America			100	
REGION(AVISITN)		Africa			110	
REGION(AVISITN)		Asia			110	
REGION(AVISITN)		Europe			110	

HbA1c after 26 weeks - change from baseline - supportive statistical analysis - full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Coefficients for TREATMENT(AVISITN) Least Squares Means Estimates Using WORK.HBA1C_MMRM Margins

Effect	TREATMENT	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	AVISITN	Row1
REGION(AVISITN)		North America			110	
REGION(AVISITN)		South America			110	
REGION(AVISITN)		Africa			120	
REGION(AVISITN)		Asia			120	
REGION(AVISITN)		Europe			120	
REGION(AVISITN)		North America			120	
REGION(AVISITN)		South America			120	
REGION(AVISITN)		Africa			130	
REGION(AVISITN)		Asia			130	
REGION(AVISITN)		Europe			130	
REGION(AVISITN)		North America			130	
REGION(AVISITN)		South America			130	
PREOAD(AVISITN)			Non-SU users		60	
PREOAD(AVISITN)			SU users		60	
PREOAD(AVISITN)			Non-SU users		70	
PREOAD(AVISITN)			SU users		70	
PREOAD(AVISITN)			Non-SU users		80	
PREOAD(AVISITN)			SU users		80	
PREOAD(AVISITN)			Non-SU users		90	
PREOAD(AVISITN)			SU users		90	
PREOAD(AVISITN)			Non-SU users		100	
PREOAD(AVISITN)			SU users		100	
PREOAD(AVISITN)			Non-SU users		110	
PREOAD(AVISITN)			SU users		110	
PREOAD(AVISITN)			Non-SU users		120	
PREOAD(AVISITN)			SU users		120	
PREOAD(AVISITN)			Non-SU users		130	
PREOAD(AVISITN)			SU users		130	
HBA1CG1(AVISITN)				<8.5	60	
HBA1CG1(AVISITN)				>=8.5	60	
HBA1CG1(AVISITN)				<8.5	70	
HBA1CG1(AVISITN)				>=8.5	70	
HBA1CG1(AVISITN)				<8.5	80	
HBA1CG1(AVISITN)				>=8.5	80	
HBA1CG1(AVISITN)				<8.5	90	
HBA1CG1(AVISITN)				>=8.5	90	
HBA1CG1(AVISITN)				<8.5	100	
HBA1CG1(AVISITN)				>=8.5	100	
HBA1CG1(AVISITN)				<8.5	110	
HBA1CG1(AVISITN)				>=8.5	110	
HBA1CG1(AVISITN)				<8.5	120	
HBA1CG1(AVISITN)				>=8.5	120	
HBA1CG1(AVISITN)				<8.5	130	
HBA1CG1(AVISITN)				>=8.5	130	
BASE(AVISITN)					60	
BASE(AVISITN)					70	
BASE(AVISITN)					80	
BASE(AVISITN)					90	
BASE(AVISITN)					100	
BASE(AVISITN)					110	
BASE(AVISITN)					120	
BASE(AVISITN)					130	

HbA1c after 26 weeks – change from baseline – supportive statistical analysis – full analysis set

TOPIC_CD=HBA1C_BLOOD_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
TREATMENT(AVISITN)	V130 IDegLira - IGlar	WORK.HBA1C_MMRM	-5.9151	0.8565	312.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
TREATMENT(AVISITN)	V130 IDegLira - IGlar	-6.91	<.0001	0.05	-7.6004	-4.2298

7: Responder for HbA1c treatment target after 26 weeks – supportive statistical analysis – full analysis set

```
Topic Code=HBA1C_BLOOD_65

The GENMOD Procedure

                     Model Information

Data Set              WORK.ADRESP
Distribution             Binomial
Link Function               Logit
Dependent Variable          AVALC    Analysis Value (C)


Number of Observations Read        1012
Number of Observations Used        1012
Number of Events                    501
Number of Trials                   1012


                      Class Level Information

Class        Levels    Values

ARM               2    IDegLira IGlar
PREOAD            2    Non-SU users SU users
REGION1           5    Africa Asia Europe North America South America
HBA1CG1           2    <8.5 >=8.5


       Response Profile

 Ordered                Total
   Value    AVALC    Frequency

       1    Y              501
       2    N              511

PROC GENMOD is modeling the probability that AVALC='Y'.


                            Parameter Information

Parameter       Effect       ARM         PREOAD          REGION1          HBA1CG1

Prm1            Intercept
Prm2            ARM          IDegLira
Prm3            ARM          IGlar
Prm4            HBA1CG1                                                   <8.5
Prm5            HBA1CG1                                                   >=8.5
Prm6            PREOAD                   Non-SU users
Prm7            PREOAD                   SU users
Prm8            REGION1                                  Africa
Prm9            REGION1                                  Asia
Prm10           REGION1                                  Europe
Prm11           REGION1                                  North America
Prm12           REGION1                                  South America
Prm13           HBA1CBL


             Criteria For Assessing Goodness Of Fit

Criterion                     DF           Value        Value/DF

Log Likelihood                          -608.7306
Full Log Likelihood                     -608.7306
AIC (smaller is better)                 1235.4612
AICC (smaller is better)                1235.6408
BIC (smaller is better)                 1279.7383
```

Responder for HbA1c treatment target after 26 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_65

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	4.7175	1.2115	2.3431	7.0920	15.16	<.0001
ARM	IDegLira	1	1.1440	0.1390	0.8717	1.4164	67.77	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.3659	0.2502	-0.8563	0.1245	2.14	0.1436
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.7778	0.1502	0.4835	1.0722	26.83	<.0001
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	-0.4428	0.2830	-0.9975	0.1119	2.45	0.1177
REGION1	Asia	1	-1.1089	0.2980	-1.6929	-0.5248	13.85	0.0002
REGION1	Europe	1	-0.1851	0.1957	-0.5686	0.1984	0.90	0.3441
REGION1	North America	1	-0.6670	0.2468	-1.1508	-0.1833	7.30	0.0069
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.5971	0.1274	-0.8467	-0.3474	21.98	<.0001
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	0.5174	0.1139	4.54	<.0001	0.05	0.2942	0.7407	1.6777
IGlar	-0.6266	0.1136	-5.52	<.0001	0.05	-0.8491	-0.4040	0.5344

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	1.3421	2.0973
IGlar	0.4278	0.6676

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.1440	0.1390	8.23	<.0001	0.05	0.8717	1.4164

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	3.1394	2.3909	4.1222

Responder for HbA1c treatment target after 26 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_70

The GENMOD Procedure

Model Information

Data Set	WORK.ADRESP
Distribution	Binomial
Link Function	Logit
Dependent Variable	AVALC Analysis Value (C)

Number of Observations Read	1012
Number of Observations Used	1012
Number of Events	680
Number of Trials	1012

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America
HBA1CG1	2	<8.5 >=8.5

Response Profile

Ordered Value	AVALC	Total Frequency
1	Y	680
2	N	332

PROC GENMOD is modeling the probability that AVALC='Y'.

Parameter Information

Parameter	Effect	ARM	PREOAD	REGION1	HBA1CG1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1				<8.5
Prm5	HBA1CG1				>=8.5
Prm6	PREOAD		Non-SU users		
Prm7	PREOAD		SU users		
Prm8	REGION1			Africa	
Prm9	REGION1			Asia	
Prm10	REGION1			Europe	
Prm11	REGION1			North America	
Prm12	REGION1			South America	
Prm13	HBA1CBL				

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Log Likelihood		-565.4628	
Full Log Likelihood		-565.4628	
AIC (smaller is better)		1148.9256	
AICC (smaller is better)		1149.1053	
BIC (smaller is better)		1193.2028	

Responder for HbA1c treatment target after 26 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_70

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	5.3421	1.2195	2.9520	7.7323	19.19	<.0001
ARM	IDegLira	1	1.0243	0.1476	0.7350	1.3136	48.16	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.2395	0.2564	-0.7421	0.2631	0.87	0.3503
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.6570	0.1635	0.3365	0.9775	16.14	<.0001
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	-0.1461	0.2948	-0.7239	0.4317	0.25	0.6202
REGION1	Asia	1	-0.7030	0.2802	-1.2523	-0.1538	6.29	0.0121
REGION1	Europe	1	0.0059	0.2048	-0.3955	0.4074	0.00	0.9769
REGION1	North America	1	-0.3218	0.2512	-0.8141	0.1706	1.64	0.2002
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.5888	0.1274	-0.8384	-0.3391	21.36	<.0001
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	1.3434	0.1287	10.44	<.0001	0.05	1.0911	1.5957	3.8321
IGlar	0.3191	0.1113	2.87	0.0041	0.05	0.1010	0.5372	1.3759

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	2.9775	4.9319
IGlar	1.1063	1.7112

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.0243	0.1476	6.94	<.0001	0.05	0.7350	1.3136

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	2.7851	2.0855	3.7194

8: Responder for HbA1c treatment target after 104 weeks – supportive statistical analysis – full analysis set

```
Topic Code=HBA1C_BLOOD_65

The GENMOD Procedure

                     Model Information

Data Set              WORK.ADRESP
Distribution             Binomial
Link Function               Logit
Dependent Variable          AVALC    Analysis Value (C)


Number of Observations Read        1012
Number of Observations Used        1012
Number of Events                    329
Number of Trials                   1012


                      Class Level Information

Class        Levels    Values

ARM               2    IDegLira IGlar
PREOAD            2    Non-SU users SU users
REGION1           5    Africa Asia Europe North America South America
HBA1CG1           2    <8.5 >=8.5


       Response Profile

 Ordered                Total
   Value    AVALC    Frequency

       1    Y              329
       2    N              683

PROC GENMOD is modeling the probability that AVALC='Y'.


                            Parameter Information

Parameter       Effect       ARM         PREOAD          REGION1          HBA1CG1

Prm1            Intercept
Prm2            ARM          IDegLira
Prm3            ARM          IGlar
Prm4            HBA1CG1                                                   <8.5
Prm5            HBA1CG1                                                   >=8.5
Prm6            PREOAD                   Non-SU users
Prm7            PREOAD                   SU users
Prm8            REGION1                                  Africa
Prm9            REGION1                                  Asia
Prm10           REGION1                                  Europe
Prm11           REGION1                                  North America
Prm12           REGION1                                  South America
Prm13           HBA1CBL


             Criteria For Assessing Goodness Of Fit

Criterion                     DF           Value        Value/DF

Log Likelihood                          -571.6755
Full Log Likelihood                     -571.6755
AIC (smaller is better)                 1161.3509
AICC (smaller is better)                1161.5306
BIC (smaller is better)                 1205.6281
```

Responder for HbA1c treatment target after 104 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_65

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	4.1319	1.3205	1.5437	6.7200	9.79	0.0018
ARM	IDegLira	1	0.9580	0.1462	0.6715	1.2446	42.94	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.1891	0.2672	-0.7128	0.3346	0.50	0.4791
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.5387	0.1514	0.2420	0.8355	12.66	0.0004
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	-0.8505	0.3160	-1.4698	-0.2312	7.24	0.0071
REGION1	Asia	1	-0.6427	0.3144	-1.2590	-0.0265	4.18	0.0409
REGION1	Europe	1	-0.3329	0.2019	-0.7287	0.0628	2.72	0.0992
REGION1	North America	1	-0.2687	0.2546	-0.7677	0.2304	1.11	0.2913
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.6142	0.1396	-0.8878	-0.3406	19.35	<.0001
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	-0.3690	0.1140	-3.24	0.0012	0.05	-0.5925	-0.1455	0.6914
IGlar	-1.3271	0.1278	-10.39	<.0001	0.05	-1.5775	-1.0766	0.2653

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.5529	0.8646
IGlar	0.2065	0.3408

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	0.9580	0.1462	6.55	<.0001	0.05	0.6715	1.2446

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	2.6065	1.9571	3.4714

Responder for HbA1c treatment target after 104 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_70

The GENMOD Procedure

Model Information

Data Set	WORK.ADRESP
Distribution	Binomial
Link Function	Logit
Dependent Variable	AVALC Analysis Value (C)

Number of Observations Read	1012
Number of Observations Used	1012
Number of Events	425
Number of Trials	1012

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America
HBA1CG1	2	<8.5 >=8.5

Response Profile

Ordered Value	AVALC	Total Frequency
1	Y	425
2	N	587

PROC GENMOD is modeling the probability that AVALC='Y'.

Parameter Information

Parameter	Effect	ARM	PREOAD	REGION1	HBA1CG1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1				<8.5
Prm5	HBA1CG1				>=8.5
Prm6	PREOAD		Non-SU users		
Prm7	PREOAD		SU users		
Prm8	REGION1			Africa	
Prm9	REGION1			Asia	
Prm10	REGION1			Europe	
Prm11	REGION1			North America	
Prm12	REGION1			South America	
Prm13	HBA1CBL				

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Log Likelihood		-611.3774	
Full Log Likelihood		-611.3774	
AIC (smaller is better)		1240.7547	
AICC (smaller is better)		1240.9343	
BIC (smaller is better)		1285.0319	

Responder for HbA1c treatment target after 104 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_70

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	4.3456	1.2371	1.9210	6.7702	12.34	0.0004
ARM	IDegLira	1	1.1013	0.1386	0.8296	1.3731	63.10	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.1668	0.2519	-0.6605	0.3268	0.44	0.5077
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.4402	0.1473	0.1515	0.7288	8.93	0.0028
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	-0.6533	0.2920	-1.2257	-0.0810	5.00	0.0253
REGION1	Asia	1	-0.4556	0.2892	-1.0223	0.1111	2.48	0.1151
REGION1	Europe	1	-0.2547	0.1958	-0.6385	0.1290	1.69	0.1933
REGION1	North America	1	-0.3657	0.2472	-0.8503	0.1189	2.19	0.1391
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.5968	0.1304	-0.8523	-0.3412	20.95	<.0001
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	0.1708	0.1100	1.55	0.1206	0.05	-0.04485	0.3865	1.1863
IGlar	-0.9305	0.1163	-8.00	<.0001	0.05	-1.1585	-0.7026	0.3943

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.9561	1.4718
IGlar	0.3140	0.4953

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.1013	0.1386	7.94	<.0001	0.05	0.8296	1.3731

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	3.0082	2.2924	3.9475

9: Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 26 weeks – supportive statistical analysis – full analysis set

```
Topic Code=HBA1C_BLOOD_65_WO_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

                     Model Information

Data Set               WORK.ADRESP
Distribution              Binomial
Link Function                Logit
Dependent Variable           AVALC    Analysis Value (C)


Number of Observations Read        1012
Number of Observations Used        1012
Number of Events                    434
Number of Trials                   1012


                      Class Level Information

Class         Levels    Values

ARM                2    IDegLira IGlar
PREOAD             2    Non-SU users SU users
REGION1            5    Africa Asia Europe North America South America
HBA1CG1            2    <8.5 >=8.5


       Response Profile

 Ordered                 Total
   Value    AVALC    Frequency

       1    Y              434
       2    N              578

PROC GENMOD is modeling the probability that AVALC='Y'.


                             Parameter Information

Parameter       Effect       ARM         PREOAD          REGION1          HBA1CG1

Prm1            Intercept
Prm2            ARM          IDegLira
Prm3            ARM          IGlar
Prm4            HBA1CG1                                                   <8.5
Prm5            HBA1CG1                                                   >=8.5
Prm6            PREOAD                   Non-SU users
Prm7            PREOAD                   SU users
Prm8            REGION1                                  Africa
Prm9            REGION1                                  Asia
Prm10           REGION1                                  Europe
Prm11           REGION1                                  North America
Prm12           REGION1                                  South America
Prm13           HBA1CBL


             Criteria For Assessing Goodness Of Fit

Criterion                     DF           Value        Value/DF

Log Likelihood                          -599.2151
Full Log Likelihood                     -599.2151
AIC (smaller is better)                 1216.4301
AICC (smaller is better)                1216.6098
BIC (smaller is better)                 1260.7073
```

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 26 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_BLOOD_65_WO_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	4.4135	1.2375	1.9880	6.8389	12.72	0.0004
ARM	IDegLira	1	1.2533	0.1409	0.9771	1.5294	79.14	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.4574	0.2553	-0.9578	0.0430	3.21	0.0732
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.7031	0.1496	0.4099	0.9963	22.09	<.0001
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	-0.2353	0.2857	-0.7953	0.3247	0.68	0.4102
REGION1	Asia	1	-0.9047	0.3074	-1.5071	-0.3023	8.66	0.0032
REGION1	Europe	1	-0.0644	0.1966	-0.4497	0.3209	0.11	0.7432
REGION1	North America	1	-0.6270	0.2532	-1.1232	-0.1308	6.13	0.0133
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.6088	0.1305	-0.8645	-0.3531	21.78	<.0001
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	0.2545	0.1118	2.28	0.0229	0.05	0.03533	0.4737	1.2898
IGlar	-0.9988	0.1191	-8.38	<.0001	0.05	-1.2322	-0.7653	0.3683

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	1.0360	1.6059
IGlar	0.2916	0.4652

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.2533	0.1409	8.90	<.0001	0.05	0.9771	1.5294

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	3.5017	2.6569	4.6153

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 26 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_BLOOD_70_WO_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Model Information

Data Set	WORK.ADRESP
Distribution	Binomial
Link Function	Logit
Dependent Variable	AVALC Analysis Value (C)

Number of Observations Read	1012
Number of Observations Used	1012
Number of Events	588
Number of Trials	1012

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America
HBA1CG1	2	<8.5 >=8.5

Response Profile

Ordered Value	AVALC	Total Frequency
1	Y	588
2	N	424

PROC GENMOD is modeling the probability that AVALC='Y'.

Parameter Information

Parameter	Effect	ARM	PREOAD	REGION1	HBA1CG1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1				<8.5
Prm5	HBA1CG1				>=8.5
Prm6	PREOAD		Non-SU users		
Prm7	PREOAD		SU users		
Prm8	REGION1			Africa	
Prm9	REGION1			Asia	
Prm10	REGION1			Europe	
Prm11	REGION1			North America	
Prm12	REGION1			South America	
Prm13	HBA1CBL				

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Log Likelihood		-610.1005	
Full Log Likelihood		-610.1005	
AIC (smaller is better)		1238.2009	
AICC (smaller is better)		1238.3806	
BIC (smaller is better)		1282.4781	

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 26 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_BLOOD_70_WO_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	4.9657	1.1885	2.6363	7.2950	17.46	<.0001
ARM	IDegLira	1	1.0830	0.1391	0.8104	1.3557	60.62	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.4451	0.2479	-0.9310	0.0409	3.22	0.0726
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.5983	0.1519	0.3005	0.8960	15.51	<.0001
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	0.0950	0.2832	-0.4601	0.6501	0.11	0.7373
REGION1	Asia	1	-0.6647	0.2790	-1.2116	-0.1179	5.68	0.0172
REGION1	Europe	1	0.1072	0.1946	-0.2743	0.4887	0.30	0.5818
REGION1	North America	1	-0.3864	0.2419	-0.8604	0.0876	2.55	0.1101
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.5944	0.1247	-0.8388	-0.3501	22.73	<.0001
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	0.9086	0.1174	7.74	<.0001	0.05	0.6785	1.1387	2.4809
IGlar	-0.1744	0.1087	-1.60	0.1086	0.05	-0.3874	0.03861	0.8400

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	1.9710	3.1228
IGlar	0.6788	1.0394

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.0830	0.1391	7.79	<.0001	0.05	0.8104	1.3557

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	2.9536	2.2488	3.8793

10: Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 104 weeks – supportive statistical analysis – full analysis set

```
Topic Code=HBA1C_BLOOD_65_WO_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

                     Model Information

Data Set               WORK.ADRESP
Distribution              Binomial
Link Function                Logit
Dependent Variable           AVALC    Analysis Value (C)


Number of Observations Read        1012
Number of Observations Used        1012
Number of Events                    300
Number of Trials                   1012


                      Class Level Information

Class         Levels    Values

ARM                2    IDegLira IGlar
PREOAD             2    Non-SU users SU users
REGION1            5    Africa Asia Europe North America South America
HBA1CG1            2    <8.5 >=8.5


       Response Profile

 Ordered                 Total
   Value    AVALC    Frequency

       1    Y              300
       2    N              712

PROC GENMOD is modeling the probability that AVALC='Y'.


                             Parameter Information

Parameter       Effect       ARM          PREOAD          REGION1          HBA1CG1

Prm1            Intercept
Prm2            ARM          IDegLira
Prm3            ARM          IGlar
Prm4            HBA1CG1                                                    <8.5
Prm5            HBA1CG1                                                    >=8.5
Prm6            PREOAD                    Non-SU users
Prm7            PREOAD                    SU users
Prm8            REGION1                                    Africa
Prm9            REGION1                                    Asia
Prm10           REGION1                                    Europe
Prm11           REGION1                                    North America
Prm12           REGION1                                    South America
Prm13           HBA1CBL


             Criteria For Assessing Goodness Of Fit

Criterion                     DF           Value        Value/DF

Log Likelihood                          -549.7947
Full Log Likelihood                     -549.7947
AIC (smaller is better)                 1117.5894
AICC (smaller is better)                1117.7691
BIC (smaller is better)                 1161.8666
```

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 104 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_BLOOD_65_WO_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	3.9534	1.3653	1.2774	6.6293	8.38	0.0038
ARM	IDegLira	1	0.9733	0.1506	0.6780	1.2685	41.75	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.1399	0.2758	-0.6806	0.4007	0.26	0.6119
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.5172	0.1548	0.2139	0.8206	11.17	0.0008
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	-0.7561	0.3221	-1.3874	-0.1248	5.51	0.0189
REGION1	Asia	1	-0.5428	0.3212	-1.1722	0.0867	2.86	0.0910
REGION1	Europe	1	-0.2850	0.2063	-0.6893	0.1193	1.91	0.1671
REGION1	North America	1	-0.4146	0.2656	-0.9352	0.1059	2.44	0.1185
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.6171	0.1445	-0.9002	-0.3339	18.24	<.0001
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	-0.5235	0.1160	-4.51	<.0001	0.05	-0.7508	-0.2961	0.5925
IGlar	-1.4967	0.1332	-11.23	<.0001	0.05	-1.7578	-1.2356	0.2239

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.4720	0.7437
IGlar	0.1724	0.2907

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	0.9733	0.1506	6.46	<.0001	0.05	0.6780	1.2685

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	2.6466	1.9700	3.5555

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 104 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_BLOOD_70_WO_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Model Information

Data Set	WORK.ADRESP
Distribution	Binomial
Link Function	Logit
Dependent Variable	AVALC Analysis Value (C)

Number of Observations Read	1012
Number of Observations Used	1012
Number of Events	391
Number of Trials	1012

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America
HBA1CG1	2	<8.5 >=8.5

Response Profile

Ordered Value	AVALC	Total Frequency
1	Y	391
2	N	621

PROC GENMOD is modeling the probability that AVALC='Y'.

Parameter Information

Parameter	Effect	ARM	PREOAD	REGION1	HBA1CG1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1				<8.5
Prm5	HBA1CG1				>=8.5
Prm6	PREOAD		Non-SU users		
Prm7	PREOAD		SU users		
Prm8	REGION1			Africa	
Prm9	REGION1			Asia	
Prm10	REGION1			Europe	
Prm11	REGION1			North America	
Prm12	REGION1			South America	
Prm13	HBA1CBL				

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Log Likelihood		-601.1462	
Full Log Likelihood		-601.1462	
AIC (smaller is better)		1220.2923	
AICC (smaller is better)		1220.4720	
BIC (smaller is better)		1264.5695	

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes after 104 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_BLOOD_70_WO_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	4.0684	1.2581	1.6026	6.5343	10.46	0.0012
ARM	IDegLira	1	1.0898	0.1405	0.8144	1.3653	60.14	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.1372	0.2560	-0.6390	0.3647	0.29	0.5921
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.4106	0.1484	0.1197	0.7015	7.65	0.0057
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	-0.5455	0.2936	-1.1210	0.0300	3.45	0.0632
REGION1	Asia	1	-0.3516	0.2913	-0.9225	0.2193	1.46	0.2274
REGION1	Europe	1	-0.2366	0.1970	-0.6228	0.1496	1.44	0.2298
REGION1	North America	1	-0.5296	0.2534	-1.0262	-0.0330	4.37	0.0366
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.5835	0.1327	-0.8435	-0.3235	19.34	<.0001
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	0.008132	0.1098	0.07	0.9410	0.05	-0.2072	0.2234	1.0082
IGlar	-1.0817	0.1194	-9.06	<.0001	0.05	-1.3158	-0.8476	0.3390

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.8129	1.2504
IGlar	0.2683	0.4284

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.0898	0.1405	7.76	<.0001	0.05	0.8144	1.3653

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	2.9738	2.2578	3.9168

11: Responder for HbA1c treatment target without weight gain after 26 weeks – supportive statistical analysis – full analysis set

```
Topic Code=HBA1C_BLOOD_65_WO_WEIGHT_GAIN

The GENMOD Procedure

                     Model Information

Data Set              WORK.ADRESP
Distribution             Binomial
Link Function               Logit
Dependent Variable          AVALC    Analysis Value (C)


Number of Observations Read        1012
Number of Observations Used        1012
Number of Events                    218
Number of Trials                   1012


                      Class Level Information

Class        Levels    Values

ARM               2    IDegLira IGlar
PREOAD            2    Non-SU users SU users
REGION1           5    Africa Asia Europe North America South America
HBA1CG1           2    <8.5 >=8.5


       Response Profile

 Ordered                Total
   Value    AVALC    Frequency

       1    Y              218
       2    N              794

PROC GENMOD is modeling the probability that AVALC='Y'.


                            Parameter Information

Parameter       Effect       ARM         PREOAD          REGION1          HBA1CG1

Prm1            Intercept
Prm2            ARM          IDegLira
Prm3            ARM          IGlar
Prm4            HBA1CG1                                                   <8.5
Prm5            HBA1CG1                                                   >=8.5
Prm6            PREOAD                   Non-SU users
Prm7            PREOAD                   SU users
Prm8            REGION1                                  Africa
Prm9            REGION1                                  Asia
Prm10           REGION1                                  Europe
Prm11           REGION1                                  North America
Prm12           REGION1                                  South America
Prm13           HBA1CBL
Prm14           WGTBL


            Criteria For Assessing Goodness Of Fit

Criterion                     DF           Value        Value/DF

Log Likelihood                          -452.4568
Full Log Likelihood                     -452.4568
AIC (smaller is better)                  924.9136
AICC (smaller is better)                 925.1334
BIC (smaller is better)                  974.1105
```

Responder for HbA1c treatment target without weight gain after 26 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_65_WO_WEIGHT_GAIN

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	-0.0068	1.5594	-3.0632	3.0495	0.00	0.9965
ARM	IDegLira	1	1.4927	0.1823	1.1354	1.8500	67.03	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.1547	0.3158	-0.7737	0.4643	0.24	0.6242
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.3690	0.1715	0.0328	0.7051	4.63	0.0315
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	0.2069	0.3614	-0.5015	0.9152	0.33	0.5670
REGION1	Asia	1	-0.3141	0.4451	-1.1864	0.5582	0.50	0.4804
REGION1	Europe	1	0.5781	0.2548	0.0788	1.0775	5.15	0.0233
REGION1	North America	1	-0.0575	0.3348	-0.7137	0.5987	0.03	0.8637
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.4443	0.1603	-0.7585	-0.1302	7.68	0.0056
WGTBL		1	0.0126	0.0043	0.0042	0.0211	8.52	0.0035
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	-0.9669	0.1311	-7.38	<.0001	0.05	-1.2238	-0.7099	0.3803
IGlar	-2.4596	0.1774	-13.87	<.0001	0.05	-2.8072	-2.1119	0.08547

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.2941	0.4917
IGlar	0.06037	0.1210

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.4927	0.1823	8.19	<.0001	0.05	1.1354	1.8500

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	4.4491	3.1123	6.3601

Responder for HbA1c treatment target without weight gain after 26 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_70_WO_WEIGHT_GAIN

The GENMOD Procedure

Model Information

Data Set	WORK.ADRESP
Distribution	Binomial
Link Function	Logit
Dependent Variable	AVALC Analysis Value (C)

Number of Observations Read	1012
Number of Observations Used	1012
Number of Events	273
Number of Trials	1012

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America
HBA1CG1	2	<8.5 >=8.5

Response Profile

Ordered Value	AVALC	Total Frequency
1	Y	273
2	N	739

PROC GENMOD is modeling the probability that AVALC='Y'.

Parameter Information

Parameter	Effect	ARM	PREOAD	REGION1	HBA1CG1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1				<8.5
Prm5	HBA1CG1				>=8.5
Prm6	PREOAD		Non-SU users		
Prm7	PREOAD		SU users		
Prm8	REGION1			Africa	
Prm9	REGION1			Asia	
Prm10	REGION1			Europe	
Prm11	REGION1			North America	
Prm12	REGION1			South America	
Prm13	HBA1CBL				
Prm14	WGTBL				

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Log Likelihood		-524.9233	
Full Log Likelihood		-524.9233	
AIC (smaller is better)		1069.8465	
AICC (smaller is better)		1070.0663	
BIC (smaller is better)		1119.0434	

Responder for HbA1c treatment target without weight gain after 26 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_70_WO_WEIGHT_GAIN

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	0.8609	1.4109	-1.9044	3.6263	0.37	0.5417
ARM	IDegLira	1	1.1970	0.1582	0.8868	1.5071	57.22	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.1022	0.2851	-0.6609	0.4566	0.13	0.7200
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.2215	0.1588	-0.0896	0.5327	1.95	0.1629
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	0.4644	0.3234	-0.1694	1.0982	2.06	0.1510
REGION1	Asia	1	0.0663	0.3600	-0.6393	0.7719	0.03	0.8538
REGION1	Europe	1	0.5640	0.2331	0.1071	1.0210	5.85	0.0156
REGION1	North America	1	0.0799	0.3012	-0.5104	0.6702	0.07	0.7908
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.4481	0.1453	-0.7329	-0.1634	9.51	0.0020
WGTBL		1	0.0091	0.0040	0.0013	0.0170	5.19	0.0227
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	-0.6362	0.1173	-5.42	<.0001	0.05	-0.8661	-0.4063	0.5293
IGlar	-1.8332	0.1442	-12.72	<.0001	0.05	-2.1157	-1.5506	0.1599

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.4206	0.6661
IGlar	0.1205	0.2121

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.1970	0.1582	7.56	<.0001	0.05	0.8868	1.5071

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	3.3101	2.4274	4.5137

12: Responder for HbA1c treatment target without weight gain after 104 weeks – supportive statistical analysis – full analysis set

```
Topic Code=HBA1C_BLOOD_65_WO_WEIGHT_GAIN

The GENMOD Procedure

                     Model Information

Data Set              WORK.ADRESP
Distribution             Binomial
Link Function               Logit
Dependent Variable          AVALC    Analysis Value (C)


Number of Observations Read        1012
Number of Observations Used        1012
Number of Events                    118
Number of Trials                   1012


                      Class Level Information

Class        Levels    Values

ARM               2    IDegLira IGlar
PREOAD            2    Non-SU users SU users
REGION1           5    Africa Asia Europe North America South America
HBA1CG1           2    <8.5 >=8.5


       Response Profile

 Ordered                Total
   Value    AVALC    Frequency

       1    Y              118
       2    N              894

PROC GENMOD is modeling the probability that AVALC='Y'.


                            Parameter Information

Parameter       Effect       ARM         PREOAD          REGION1          HBA1CG1

Prm1            Intercept
Prm2            ARM          IDegLira
Prm3            ARM          IGlar
Prm4            HBA1CG1                                                   <8.5
Prm5            HBA1CG1                                                   >=8.5
Prm6            PREOAD                   Non-SU users
Prm7            PREOAD                   SU users
Prm8            REGION1                                  Africa
Prm9            REGION1                                  Asia
Prm10           REGION1                                  Europe
Prm11           REGION1                                  North America
Prm12           REGION1                                  South America
Prm13           HBA1CBL
Prm14           WGTBL


            Criteria For Assessing Goodness Of Fit

Criterion                     DF           Value        Value/DF

Log Likelihood                          -331.7826
Full Log Likelihood                     -331.7826
AIC (smaller is better)                  683.5651
AICC (smaller is better)                 683.7849
BIC (smaller is better)                  732.7619
```

Responder for HbA1c treatment target without weight gain after 104 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_65_WO_WEIGHT_GAIN

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	-0.1576	1.9613	-4.0017	3.6865	0.01	0.9360
ARM	IDegLira	1	1.1670	0.2275	0.7211	1.6129	26.31	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	0.1366	0.4003	-0.6479	0.9211	0.12	0.7329
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.1511	0.2117	-0.2640	0.5661	0.51	0.4756
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	0.3212	0.4343	-0.5300	1.1723	0.55	0.4596
REGION1	Asia	1	0.2353	0.4747	-0.6951	1.1657	0.25	0.6202
REGION1	Europe	1	0.3382	0.3180	-0.2850	0.9614	1.13	0.2875
REGION1	North America	1	-0.0689	0.4221	-0.8961	0.7583	0.03	0.8703
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.4272	0.2022	-0.8235	-0.0309	4.46	0.0346
WGTBL		1	0.0064	0.0052	-0.0038	0.0166	1.50	0.2209
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	-1.7368	0.1563	-11.11	<.0001	0.05	-2.0431	-1.4305	0.1761
IGlar	-2.9038	0.2147	-13.52	<.0001	0.05	-3.3246	-2.4830	0.05482

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.1296	0.2392
IGlar	0.03599	0.08350

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.1670	0.2275	5.13	<.0001	0.05	0.7211	1.6129

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	3.2122	2.0566	5.0172

Responder for HbA1c treatment target without weight gain after 104 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_70_WO_WEIGHT_GAIN

The GENMOD Procedure

Model Information

Data Set	WORK.ADRESP
Distribution	Binomial
Link Function	Logit
Dependent Variable	AVALC Analysis Value (C)

Number of Observations Read	1012
Number of Observations Used	1012
Number of Events	138
Number of Trials	1012

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America
HBA1CG1	2	<8.5 >=8.5

Response Profile

Ordered Value	AVALC	Total Frequency
1	Y	138
2	N	874

PROC GENMOD is modeling the probability that AVALC='Y'.

Parameter Information

Parameter	Effect	ARM	PREOAD	REGION1	HBA1CG1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1				<8.5
Prm5	HBA1CG1				>=8.5
Prm6	PREOAD		Non-SU users		
Prm7	PREOAD		SU users		
Prm8	REGION1			Africa	
Prm9	REGION1			Asia	
Prm10	REGION1			Europe	
Prm11	REGION1			North America	
Prm12	REGION1			South America	
Prm13	HBA1CBL				
Prm14	WGTBL				

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Log Likelihood		-362.5736	
Full Log Likelihood		-362.5736	
AIC (smaller is better)		745.1472	
AICC (smaller is better)		745.3669	
BIC (smaller is better)		794.3440	

Responder for HbA1c treatment target without weight gain after 104 weeks – supportive statistical analysis – full analysis set

Topic Code=HBA1C_BLOOD_70_WO_WEIGHT_GAIN

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	-0.8911	1.8322	-4.4822	2.7000	0.24	0.6267
ARM	IDegLira	1	1.2884	0.2163	0.8646	1.7123	35.50	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	0.2350	0.3749	-0.4998	0.9697	0.39	0.5308
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.0387	0.2015	-0.3563	0.4336	0.04	0.8477
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	0.2639	0.4077	-0.5352	1.0630	0.42	0.5175
REGION1	Asia	1	0.3309	0.4366	-0.5248	1.1865	0.57	0.4485
REGION1	Europe	1	0.2993	0.2960	-0.2809	0.8795	1.02	0.3120
REGION1	North America	1	-0.1449	0.3957	-0.9204	0.6307	0.13	0.7143
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.3656	0.1883	-0.7347	0.0034	3.77	0.0521
WGTBL		1	0.0101	0.0049	0.0005	0.0198	4.26	0.0391
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	-1.5143	0.1455	-10.40	<.0001	0.05	-1.7995	-1.2290	0.2200
IGlar	-2.8027	0.2042	-13.72	<.0001	0.05	-3.2030	-2.4024	0.06065

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.1654	0.2926
IGlar	0.04064	0.09050

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.2884	0.2163	5.96	<.0001	0.05	0.8646	1.7123

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	3.6270	2.3740	5.5415

13: Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes and weight gain after 26 weeks – supportive statistical analysis – full analysis set

```
Topic Code=HBA1C_65_WO_WEIGHT_GAIN_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

                     Model Information

Data Set               WORK.ADRESP
Distribution              Binomial
Link Function                Logit
Dependent Variable           AVALC    Analysis Value (C)


Number of Observations Read        1012
Number of Observations Used        1012
Number of Events                    197
Number of Trials                   1012


                      Class Level Information

Class         Levels    Values

ARM                2    IDegLira IGlar
PREOAD             2    Non-SU users SU users
REGION1            5    Africa Asia Europe North America South America
HBA1CG1            2    <8.5 >=8.5


       Response Profile

 Ordered                 Total
   Value    AVALC    Frequency

       1    Y              197
       2    N              815

PROC GENMOD is modeling the probability that AVALC='Y'.


                             Parameter Information

Parameter       Effect       ARM         PREOAD          REGION1          HBA1CG1

Prm1            Intercept
Prm2            ARM          IDegLira
Prm3            ARM          IGlar
Prm4            HBA1CG1                                                   <8.5
Prm5            HBA1CG1                                                   >=8.5
Prm6            PREOAD                   Non-SU users
Prm7            PREOAD                   SU users
Prm8            REGION1                                  Africa
Prm9            REGION1                                  Asia
Prm10           REGION1                                  Europe
Prm11           REGION1                                  North America
Prm12           REGION1                                  South America
Prm13           HBA1CBL
Prm14           WGTBL


             Criteria For Assessing Goodness Of Fit

Criterion                     DF           Value        Value/DF

Log Likelihood                          -424.2283
Full Log Likelihood                     -424.2283
AIC (smaller is better)                  868.4567
AICC (smaller is better)                 868.6764
BIC (smaller is better)                  917.6535
```

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes and weight gain after 26 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_65_WO_WEIGHT_GAIN_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	0.2926	1.6420	-2.9258	3.5109	0.03	0.8586
ARM	IDegLira	1	1.5000	0.1918	1.1241	1.8760	61.15	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.2290	0.3309	-0.8775	0.4195	0.48	0.4888
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.4097	0.1775	0.0617	0.7577	5.33	0.0210
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	0.2975	0.3834	-0.4540	1.0489	0.60	0.4379
REGION1	Asia	1	-0.1921	0.4753	-1.1237	0.7395	0.16	0.6861
REGION1	Europe	1	0.7059	0.2737	0.1695	1.2423	6.65	0.0099
REGION1	North America	1	0.0159	0.3577	-0.6852	0.7171	0.00	0.9645
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.5147	0.1693	-0.8466	-0.1828	9.24	0.0024
WGTBL		1	0.0132	0.0045	0.0045	0.0220	8.73	0.0031
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	-1.1397	0.1378	-8.27	<.0001	0.05	-1.4097	-0.8696	0.3199
IGlar	-2.6397	0.1891	-13.96	<.0001	0.05	-3.0103	-2.2690	0.07138

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.2442	0.4191
IGlar	0.04928	0.1034

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.5000	0.1918	7.82	<.0001	0.05	1.1241	1.8760

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	4.4818	3.0773	6.5273

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes and weight gain after 26 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_70_WO_WEIGHT_GAIN_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Model Information

Data Set	WORK.ADRESP
Distribution	Binomial
Link Function	Logit
Dependent Variable	AVALC Analysis Value (C)

Number of Observations Read	1012
Number of Observations Used	1012
Number of Events	247
Number of Trials	1012

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America
HBA1CG1	2	<8.5 >=8.5

Response Profile

Ordered Value	AVALC	Total Frequency
1	Y	247
2	N	765

PROC GENMOD is modeling the probability that AVALC='Y'.

Parameter Information

Parameter	Effect	ARM	PREOAD	REGION1	HBA1CG1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1				<8.5
Prm5	HBA1CG1				>=8.5
Prm6	PREOAD		Non-SU users		
Prm7	PREOAD		SU users		
Prm8	REGION1			Africa	
Prm9	REGION1			Asia	
Prm10	REGION1			Europe	
Prm11	REGION1			North America	
Prm12	REGION1			South America	
Prm13	HBA1CBL				
Prm14	WGTBL				

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Log Likelihood		-497.9125	
Full Log Likelihood		-497.9125	
AIC (smaller is better)		1015.8250	
AICC (smaller is better)		1016.0448	
BIC (smaller is better)		1065.0219	

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes and weight gain after 26 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_70_WO_WEIGHT_GAIN_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	1.3824	1.4728	-1.5043	4.2691	0.88	0.3479
ARM	IDegLira	1	1.1986	0.1649	0.8754	1.5219	52.83	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.2553	0.2962	-0.8358	0.3253	0.74	0.3888
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.3051	0.1632	-0.0148	0.6249	3.50	0.0616
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	0.6116	0.3378	-0.0505	1.2737	3.28	0.0702
REGION1	Asia	1	0.2305	0.3757	-0.5058	0.9668	0.38	0.5395
REGION1	Europe	1	0.6936	0.2481	0.2074	1.1799	7.82	0.0052
REGION1	North America	1	0.1070	0.3211	-0.5224	0.7364	0.11	0.7389
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.5245	0.1521	-0.8227	-0.2263	11.88	0.0006
WGTBL		1	0.0082	0.0041	0.0001	0.0163	3.94	0.0472
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	-0.7867	0.1208	-6.51	<.0001	0.05	-1.0235	-0.5500	0.4553
IGlar	-1.9854	0.1514	-13.11	<.0001	0.05	-2.2821	-1.6886	0.1373

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.3593	0.5769
IGlar	0.1021	0.1848

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.1986	0.1649	7.27	<.0001	0.05	0.8754	1.5219

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	3.3156	2.3999	4.5808

14: Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes and weight gain after 104 weeks – supportive statistical analysis – full analysis set

```
Topic Code=HBA1C_65_WO_WEIGHT_GAIN_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

                     Model Information

Data Set               WORK.ADRESP
Distribution              Binomial
Link Function                Logit
Dependent Variable           AVALC    Analysis Value (C)


Number of Observations Read        1012
Number of Observations Used        1012
Number of Events                    112
Number of Trials                   1012


                      Class Level Information

Class         Levels    Values

ARM                2    IDegLira IGlar
PREOAD             2    Non-SU users SU users
REGION1            5    Africa Asia Europe North America South America
HBA1CG1            2    <8.5 >=8.5


       Response Profile

 Ordered                 Total
   Value    AVALC    Frequency

       1    Y              112
       2    N              900

PROC GENMOD is modeling the probability that AVALC='Y'.


                             Parameter Information

Parameter       Effect       ARM         PREOAD          REGION1          HBA1CG1

Prm1            Intercept
Prm2            ARM          IDegLira
Prm3            ARM          IGlar
Prm4            HBA1CG1                                                   <8.5
Prm5            HBA1CG1                                                   >=8.5
Prm6            PREOAD                   Non-SU users
Prm7            PREOAD                   SU users
Prm8            REGION1                                  Africa
Prm9            REGION1                                  Asia
Prm10           REGION1                                  Europe
Prm11           REGION1                                  North America
Prm12           REGION1                                  South America
Prm13           HBA1CBL
Prm14           WGTBL


             Criteria For Assessing Goodness Of Fit

Criterion                     DF           Value        Value/DF

Log Likelihood                          -320.2441
Full Log Likelihood                     -320.2441
AIC (smaller is better)                  660.4883
AICC (smaller is better)                 660.7081
BIC (smaller is better)                  709.6851
```

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes and weight gain after 104 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_65_WO_WEIGHT_GAIN_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	-0.3508	2.0141	-4.2983	3.5967	0.03	0.8617
ARM	IDegLira	1	1.1301	0.2319	0.6756	1.5846	23.75	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	0.1495	0.4112	-0.6565	0.9554	0.13	0.7162
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.1613	0.2161	-0.2622	0.5849	0.56	0.4553
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	0.2726	0.4486	-0.6066	1.1518	0.37	0.5433
REGION1	Asia	1	0.1722	0.4977	-0.8032	1.1477	0.12	0.7293
REGION1	Europe	1	0.3820	0.3260	-0.2569	1.0209	1.37	0.2412
REGION1	North America	1	-0.2068	0.4445	-1.0780	0.6645	0.22	0.6419
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.4216	0.2076	-0.8285	-0.0147	4.12	0.0423
WGTBL		1	0.0074	0.0053	-0.0030	0.0179	1.96	0.1620
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	-1.8551	0.1631	-11.38	<.0001	0.05	-2.1747	-1.5355	0.1564
IGlar	-2.9852	0.2212	-13.50	<.0001	0.05	-3.4188	-2.5517	0.05053

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.1136	0.2153
IGlar	0.03275	0.07795

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.1301	0.2319	4.87	<.0001	0.05	0.6756	1.5846

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	3.0960	1.9652	4.8775

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes and weight gain after 104 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_70_WO_WEIGHT_GAIN_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Model Information

Data Set	WORK.ADRESP
Distribution	Binomial
Link Function	Logit
Dependent Variable	AVALC Analysis Value (C)

Number of Observations Read	1012
Number of Observations Used	1012
Number of Events	132
Number of Trials	1012

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America
HBA1CG1	2	<8.5 >=8.5

Response Profile

Ordered Value	AVALC	Total Frequency
1	Y	132
2	N	880

PROC GENMOD is modeling the probability that AVALC='Y'.

Parameter Information

Parameter	Effect	ARM	PREOAD	REGION1	HBA1CG1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1				<8.5
Prm5	HBA1CG1				>=8.5
Prm6	PREOAD		Non-SU users		
Prm7	PREOAD		SU users		
Prm8	REGION1			Africa	
Prm9	REGION1			Asia	
Prm10	REGION1			Europe	
Prm11	REGION1			North America	
Prm12	REGION1			South America	
Prm13	HBA1CBL				
Prm14	WGTBL				

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Log Likelihood		-352.2166	
Full Log Likelihood		-352.2166	
AIC (smaller is better)		724.4331	
AICC (smaller is better)		724.6529	
BIC (smaller is better)		773.6300	

Responder for HbA1c treatment target without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes and weight gain after 104 weeks - supportive statistical analysis - full analysis set

Topic Code=HBA1C_70_WO_WEIGHT_GAIN_A2013_SEVERE_CONF_SYMP_HYPO

The GENMOD Procedure

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	-1.1024	1.8725	-4.7725	2.5677	0.35	0.5561
ARM	IDegLira	1	1.2584	0.2199	0.8275	1.6893	32.76	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	0.2505	0.3833	-0.5008	1.0017	0.43	0.5135
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	0.0440	0.2050	-0.3577	0.4457	0.05	0.8300
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	0.2169	0.4186	-0.6036	1.0373	0.27	0.6044
REGION1	Asia	1	0.2835	0.4524	-0.6032	1.1702	0.39	0.5309
REGION1	Europe	1	0.3358	0.3019	-0.2558	0.9275	1.24	0.2659
REGION1	North America	1	-0.2696	0.4132	-1.0794	0.5402	0.43	0.5141
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
HBA1CBL		1	-0.3571	0.1923	-0.7340	0.0199	3.45	0.0634
WGTBL		1	0.0112	0.0050	0.0014	0.0210	5.01	0.0252
Scale		0	1.0000	0.0000	1.0000	1.0000		

NOTE: The scale parameter was held fixed.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	-1.6166	0.1506	-10.74	<.0001	0.05	-1.9117	-1.3215	0.1986
IGlar	-2.8750	0.2095	-13.72	<.0001	0.05	-3.2855	-2.4644	0.05642

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	0.1478	0.2667
IGlar	0.03742	0.08506

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	1.2584	0.2199	5.72	<.0001	0.05	0.8275	1.6893

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	3.5197	2.2875	5.4155

15: Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

```
topic_cd=BODY_WEIGHT

The Mixed Procedure

                  Model Information

Data Set                      WORK.BW_MMRM
Dependent Variable            AVAL
Covariance Structure          Unstructured
Subject Effect                USUBJID
Estimation Method             REML
Residual Variance Method      None
Fixed Effects SE Method       Kenward-Roger
Degrees of Freedom Method     Kenward-Roger


               Class Level Information

Class        Levels    Values

treatment         2    IDegLira IGlar
region            5    Africa Asia Europe North
                       America South America
avisitn           6    50 60 70 90 110 130
```

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228/[redacted] NN9068-4228/[redacted]

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	21
Columns in X	73
Columns in Z	0
Subjects	1012
Max Obs per Subject	6

Number of Observations

Number of Observations Read	6072
Number of Observations Used	4710
Number of Observations Not Used	1362

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	25164.24573730	
1	2	20801.70333156	0.00212677
2	1	20786.35816555	0.00025819
3	1	20784.64160381	0.00000556
4	1	20784.60710117	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	2.7056
UN(2,1)	USUBJID	2.6339
UN(2,2)	USUBJID	6.2372
UN(3,1)	USUBJID	2.8816
UN(3,2)	USUBJID	6.4627
UN(3,3)	USUBJID	11.5897
UN(4,1)	USUBJID	2.6868
UN(4,2)	USUBJID	5.6714

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(4,3)	USUBJID	10.7060
UN(4,4)	USUBJID	17.5737
UN(5,1)	USUBJID	2.4203
UN(5,2)	USUBJID	5.0242
UN(5,3)	USUBJID	10.5416
UN(5,4)	USUBJID	16.2041
UN(5,5)	USUBJID	22.9400
UN(6,1)	USUBJID	2.4726
UN(6,2)	USUBJID	4.7116
UN(6,3)	USUBJID	9.5346
UN(6,4)	USUBJID	15.7463
UN(6,5)	USUBJID	20.0930
UN(6,6)	USUBJID	24.6992

Fit Statistics

-2 Res Log Likelihood	20784.6
AIC (Smaller is Better)	20826.6
AICC (Smaller is Better)	20826.8
BIC (Smaller is Better)	20929.9

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
20	4379.64	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	6	808	11.11	<.0001
region(avisitn)	24	1853	1.49	0.0605
PREOAD(avisitn)	6	772	2.89	0.0086
HBA1CG1(avisitn)	6	811	6.69	<.0001
base(avisitn)	6	804	20607.6	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0879
region(avisitn)		Asia			50	0.0909
region(avisitn)		Europe			50	0.4911
region(avisitn)		North America			50	0.1502
region(avisitn)		South America			50	0.1798
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3538
PREOAD(avisitn)			SU users		50	0.6462
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5306
HBA1CG1(avisitn)				>=8.5	50	0.4694
HBA1CG1(avisitn)				<8.5	60	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	89.392
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IDegLira	WORK.BW_MMRM	88.9978	0.07412	983.6	1200.65

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira	<.0001	0.05	88.8523	89.1432

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0879

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			50	0.0909
region(avisitn)		Europe			50	0.4911
region(avisitn)		North America			50	0.1502
region(avisitn)		South America			50	0.1798
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3538
PREOAD(avisitn)			SU users		50	0.6462
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5306
HBA1CG1(avisitn)				>=8.5	50	0.4694
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	89.392
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IGlar	WORK.BW_MMRM	89.5165	0.07424	984.5	1205.76

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IGlar	<.0001	0.05	89.3708	89.6621

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	-1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V050 IDegLira - IGlar	WORK.BW_MMRM	-0.5187	0.1054	984

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira - IGlar	-4.92	<.0001	0.05	-0.7255	-0.3119

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	89.392
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.BW_MMRM	89.3745	0.1131	974.8	790.47

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	<.0001	0.05	89.1526	89.5964

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	89.392
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.BW_MMRM	90.3277	0.1136	980.1	795.06

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	90.1048	90.5507

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.BW_MMRM	-0.9532	0.1610	977.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	-5.92	<.0001	0.05	-1.2692	-0.6372

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	89.392
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.BW_MMRM	89.9307	0.1548	959.5	580.78

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	89.6268	90.2346

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	89.392
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.BW_MMRM	91.4966	0.1563	970.9	585.31

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	91.1898	91.8034

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.BW_MMRM	-1.5659	0.2210	965.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-7.08	<.0001	0.05	-1.9996	-1.1321

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	89.392
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.BW_MMRM	90.5751	0.2006	827.8	451.46

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	90.1813	90.9689

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	89.392
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.BW_MMRM	92.6756	0.2192	916.6	422.69

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	92.2453	93.1059

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.BW_MMRM	-2.1005	0.2972	873.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-7.07	<.0001	0.05	-2.6838	-1.5172

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	89.392
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.BW_MMRM	90.8081	0.2387	738.3	380.37

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	90.3394	91.2768

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	89.392
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.BW_MMRM	93.1016	0.2733	818.3	340.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	92.5652	93.6380

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.BW_MMRM	-2.2935	0.3613	781

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	-6.35	<.0001	0.05	-3.0026	-1.5843

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	89.392

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.BW_MMRM	91.0772	0.2550	653.1	357.16

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	90.5764	91.5779

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	89.392

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.BW_MMRM	92.7781	0.3042	732.5	305.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	92.1810	93.3752

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.BW_MMRM	-1.7009	0.3936	695.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.32	<.0001	0.05	-2.4736	-0.9282

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Model Information

Data Set	WORK.BW_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	6	50 60 70 90 110 130

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	21
Columns in X	73
Columns in Z	0
Subjects	1012
Max Obs per Subject	6

Number of Observations

Number of Observations Read	6072
Number of Observations Used	4710
Number of Observations Not Used	1362

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	32535.39312323	
1	2	28172.85071750	0.00132758
2	1	28157.50555146	0.00016109
3	1	28155.78898975	0.00000347
4	1	28155.75448709	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	13.1503
UN(2,1)	USUBJID	12.8016
UN(2,2)	USUBJID	30.3152
UN(3,1)	USUBJID	14.0056
UN(3,2)	USUBJID	31.4112
UN(3,3)	USUBJID	56.3303
UN(4,1)	USUBJID	13.0587
UN(4,2)	USUBJID	27.5648

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(4,3)	USUBJID	52.0350
UN(4,4)	USUBJID	85.4144
UN(5,1)	USUBJID	11.7635
UN(5,2)	USUBJID	24.4195
UN(5,3)	USUBJID	51.2358
UN(5,4)	USUBJID	78.7577
UN(5,5)	USUBJID	111.50
UN(6,1)	USUBJID	12.0175
UN(6,2)	USUBJID	22.9003
UN(6,3)	USUBJID	46.3414
UN(6,4)	USUBJID	76.5328
UN(6,5)	USUBJID	97.6590
UN(6,6)	USUBJID	120.05

Fit Statistics

-2 Res Log Likelihood	28155.8
AIC (Smaller is Better)	28197.8
AICC (Smaller is Better)	28198.0
BIC (Smaller is Better)	28301.1

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
20	4379.64	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	6	808	11.11	<.0001
region(avisitn)	24	1853	1.49	0.0605
PREOAD(avisitn)	6	772	2.89	0.0086
HBA1CG1(avisitn)	6	811	6.69	<.0001
base(avisitn)	6	804	20607.6	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0879
region(avisitn)		Asia			50	0.0909
region(avisitn)		Europe			50	0.4911
region(avisitn)		North America			50	0.1502
region(avisitn)		South America			50	0.1798
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3538
PREOAD(avisitn)			SU users		50	0.6462
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5306
HBA1CG1(avisitn)				>=8.5	50	0.4694
HBA1CG1(avisitn)				<8.5	60	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	197.07
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IDegLira	WORK.BW_MMRM	196.21	0.1634	983.6	1200.65

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira	<.0001	0.05	195.89	196.53

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0879

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			50	0.0909
region(avisitn)		Europe			50	0.4911
region(avisitn)		North America			50	0.1502
region(avisitn)		South America			50	0.1798
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3538
PREOAD(avisitn)			SU users		50	0.6462
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5306
HBA1CG1(avisitn)				>=8.5	50	0.4694
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	197.07
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IGlar	WORK.BW_MMRM	197.35	0.1637	984.5	1205.76

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IGlar	<.0001	0.05	197.03	197.67

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	-1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V050 IDegLira - IGlar	WORK.BW_MMRM	-1.1435	0.2323	984

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira - IGlar	-4.92	<.0001	0.05	-1.5994	-0.6876

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	197.07
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.BW_MMRM	197.04	0.2493	974.8	790.47

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	<.0001	0.05	196.55	197.53

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	197.07
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.BW_MMRM	199.14	0.2505	980.1	795.06

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	198.65	199.63

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.BW_MMRM	-2.1014	0.3550	977.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	-5.92	<.0001	0.05	-2.7980	-1.4048

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	197.07
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.BW_MMRM	198.26	0.3414	959.5	580.78

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	197.59	198.93

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	197.07
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.BW_MMRM	201.72	0.3446	970.9	585.31

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	201.04	202.39

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.BW_MMRM	-3.4522	0.4873	965.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-7.08	<.0001	0.05	-4.4084	-2.4959

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	197.07
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.BW_MMRM	199.68	0.4423	827.8	451.46

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	198.82	200.55

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	197.07
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.BW_MMRM	204.31	0.4834	916.6	422.69

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	203.37	205.26

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.BW_MMRM	-4.6308	0.6552	873.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-7.07	<.0001	0.05	-5.9167	-3.3449

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	197.07
base(avisitn)					130	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.BW_MMRM	200.20	0.5263	738.3	380.37

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	199.16	201.23

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	197.07
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.BW_MMRM	205.25	0.6025	818.3	340.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	204.07	206.44

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.BW_MMRM	-5.0563	0.7964	781

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	-6.35	<.0001	0.05	-6.6197	-3.4928

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	197.07

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.BW_MMRM	200.79	0.5622	653.1	357.16

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	199.69	201.89

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	197.07

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.BW_MMRM	204.54	0.6705	732.5	305.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	203.22	205.86

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.BW_MMRM	-3.7498	0.8676	695.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.32	<.0001	0.05	-5.4533	-2.0463

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Model Information

Data Set	WORK.BW_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	6	50 60 70 90 110 130

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

               Class Level Information

Class        Levels    Values

USUBJID        1012    NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
```

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	21
Columns in X	73
Columns in Z	0
Subjects	1012
Max Obs per Subject	6

Number of Observations

Number of Observations Read	6072
Number of Observations Used	4710
Number of Observations Not Used	1362

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	25164.24573730	
1	2	20801.70333156	0.00212677
2	1	20786.35816555	0.00025819
3	1	20784.64160381	0.00000556
4	1	20784.60710117	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	2.7056
UN(2,1)	USUBJID	2.6339
UN(2,2)	USUBJID	6.2372
UN(3,1)	USUBJID	2.8816
UN(3,2)	USUBJID	6.4627
UN(3,3)	USUBJID	11.5897
UN(4,1)	USUBJID	2.6868
UN(4,2)	USUBJID	5.6714

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(4,3)	USUBJID	10.7060
UN(4,4)	USUBJID	17.5737
UN(5,1)	USUBJID	2.4203
UN(5,2)	USUBJID	5.0242
UN(5,3)	USUBJID	10.5416
UN(5,4)	USUBJID	16.2041
UN(5,5)	USUBJID	22.9400
UN(6,1)	USUBJID	2.4726
UN(6,2)	USUBJID	4.7116
UN(6,3)	USUBJID	9.5346
UN(6,4)	USUBJID	15.7463
UN(6,5)	USUBJID	20.0930
UN(6,6)	USUBJID	24.6992

Fit Statistics

-2 Res Log Likelihood	20784.6
AIC (Smaller is Better)	20826.6
AICC (Smaller is Better)	20826.8
BIC (Smaller is Better)	20929.9

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
20	4379.64	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	6	808	11.11	<.0001
region(avisitn)	24	1853	1.49	0.0605
PREOAD(avisitn)	6	772	2.89	0.0086
HBA1CG1(avisitn)	6	811	6.69	<.0001
base(avisitn)	6	804	7.23	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0879
region(avisitn)		Asia			50	0.0909
region(avisitn)		Europe			50	0.4911
region(avisitn)		North America			50	0.1502
region(avisitn)		South America			50	0.1798
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3538
PREOAD(avisitn)			SU users		50	0.6462
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5306
HBA1CG1(avisitn)				>=8.5	50	0.4694
HBA1CG1(avisitn)				<8.5	60	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	89.392
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IDegLira	WORK.BW_MMRM	-0.3938	0.07412	983.6	-5.31

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira	<.0001	0.05	-0.5392	-0.2483

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0879

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			50	0.0909
region(avisitn)		Europe			50	0.4911
region(avisitn)		North America			50	0.1502
region(avisitn)		South America			50	0.1798
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3538
PREOAD(avisitn)			SU users		50	0.6462
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5306
HBA1CG1(avisitn)				>=8.5	50	0.4694
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	89.392
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IGlar	WORK.BW_MMRM	0.1249	0.07424	984.5	1.68

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IGlar	0.0928	0.05	-0.02077	0.2706

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	-1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V050 IDegLira - IGlar	WORK.BW_MMRM	-0.5187	0.1054	984

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira - IGlar	-4.92	<.0001	0.05	-0.7255	-0.3119

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	89.392
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.BW_MMRM	-0.01701	0.1131	974.8	-0.15

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	0.8804	0.05	-0.2389	0.2049

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	89.392
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.BW_MMRM	0.9362	0.1136	980.1	8.24

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	0.7132	1.1591

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.BW_MMRM	-0.9532	0.1610	977.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	-5.92	<.0001	0.05	-1.2692	-0.6372

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	89.392
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.BW_MMRM	0.5392	0.1548	959.5	3.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	0.0005	0.05	0.2353	0.8430

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	89.392
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.BW_MMRM	2.1051	0.1563	970.9	13.47

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	1.7983	2.4118

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.BW_MMRM	-1.5659	0.2210	965.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-7.08	<.0001	0.05	-1.9996	-1.1321

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	89.392
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.BW_MMRM	1.1835	0.2006	827.8	5.90

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	0.7897	1.5773

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	89.392
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.BW_MMRM	3.2840	0.2192	916.6	14.98

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	2.8537	3.7143

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.BW_MMRM	-2.1005	0.2972	873.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-7.07	<.0001	0.05	-2.6838	-1.5172

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	89.392
base(avisitn)					130	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.BW_MMRM	1.4166	0.2387	738.3	5.93

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	0.9479	1.8853

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	89.392
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.BW_MMRM	3.7101	0.2733	818.3	13.58

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	3.1736	4.2465

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.BW_MMRM	-2.2935	0.3613	781

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	-6.35	<.0001	0.05	-3.0026	-1.5843

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	89.392

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.BW_MMRM	1.6856	0.2550	653.1	6.61

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	1.1849	2.1864

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	89.392

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.BW_MMRM	3.3865	0.3042	732.5	11.13

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	2.7894	3.9836

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.BW_MMRM	-1.7009	0.3936	695.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.32	<.0001	0.05	-2.4736	-0.9282

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Model Information

Data Set	WORK.BW_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	6	50 60 70 90 110 130

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228 [redacted] NN9068-4228

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
```

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
```

[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228 [redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Body weight after 26 and 104 weeks - change from baseline - supportive statistical
analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
```

[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	21
Columns in X	73
Columns in Z	0
Subjects	1012
Max Obs per Subject	6

Number of Observations

Number of Observations Read	6072
Number of Observations Used	4710
Number of Observations Not Used	1362

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	32535.39312323	
1	2	28172.85071750	0.00132758
2	1	28157.50555148	0.00016109
3	1	28155.78898974	0.00000347
4	1	28155.75448710	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	13.1503
UN(2,1)	USUBJID	12.8016
UN(2,2)	USUBJID	30.3152
UN(3,1)	USUBJID	14.0056
UN(3,2)	USUBJID	31.4112
UN(3,3)	USUBJID	56.3303
UN(4,1)	USUBJID	13.0587
UN(4,2)	USUBJID	27.5648

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(4,3)	USUBJID	52.0350
UN(4,4)	USUBJID	85.4144
UN(5,1)	USUBJID	11.7635
UN(5,2)	USUBJID	24.4195
UN(5,3)	USUBJID	51.2358
UN(5,4)	USUBJID	78.7577
UN(5,5)	USUBJID	111.50
UN(6,1)	USUBJID	12.0175
UN(6,2)	USUBJID	22.9003
UN(6,3)	USUBJID	46.3414
UN(6,4)	USUBJID	76.5328
UN(6,5)	USUBJID	97.6590
UN(6,6)	USUBJID	120.05

Fit Statistics

-2 Res Log Likelihood	28155.8
AIC (Smaller is Better)	28197.8
AICC (Smaller is Better)	28198.0
BIC (Smaller is Better)	28301.1

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
20	4379.64	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	6	808	11.11	<.0001
region(avisitn)	24	1853	1.49	0.0605
PREOAD(avisitn)	6	772	2.89	0.0086
HBA1CG1(avisitn)	6	811	6.69	<.0001
base(avisitn)	6	804	7.23	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0879
region(avisitn)		Asia			50	0.0909
region(avisitn)		Europe			50	0.4911
region(avisitn)		North America			50	0.1502
region(avisitn)		South America			50	0.1798
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3538
PREOAD(avisitn)			SU users		50	0.6462
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5306
HBA1CG1(avisitn)				>=8.5	50	0.4694
HBA1CG1(avisitn)				<8.5	60	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	197.07
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IDegLira	WORK.BW_MMRM	-0.8681	0.1634	983.6	-5.31

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira	<.0001	0.05	-1.1888	-0.5474

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0879

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			50	0.0909
region(avisitn)		Europe			50	0.4911
region(avisitn)		North America			50	0.1502
region(avisitn)		South America			50	0.1798
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3538
PREOAD(avisitn)			SU users		50	0.6462
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5306
HBA1CG1(avisitn)				>=8.5	50	0.4694
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	197.07
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IGlar	WORK.BW_MMRM	0.2754	0.1637	984.5	1.68

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IGlar	0.0928	0.05	-0.04580	0.5966

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	-1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V050 IDegLira - IGlar	WORK.BW_MMRM	-1.1435	0.2323	984

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira - IGlar	-4.92	<.0001	0.05	-1.5994	-0.6876

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	197.07
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.BW_MMRM	-0.03751	0.2493	974.8	-0.15

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	0.8804	0.05	-0.5267	0.4517

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	197.07
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.BW_MMRM	2.0639	0.2505	980.1	8.24

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	1.5724	2.5554

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.BW_MMRM	-2.1014	0.3550	977.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	-5.92	<.0001	0.05	-2.7980	-1.4048

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	197.07
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.BW_MMRM	1.1887	0.3414	959.5	3.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	0.0005	0.05	0.5187	1.8586

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	197.07
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.BW_MMRM	4.6409	0.3446	970.9	13.47

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	3.9646	5.3172

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.BW_MMRM	-3.4522	0.4873	965.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-7.08	<.0001	0.05	-4.4084	-2.4959

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	197.07
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.BW_MMRM	2.6092	0.4423	827.8	5.90

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	1.7411	3.4774

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	197.07
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.BW_MMRM	7.2401	0.4834	916.6	14.98

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	6.2914	8.1887

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.BW_MMRM	-4.6308	0.6552	873.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-7.07	<.0001	0.05	-5.9167	-3.3449

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	197.07
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.BW_MMRM	3.1231	0.5263	738.3	5.93

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	2.0898	4.1563

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	197.07
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.BW_MMRM	8.1793	0.6025	818.3	13.58

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	6.9967	9.3619

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.BW_MMRM	-5.0563	0.7964	781

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	-6.35	<.0001	0.05	-6.6197	-3.4928

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	197.07

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.BW_MMRM	3.7162	0.5622	653.1	6.61

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	2.6123	4.8201

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					50	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	197.07

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.BW_MMRM	7.4660	0.6705	732.5	11.13

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	6.1496	8.7824

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Body weight after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.BW_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Body weight after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=BODY_WEIGHT_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.BW_MMRM	-3.7498	0.8676	695.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.32	<.0001	0.05	-5.4533	-2.0463

16: Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Model Information

Data Set	WORK.FPG_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	6	50 60 70 90 110 130

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1001	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228	[redacted]
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	21
Columns in X	73
Columns in Z	0
Subjects	1001
Max Obs per Subject	6

Number of Observations

Number of Observations Read	6072
Number of Observations Used	4643
Number of Observations Not Used	1429

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	18768.27527518	
1	3	18054.19347362	0.00231122
2	1	18041.48848530	0.00022884
3	1	18040.30617958	0.00000374
4	1	18040.28802367	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	3.8041
UN(2,1)	USUBJID	1.5394
UN(2,2)	USUBJID	3.5548
UN(3,1)	USUBJID	0.9267
UN(3,2)	USUBJID	1.5489
UN(3,3)	USUBJID	3.8329
UN(4,1)	USUBJID	0.9208
UN(4,2)	USUBJID	1.4086
UN(4,3)	USUBJID	1.6360
UN(4,4)	USUBJID	3.2135
UN(5,1)	USUBJID	0.7911
UN(5,2)	USUBJID	1.2520
UN(5,3)	USUBJID	1.3757
UN(5,4)	USUBJID	1.5933
UN(5,5)	USUBJID	3.1032
UN(6,1)	USUBJID	0.6208
UN(6,2)	USUBJID	1.0326
UN(6,3)	USUBJID	1.1398
UN(6,4)	USUBJID	1.1595

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(6,5)	USUBJID	1.1648
UN(6,6)	USUBJID	2.6962

Fit Statistics

-2 Res Log Likelihood	18040.3
AIC (Smaller is Better)	18082.3
AICC (Smaller is Better)	18082.5
BIC (Smaller is Better)	18185.4

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
20	727.99	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	6	624	16.79	<.0001
region(avisitn)	24	1526	2.77	<.0001
PREOAD(avisitn)	6	588	2.49	0.0220
HBA1CG1(avisitn)	6	613	0.80	0.5728
base(avisitn)	6	634	38.13	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0869
region(avisitn)		Asia			50	0.0919
region(avisitn)		Europe			50	0.4915
region(avisitn)		North America			50	0.1479

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			50	0.1818
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3516
PREOAD(avisitn)			SU users		50	0.6484
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5315
HBA1CG1(avisitn)				>=8.5	50	0.4685
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	9.9199
base(avisitn)					60	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IDegLira	WORK.FPG_MMRM	6.5076	0.08858	969.4	73.47

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira	<.0001	0.05	6.3337	6.6814

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0869
region(avisitn)		Asia			50	0.0919
region(avisitn)		Europe			50	0.4915
region(avisitn)		North America			50	0.1479
region(avisitn)		South America			50	0.1818
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3516
PREOAD(avisitn)			SU users		50	0.6484
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5315
HBA1CG1(avisitn)				>=8.5	50	0.4685
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	9.9199
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IGlar	WORK.FPG_MMRM	7.6935	0.08877	969.1	86.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IGlar	<.0001	0.05	7.5193	7.8677

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	-1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V050 IDegLira - IGlar	WORK.FPG_MMRM	-1.1859	0.1259	969.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira - IGlar	-9.42	<.0001	0.05	-1.4331	-0.9388

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0869
region(avisitn)		Asia			60	0.0919
region(avisitn)		Europe			60	0.4915
region(avisitn)		North America			60	0.1479
region(avisitn)		South America			60	0.1818
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3516
PREOAD(avisitn)			SU users		60	0.6484
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5315
HBA1CG1(avisitn)				>=8.5	60	0.4685
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	9.9199
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.FPG_MMRM	5.9925	0.08609	945.8	69.61

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	<.0001	0.05	5.8235	6.1614

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0869
region(avisitn)		Asia			60	0.0919
region(avisitn)		Europe			60	0.4915
region(avisitn)		North America			60	0.1479
region(avisitn)		South America			60	0.1818
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3516
PREOAD(avisitn)			SU users		60	0.6484
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5315
HBA1CG1(avisitn)				>=8.5	60	0.4685
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	9.9199
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.FPG_MMRM	6.8127	0.08660	947.2	78.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	6.6427	6.9826

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.FPG_MMRM	-0.8202	0.1226	946.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	-6.69	<.0001	0.05	-1.0608	-0.5796

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0869

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	0.0919
region(avisitn)		Europe			70	0.4915
region(avisitn)		North America			70	0.1479
region(avisitn)		South America			70	0.1818
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3516
PREOAD(avisitn)			SU users		70	0.6484
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5315
HBA1CG1(avisitn)				>=8.5	70	0.4685
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	9.9199
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.FPG_MMRM	5.8852	0.09015	910.4	65.28

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	5.7082	6.0621

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0869
region(avisitn)		Asia			70	0.0919
region(avisitn)		Europe			70	0.4915
region(avisitn)		North America			70	0.1479
region(avisitn)		South America			70	0.1818
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3516
PREOAD(avisitn)			SU users		70	0.6484
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5315
HBA1CG1(avisitn)				>=8.5	70	0.4685
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	9.9199
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.FPG_MMRM	6.3771	0.09128	914.3	69.86

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	6.1980	6.5562

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.FPG_MMRM	-0.4919	0.1288	912.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.82	0.0001	0.05	-0.7448	-0.2391

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0869
region(avisitn)		Asia			90	0.0919
region(avisitn)		Europe			90	0.4915
region(avisitn)		North America			90	0.1479
region(avisitn)		South America			90	0.1818
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3516
PREOAD(avisitn)			SU users		90	0.6484
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5315
HBA1CG1(avisitn)				>=8.5	90	0.4685
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	9.9199
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.FPG_MMRM	6.0787	0.08895	546.2	68.34

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	5.9040	6.2534

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0869
region(avisitn)		Asia			90	0.0919
region(avisitn)		Europe			90	0.4915
region(avisitn)		North America			90	0.1479
region(avisitn)		South America			90	0.1818
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3516
PREOAD(avisitn)			SU users		90	0.6484
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5315
HBA1CG1(avisitn)				>=8.5	90	0.4685
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	9.9199
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.FPG_MMRM	6.6540	0.1011	631.1	65.81

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	6.4555	6.8526

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.FPG_MMRM	-0.5753	0.1344	590.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-4.28	<.0001	0.05	-0.8392	-0.3115

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0869
region(avisitn)		Asia			110	0.0919
region(avisitn)		Europe			110	0.4915
region(avisitn)		North America			110	0.1479
region(avisitn)		South America			110	0.1818

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3516
PREOAD(avisitn)			SU users		110	0.6484
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5315
HBA1CG1(avisitn)				>=8.5	110	0.4685
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	9.9199
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.FPG_MMRM	6.0732	0.09273	479.2	65.49

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	5.8910	6.2554

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0869
region(avisitn)		Asia			110	0.0919
region(avisitn)		Europe			110	0.4915
region(avisitn)		North America			110	0.1479
region(avisitn)		South America			110	0.1818
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3516

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	0.6484
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5315
HBA1CG1(avisitn)				>=8.5	110	0.4685
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	9.9199
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.FPG_MMRM	6.6105	0.1111	551.1	59.51

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	6.3923	6.8287

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.FPG_MMRM	-0.5373	0.1434	517.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	-3.75	0.0002	0.05	-0.8190	-0.2556

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0869
region(avisitn)		Asia			130	0.0919
region(avisitn)		Europe			130	0.4915
region(avisitn)		North America			130	0.1479
region(avisitn)		South America			130	0.1818
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3516
PREOAD(avisitn)			SU users		130	0.6484
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5315
HBA1CG1(avisitn)				>=8.5	130	0.4685
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	9.9199

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.FPG_MMRM	5.9560	0.09031	446.2	65.95

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	5.7785	6.1335

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0869
region(avisitn)		Asia			130	0.0919
region(avisitn)		Europe			130	0.4915
region(avisitn)		North America			130	0.1479
region(avisitn)		South America			130	0.1818
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3516
PREOAD(avisitn)			SU users		130	0.6484
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5315
HBA1CG1(avisitn)				>=8.5	130	0.4685
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	9.9199

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.FPG_MMRM	6.4331	0.1153	510.8	55.81

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	6.2066	6.6595

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.FPG_MMRM	-0.4771	0.1443	484.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.31	0.0010	0.05	-0.7606	-0.1935

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Model Information

Data Set	WORK.FPG_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	6	50 60 70 90 110 130

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1001	NN9068-4228/[redacted] NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/ [redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/ [redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/ [redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	21
Columns in X	73
Columns in Z	0
Subjects	1001
Max Obs per Subject	6

Number of Observations

Number of Observations Read	6072
Number of Observations Used	4643
Number of Observations Not Used	1429

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	45340.99717272	
1	3	44626.91537116	0.00061433
2	1	44614.21038284	0.00006077
3	1	44613.02807712	0.00000099
4	1	44613.00992121	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	1235.26
UN(2,1)	USUBJID	499.88
UN(2,2)	USUBJID	1154.33
UN(3,1)	USUBJID	300.92
UN(3,2)	USUBJID	502.95
UN(3,3)	USUBJID	1244.63
UN(4,1)	USUBJID	299.00
UN(4,2)	USUBJID	457.39
UN(4,3)	USUBJID	531.25
UN(4,4)	USUBJID	1043.50
UN(5,1)	USUBJID	256.88
UN(5,2)	USUBJID	406.54
UN(5,3)	USUBJID	446.72
UN(5,4)	USUBJID	517.37
UN(5,5)	USUBJID	1007.66
UN(6,1)	USUBJID	201.59
UN(6,2)	USUBJID	335.32
UN(6,3)	USUBJID	370.12
UN(6,4)	USUBJID	376.50

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(6,5)	USUBJID	378.24
UN(6,6)	USUBJID	875.51

Fit Statistics

-2 Res Log Likelihood	44613.0
AIC (Smaller is Better)	44655.0
AICC (Smaller is Better)	44655.2
BIC (Smaller is Better)	44758.1

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
20	727.99	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	6	624	16.79	<.0001
region(avisitn)	24	1526	2.77	<.0001
PREOAD(avisitn)	6	588	2.49	0.0220
HBA1CG1(avisitn)	6	613	0.80	0.5728
base(avisitn)	6	634	38.13	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0869
region(avisitn)		Asia			50	0.0919
region(avisitn)		Europe			50	0.4915
region(avisitn)		North America			50	0.1479

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			50	0.1818
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3516
PREOAD(avisitn)			SU users		50	0.6484
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5315
HBA1CG1(avisitn)				>=8.5	50	0.4685
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	178.76
base(avisitn)					60	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IDegLira	WORK.FPG_MMRM	117.27	1.5962	969.4	73.47

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira	<.0001	0.05	114.13	120.40

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0869
region(avisitn)		Asia			50	0.0919
region(avisitn)		Europe			50	0.4915
region(avisitn)		North America			50	0.1479
region(avisitn)		South America			50	0.1818
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3516
PREOAD(avisitn)			SU users		50	0.6484
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5315
HBA1CG1(avisitn)				>=8.5	50	0.4685
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	178.76
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IGlar	WORK.FPG_MMRM	138.64	1.5996	969.1	86.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IGlar	<.0001	0.05	135.50	141.78

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	-1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V050 IDegLira - IGlar	WORK.FPG_MMRM	-21.3702	2.2695	969.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira - IGlar	-9.42	<.0001	0.05	-25.8239	-16.9165

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0869
region(avisitn)		Asia			60	0.0919
region(avisitn)		Europe			60	0.4915
region(avisitn)		North America			60	0.1479
region(avisitn)		South America			60	0.1818
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3516
PREOAD(avisitn)			SU users		60	0.6484
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5315
HBA1CG1(avisitn)				>=8.5	60	0.4685
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	178.76
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.FPG_MMRM	107.98	1.5513	945.8	69.61

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	<.0001	0.05	104.94	111.03

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0869
region(avisitn)		Asia			60	0.0919
region(avisitn)		Europe			60	0.4915
region(avisitn)		North America			60	0.1479
region(avisitn)		South America			60	0.1818
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3516
PREOAD(avisitn)			SU users		60	0.6484
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5315
HBA1CG1(avisitn)				>=8.5	60	0.4685
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	178.76
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.FPG_MMRM	122.76	1.5605	947.2	78.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	119.70	125.83

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.FPG_MMRM	-14.7799	2.2096	946.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	-6.69	<.0001	0.05	-19.1163	-10.4436

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0869

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	0.0919
region(avisitn)		Europe			70	0.4915
region(avisitn)		North America			70	0.1479
region(avisitn)		South America			70	0.1818
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3516
PREOAD(avisitn)			SU users		70	0.6484
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5315
HBA1CG1(avisitn)				>=8.5	70	0.4685
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	178.76
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.FPG_MMRM	106.05	1.6245	910.4	65.28

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	102.86	109.24

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0869
region(avisitn)		Asia			70	0.0919
region(avisitn)		Europe			70	0.4915
region(avisitn)		North America			70	0.1479
region(avisitn)		South America			70	0.1818
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3516
PREOAD(avisitn)			SU users		70	0.6484
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5315
HBA1CG1(avisitn)				>=8.5	70	0.4685
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	178.76
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.FPG_MMRM	114.92	1.6448	914.3	69.86

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	111.69	118.14

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.FPG_MMRM	-8.8648	2.3215	912.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.82	0.0001	0.05	-13.4209	-4.3086

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0869
region(avisitn)		Asia			90	0.0919
region(avisitn)		Europe			90	0.4915
region(avisitn)		North America			90	0.1479
region(avisitn)		South America			90	0.1818
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3516
PREOAD(avisitn)			SU users		90	0.6484
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5315
HBA1CG1(avisitn)				>=8.5	90	0.4685
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	178.76
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.FPG_MMRM	109.54	1.6028	546.2	68.34

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	106.39	112.69

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0869
region(avisitn)		Asia			90	0.0919
region(avisitn)		Europe			90	0.4915
region(avisitn)		North America			90	0.1479
region(avisitn)		South America			90	0.1818
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3516
PREOAD(avisitn)			SU users		90	0.6484
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5315
HBA1CG1(avisitn)				>=8.5	90	0.4685
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	178.76
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.FPG_MMRM	119.91	1.8219	631.1	65.81

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	116.33	123.48

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.FPG_MMRM	-10.3673	2.4210	590.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-4.28	<.0001	0.05	-15.1222	-5.6124

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0869
region(avisitn)		Asia			110	0.0919
region(avisitn)		Europe			110	0.4915
region(avisitn)		North America			110	0.1479
region(avisitn)		South America			110	0.1818

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3516
PREOAD(avisitn)			SU users		110	0.6484
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5315
HBA1CG1(avisitn)				>=8.5	110	0.4685
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	178.76
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.FPG_MMRM	109.44	1.6711	479.2	65.49

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	106.16	112.72

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0869
region(avisitn)		Asia			110	0.0919
region(avisitn)		Europe			110	0.4915
region(avisitn)		North America			110	0.1479
region(avisitn)		South America			110	0.1818
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3516

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	0.6484
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5315
HBA1CG1(avisitn)				>=8.5	110	0.4685
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	178.76
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.FPG_MMRM	119.12	2.0017	551.1	59.51

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	115.19	123.05

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.FPG_MMRM	-9.6825	2.5841	517.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	-3.75	0.0002	0.05	-14.7591	-4.6059

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0869
region(avisitn)		Asia			130	0.0919
region(avisitn)		Europe			130	0.4915
region(avisitn)		North America			130	0.1479
region(avisitn)		South America			130	0.1818
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3516
PREOAD(avisitn)			SU users		130	0.6484
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5315
HBA1CG1(avisitn)				>=8.5	130	0.4685
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	178.76

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.FPG_MMRM	107.33	1.6274	446.2	65.95

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	104.13	110.53

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0869
region(avisitn)		Asia			130	0.0919
region(avisitn)		Europe			130	0.4915
region(avisitn)		North America			130	0.1479
region(avisitn)		South America			130	0.1818
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3516
PREOAD(avisitn)			SU users		130	0.6484
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5315
HBA1CG1(avisitn)				>=8.5	130	0.4685
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	178.76

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.FPG_MMRM	115.92	2.0771	510.8	55.81

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	111.84	120.00

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.FPG_MMRM	-8.5969	2.6005	484.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.31	0.0010	0.05	-13.7066	-3.4872

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Model Information

Data Set	WORK.FPG_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	6	50 60 70 90 110 130

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1001	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

```
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
```

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	21
Columns in X	73
Columns in Z	0
Subjects	1001
Max Obs per Subject	6

Number of Observations

Number of Observations Read	6072
Number of Observations Used	4643
Number of Observations Not Used	1429

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	18768.27527519	
1	3	18054.19347362	0.00231122
2	1	18041.48848530	0.00022884
3	1	18040.30617958	0.00000374
4	1	18040.28802367	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	3.8041
UN(2,1)	USUBJID	1.5394
UN(2,2)	USUBJID	3.5548
UN(3,1)	USUBJID	0.9267
UN(3,2)	USUBJID	1.5489
UN(3,3)	USUBJID	3.8329
UN(4,1)	USUBJID	0.9208
UN(4,2)	USUBJID	1.4086
UN(4,3)	USUBJID	1.6360
UN(4,4)	USUBJID	3.2135
UN(5,1)	USUBJID	0.7911
UN(5,2)	USUBJID	1.2520
UN(5,3)	USUBJID	1.3757
UN(5,4)	USUBJID	1.5933
UN(5,5)	USUBJID	3.1032
UN(6,1)	USUBJID	0.6208
UN(6,2)	USUBJID	1.0326
UN(6,3)	USUBJID	1.1398
UN(6,4)	USUBJID	1.1595

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(6,5)	USUBJID	1.1648
UN(6,6)	USUBJID	2.6962

Fit Statistics

-2 Res Log Likelihood	18040.3
AIC (Smaller is Better)	18082.3
AICC (Smaller is Better)	18082.5
BIC (Smaller is Better)	18185.4

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
20	727.99	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	6	624	16.79	<.0001
region(avisitn)	24	1526	2.77	<.0001
PREOAD(avisitn)	6	588	2.49	0.0220
HBA1CG1(avisitn)	6	613	0.80	0.5728
base(avisitn)	6	634	382.71	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0869
region(avisitn)		Asia			50	0.0919
region(avisitn)		Europe			50	0.4915
region(avisitn)		North America			50	0.1479

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			50	0.1818
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3516
PREOAD(avisitn)			SU users		50	0.6484
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5315
HBA1CG1(avisitn)				>=8.5	50	0.4685
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	9.9199
base(avisitn)					60	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IDegLira	WORK.FPG_MMRM	-3.4123	0.08858	969.4	-38.52

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira	<.0001	0.05	-3.5862	-3.2385

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0869
region(avisitn)		Asia			50	0.0919
region(avisitn)		Europe			50	0.4915
region(avisitn)		North America			50	0.1479
region(avisitn)		South America			50	0.1818
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3516
PREOAD(avisitn)			SU users		50	0.6484
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5315
HBA1CG1(avisitn)				>=8.5	50	0.4685
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	9.9199
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IGlar	WORK.FPG_MMRM	-2.2264	0.08877	969.1	-25.08

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IGlar	<.0001	0.05	-2.4006	-2.0522

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	-1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V050 IDegLira - IGlar	WORK.FPG_MMRM	-1.1859	0.1259	969.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira - IGlar	-9.42	<.0001	0.05	-1.4331	-0.9388

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0869
region(avisitn)		Asia			60	0.0919
region(avisitn)		Europe			60	0.4915
region(avisitn)		North America			60	0.1479
region(avisitn)		South America			60	0.1818
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3516
PREOAD(avisitn)			SU users		60	0.6484
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5315
HBA1CG1(avisitn)				>=8.5	60	0.4685
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	9.9199
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.FPG_MMRM	-3.9275	0.08609	945.8	-45.62

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	<.0001	0.05	-4.0964	-3.7585

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0869
region(avisitn)		Asia			60	0.0919
region(avisitn)		Europe			60	0.4915
region(avisitn)		North America			60	0.1479
region(avisitn)		South America			60	0.1818
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3516
PREOAD(avisitn)			SU users		60	0.6484
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5315
HBA1CG1(avisitn)				>=8.5	60	0.4685
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	9.9199
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.FPG_MMRM	-3.1073	0.08660	947.2	-35.88

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	-3.2772	-2.9373

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.FPG_MMRM	-0.8202	0.1226	946.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	-6.69	<.0001	0.05	-1.0608	-0.5796

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0869

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	0.0919
region(avisitn)		Europe			70	0.4915
region(avisitn)		North America			70	0.1479
region(avisitn)		South America			70	0.1818
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3516
PREOAD(avisitn)			SU users		70	0.6484
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5315
HBA1CG1(avisitn)				>=8.5	70	0.4685
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	9.9199
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.FPG_MMRM	-4.0348	0.09015	910.4	-44.76

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	-4.2117	-3.8578

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0869
region(avisitn)		Asia			70	0.0919
region(avisitn)		Europe			70	0.4915
region(avisitn)		North America			70	0.1479
region(avisitn)		South America			70	0.1818
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3516
PREOAD(avisitn)			SU users		70	0.6484
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5315
HBA1CG1(avisitn)				>=8.5	70	0.4685
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	9.9199
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.FPG_MMRM	-3.5428	0.09128	914.3	-38.81

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	-3.7220	-3.3637

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.FPG_MMRM	-0.4919	0.1288	912.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.82	0.0001	0.05	-0.7448	-0.2391

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0869
region(avisitn)		Asia			90	0.0919
region(avisitn)		Europe			90	0.4915
region(avisitn)		North America			90	0.1479
region(avisitn)		South America			90	0.1818
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3516
PREOAD(avisitn)			SU users		90	0.6484
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5315
HBA1CG1(avisitn)				>=8.5	90	0.4685
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	9.9199
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.FPG_MMRM	-3.8412	0.08895	546.2	-43.19

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	-4.0159	-3.6665

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0869
region(avisitn)		Asia			90	0.0919
region(avisitn)		Europe			90	0.4915
region(avisitn)		North America			90	0.1479
region(avisitn)		South America			90	0.1818
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3516
PREOAD(avisitn)			SU users		90	0.6484
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5315
HBA1CG1(avisitn)				>=8.5	90	0.4685
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	9.9199
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.FPG_MMRM	-3.2659	0.1011	631.1	-32.30

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	-3.4644	-3.0674

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.FPG_MMRM	-0.5753	0.1344	590.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-4.28	<.0001	0.05	-0.8392	-0.3115

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0869
region(avisitn)		Asia			110	0.0919
region(avisitn)		Europe			110	0.4915
region(avisitn)		North America			110	0.1479
region(avisitn)		South America			110	0.1818

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3516
PREOAD(avisitn)			SU users		110	0.6484
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5315
HBA1CG1(avisitn)				>=8.5	110	0.4685
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	9.9199
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.FPG_MMRM	-3.8467	0.09273	479.2	-41.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	-4.0289	-3.6645

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0869
region(avisitn)		Asia			110	0.0919
region(avisitn)		Europe			110	0.4915
region(avisitn)		North America			110	0.1479
region(avisitn)		South America			110	0.1818
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3516

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	0.6484
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5315
HBA1CG1(avisitn)				>=8.5	110	0.4685
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	9.9199
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.FPG_MMRM	-3.3094	0.1111	551.1	-29.79

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	-3.5276	-3.0912

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.FPG_MMRM	-0.5373	0.1434	517.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	-3.75	0.0002	0.05	-0.8190	-0.2556

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0869
region(avisitn)		Asia			130	0.0919
region(avisitn)		Europe			130	0.4915
region(avisitn)		North America			130	0.1479
region(avisitn)		South America			130	0.1818
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3516
PREOAD(avisitn)			SU users		130	0.6484
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5315
HBA1CG1(avisitn)				>=8.5	130	0.4685
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	9.9199

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.FPG_MMRM	-3.9639	0.09031	446.2	-43.89

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	-4.1414	-3.7864

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0869
region(avisitn)		Asia			130	0.0919
region(avisitn)		Europe			130	0.4915
region(avisitn)		North America			130	0.1479
region(avisitn)		South America			130	0.1818
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3516
PREOAD(avisitn)			SU users		130	0.6484
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5315
HBA1CG1(avisitn)				>=8.5	130	0.4685
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	9.9199

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.FPG_MMRM	-3.4869	0.1153	510.8	-30.25

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	-3.7133	-3.2604

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.FPG_MMRM	-0.4771	0.1443	484.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.31	0.0010	0.05	-0.7606	-0.1935

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Model Information

Data Set	WORK.FPG_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	6	50 60 70 90 110 130

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1001	NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive
statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

```
Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive
statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	21
Columns in X	73
Columns in Z	0
Subjects	1001
Max Obs per Subject	6

Number of Observations

Number of Observations Read	6072
Number of Observations Used	4643
Number of Observations Not Used	1429

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	45340.99717272	
1	3	44626.91537116	0.00061433
2	1	44614.21038284	0.00006077
3	1	44613.02807712	0.00000099
4	1	44613.00992121	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	1235.26
UN(2,1)	USUBJID	499.88
UN(2,2)	USUBJID	1154.33
UN(3,1)	USUBJID	300.92
UN(3,2)	USUBJID	502.95
UN(3,3)	USUBJID	1244.63
UN(4,1)	USUBJID	299.00
UN(4,2)	USUBJID	457.39
UN(4,3)	USUBJID	531.25
UN(4,4)	USUBJID	1043.50
UN(5,1)	USUBJID	256.88
UN(5,2)	USUBJID	406.54
UN(5,3)	USUBJID	446.72
UN(5,4)	USUBJID	517.37
UN(5,5)	USUBJID	1007.66
UN(6,1)	USUBJID	201.59
UN(6,2)	USUBJID	335.32
UN(6,3)	USUBJID	370.12
UN(6,4)	USUBJID	376.50

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(6,5)	USUBJID	378.24
UN(6,6)	USUBJID	875.51

Fit Statistics

-2 Res Log Likelihood	44613.0
AIC (Smaller is Better)	44655.0
AICC (Smaller is Better)	44655.2
BIC (Smaller is Better)	44758.1

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
20	727.99	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	6	624	16.79	<.0001
region(avisitn)	24	1526	2.77	<.0001
PREOAD(avisitn)	6	588	2.49	0.0220
HBA1CG1(avisitn)	6	613	0.80	0.5728
base(avisitn)	6	634	382.71	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0869
region(avisitn)		Asia			50	0.0919
region(avisitn)		Europe			50	0.4915
region(avisitn)		North America			50	0.1479

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			50	0.1818
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3516
PREOAD(avisitn)			SU users		50	0.6484
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5315
HBA1CG1(avisitn)				>=8.5	50	0.4685
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	178.76
base(avisitn)					60	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IDegLira	WORK.FPG_MMRM	-61.4905	1.5962	969.4	-38.52

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira	<.0001	0.05	-64.6230	-58.3581

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	0.0869
region(avisitn)		Asia			50	0.0919
region(avisitn)		Europe			50	0.4915
region(avisitn)		North America			50	0.1479
region(avisitn)		South America			50	0.1818
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	0.3516
PREOAD(avisitn)			SU users		50	0.6484
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	0.5315
HBA1CG1(avisitn)				>=8.5	50	0.4685
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	178.76
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V050 IGlar	WORK.FPG_MMRM	-40.1203	1.5996	969.1	-25.08

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IGlar	<.0001	0.05	-43.2595	-36.9812

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	1
treatment(avisitn)	IGlar				50	-1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V050 IDegLira - IGlar	WORK.FPG_MMRM	-21.3702	2.2695	969.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V050 IDegLira - IGlar	-9.42	<.0001	0.05	-25.8239	-16.9165

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0869
region(avisitn)		Asia			60	0.0919
region(avisitn)		Europe			60	0.4915
region(avisitn)		North America			60	0.1479
region(avisitn)		South America			60	0.1818
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3516
PREOAD(avisitn)			SU users		60	0.6484
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5315
HBA1CG1(avisitn)				>=8.5	60	0.4685
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	178.76
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.FPG_MMRM	-70.7727	1.5513	945.8	-45.62

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	<.0001	0.05	-73.8171	-67.7284

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	0.0869
region(avisitn)		Asia			60	0.0919
region(avisitn)		Europe			60	0.4915
region(avisitn)		North America			60	0.1479
region(avisitn)		South America			60	0.1818
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	0.3516
PREOAD(avisitn)			SU users		60	0.6484
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	0.5315
HBA1CG1(avisitn)				>=8.5	60	0.4685
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	178.76
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.FPG_MMRM	-55.9928	1.5605	947.2	-35.88

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	-59.0553	-52.9303

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.FPG_MMRM	-14.7799	2.2096	946.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	-6.69	<.0001	0.05	-19.1163	-10.4436

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0869

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	0.0919
region(avisitn)		Europe			70	0.4915
region(avisitn)		North America			70	0.1479
region(avisitn)		South America			70	0.1818
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3516
PREOAD(avisitn)			SU users		70	0.6484
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5315
HBA1CG1(avisitn)				>=8.5	70	0.4685
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	178.76
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.FPG_MMRM	-72.7065	1.6245	910.4	-44.76

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	-75.8947	-69.5183

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0869
region(avisitn)		Asia			70	0.0919
region(avisitn)		Europe			70	0.4915
region(avisitn)		North America			70	0.1479
region(avisitn)		South America			70	0.1818
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3516
PREOAD(avisitn)			SU users		70	0.6484
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5315
HBA1CG1(avisitn)				>=8.5	70	0.4685
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	178.76
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.FPG_MMRM	-63.8418	1.6448	914.3	-38.81

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	-67.0698	-60.6137

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.FPG_MMRM	-8.8648	2.3215	912.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.82	0.0001	0.05	-13.4209	-4.3086

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0869
region(avisitn)		Asia			90	0.0919
region(avisitn)		Europe			90	0.4915
region(avisitn)		North America			90	0.1479
region(avisitn)		South America			90	0.1818
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3516
PREOAD(avisitn)			SU users		90	0.6484
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5315
HBA1CG1(avisitn)				>=8.5	90	0.4685
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	178.76
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.FPG_MMRM	-69.2188	1.6028	546.2	-43.19

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	-72.3673	-66.0703

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0869
region(avisitn)		Asia			90	0.0919
region(avisitn)		Europe			90	0.4915
region(avisitn)		North America			90	0.1479
region(avisitn)		South America			90	0.1818
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3516
PREOAD(avisitn)			SU users		90	0.6484
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5315
HBA1CG1(avisitn)				>=8.5	90	0.4685
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	178.76
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.FPG_MMRM	-58.8515	1.8219	631.1	-32.30

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	-62.4292	-55.2739

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.FPG_MMRM	-10.3673	2.4210	590.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-4.28	<.0001	0.05	-15.1222	-5.6124

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0869
region(avisitn)		Asia			110	0.0919
region(avisitn)		Europe			110	0.4915
region(avisitn)		North America			110	0.1479
region(avisitn)		South America			110	0.1818

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3516
PREOAD(avisitn)			SU users		110	0.6484
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5315
HBA1CG1(avisitn)				>=8.5	110	0.4685
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	178.76
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.FPG_MMRM	-69.3180	1.6711	479.2	-41.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	-72.6016	-66.0345

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0869
region(avisitn)		Asia			110	0.0919
region(avisitn)		Europe			110	0.4915
region(avisitn)		North America			110	0.1479
region(avisitn)		South America			110	0.1818
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3516

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		110	0.6484
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5315
HBA1CG1(avisitn)				>=8.5	110	0.4685
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	178.76
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.FPG_MMRM	-59.6355	2.0017	551.1	-29.79

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	-63.5674	-55.7036

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	

Fasting plasma glucose after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.FPG_MMRM	-9.6825	2.5841	517.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	-3.75	0.0002	0.05	-14.7591	-4.6059

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0869
region(avisitn)		Asia			130	0.0919
region(avisitn)		Europe			130	0.4915
region(avisitn)		North America			130	0.1479
region(avisitn)		South America			130	0.1818
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3516
PREOAD(avisitn)			SU users		130	0.6484
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5315
HBA1CG1(avisitn)				>=8.5	130	0.4685
base(avisitn)					50	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	178.76

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.FPG_MMRM	-71.4300	1.6274	446.2	-43.89

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	-74.6284	-68.2316

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0869
region(avisitn)		Asia			130	0.0919
region(avisitn)		Europe			130	0.4915
region(avisitn)		North America			130	0.1479
region(avisitn)		South America			130	0.1818
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3516
PREOAD(avisitn)			SU users		130	0.6484
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5315
HBA1CG1(avisitn)				>=8.5	130	0.4685
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	178.76

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.FPG_MMRM	-62.8331	2.0771	510.8	-30.25

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	-66.9138	-58.7523

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				50	
treatment(avisitn)	IGlar				50	
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			50	
region(avisitn)		Asia			50	
region(avisitn)		Europe			50	
region(avisitn)		North America			50	
region(avisitn)		South America			50	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	

Fasting plasma glucose after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=FPG_PLASMA_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FPG_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		50	
PREOAD(avisitn)			SU users		50	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	50	
HBA1CG1(avisitn)				>=8.5	50	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					50	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.FPG_MMRM	-8.5969	2.6005	484.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.31	0.0010	0.05	-13.7066	-3.4872

17: 9-point self-measured plasma glucose profile after 26 weeks – supportive statistical analysis – full analysis set

```
Parameter Code=C105585Y

The Mixed Procedure

                  Model Information

Data Set                     WORK.ADPROF3
Dependent Variable           AVAL
Covariance Structure         Compound Symmetry
Subject Effect               USUBJID
Estimation Method            REML
Residual Variance Method     Profile
Fixed Effects SE Method      Kenward-Roger
Degrees of Freedom Method    Kenward-Roger
```

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
TRTP	2	IDegLira IGlar
ATPTN	9	1 2 3 4 5 6 7 8 9
REGION1	5	Africa Asia Europe North America South America

Dimensions

Covariance Parameters	2
Columns in X	64
Columns in Z	0
Subjects	1012
Max Obs per Subject	9

Number of Observations

Number of Observations Read	9108
Number of Observations Used	7516
Number of Observations Not Used	1592

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	33190.53415465	
1	2	31003.77184791	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate	Standard Error	Z Value	Pr Z	Alpha	Lower	Upper
CS	USUBJID	1.9423	0.1107	17.55	<.0001	0.05	1.7254	2.1593
Residual		2.8927	0.05030	57.51	<.0001	0.05	2.7966	2.9939

Asymptotic Covariance Matrix of Estimates

Row	Cov Parm	CovP1	CovP2
1	CS	0.01225	-0.00029
2	Residual	-0.00029	0.002530

Fit Statistics

-2 Res Log Likelihood	31003.8
AIC (Smaller is Better)	31007.8
AICC (Smaller is Better)	31007.8
BIC (Smaller is Better)	31017.6

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
1	2186.76	<.0001

Solution for Fixed Effects

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Estimate	Standard Error	DF	t Value	Pr > |t|
Intercept				5.3618	0.1892	3303	28.35	<.0001
TRTP(ATPTN)	IDegLira		1	0.04382	0.2258	6820	0.19	0.8461
TRTP(ATPTN)	IGlar		1	0.05183	0.2069	6617	0.25	0.8022
TRTP(ATPTN)	IDegLira		2	2.8792	0.2270	6843	12.68	<.0001
TRTP(ATPTN)	IGlar		2	3.2852	0.2076	6618	15.82	<.0001
TRTP(ATPTN)	IDegLira		3	0.9137	0.2259	6820	4.04	<.0001
TRTP(ATPTN)	IGlar		3	1.3015	0.2070	6617	6.29	<.0001
TRTP(ATPTN)	IDegLira		4	2.7883	0.2272	6845	12.27	<.0001
TRTP(ATPTN)	IGlar		4	3.5271	0.2080	6619	16.96	<.0001
TRTP(ATPTN)	IDegLira		5	1.4598	0.2264	6831	6.45	<.0001
TRTP(ATPTN)	IGlar		5	1.6905	0.2076	6619	8.14	<.0001
TRTP(ATPTN)	IDegLira		6	2.8533	0.2268	6839	12.58	<.0001
TRTP(ATPTN)	IGlar		6	3.6246	0.2079	6619	17.44	<.0001
TRTP(ATPTN)	IDegLira		7	2.0238	0.2278	6859	8.88	<.0001
TRTP(ATPTN)	IGlar		7	2.6335	0.2095	6622	12.57	<.0001
TRTP(ATPTN)	IDegLira		8	0.3522	0.2277	6856	1.55	0.1219
TRTP(ATPTN)	IGlar		8	0.5444	0.2091	6621	2.60	0.0092
TRTP(ATPTN)	IDegLira		9	-0.06223	0.1521	3351	-0.41	0.6825
TRTP(ATPTN)	IGlar		9	0	.	.	.	.
REGION1(ATPTN)		Africa	1	0.3252	0.3150	3292	1.03	0.3019
REGION1(ATPTN)		Asia	1	-0.2311	0.2925	3292	-0.79	0.4296
REGION1(ATPTN)		Europe	1	0.2449	0.2010	3292	1.22	0.2231
REGION1(ATPTN)		North America	1	0.4715	0.2781	3331	1.70	0.0901
REGION1(ATPTN)		South America	1	0	.	.	.	.
REGION1(ATPTN)		Africa	2	-0.3319	0.3228	3511	-1.03	0.3039
REGION1(ATPTN)		Asia	2	0.1585	0.2931	3310	0.54	0.5886
REGION1(ATPTN)		Europe	2	0.1582	0.2022	3345	0.78	0.4339
REGION1(ATPTN)		North America	2	0.2514	0.2794	3372	0.90	0.3684
REGION1(ATPTN)		South America	2	0	.	.	.	.
REGION1(ATPTN)		Africa	3	-0.6456	0.3186	3388	-2.03	0.0428
REGION1(ATPTN)		Asia	3	-0.3876	0.2925	3292	-1.33	0.1852
REGION1(ATPTN)		Europe	3	-0.2977	0.2013	3304	-1.48	0.1392
REGION1(ATPTN)		North America	3	-0.00702	0.2775	3310	-0.03	0.9798
REGION1(ATPTN)		South America	3	0	.	.	.	.
REGION1(ATPTN)		Africa	4	-1.0564	0.3193	3410	-3.31	0.0009
REGION1(ATPTN)		Asia	4	0.9393	0.2933	3317	3.20	0.0014
REGION1(ATPTN)		Europe	4	-0.1958	0.2023	3353	-0.97	0.3333
REGION1(ATPTN)		North America	4	-0.3131	0.2790	3358	-1.12	0.2618
REGION1(ATPTN)		South America	4	0	.	.	.	.
REGION1(ATPTN)		Africa	5	-0.7020	0.3189	3398	-2.20	0.0278
REGION1(ATPTN)		Asia	5	-0.2027	0.2929	3305	-0.69	0.4890
REGION1(ATPTN)		Europe	5	-0.08562	0.2018	3327	-0.42	0.6713
REGION1(ATPTN)		North America	5	-0.2258	0.2780	3324	-0.81	0.4166
REGION1(ATPTN)		South America	5	0	.	.	.	.
REGION1(ATPTN)		Africa	6	-0.3460	0.3203	3439	-1.08	0.2801
REGION1(ATPTN)		Asia	6	0.9025	0.2939	3336	3.07	0.0021
REGION1(ATPTN)		Europe	6	0.1553	0.2022	3347	0.77	0.4424
REGION1(ATPTN)		North America	6	-0.3403	0.2794	3370	-1.22	0.2233
REGION1(ATPTN)		South America	6	0	.	.	.	.
REGION1(ATPTN)		Africa	7	0.2330	0.3198	3427	0.73	0.4663
REGION1(ATPTN)		Asia	7	1.5255	0.2940	3339	5.19	<.0001
REGION1(ATPTN)		Europe	7	-0.1209	0.2039	3424	-0.59	0.5531
REGION1(ATPTN)		North America	7	0.01975	0.2809	3421	0.07	0.9440
REGION1(ATPTN)		South America	7	0	.	.	.	.

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Solution for Fixed Effects

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Estimate	Standard Error	DF	t Value	Pr > |t|
REGION1(ATPTN)		Africa	8	-0.1158	0.3185	3388	-0.36	0.7163
REGION1(ATPTN)		Asia	8	0.1474	0.2945	3355	0.50	0.6168
REGION1(ATPTN)		Europe	8	0.02421	0.2036	3410	0.12	0.9053
REGION1(ATPTN)		North America	8	0.03267	0.2839	3519	0.12	0.9084
REGION1(ATPTN)		South America	8	0	.	.	.	.
REGION1(ATPTN)		Africa	9	0.3909	0.3183	3391	1.23	0.2195
REGION1(ATPTN)		Asia	9	-0.1043	0.2925	3292	-0.36	0.7214
REGION1(ATPTN)		Europe	9	0.3120	0.2014	3310	1.55	0.1215
REGION1(ATPTN)		North America	9	0.4412	0.2793	3368	1.58	0.1142
REGION1(ATPTN)		South America	9	0	.	.	.	.

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
TRTP(ATPTN)	9	6327	6.51	<.0001
REGION1(ATPTN)	36	7077	4.74	<.0001

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1	1					
TRTP(ATPTN)	IGlar		1		1				
TRTP(ATPTN)	IDegLira		2			1			
TRTP(ATPTN)	IGlar		2				1		
TRTP(ATPTN)	IDegLira		3					1	

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9	Row10	Row11	Row12
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1						
TRTP(ATPTN)	IGlar		1						
TRTP(ATPTN)	IDegLira		2						
TRTP(ATPTN)	IGlar		2						
TRTP(ATPTN)	IDegLira		3						

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row13	Row14	Row15	Row16	Row17	Row18
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1						
TRTP(ATPTN)	IGlar		1						
TRTP(ATPTN)	IDegLira		2						
TRTP(ATPTN)	IGlar		2						
TRTP(ATPTN)	IDegLira		3						

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
TRTP(ATPTN)	IGlar		3						1
TRTP(ATPTN)	IDegLira		4						
TRTP(ATPTN)	IGlar		4						
TRTP(ATPTN)	IDegLira		5						
TRTP(ATPTN)	IGlar		5						
TRTP(ATPTN)	IDegLira		6						
TRTP(ATPTN)	IGlar		6						
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1	0.0879	0.0879				
REGION1(ATPTN)		Asia	1	0.0909	0.0909				
REGION1(ATPTN)		Europe	1	0.4911	0.4911				
REGION1(ATPTN)		North America	1	0.1502	0.1502				
REGION1(ATPTN)		South America	1	0.1798	0.1798				
REGION1(ATPTN)		Africa	2			0.0879	0.0879		
REGION1(ATPTN)		Asia	2			0.0909	0.0909		
REGION1(ATPTN)		Europe	2			0.4911	0.4911		
REGION1(ATPTN)		North America	2			0.1502	0.1502		
REGION1(ATPTN)		South America	2			0.1798	0.1798		
REGION1(ATPTN)		Africa	3					0.0879	0.0879
REGION1(ATPTN)		Asia	3					0.0909	0.0909
REGION1(ATPTN)		Europe	3					0.4911	0.4911
REGION1(ATPTN)		North America	3					0.1502	0.1502
REGION1(ATPTN)		South America	3					0.1798	0.1798
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9	Row10	Row11	Row12
TRTP(ATPTN)	IGlar		3						
TRTP(ATPTN)	IDegLira		4	1					
TRTP(ATPTN)	IGlar		4		1				
TRTP(ATPTN)	IDegLira		5			1			
TRTP(ATPTN)	IGlar		5				1		
TRTP(ATPTN)	IDegLira		6					1	
TRTP(ATPTN)	IGlar		6						1
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4	0.0879	0.0879				
REGION1(ATPTN)		Asia	4	0.0909	0.0909				
REGION1(ATPTN)		Europe	4	0.4911	0.4911				
REGION1(ATPTN)		North America	4	0.1502	0.1502				
REGION1(ATPTN)		South America	4	0.1798	0.1798				
REGION1(ATPTN)		Africa	5			0.0879	0.0879		
REGION1(ATPTN)		Asia	5			0.0909	0.0909		
REGION1(ATPTN)		Europe	5			0.4911	0.4911		
REGION1(ATPTN)		North America	5			0.1502	0.1502		
REGION1(ATPTN)		South America	5			0.1798	0.1798		
REGION1(ATPTN)		Africa	6					0.0879	0.0879
REGION1(ATPTN)		Asia	6					0.0909	0.0909
REGION1(ATPTN)		Europe	6					0.4911	0.4911
REGION1(ATPTN)		North America	6					0.1502	0.1502
REGION1(ATPTN)		South America	6					0.1798	0.1798
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row13	Row14	Row15	Row16	Row17	Row18
TRTP(ATPTN)	IGlar		3						
TRTP(ATPTN)	IDegLira		4						
TRTP(ATPTN)	IGlar		4						
TRTP(ATPTN)	IDegLira		5						
TRTP(ATPTN)	IGlar		5						
TRTP(ATPTN)	IDegLira		6						
TRTP(ATPTN)	IGlar		6						
TRTP(ATPTN)	IDegLira		7	1					
TRTP(ATPTN)	IGlar		7		1				
TRTP(ATPTN)	IDegLira		8			1			
TRTP(ATPTN)	IGlar		8				1		
TRTP(ATPTN)	IDegLira		9					1	
TRTP(ATPTN)	IGlar		9						1
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7	0.0879	0.0879				
REGION1(ATPTN)		Asia	7	0.0909	0.0909				
REGION1(ATPTN)		Europe	7	0.4911	0.4911				
REGION1(ATPTN)		North America	7	0.1502	0.1502				
REGION1(ATPTN)		South America	7	0.1798	0.1798				
REGION1(ATPTN)		Africa	8			0.0879	0.0879		
REGION1(ATPTN)		Asia	8			0.0909	0.0909		
REGION1(ATPTN)		Europe	8			0.4911	0.4911		
REGION1(ATPTN)		North America	8			0.1502	0.1502		
REGION1(ATPTN)		South America	8			0.1798	0.1798		
REGION1(ATPTN)		Africa	9					0.0879	0.0879
REGION1(ATPTN)		Asia	9					0.0909	0.0909
REGION1(ATPTN)		Europe	9					0.4911	0.4911
REGION1(ATPTN)		North America	9					0.1502	0.1502
REGION1(ATPTN)		South America	9					0.1798	0.1798

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Least Squares Means Estimates

Effect	Label	Margins	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha
TRTP(ATPTN)	1IDegLira	WORK.ADPROF3	5.6043	0.1058	3303	52.96	<.0001	0.05
TRTP(ATPTN)	1IGlar	WORK.ADPROF3	5.6123	0.1084	3301	51.77	<.0001	0.05
TRTP(ATPTN)	2IDegLira	WORK.ADPROF3	8.3417	0.1069	3396	78.04	<.0001	0.05
TRTP(ATPTN)	2IGlar	WORK.ADPROF3	8.7476	0.1088	3329	80.39	<.0001	0.05
TRTP(ATPTN)	3IDegLira	WORK.ADPROF3	6.0362	0.1059	3314	56.98	<.0001	0.05
TRTP(ATPTN)	3IGlar	WORK.ADPROF3	6.4240	0.1090	3345	58.93	<.0001	0.05
TRTP(ATPTN)	4IDegLira	WORK.ADPROF3	7.9994	0.1061	3328	75.38	<.0001	0.05
TRTP(ATPTN)	4IGlar	WORK.ADPROF3	8.7382	0.1090	3346	80.16	<.0001	0.05
TRTP(ATPTN)	5IDegLira	WORK.ADPROF3	6.6654	0.1060	3319	62.88	<.0001	0.05
TRTP(ATPTN)	5IGlar	WORK.ADPROF3	6.8962	0.1089	3338	63.31	<.0001	0.05
TRTP(ATPTN)	6IDegLira	WORK.ADPROF3	8.2919	0.1065	3364	77.84	<.0001	0.05
TRTP(ATPTN)	6IGlar	WORK.ADPROF3	9.0632	0.1091	3355	83.06	<.0001	0.05
TRTP(ATPTN)	7IDegLira	WORK.ADPROF3	7.4883	0.1069	3400	70.03	<.0001	0.05
TRTP(ATPTN)	7IGlar	WORK.ADPROF3	8.0980	0.1098	3417	73.73	<.0001	0.05
TRTP(ATPTN)	8IDegLira	WORK.ADPROF3	5.7340	0.1074	3442	53.38	<.0001	0.05
TRTP(ATPTN)	8IGlar	WORK.ADPROF3	5.9262	0.1098	3416	53.96	<.0001	0.05
TRTP(ATPTN)	9IDegLira	WORK.ADPROF3	5.5439	0.1061	3331	52.23	<.0001	0.05
TRTP(ATPTN)	9IGlar	WORK.ADPROF3	5.6062	0.1094	3380	51.26	<.0001	0.05

Least Squares Means Estimates

Effect	Label	Lower	Upper
TRTP(ATPTN)	1IDegLira	5.3968	5.8117
TRTP(ATPTN)	1IGlar	5.3998	5.8248
TRTP(ATPTN)	2IDegLira	8.1321	8.5512
TRTP(ATPTN)	2IGlar	8.5343	8.9610
TRTP(ATPTN)	3IDegLira	5.8285	6.2439
TRTP(ATPTN)	3IGlar	6.2102	6.6377
TRTP(ATPTN)	4IDegLira	7.7913	8.2074
TRTP(ATPTN)	4IGlar	8.5245	8.9520
TRTP(ATPTN)	5IDegLira	6.4576	6.8732
TRTP(ATPTN)	5IGlar	6.6826	7.1097
TRTP(ATPTN)	6IDegLira	8.0830	8.5008
TRTP(ATPTN)	6IGlar	8.8493	9.2771
TRTP(ATPTN)	7IDegLira	7.2787	7.6980
TRTP(ATPTN)	7IGlar	7.8827	8.3134
TRTP(ATPTN)	8IDegLira	5.5234	5.9446
TRTP(ATPTN)	8IGlar	5.7109	6.1416
TRTP(ATPTN)	9IDegLira	5.3358	5.7520
TRTP(ATPTN)	9IGlar	5.3917	5.8206

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
Intercept									

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
Intercept						

9-point self-measured plasma glucose profile after 26 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
TRTP(ATPTN)	IDegLira		1	1					
TRTP(ATPTN)	IGlar		1	-1					
TRTP(ATPTN)	IDegLira		2		1				
TRTP(ATPTN)	IGlar		2		-1				
TRTP(ATPTN)	IDegLira		3			1			
TRTP(ATPTN)	IGlar		3			-1			
TRTP(ATPTN)	IDegLira		4				1		
TRTP(ATPTN)	IGlar		4				-1		
TRTP(ATPTN)	IDegLira		5					1	
TRTP(ATPTN)	IGlar		5					-1	
TRTP(ATPTN)	IDegLira		6						1
TRTP(ATPTN)	IGlar		6						-1
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
TRTP(ATPTN)	IDegLira		1			
TRTP(ATPTN)	IGlar		1			
TRTP(ATPTN)	IDegLira		2			
TRTP(ATPTN)	IGlar		2			
TRTP(ATPTN)	IDegLira		3			
TRTP(ATPTN)	IGlar		3			
TRTP(ATPTN)	IDegLira		4			
TRTP(ATPTN)	IGlar		4			
TRTP(ATPTN)	IDegLira		5			
TRTP(ATPTN)	IGlar		5			
TRTP(ATPTN)	IDegLira		6			
TRTP(ATPTN)	IGlar		6			
TRTP(ATPTN)	IDegLira		7	1		
TRTP(ATPTN)	IGlar		7	-1		
TRTP(ATPTN)	IDegLira		8		1	
TRTP(ATPTN)	IGlar		8		-1	
TRTP(ATPTN)	IDegLira		9			1
TRTP(ATPTN)	IGlar		9			-1
REGION1(ATPTN)		Africa	1			
REGION1(ATPTN)		Asia	1			
REGION1(ATPTN)		Europe	1			
REGION1(ATPTN)		North America	1			
REGION1(ATPTN)		South America	1			
REGION1(ATPTN)		Africa	2			
REGION1(ATPTN)		Asia	2			
REGION1(ATPTN)		Europe	2			
REGION1(ATPTN)		North America	2			
REGION1(ATPTN)		South America	2			
REGION1(ATPTN)		Africa	3			
REGION1(ATPTN)		Asia	3			
REGION1(ATPTN)		Europe	3			
REGION1(ATPTN)		North America	3			
REGION1(ATPTN)		South America	3			
REGION1(ATPTN)		Africa	4			
REGION1(ATPTN)		Asia	4			
REGION1(ATPTN)		Europe	4			
REGION1(ATPTN)		North America	4			
REGION1(ATPTN)		South America	4			
REGION1(ATPTN)		Africa	5			
REGION1(ATPTN)		Asia	5			
REGION1(ATPTN)		Europe	5			
REGION1(ATPTN)		North America	5			
REGION1(ATPTN)		South America	5			
REGION1(ATPTN)		Africa	6			
REGION1(ATPTN)		Asia	6			
REGION1(ATPTN)		Europe	6			
REGION1(ATPTN)		North America	6			
REGION1(ATPTN)		South America	6			
REGION1(ATPTN)		Africa	7			
REGION1(ATPTN)		Asia	7			
REGION1(ATPTN)		Europe	7			
REGION1(ATPTN)		North America	7			
REGION1(ATPTN)		South America	7			
REGION1(ATPTN)		Africa	8			
REGION1(ATPTN)		Asia	8			
REGION1(ATPTN)		Europe	8			
REGION1(ATPTN)		North America	8			
REGION1(ATPTN)		South America	8			
REGION1(ATPTN)		Africa	9			
REGION1(ATPTN)		Asia	9			

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
REGION1(ATPTN)		Europe	9			
REGION1(ATPTN)		North America	9			
REGION1(ATPTN)		South America	9			

Least Squares Means Estimates

Effect	Label	Margins	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha
TRTP(ATPTN)	1Treatment contrast	WORK.ADPROF3	-0.00801	0.1513	3300	-0.05	0.9578	0.05
TRTP(ATPTN)	2Treatment contrast	WORK.ADPROF3	-0.4060	0.1523	3359	-2.67	0.0077	0.05
TRTP(ATPTN)	3Treatment contrast	WORK.ADPROF3	-0.3877	0.1518	3328	-2.55	0.0107	0.05
TRTP(ATPTN)	4Treatment contrast	WORK.ADPROF3	-0.7389	0.1519	3336	-4.86	<.0001	0.05
TRTP(ATPTN)	5Treatment contrast	WORK.ADPROF3	-0.2307	0.1518	3327	-1.52	0.1285	0.05
TRTP(ATPTN)	6Treatment contrast	WORK.ADPROF3	-0.7713	0.1522	3356	-5.07	<.0001	0.05
TRTP(ATPTN)	7Treatment contrast	WORK.ADPROF3	-0.6097	0.1531	3408	-3.98	<.0001	0.05
TRTP(ATPTN)	8Treatment contrast	WORK.ADPROF3	-0.1922	0.1533	3422	-1.25	0.2100	0.05
TRTP(ATPTN)	9Treatment contrast	WORK.ADPROF3	-0.06223	0.1521	3351	-0.41	0.6825	0.05

Least Squares Means Estimates

Effect	Label	Lower	Upper
TRTP(ATPTN)	1Treatment contrast	-0.3046	0.2885
TRTP(ATPTN)	2Treatment contrast	-0.7046	-0.1074
TRTP(ATPTN)	3Treatment contrast	-0.6853	-0.09015
TRTP(ATPTN)	4Treatment contrast	-1.0367	-0.4410
TRTP(ATPTN)	5Treatment contrast	-0.5283	0.06681
TRTP(ATPTN)	6Treatment contrast	-1.0698	-0.4728
TRTP(ATPTN)	7Treatment contrast	-0.9098	-0.3095
TRTP(ATPTN)	8Treatment contrast	-0.4928	0.1084
TRTP(ATPTN)	9Treatment contrast	-0.3605	0.2361

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Model Information

Data Set	WORK.ADPROF3
Dependent Variable	AVAL
Covariance Structure	Compound Symmetry
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	Profile
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks – supportive statistical analysis – full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228/ [redacted]

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
TRTP	2	IDegLira IGlar
ATPTN	9	1 2 3 4 5 6 7 8 9
REGION1	5	Africa Asia Europe North America South America

Dimensions

Covariance Parameters	2
Columns in X	64
Columns in Z	0
Subjects	1012
Max Obs per Subject	9

Number of Observations

Number of Observations Read	9108
Number of Observations Used	7516
Number of Observations Not Used	1592

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	76343.01528619	
1	2	74156.25297945	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate	Standard Error	Z Value	Pr Z	Alpha	Lower	Upper
CS	USUBJID	630.72	35.9428	17.55	<.0001	0.05	560.27	701.17
Residual		939.32	16.3320	57.51	<.0001	0.05	908.11	972.17

Asymptotic Covariance Matrix of Estimates

Row	Cov Parm	CovP1	CovP2
1	CS	1291.89	-30.5656
2	Residual	-30.5656	266.73

Fit Statistics

-2 Res Log Likelihood	74156.3
AIC (Smaller is Better)	74160.3
AICC (Smaller is Better)	74160.3
BIC (Smaller is Better)	74170.1

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
1	2186.76	<.0001

Solution for Fixed Effects

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Estimate	Standard Error	DF	t Value	Pr > |t|
Intercept				96.6193	3.4086	3303	28.35	<.0001
TRTP(ATPTN)	IDegLira		1	0.7896	4.0691	6820	0.19	0.8461
TRTP(ATPTN)	IGlar		1	0.9340	3.7283	6617	0.25	0.8022
TRTP(ATPTN)	IDegLira		2	51.8830	4.0912	6843	12.68	<.0001
TRTP(ATPTN)	IGlar		2	59.1986	3.7412	6618	15.82	<.0001
TRTP(ATPTN)	IDegLira		3	16.4649	4.0706	6820	4.04	<.0001
TRTP(ATPTN)	IGlar		3	23.4521	3.7301	6617	6.29	<.0001
TRTP(ATPTN)	IDegLira		4	50.2447	4.0933	6845	12.27	<.0001
TRTP(ATPTN)	IGlar		4	63.5588	3.7475	6619	16.96	<.0001
TRTP(ATPTN)	IDegLira		5	26.3049	4.0798	6831	6.45	<.0001
TRTP(ATPTN)	IGlar		5	30.4629	3.7407	6619	8.14	<.0001
TRTP(ATPTN)	IDegLira		6	51.4166	4.0875	6839	12.58	<.0001
TRTP(ATPTN)	IGlar		6	65.3157	3.7455	6619	17.44	<.0001
TRTP(ATPTN)	IDegLira		7	36.4690	4.1052	6859	8.88	<.0001
TRTP(ATPTN)	IGlar		7	47.4550	3.7750	6622	12.57	<.0001
TRTP(ATPTN)	IDegLira		8	6.3471	4.1028	6856	1.55	0.1219
TRTP(ATPTN)	IGlar		8	9.8109	3.7680	6621	2.60	0.0092
TRTP(ATPTN)	IDegLira		9	-1.1214	2.7415	3351	-0.41	0.6825
TRTP(ATPTN)	IGlar		9	0	.	.	.	.
REGION1(ATPTN)		Africa	1	5.8607	5.6761	3292	1.03	0.3019
REGION1(ATPTN)		Asia	1	-4.1639	5.2707	3292	-0.79	0.4296
REGION1(ATPTN)		Europe	1	4.4132	3.6219	3292	1.22	0.2231
REGION1(ATPTN)		North America	1	8.4956	5.0111	3331	1.70	0.0901
REGION1(ATPTN)		South America	1	0	.	.	.	.
REGION1(ATPTN)		Africa	2	-5.9807	5.8161	3511	-1.03	0.3039
REGION1(ATPTN)		Asia	2	2.8564	5.2810	3310	0.54	0.5886
REGION1(ATPTN)		Europe	2	2.8512	3.6428	3345	0.78	0.4339
REGION1(ATPTN)		North America	2	4.5295	5.0349	3372	0.90	0.3684
REGION1(ATPTN)		South America	2	0	.	.	.	.
REGION1(ATPTN)		Africa	3	-11.6344	5.7409	3388	-2.03	0.0428
REGION1(ATPTN)		Asia	3	-6.9841	5.2707	3292	-1.33	0.1852
REGION1(ATPTN)		Europe	3	-5.3649	3.6268	3304	-1.48	0.1392
REGION1(ATPTN)		North America	3	-0.1264	5.0012	3310	-0.03	0.9798
REGION1(ATPTN)		South America	3	0	.	.	.	.
REGION1(ATPTN)		Africa	4	-19.0354	5.7540	3410	-3.31	0.0009
REGION1(ATPTN)		Asia	4	16.9258	5.2851	3317	3.20	0.0014
REGION1(ATPTN)		Europe	4	-3.5282	3.6459	3353	-0.97	0.3333
REGION1(ATPTN)		North America	4	-5.6428	5.0282	3358	-1.12	0.2618
REGION1(ATPTN)		South America	4	0	.	.	.	.
REGION1(ATPTN)		Africa	5	-12.6492	5.7472	3398	-2.20	0.0278
REGION1(ATPTN)		Asia	5	-3.6519	5.2781	3305	-0.69	0.4890
REGION1(ATPTN)		Europe	5	-1.5429	3.6359	3327	-0.42	0.6713
REGION1(ATPTN)		North America	5	-4.0693	5.0090	3324	-0.81	0.4166
REGION1(ATPTN)		South America	5	0	.	.	.	.
REGION1(ATPTN)		Africa	6	-6.2353	5.7719	3439	-1.08	0.2801
REGION1(ATPTN)		Asia	6	16.2639	5.2955	3336	3.07	0.0021
REGION1(ATPTN)		Europe	6	2.7992	3.6435	3347	0.77	0.4424
REGION1(ATPTN)		North America	6	-6.1317	5.0346	3370	-1.22	0.2233
REGION1(ATPTN)		South America	6	0	.	.	.	.
REGION1(ATPTN)		Africa	7	4.1992	5.7631	3427	0.73	0.4663
REGION1(ATPTN)		Asia	7	27.4893	5.2974	3339	5.19	<.0001
REGION1(ATPTN)		Europe	7	-2.1789	3.6736	3424	-0.59	0.5531
REGION1(ATPTN)		North America	7	0.3559	5.0622	3421	0.07	0.9440
REGION1(ATPTN)		South America	7	0	.	.	.	.

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Solution for Fixed Effects

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Estimate	Standard Error	DF	t Value	Pr > |t|
REGION1(ATPTN)		Africa	8	-2.0860	5.7393	3388	-0.36	0.7163
REGION1(ATPTN)		Asia	8	2.6553	5.3062	3355	0.50	0.6168
REGION1(ATPTN)		Europe	8	0.4363	3.6681	3410	0.12	0.9053
REGION1(ATPTN)		North America	8	0.5886	5.1151	3519	0.12	0.9084
REGION1(ATPTN)		South America	8	0	.	.	.	.
REGION1(ATPTN)		Africa	9	7.0449	5.7361	3391	1.23	0.2195
REGION1(ATPTN)		Asia	9	-1.8796	5.2708	3292	-0.36	0.7214
REGION1(ATPTN)		Europe	9	5.6220	3.6293	3310	1.55	0.1215
REGION1(ATPTN)		North America	9	7.9505	5.0325	3368	1.58	0.1142
REGION1(ATPTN)		South America	9	0	.	.	.	.

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
TRTP(ATPTN)	9	6327	6.51	<.0001
REGION1(ATPTN)	36	7077	4.74	<.0001

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1	1					
TRTP(ATPTN)	IGlar		1		1				
TRTP(ATPTN)	IDegLira		2			1			
TRTP(ATPTN)	IGlar		2				1		
TRTP(ATPTN)	IDegLira		3					1	

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9	Row10	Row11	Row12
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1						
TRTP(ATPTN)	IGlar		1						
TRTP(ATPTN)	IDegLira		2						
TRTP(ATPTN)	IGlar		2						
TRTP(ATPTN)	IDegLira		3						

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row13	Row14	Row15	Row16	Row17	Row18
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1						
TRTP(ATPTN)	IGlar		1						
TRTP(ATPTN)	IDegLira		2						
TRTP(ATPTN)	IGlar		2						
TRTP(ATPTN)	IDegLira		3						

9-point self-measured plasma glucose profile after 26 weeks – supportive statistical analysis – full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
TRTP(ATPTN)	IGlar		3						1
TRTP(ATPTN)	IDegLira		4						
TRTP(ATPTN)	IGlar		4						
TRTP(ATPTN)	IDegLira		5						
TRTP(ATPTN)	IGlar		5						
TRTP(ATPTN)	IDegLira		6						
TRTP(ATPTN)	IGlar		6						
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1	0.0879	0.0879				
REGION1(ATPTN)		Asia	1	0.0909	0.0909				
REGION1(ATPTN)		Europe	1	0.4911	0.4911				
REGION1(ATPTN)		North America	1	0.1502	0.1502				
REGION1(ATPTN)		South America	1	0.1798	0.1798				
REGION1(ATPTN)		Africa	2			0.0879	0.0879		
REGION1(ATPTN)		Asia	2			0.0909	0.0909		
REGION1(ATPTN)		Europe	2			0.4911	0.4911		
REGION1(ATPTN)		North America	2			0.1502	0.1502		
REGION1(ATPTN)		South America	2			0.1798	0.1798		
REGION1(ATPTN)		Africa	3					0.0879	0.0879
REGION1(ATPTN)		Asia	3					0.0909	0.0909
REGION1(ATPTN)		Europe	3					0.4911	0.4911
REGION1(ATPTN)		North America	3					0.1502	0.1502
REGION1(ATPTN)		South America	3					0.1798	0.1798
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9	Row10	Row11	Row12
TRTP(ATPTN)	IGlar		3						
TRTP(ATPTN)	IDegLira		4	1					
TRTP(ATPTN)	IGlar		4		1				
TRTP(ATPTN)	IDegLira		5			1			
TRTP(ATPTN)	IGlar		5				1		
TRTP(ATPTN)	IDegLira		6					1	
TRTP(ATPTN)	IGlar		6						1
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4	0.0879	0.0879				
REGION1(ATPTN)		Asia	4	0.0909	0.0909				
REGION1(ATPTN)		Europe	4	0.4911	0.4911				
REGION1(ATPTN)		North America	4	0.1502	0.1502				
REGION1(ATPTN)		South America	4	0.1798	0.1798				
REGION1(ATPTN)		Africa	5			0.0879	0.0879		
REGION1(ATPTN)		Asia	5			0.0909	0.0909		
REGION1(ATPTN)		Europe	5			0.4911	0.4911		
REGION1(ATPTN)		North America	5			0.1502	0.1502		
REGION1(ATPTN)		South America	5			0.1798	0.1798		
REGION1(ATPTN)		Africa	6					0.0879	0.0879
REGION1(ATPTN)		Asia	6					0.0909	0.0909
REGION1(ATPTN)		Europe	6					0.4911	0.4911
REGION1(ATPTN)		North America	6					0.1502	0.1502
REGION1(ATPTN)		South America	6					0.1798	0.1798
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row13	Row14	Row15	Row16	Row17	Row18
TRTP(ATPTN)	IGlar		3						
TRTP(ATPTN)	IDegLira		4						
TRTP(ATPTN)	IGlar		4						
TRTP(ATPTN)	IDegLira		5						
TRTP(ATPTN)	IGlar		5						
TRTP(ATPTN)	IDegLira		6						
TRTP(ATPTN)	IGlar		6						
TRTP(ATPTN)	IDegLira		7	1					
TRTP(ATPTN)	IGlar		7		1				
TRTP(ATPTN)	IDegLira		8			1			
TRTP(ATPTN)	IGlar		8				1		
TRTP(ATPTN)	IDegLira		9					1	
TRTP(ATPTN)	IGlar		9						1
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7	0.0879	0.0879				
REGION1(ATPTN)		Asia	7	0.0909	0.0909				
REGION1(ATPTN)		Europe	7	0.4911	0.4911				
REGION1(ATPTN)		North America	7	0.1502	0.1502				
REGION1(ATPTN)		South America	7	0.1798	0.1798				
REGION1(ATPTN)		Africa	8			0.0879	0.0879		
REGION1(ATPTN)		Asia	8			0.0909	0.0909		
REGION1(ATPTN)		Europe	8			0.4911	0.4911		
REGION1(ATPTN)		North America	8			0.1502	0.1502		
REGION1(ATPTN)		South America	8			0.1798	0.1798		
REGION1(ATPTN)		Africa	9					0.0879	0.0879
REGION1(ATPTN)		Asia	9					0.0909	0.0909
REGION1(ATPTN)		Europe	9					0.4911	0.4911
REGION1(ATPTN)		North America	9					0.1502	0.1502
REGION1(ATPTN)		South America	9					0.1798	0.1798

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Least Squares Means Estimates

Effect	Label	Margins	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha
TRTP(ATPTN)	1IDegLira	WORK.ADPROF3	100.99	1.9067	3303	52.96	<.0001	0.05
TRTP(ATPTN)	1IGlar	WORK.ADPROF3	101.13	1.9534	3301	51.77	<.0001	0.05
TRTP(ATPTN)	2IDegLira	WORK.ADPROF3	150.32	1.9261	3396	78.04	<.0001	0.05
TRTP(ATPTN)	2IGlar	WORK.ADPROF3	157.63	1.9608	3329	80.39	<.0001	0.05
TRTP(ATPTN)	3IDegLira	WORK.ADPROF3	108.77	1.9090	3314	56.98	<.0001	0.05
TRTP(ATPTN)	3IGlar	WORK.ADPROF3	115.76	1.9643	3345	58.93	<.0001	0.05
TRTP(ATPTN)	4IDegLira	WORK.ADPROF3	144.15	1.9122	3328	75.38	<.0001	0.05
TRTP(ATPTN)	4IGlar	WORK.ADPROF3	157.46	1.9645	3346	80.16	<.0001	0.05
TRTP(ATPTN)	5IDegLira	WORK.ADPROF3	120.11	1.9100	3319	62.88	<.0001	0.05
TRTP(ATPTN)	5IGlar	WORK.ADPROF3	124.27	1.9628	3338	63.31	<.0001	0.05
TRTP(ATPTN)	6IDegLira	WORK.ADPROF3	149.42	1.9196	3364	77.84	<.0001	0.05
TRTP(ATPTN)	6IGlar	WORK.ADPROF3	163.32	1.9663	3355	83.06	<.0001	0.05
TRTP(ATPTN)	7IDegLira	WORK.ADPROF3	134.94	1.9269	3400	70.03	<.0001	0.05
TRTP(ATPTN)	7IGlar	WORK.ADPROF3	145.93	1.9792	3417	73.73	<.0001	0.05
TRTP(ATPTN)	8IDegLira	WORK.ADPROF3	103.33	1.9356	3442	53.38	<.0001	0.05
TRTP(ATPTN)	8IGlar	WORK.ADPROF3	106.79	1.9791	3416	53.96	<.0001	0.05
TRTP(ATPTN)	9IDegLira	WORK.ADPROF3	99.9017	1.9127	3331	52.23	<.0001	0.05
TRTP(ATPTN)	9IGlar	WORK.ADPROF3	101.02	1.9708	3380	51.26	<.0001	0.05

Least Squares Means Estimates

Effect	Label	Lower	Upper
TRTP(ATPTN)	1IDegLira	97.2507	104.73
TRTP(ATPTN)	1IGlar	97.3036	104.96
TRTP(ATPTN)	2IDegLira	146.54	154.09
TRTP(ATPTN)	2IGlar	153.79	161.48
TRTP(ATPTN)	3IDegLira	105.03	112.52
TRTP(ATPTN)	3IGlar	111.91	119.61
TRTP(ATPTN)	4IDegLira	140.40	147.90
TRTP(ATPTN)	4IGlar	153.61	161.31
TRTP(ATPTN)	5IDegLira	116.37	123.86
TRTP(ATPTN)	5IGlar	120.42	128.12
TRTP(ATPTN)	6IDegLira	145.66	153.18
TRTP(ATPTN)	6IGlar	159.46	167.17
TRTP(ATPTN)	7IDegLira	131.16	138.72
TRTP(ATPTN)	7IGlar	142.05	149.81
TRTP(ATPTN)	8IDegLira	99.5320	107.12
TRTP(ATPTN)	8IGlar	102.91	110.67
TRTP(ATPTN)	9IDegLira	96.1515	103.65
TRTP(ATPTN)	9IGlar	97.1590	104.89

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
Intercept									

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
Intercept						

9-point self-measured plasma glucose profile after 26 weeks – supportive statistical analysis – full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
TRTP(ATPTN)	IDegLira		1	1					
TRTP(ATPTN)	IGlar		1	-1					
TRTP(ATPTN)	IDegLira		2		1				
TRTP(ATPTN)	IGlar		2		-1				
TRTP(ATPTN)	IDegLira		3			1			
TRTP(ATPTN)	IGlar		3			-1			
TRTP(ATPTN)	IDegLira		4				1		
TRTP(ATPTN)	IGlar		4				-1		
TRTP(ATPTN)	IDegLira		5					1	
TRTP(ATPTN)	IGlar		5					-1	
TRTP(ATPTN)	IDegLira		6						1
TRTP(ATPTN)	IGlar		6						-1
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						

9-point self-measured plasma glucose profile after 26 weeks – supportive statistical analysis – full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
TRTP(ATPTN)	IDegLira		1			
TRTP(ATPTN)	IGlar		1			
TRTP(ATPTN)	IDegLira		2			
TRTP(ATPTN)	IGlar		2			
TRTP(ATPTN)	IDegLira		3			
TRTP(ATPTN)	IGlar		3			
TRTP(ATPTN)	IDegLira		4			
TRTP(ATPTN)	IGlar		4			
TRTP(ATPTN)	IDegLira		5			
TRTP(ATPTN)	IGlar		5			
TRTP(ATPTN)	IDegLira		6			
TRTP(ATPTN)	IGlar		6			
TRTP(ATPTN)	IDegLira		7	1		
TRTP(ATPTN)	IGlar		7	-1		
TRTP(ATPTN)	IDegLira		8		1	
TRTP(ATPTN)	IGlar		8		-1	
TRTP(ATPTN)	IDegLira		9			1
TRTP(ATPTN)	IGlar		9			-1
REGION1(ATPTN)		Africa	1			
REGION1(ATPTN)		Asia	1			
REGION1(ATPTN)		Europe	1			
REGION1(ATPTN)		North America	1			
REGION1(ATPTN)		South America	1			
REGION1(ATPTN)		Africa	2			
REGION1(ATPTN)		Asia	2			
REGION1(ATPTN)		Europe	2			
REGION1(ATPTN)		North America	2			
REGION1(ATPTN)		South America	2			
REGION1(ATPTN)		Africa	3			
REGION1(ATPTN)		Asia	3			
REGION1(ATPTN)		Europe	3			
REGION1(ATPTN)		North America	3			
REGION1(ATPTN)		South America	3			
REGION1(ATPTN)		Africa	4			
REGION1(ATPTN)		Asia	4			
REGION1(ATPTN)		Europe	4			
REGION1(ATPTN)		North America	4			
REGION1(ATPTN)		South America	4			
REGION1(ATPTN)		Africa	5			
REGION1(ATPTN)		Asia	5			
REGION1(ATPTN)		Europe	5			
REGION1(ATPTN)		North America	5			
REGION1(ATPTN)		South America	5			
REGION1(ATPTN)		Africa	6			
REGION1(ATPTN)		Asia	6			
REGION1(ATPTN)		Europe	6			
REGION1(ATPTN)		North America	6			
REGION1(ATPTN)		South America	6			
REGION1(ATPTN)		Africa	7			
REGION1(ATPTN)		Asia	7			
REGION1(ATPTN)		Europe	7			
REGION1(ATPTN)		North America	7			
REGION1(ATPTN)		South America	7			
REGION1(ATPTN)		Africa	8			
REGION1(ATPTN)		Asia	8			
REGION1(ATPTN)		Europe	8			
REGION1(ATPTN)		North America	8			
REGION1(ATPTN)		South America	8			
REGION1(ATPTN)		Africa	9			
REGION1(ATPTN)		Asia	9			

9-point self-measured plasma glucose profile after 26 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
REGION1(ATPTN)		Europe	9			
REGION1(ATPTN)		North America	9			
REGION1(ATPTN)		South America	9			

Least Squares Means Estimates

Effect	Label	Margins	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha
TRTP(ATPTN)	1Treatment contrast	WORK.ADPROF3	-0.1444	2.7256	3300	-0.05	0.9578	0.05
TRTP(ATPTN)	2Treatment contrast	WORK.ADPROF3	-7.3157	2.7442	3359	-2.67	0.0077	0.05
TRTP(ATPTN)	3Treatment contrast	WORK.ADPROF3	-6.9872	2.7351	3328	-2.55	0.0107	0.05
TRTP(ATPTN)	4Treatment contrast	WORK.ADPROF3	-13.3142	2.7374	3336	-4.86	<.0001	0.05
TRTP(ATPTN)	5Treatment contrast	WORK.ADPROF3	-4.1580	2.7347	3327	-1.52	0.1285	0.05
TRTP(ATPTN)	6Treatment contrast	WORK.ADPROF3	-13.8991	2.7435	3356	-5.07	<.0001	0.05
TRTP(ATPTN)	7Treatment contrast	WORK.ADPROF3	-10.9860	2.7584	3408	-3.98	<.0001	0.05
TRTP(ATPTN)	8Treatment contrast	WORK.ADPROF3	-3.4637	2.7627	3422	-1.25	0.2100	0.05
TRTP(ATPTN)	9Treatment contrast	WORK.ADPROF3	-1.1214	2.7415	3351	-0.41	0.6825	0.05

Least Squares Means Estimates

Effect	Label	Lower	Upper
TRTP(ATPTN)	1Treatment contrast	-5.4884	5.1996
TRTP(ATPTN)	2Treatment contrast	-12.6961	-1.9353
TRTP(ATPTN)	3Treatment contrast	-12.3499	-1.6245
TRTP(ATPTN)	4Treatment contrast	-18.6813	-7.9470
TRTP(ATPTN)	5Treatment contrast	-9.5199	1.2038
TRTP(ATPTN)	6Treatment contrast	-19.2782	-8.5200
TRTP(ATPTN)	7Treatment contrast	-16.3943	-5.5777
TRTP(ATPTN)	8Treatment contrast	-8.8804	1.9529
TRTP(ATPTN)	9Treatment contrast	-6.4966	4.2537

18: 9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

```
Parameter Code=C105585Y

The Mixed Procedure

                  Model Information

Data Set                      WORK.ADPROF3
Dependent Variable            AVAL
Covariance Structure          Compound Symmetry
Subject Effect                USUBJID
Estimation Method             REML
Residual Variance Method      Profile
Fixed Effects SE Method       Kenward-Roger
Degrees of Freedom Method     Kenward-Roger
```

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228	[redacted]
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

```
9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis –
full analysis set

Parameter Code=C105585Y

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
TRTP	2	IDegLira IGlar
ATPTN	9	1 2 3 4 5 6 7 8 9
REGION1	5	Africa Asia Europe North America South America

Dimensions

Covariance Parameters	2
Columns in X	64
Columns in Z	0
Subjects	1012
Max Obs per Subject	9

Number of Observations

Number of Observations Read	9108
Number of Observations Used	4109
Number of Observations Not Used	4999

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	17347.26951293	
1	2	16278.15697498	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate	Standard Error	Z Value	Pr Z	Alpha	Lower	Upper
CS	USUBJID	1.4989	0.1180	12.70	<.0001	0.05	1.2676	1.7302
Residual		2.4876	0.05867	42.40	<.0001	0.05	2.3765	2.6067

Asymptotic Covariance Matrix of Estimates

Row	Cov Parm	CovP1	CovP2
1	CS	0.01392	-0.00040
2	Residual	-0.00040	0.003442

Fit Statistics

-2 Res Log Likelihood	16278.2
AIC (Smaller is Better)	16282.2
AICC (Smaller is Better)	16282.2
BIC (Smaller is Better)	16292.0

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
1	1069.11	<.0001

Solution for Fixed Effects

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Estimate	Standard Error	DF	t Value	Pr > |t|
Intercept				5.6430	0.2421	1924	23.31	<.0001
TRTP(ATPTN)	IDegLira		1	-0.1226	0.2822	3726	-0.43	0.6639
TRTP(ATPTN)	IGlar		1	-0.1276	0.2704	3597	-0.47	0.6370
TRTP(ATPTN)	IDegLira		2	2.3698	0.2830	3731	8.37	<.0001
TRTP(ATPTN)	IGlar		2	3.0298	0.2713	3598	11.17	<.0001
TRTP(ATPTN)	IDegLira		3	0.8060	0.2823	3725	2.85	0.0043
TRTP(ATPTN)	IGlar		3	1.1185	0.2708	3597	4.13	<.0001
TRTP(ATPTN)	IDegLira		4	2.6159	0.2823	3725	9.27	<.0001
TRTP(ATPTN)	IGlar		4	3.6865	0.2708	3597	13.61	<.0001
TRTP(ATPTN)	IDegLira		5	1.3911	0.2823	3725	4.93	<.0001
TRTP(ATPTN)	IGlar		5	1.8317	0.2707	3597	6.77	<.0001
TRTP(ATPTN)	IDegLira		6	2.6198	0.2823	3725	9.28	<.0001
TRTP(ATPTN)	IGlar		6	3.4970	0.2708	3597	12.91	<.0001
TRTP(ATPTN)	IDegLira		7	2.0777	0.2838	3737	7.32	<.0001
TRTP(ATPTN)	IGlar		7	2.5005	0.2718	3599	9.20	<.0001
TRTP(ATPTN)	IDegLira		8	0.2321	0.2838	3738	0.82	0.4135
TRTP(ATPTN)	IGlar		8	0.5525	0.2720	3599	2.03	0.0423
TRTP(ATPTN)	IDegLira		9	-0.03094	0.1929	1938	-0.16	0.8726
TRTP(ATPTN)	IGlar		9	0	.	.	.	.
REGION1(ATPTN)		Africa	1	0.2598	0.4088	1918	0.64	0.5253
REGION1(ATPTN)		Asia	1	-0.5239	0.3916	1918	-1.34	0.1812
REGION1(ATPTN)		Europe	1	0.006502	0.2411	1918	0.03	0.9785
REGION1(ATPTN)		North America	1	0.7130	0.3473	1918	2.05	0.0402
REGION1(ATPTN)		South America	1	0	.	.	.	.
REGION1(ATPTN)		Africa	2	0.04722	0.4092	1923	0.12	0.9081
REGION1(ATPTN)		Asia	2	-0.6574	0.3920	1923	-1.68	0.0937
REGION1(ATPTN)		Europe	2	-0.00499	0.2428	1949	-0.02	0.9836
REGION1(ATPTN)		North America	2	0.2670	0.3529	1990	0.76	0.4494
REGION1(ATPTN)		South America	2	0	.	.	.	.
REGION1(ATPTN)		Africa	3	0.4834	0.4088	1918	1.18	0.2372
REGION1(ATPTN)		Asia	3	-0.4317	0.3916	1918	-1.10	0.2704
REGION1(ATPTN)		Europe	3	-0.6766	0.2419	1932	-2.80	0.0052
REGION1(ATPTN)		North America	3	-0.2225	0.3508	1959	-0.63	0.5260
REGION1(ATPTN)		South America	3	0	.	.	.	.
REGION1(ATPTN)		Africa	4	-0.5626	0.4088	1918	-1.38	0.1689
REGION1(ATPTN)		Asia	4	0.1540	0.3916	1918	0.39	0.6943
REGION1(ATPTN)		Europe	4	-0.6274	0.2420	1934	-2.59	0.0096
REGION1(ATPTN)		North America	4	-0.8197	0.3492	1935	-2.35	0.0190
REGION1(ATPTN)		South America	4	0	.	.	.	.
REGION1(ATPTN)		Africa	5	0.1463	0.4088	1918	0.36	0.7205
REGION1(ATPTN)		Asia	5	-0.3195	0.3916	1918	-0.82	0.4147
REGION1(ATPTN)		Europe	5	-0.7745	0.2417	1928	-3.20	0.0014
REGION1(ATPTN)		North America	5	-0.1772	0.3492	1935	-0.51	0.6119
REGION1(ATPTN)		South America	5	0	.	.	.	.
REGION1(ATPTN)		Africa	6	0.2683	0.4088	1918	0.66	0.5117
REGION1(ATPTN)		Asia	6	0.3756	0.3916	1918	0.96	0.3376
REGION1(ATPTN)		Europe	6	-0.1428	0.2419	1932	-0.59	0.5550
REGION1(ATPTN)		North America	6	-0.1325	0.3508	1959	-0.38	0.7056
REGION1(ATPTN)		South America	6	0	.	.	.	.
REGION1(ATPTN)		Africa	7	0.08568	0.4096	1928	0.21	0.8343
REGION1(ATPTN)		Asia	7	0.6665	0.3951	1964	1.69	0.0918
REGION1(ATPTN)		Europe	7	-0.5998	0.2436	1968	-2.46	0.0139
REGION1(ATPTN)		North America	7	0.1610	0.3517	1972	0.46	0.6471
REGION1(ATPTN)		South America	7	0	.	.	.	.

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Solution for Fixed Effects

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Estimate	Standard Error	DF	t Value	Pr > |t|
REGION1(ATPTN)		Africa	8	-0.1636	0.4165	2015	-0.39	0.6945
REGION1(ATPTN)		Asia	8	-0.09487	0.3951	1964	-0.24	0.8103
REGION1(ATPTN)		Europe	8	-0.3641	0.2436	1968	-1.49	0.1352
REGION1(ATPTN)		North America	8	0.03645	0.3533	1996	0.10	0.9178
REGION1(ATPTN)		South America	8	0	.	.	.	.
REGION1(ATPTN)		Africa	9	0.1154	0.4123	1962	0.28	0.7797
REGION1(ATPTN)		Asia	9	-0.7615	0.3916	1918	-1.94	0.0520
REGION1(ATPTN)		Europe	9	-0.2166	0.2415	1925	-0.90	0.3698
REGION1(ATPTN)		North America	9	0.05380	0.3492	1935	0.15	0.8776
REGION1(ATPTN)		South America	9	0	.	.	.	.

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
TRTP(ATPTN)	9	3437	6.26	<.0001
REGION1(ATPTN)	36	3836	2.55	<.0001

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1	1					
TRTP(ATPTN)	IGlar		1		1				
TRTP(ATPTN)	IDegLira		2			1			
TRTP(ATPTN)	IGlar		2				1		
TRTP(ATPTN)	IDegLira		3					1	

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9	Row10	Row11	Row12
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1						
TRTP(ATPTN)	IGlar		1						
TRTP(ATPTN)	IDegLira		2						
TRTP(ATPTN)	IGlar		2						
TRTP(ATPTN)	IDegLira		3						

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row13	Row14	Row15	Row16	Row17	Row18
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1						
TRTP(ATPTN)	IGlar		1						
TRTP(ATPTN)	IDegLira		2						
TRTP(ATPTN)	IGlar		2						
TRTP(ATPTN)	IDegLira		3						

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
TRTP(ATPTN)	IGlar		3						1
TRTP(ATPTN)	IDegLira		4						
TRTP(ATPTN)	IGlar		4						
TRTP(ATPTN)	IDegLira		5						
TRTP(ATPTN)	IGlar		5						
TRTP(ATPTN)	IDegLira		6						
TRTP(ATPTN)	IGlar		6						
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1	0.0879	0.0879				
REGION1(ATPTN)		Asia	1	0.0909	0.0909				
REGION1(ATPTN)		Europe	1	0.4911	0.4911				
REGION1(ATPTN)		North America	1	0.1502	0.1502				
REGION1(ATPTN)		South America	1	0.1798	0.1798				
REGION1(ATPTN)		Africa	2			0.0879	0.0879		
REGION1(ATPTN)		Asia	2			0.0909	0.0909		
REGION1(ATPTN)		Europe	2			0.4911	0.4911		
REGION1(ATPTN)		North America	2			0.1502	0.1502		
REGION1(ATPTN)		South America	2			0.1798	0.1798		
REGION1(ATPTN)		Africa	3					0.0879	0.0879
REGION1(ATPTN)		Asia	3					0.0909	0.0909
REGION1(ATPTN)		Europe	3					0.4911	0.4911
REGION1(ATPTN)		North America	3					0.1502	0.1502
REGION1(ATPTN)		South America	3					0.1798	0.1798
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9	Row10	Row11	Row12
TRTP(ATPTN)	IGlar		3						
TRTP(ATPTN)	IDegLira		4	1					
TRTP(ATPTN)	IGlar		4		1				
TRTP(ATPTN)	IDegLira		5			1			
TRTP(ATPTN)	IGlar		5				1		
TRTP(ATPTN)	IDegLira		6					1	
TRTP(ATPTN)	IGlar		6						1
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4	0.0879	0.0879				
REGION1(ATPTN)		Asia	4	0.0909	0.0909				
REGION1(ATPTN)		Europe	4	0.4911	0.4911				
REGION1(ATPTN)		North America	4	0.1502	0.1502				
REGION1(ATPTN)		South America	4	0.1798	0.1798				
REGION1(ATPTN)		Africa	5			0.0879	0.0879		
REGION1(ATPTN)		Asia	5			0.0909	0.0909		
REGION1(ATPTN)		Europe	5			0.4911	0.4911		
REGION1(ATPTN)		North America	5			0.1502	0.1502		
REGION1(ATPTN)		South America	5			0.1798	0.1798		
REGION1(ATPTN)		Africa	6					0.0879	0.0879
REGION1(ATPTN)		Asia	6					0.0909	0.0909
REGION1(ATPTN)		Europe	6					0.4911	0.4911
REGION1(ATPTN)		North America	6					0.1502	0.1502
REGION1(ATPTN)		South America	6					0.1798	0.1798
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row13	Row14	Row15	Row16	Row17	Row18
TRTP(ATPTN)	IGlar		3						
TRTP(ATPTN)	IDegLira		4						
TRTP(ATPTN)	IGlar		4						
TRTP(ATPTN)	IDegLira		5						
TRTP(ATPTN)	IGlar		5						
TRTP(ATPTN)	IDegLira		6						
TRTP(ATPTN)	IGlar		6						
TRTP(ATPTN)	IDegLira		7	1					
TRTP(ATPTN)	IGlar		7		1				
TRTP(ATPTN)	IDegLira		8			1			
TRTP(ATPTN)	IGlar		8				1		
TRTP(ATPTN)	IDegLira		9					1	
TRTP(ATPTN)	IGlar		9						1
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7	0.0879	0.0879				
REGION1(ATPTN)		Asia	7	0.0909	0.0909				
REGION1(ATPTN)		Europe	7	0.4911	0.4911				
REGION1(ATPTN)		North America	7	0.1502	0.1502				
REGION1(ATPTN)		South America	7	0.1798	0.1798				
REGION1(ATPTN)		Africa	8			0.0879	0.0879		
REGION1(ATPTN)		Asia	8			0.0909	0.0909		
REGION1(ATPTN)		Europe	8			0.4911	0.4911		
REGION1(ATPTN)		North America	8			0.1502	0.1502		
REGION1(ATPTN)		South America	8			0.1798	0.1798		
REGION1(ATPTN)		Africa	9					0.0879	0.0879
REGION1(ATPTN)		Asia	9					0.0909	0.0909
REGION1(ATPTN)		Europe	9					0.4911	0.4911
REGION1(ATPTN)		North America	9					0.1502	0.1502
REGION1(ATPTN)		South America	9					0.1798	0.1798

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Least Squares Means Estimates

Effect	Label	Margins	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha
TRTP(ATPTN)	1IDegLira	WORK.ADPROF3	5.6059	0.1174	1918	47.75	<.0001	0.05
TRTP(ATPTN)	1IGlar	WORK.ADPROF3	5.6009	0.1534	1918	36.51	<.0001	0.05
TRTP(ATPTN)	2IDegLira	WORK.ADPROF3	7.9948	0.1188	1969	67.30	<.0001	0.05
TRTP(ATPTN)	2IGlar	WORK.ADPROF3	8.6548	0.1552	1967	55.76	<.0001	0.05
TRTP(ATPTN)	3IDegLira	WORK.ADPROF3	6.0866	0.1184	1953	51.40	<.0001	0.05
TRTP(ATPTN)	3IGlar	WORK.ADPROF3	6.3991	0.1548	1953	41.34	<.0001	0.05
TRTP(ATPTN)	4IDegLira	WORK.ADPROF3	7.7922	0.1183	1949	65.85	<.0001	0.05
TRTP(ATPTN)	4IGlar	WORK.ADPROF3	8.8628	0.1548	1952	57.26	<.0001	0.05
TRTP(ATPTN)	5IDegLira	WORK.ADPROF3	6.6110	0.1181	1938	55.99	<.0001	0.05
TRTP(ATPTN)	5IGlar	WORK.ADPROF3	7.0515	0.1545	1943	45.65	<.0001	0.05
TRTP(ATPTN)	6IDegLira	WORK.ADPROF3	8.2305	0.1184	1953	69.50	<.0001	0.05
TRTP(ATPTN)	6IGlar	WORK.ADPROF3	9.1077	0.1548	1953	58.84	<.0001	0.05
TRTP(ATPTN)	7IDegLira	WORK.ADPROF3	7.5184	0.1188	1970	63.28	<.0001	0.05
TRTP(ATPTN)	7IGlar	WORK.ADPROF3	7.9413	0.1558	1988	50.95	<.0001	0.05
TRTP(ATPTN)	8IDegLira	WORK.ADPROF3	5.6788	0.1193	1989	47.62	<.0001	0.05
TRTP(ATPTN)	8IGlar	WORK.ADPROF3	5.9992	0.1562	2001	38.40	<.0001	0.05
TRTP(ATPTN)	9IDegLira	WORK.ADPROF3	5.4547	0.1181	1943	46.18	<.0001	0.05
TRTP(ATPTN)	9IGlar	WORK.ADPROF3	5.4856	0.1541	1935	35.60	<.0001	0.05

Least Squares Means Estimates

Effect	Label	Lower	Upper
TRTP(ATPTN)	1IDegLira	5.3757	5.8361
TRTP(ATPTN)	1IGlar	5.3000	5.9018
TRTP(ATPTN)	2IDegLira	7.7619	8.2278
TRTP(ATPTN)	2IGlar	8.3504	8.9592
TRTP(ATPTN)	3IDegLira	5.8543	6.3188
TRTP(ATPTN)	3IGlar	6.0955	6.7027
TRTP(ATPTN)	4IDegLira	7.5602	8.0243
TRTP(ATPTN)	4IGlar	8.5593	9.1664
TRTP(ATPTN)	5IDegLira	6.3794	6.8426
TRTP(ATPTN)	5IGlar	6.7486	7.3544
TRTP(ATPTN)	6IDegLira	7.9982	8.4627
TRTP(ATPTN)	6IGlar	8.8042	9.4113
TRTP(ATPTN)	7IDegLira	7.2854	7.7514
TRTP(ATPTN)	7IGlar	7.6356	8.2469
TRTP(ATPTN)	8IDegLira	5.4449	5.9127
TRTP(ATPTN)	8IGlar	5.6928	6.3056
TRTP(ATPTN)	9IDegLira	5.2230	5.6863
TRTP(ATPTN)	9IGlar	5.1834	5.7878

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
Intercept									

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
Intercept						

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
TRTP(ATPTN)	IDegLira		1	1					
TRTP(ATPTN)	IGlar		1	-1					
TRTP(ATPTN)	IDegLira		2		1				
TRTP(ATPTN)	IGlar		2		-1				
TRTP(ATPTN)	IDegLira		3			1			
TRTP(ATPTN)	IGlar		3			-1			
TRTP(ATPTN)	IDegLira		4				1		
TRTP(ATPTN)	IGlar		4				-1		
TRTP(ATPTN)	IDegLira		5					1	
TRTP(ATPTN)	IGlar		5					-1	
TRTP(ATPTN)	IDegLira		6						1
TRTP(ATPTN)	IGlar		6						-1
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
TRTP(ATPTN)	IDegLira		1			
TRTP(ATPTN)	IGlar		1			
TRTP(ATPTN)	IDegLira		2			
TRTP(ATPTN)	IGlar		2			
TRTP(ATPTN)	IDegLira		3			
TRTP(ATPTN)	IGlar		3			
TRTP(ATPTN)	IDegLira		4			
TRTP(ATPTN)	IGlar		4			
TRTP(ATPTN)	IDegLira		5			
TRTP(ATPTN)	IGlar		5			
TRTP(ATPTN)	IDegLira		6			
TRTP(ATPTN)	IGlar		6			
TRTP(ATPTN)	IDegLira		7	1		
TRTP(ATPTN)	IGlar		7	-1		
TRTP(ATPTN)	IDegLira		8		1	
TRTP(ATPTN)	IGlar		8		-1	
TRTP(ATPTN)	IDegLira		9			1
TRTP(ATPTN)	IGlar		9			-1
REGION1(ATPTN)		Africa	1			
REGION1(ATPTN)		Asia	1			
REGION1(ATPTN)		Europe	1			
REGION1(ATPTN)		North America	1			
REGION1(ATPTN)		South America	1			
REGION1(ATPTN)		Africa	2			
REGION1(ATPTN)		Asia	2			
REGION1(ATPTN)		Europe	2			
REGION1(ATPTN)		North America	2			
REGION1(ATPTN)		South America	2			
REGION1(ATPTN)		Africa	3			
REGION1(ATPTN)		Asia	3			
REGION1(ATPTN)		Europe	3			
REGION1(ATPTN)		North America	3			
REGION1(ATPTN)		South America	3			
REGION1(ATPTN)		Africa	4			
REGION1(ATPTN)		Asia	4			
REGION1(ATPTN)		Europe	4			
REGION1(ATPTN)		North America	4			
REGION1(ATPTN)		South America	4			
REGION1(ATPTN)		Africa	5			
REGION1(ATPTN)		Asia	5			
REGION1(ATPTN)		Europe	5			
REGION1(ATPTN)		North America	5			
REGION1(ATPTN)		South America	5			
REGION1(ATPTN)		Africa	6			
REGION1(ATPTN)		Asia	6			
REGION1(ATPTN)		Europe	6			
REGION1(ATPTN)		North America	6			
REGION1(ATPTN)		South America	6			
REGION1(ATPTN)		Africa	7			
REGION1(ATPTN)		Asia	7			
REGION1(ATPTN)		Europe	7			
REGION1(ATPTN)		North America	7			
REGION1(ATPTN)		South America	7			
REGION1(ATPTN)		Africa	8			
REGION1(ATPTN)		Asia	8			
REGION1(ATPTN)		Europe	8			
REGION1(ATPTN)		North America	8			
REGION1(ATPTN)		South America	8			
REGION1(ATPTN)		Africa	9			
REGION1(ATPTN)		Asia	9			

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=C105585Y

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
REGION1(ATPTN)		Europe	9			
REGION1(ATPTN)		North America	9			
REGION1(ATPTN)		South America	9			

Least Squares Means Estimates

Effect	Label	Margins	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha
TRTP(ATPTN)	1Treatment contrast	WORK.ADPROF3	0.004985	0.1920	1918	0.03	0.9793	0.05
TRTP(ATPTN)	2Treatment contrast	WORK.ADPROF3	-0.6600	0.1942	1967	-3.40	0.0007	0.05
TRTP(ATPTN)	3Treatment contrast	WORK.ADPROF3	-0.3125	0.1937	1953	-1.61	0.1068	0.05
TRTP(ATPTN)	4Treatment contrast	WORK.ADPROF3	-1.0706	0.1937	1953	-5.53	<.0001	0.05
TRTP(ATPTN)	5Treatment contrast	WORK.ADPROF3	-0.4405	0.1933	1942	-2.28	0.0227	0.05
TRTP(ATPTN)	6Treatment contrast	WORK.ADPROF3	-0.8773	0.1937	1953	-4.53	<.0001	0.05
TRTP(ATPTN)	7Treatment contrast	WORK.ADPROF3	-0.4228	0.1948	1982	-2.17	0.0301	0.05
TRTP(ATPTN)	8Treatment contrast	WORK.ADPROF3	-0.3204	0.1952	1993	-1.64	0.1009	0.05
TRTP(ATPTN)	9Treatment contrast	WORK.ADPROF3	-0.03094	0.1929	1938	-0.16	0.8726	0.05

Least Squares Means Estimates

Effect	Label	Lower	Upper
TRTP(ATPTN)	1Treatment contrast	-0.3715	0.3815
TRTP(ATPTN)	2Treatment contrast	-1.0409	-0.2791
TRTP(ATPTN)	3Treatment contrast	-0.6924	0.06736
TRTP(ATPTN)	4Treatment contrast	-1.4505	-0.6907
TRTP(ATPTN)	5Treatment contrast	-0.8195	-0.06153
TRTP(ATPTN)	6Treatment contrast	-1.2571	-0.4974
TRTP(ATPTN)	7Treatment contrast	-0.8048	-0.04085
TRTP(ATPTN)	8Treatment contrast	-0.7032	0.06245
TRTP(ATPTN)	9Treatment contrast	-0.4093	0.3474

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Model Information

Data Set	WORK.ADPROF3
Dependent Variable	AVAL
Covariance Structure	Compound Symmetry
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	Profile
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

NN9068-4228 [redacted]

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

		NN9068-4228/[redacted]
TRTP	2	IDegLira IG1
ATPTN	9	1 2 3 4 5 6 7 8 9
REGION1	5	Africa Asia Europe North America South America

Dimensions

Covariance Parameters	2
Columns in X	64
Columns in Z	0
Subjects	1012
Max Obs per Subject	9

Number of Observations

Number of Observations Read	9108
Number of Observations Used	4109
Number of Observations Not Used	4999

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	40797.19057811	
1	2	39728.07804016	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate	Standard Error	Z Value	Pr Z	Alpha	Lower	Upper
CS	USUBJID	486.72	38.3140	12.70	<.0001	0.05	411.63	561.82
Residual		807.78	19.0518	42.40	<.0001	0.05	771.70	846.46

Asymptotic Covariance Matrix of Estimates

Row	Cov Parm	CovP1	CovP2
1	CS	1467.96	-41.8508
2	Residual	-41.8508	362.97

Fit Statistics

-2 Res Log Likelihood	39728.1
AIC (Smaller is Better)	39732.1
AICC (Smaller is Better)	39732.1
BIC (Smaller is Better)	39741.9

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
1	1069.11	<.0001

Solution for Fixed Effects

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Estimate	Standard Error	DF	t Value	Pr > |t|
Intercept				101.69	4.3622	1924	23.31	<.0001
TRTP(ATPTN)	IDegLira		1	-2.2095	5.0845	3726	-0.43	0.6639
TRTP(ATPTN)	IGlar		1	-2.2993	4.8719	3597	-0.47	0.6370
TRTP(ATPTN)	IDegLira		2	42.7033	5.1005	3731	8.37	<.0001
TRTP(ATPTN)	IGlar		2	54.5965	4.8892	3598	11.17	<.0001
TRTP(ATPTN)	IDegLira		3	14.5236	5.0877	3725	2.85	0.0043
TRTP(ATPTN)	IGlar		3	20.1553	4.8801	3597	4.13	<.0001
TRTP(ATPTN)	IDegLira		4	47.1393	5.0877	3725	9.27	<.0001
TRTP(ATPTN)	IGlar		4	66.4311	4.8801	3597	13.61	<.0001
TRTP(ATPTN)	IDegLira		5	25.0681	5.0871	3725	4.93	<.0001
TRTP(ATPTN)	IGlar		5	33.0065	4.8775	3597	6.77	<.0001
TRTP(ATPTN)	IDegLira		6	47.2082	5.0877	3725	9.28	<.0001
TRTP(ATPTN)	IGlar		6	63.0163	4.8801	3597	12.91	<.0001
TRTP(ATPTN)	IDegLira		7	37.4396	5.1137	3737	7.32	<.0001
TRTP(ATPTN)	IGlar		7	45.0592	4.8987	3599	9.20	<.0001
TRTP(ATPTN)	IDegLira		8	4.1832	5.1144	3738	0.82	0.4135
TRTP(ATPTN)	IGlar		8	9.9564	4.9009	3599	2.03	0.0423
TRTP(ATPTN)	IDegLira		9	-0.5575	3.4764	1938	-0.16	0.8726
TRTP(ATPTN)	IGlar		9	0	.	.	.	.
REGION1(ATPTN)		Africa	1	4.6809	7.3673	1918	0.64	0.5253
REGION1(ATPTN)		Asia	1	-9.4400	7.0569	1918	-1.34	0.1812
REGION1(ATPTN)		Europe	1	0.1172	4.3446	1918	0.03	0.9785
REGION1(ATPTN)		North America	1	12.8484	6.2574	1918	2.05	0.0402
REGION1(ATPTN)		South America	1	0	.	.	.	.
REGION1(ATPTN)		Africa	2	0.8510	7.3740	1923	0.12	0.9081
REGION1(ATPTN)		Asia	2	-11.8457	7.0639	1923	-1.68	0.0937
REGION1(ATPTN)		Europe	2	-0.08986	4.3747	1949	-0.02	0.9836
REGION1(ATPTN)		North America	2	4.8112	6.3590	1990	0.76	0.4494
REGION1(ATPTN)		South America	2	0	.	.	.	.
REGION1(ATPTN)		Africa	3	8.7116	7.3673	1918	1.18	0.2372
REGION1(ATPTN)		Asia	3	-7.7793	7.0570	1918	-1.10	0.2704
REGION1(ATPTN)		Europe	3	-12.1917	4.3595	1932	-2.80	0.0052
REGION1(ATPTN)		North America	3	-4.0095	6.3215	1959	-0.63	0.5260
REGION1(ATPTN)		South America	3	0	.	.	.	.
REGION1(ATPTN)		Africa	4	-10.1384	7.3673	1918	-1.38	0.1689
REGION1(ATPTN)		Asia	4	2.7744	7.0570	1918	0.39	0.6943
REGION1(ATPTN)		Europe	4	-11.3049	4.3614	1934	-2.59	0.0096
REGION1(ATPTN)		North America	4	-14.7718	6.2924	1935	-2.35	0.0190
REGION1(ATPTN)		South America	4	0	.	.	.	.
REGION1(ATPTN)		Africa	5	2.6359	7.3673	1918	0.36	0.7205
REGION1(ATPTN)		Asia	5	-5.7571	7.0569	1918	-0.82	0.4147
REGION1(ATPTN)		Europe	5	-13.9557	4.3560	1928	-3.20	0.0014
REGION1(ATPTN)		North America	5	-3.1934	6.2924	1935	-0.51	0.6119
REGION1(ATPTN)		South America	5	0	.	.	.	.
REGION1(ATPTN)		Africa	6	4.8356	7.3673	1918	0.66	0.5117
REGION1(ATPTN)		Asia	6	6.7682	7.0570	1918	0.96	0.3376
REGION1(ATPTN)		Europe	6	-2.5736	4.3596	1932	-0.59	0.5550
REGION1(ATPTN)		North America	6	-2.3882	6.3215	1959	-0.38	0.7056
REGION1(ATPTN)		South America	6	0	.	.	.	.
REGION1(ATPTN)		Africa	7	1.5439	7.3808	1928	0.21	0.8343
REGION1(ATPTN)		Asia	7	12.0099	7.1201	1964	1.69	0.0918
REGION1(ATPTN)		Europe	7	-10.8081	4.3897	1968	-2.46	0.0139
REGION1(ATPTN)		North America	7	2.9016	6.3373	1972	0.46	0.6471
REGION1(ATPTN)		South America	7	0	.	.	.	.

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Solution for Fixed Effects

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Estimate	Standard Error	DF	t Value	Pr > |t|
REGION1(ATPTN)		Africa	8	-2.9481	7.5059	2015	-0.39	0.6945
REGION1(ATPTN)		Asia	8	-1.7095	7.1201	1964	-0.24	0.8103
REGION1(ATPTN)		Europe	8	-6.5614	4.3898	1968	-1.49	0.1352
REGION1(ATPTN)		North America	8	0.6569	6.3672	1996	0.10	0.9178
REGION1(ATPTN)		South America	8	0	.	.	.	.
REGION1(ATPTN)		Africa	9	2.0787	7.4298	1962	0.28	0.7797
REGION1(ATPTN)		Asia	9	-13.7228	7.0569	1918	-1.94	0.0520
REGION1(ATPTN)		Europe	9	-3.9036	4.3518	1925	-0.90	0.3698
REGION1(ATPTN)		North America	9	0.9694	6.2924	1935	0.15	0.8776
REGION1(ATPTN)		South America	9	0	.	.	.	.

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
TRTP(ATPTN)	9	3437	6.26	<.0001
REGION1(ATPTN)	36	3836	2.55	<.0001

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1	1					
TRTP(ATPTN)	IGlar		1		1				
TRTP(ATPTN)	IDegLira		2			1			
TRTP(ATPTN)	IGlar		2				1		
TRTP(ATPTN)	IDegLira		3					1	

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9	Row10	Row11	Row12
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1						
TRTP(ATPTN)	IGlar		1						
TRTP(ATPTN)	IDegLira		2						
TRTP(ATPTN)	IGlar		2						
TRTP(ATPTN)	IDegLira		3						

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row13	Row14	Row15	Row16	Row17	Row18
Intercept				1	1	1	1	1	1
TRTP(ATPTN)	IDegLira		1						
TRTP(ATPTN)	IGlar		1						
TRTP(ATPTN)	IDegLira		2						
TRTP(ATPTN)	IGlar		2						
TRTP(ATPTN)	IDegLira		3						

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
TRTP(ATPTN)	IGlar		3						1
TRTP(ATPTN)	IDegLira		4						
TRTP(ATPTN)	IGlar		4						
TRTP(ATPTN)	IDegLira		5						
TRTP(ATPTN)	IGlar		5						
TRTP(ATPTN)	IDegLira		6						
TRTP(ATPTN)	IGlar		6						
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1	0.0879	0.0879				
REGION1(ATPTN)		Asia	1	0.0909	0.0909				
REGION1(ATPTN)		Europe	1	0.4911	0.4911				
REGION1(ATPTN)		North America	1	0.1502	0.1502				
REGION1(ATPTN)		South America	1	0.1798	0.1798				
REGION1(ATPTN)		Africa	2			0.0879	0.0879		
REGION1(ATPTN)		Asia	2			0.0909	0.0909		
REGION1(ATPTN)		Europe	2			0.4911	0.4911		
REGION1(ATPTN)		North America	2			0.1502	0.1502		
REGION1(ATPTN)		South America	2			0.1798	0.1798		
REGION1(ATPTN)		Africa	3					0.0879	0.0879
REGION1(ATPTN)		Asia	3					0.0909	0.0909
REGION1(ATPTN)		Europe	3					0.4911	0.4911
REGION1(ATPTN)		North America	3					0.1502	0.1502
REGION1(ATPTN)		South America	3					0.1798	0.1798
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9	Row10	Row11	Row12
TRTP(ATPTN)	IGlar		3						
TRTP(ATPTN)	IDegLira		4	1					
TRTP(ATPTN)	IGlar		4		1				
TRTP(ATPTN)	IDegLira		5			1			
TRTP(ATPTN)	IGlar		5				1		
TRTP(ATPTN)	IDegLira		6					1	
TRTP(ATPTN)	IGlar		6						1
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4	0.0879	0.0879				
REGION1(ATPTN)		Asia	4	0.0909	0.0909				
REGION1(ATPTN)		Europe	4	0.4911	0.4911				
REGION1(ATPTN)		North America	4	0.1502	0.1502				
REGION1(ATPTN)		South America	4	0.1798	0.1798				
REGION1(ATPTN)		Africa	5			0.0879	0.0879		
REGION1(ATPTN)		Asia	5			0.0909	0.0909		
REGION1(ATPTN)		Europe	5			0.4911	0.4911		
REGION1(ATPTN)		North America	5			0.1502	0.1502		
REGION1(ATPTN)		South America	5			0.1798	0.1798		
REGION1(ATPTN)		Africa	6					0.0879	0.0879
REGION1(ATPTN)		Asia	6					0.0909	0.0909
REGION1(ATPTN)		Europe	6					0.4911	0.4911
REGION1(ATPTN)		North America	6					0.1502	0.1502
REGION1(ATPTN)		South America	6					0.1798	0.1798
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row13	Row14	Row15	Row16	Row17	Row18
TRTP(ATPTN)	IGlar		3						
TRTP(ATPTN)	IDegLira		4						
TRTP(ATPTN)	IGlar		4						
TRTP(ATPTN)	IDegLira		5						
TRTP(ATPTN)	IGlar		5						
TRTP(ATPTN)	IDegLira		6						
TRTP(ATPTN)	IGlar		6						
TRTP(ATPTN)	IDegLira		7	1					
TRTP(ATPTN)	IGlar		7		1				
TRTP(ATPTN)	IDegLira		8			1			
TRTP(ATPTN)	IGlar		8				1		
TRTP(ATPTN)	IDegLira		9					1	
TRTP(ATPTN)	IGlar		9						1
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7	0.0879	0.0879				
REGION1(ATPTN)		Asia	7	0.0909	0.0909				
REGION1(ATPTN)		Europe	7	0.4911	0.4911				
REGION1(ATPTN)		North America	7	0.1502	0.1502				
REGION1(ATPTN)		South America	7	0.1798	0.1798				
REGION1(ATPTN)		Africa	8			0.0879	0.0879		
REGION1(ATPTN)		Asia	8			0.0909	0.0909		
REGION1(ATPTN)		Europe	8			0.4911	0.4911		
REGION1(ATPTN)		North America	8			0.1502	0.1502		
REGION1(ATPTN)		South America	8			0.1798	0.1798		
REGION1(ATPTN)		Africa	9					0.0879	0.0879
REGION1(ATPTN)		Asia	9					0.0909	0.0909
REGION1(ATPTN)		Europe	9					0.4911	0.4911
REGION1(ATPTN)		North America	9					0.1502	0.1502
REGION1(ATPTN)		South America	9					0.1798	0.1798

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Least Squares Means Estimates

Effect	Label	Margins	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha
TRTP(ATPTN)	1IDegLira	WORK.ADPROF3	101.02	2.1154	1918	47.75	<.0001	0.05
TRTP(ATPTN)	1IGlar	WORK.ADPROF3	100.93	2.7645	1918	36.51	<.0001	0.05
TRTP(ATPTN)	2IDegLira	WORK.ADPROF3	144.07	2.1406	1969	67.30	<.0001	0.05
TRTP(ATPTN)	2IGlar	WORK.ADPROF3	155.96	2.7970	1967	55.76	<.0001	0.05
TRTP(ATPTN)	3IDegLira	WORK.ADPROF3	109.68	2.1338	1953	51.40	<.0001	0.05
TRTP(ATPTN)	3IGlar	WORK.ADPROF3	115.31	2.7893	1953	41.34	<.0001	0.05
TRTP(ATPTN)	4IDegLira	WORK.ADPROF3	140.42	2.1323	1949	65.85	<.0001	0.05
TRTP(ATPTN)	4IGlar	WORK.ADPROF3	159.71	2.7892	1952	57.26	<.0001	0.05
TRTP(ATPTN)	5IDegLira	WORK.ADPROF3	119.13	2.1277	1938	55.99	<.0001	0.05
TRTP(ATPTN)	5IGlar	WORK.ADPROF3	127.07	2.7833	1943	45.65	<.0001	0.05
TRTP(ATPTN)	6IDegLira	WORK.ADPROF3	148.31	2.1339	1953	69.50	<.0001	0.05
TRTP(ATPTN)	6IGlar	WORK.ADPROF3	164.12	2.7893	1953	58.84	<.0001	0.05
TRTP(ATPTN)	7IDegLira	WORK.ADPROF3	135.48	2.1410	1970	63.28	<.0001	0.05
TRTP(ATPTN)	7IGlar	WORK.ADPROF3	143.10	2.8084	1988	50.95	<.0001	0.05
TRTP(ATPTN)	8IDegLira	WORK.ADPROF3	102.33	2.1489	1989	47.62	<.0001	0.05
TRTP(ATPTN)	8IGlar	WORK.ADPROF3	108.10	2.8152	2001	38.40	<.0001	0.05
TRTP(ATPTN)	9IDegLira	WORK.ADPROF3	98.2932	2.1286	1943	46.18	<.0001	0.05
TRTP(ATPTN)	9IGlar	WORK.ADPROF3	98.8507	2.7764	1935	35.60	<.0001	0.05

Least Squares Means Estimates

Effect	Label	Lower	Upper
TRTP(ATPTN)	1IDegLira	96.8695	105.17
TRTP(ATPTN)	1IGlar	95.5066	106.35
TRTP(ATPTN)	2IDegLira	139.87	148.26
TRTP(ATPTN)	2IGlar	150.47	161.45
TRTP(ATPTN)	3IDegLira	105.49	113.86
TRTP(ATPTN)	3IGlar	109.84	120.78
TRTP(ATPTN)	4IDegLira	136.23	144.60
TRTP(ATPTN)	4IGlar	154.24	165.18
TRTP(ATPTN)	5IDegLira	114.96	123.30
TRTP(ATPTN)	5IGlar	121.61	132.53
TRTP(ATPTN)	6IDegLira	144.13	152.50
TRTP(ATPTN)	6IGlar	158.65	169.59
TRTP(ATPTN)	7IDegLira	131.28	139.68
TRTP(ATPTN)	7IGlar	137.59	148.61
TRTP(ATPTN)	8IDegLira	98.1174	106.55
TRTP(ATPTN)	8IGlar	102.58	113.63
TRTP(ATPTN)	9IDegLira	94.1185	102.47
TRTP(ATPTN)	9IGlar	93.4057	104.30

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
Intercept									

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
Intercept						

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
TRTP(ATPTN)	IDegLira		1	1					
TRTP(ATPTN)	IGlar		1	-1					
TRTP(ATPTN)	IDegLira		2		1				
TRTP(ATPTN)	IGlar		2		-1				
TRTP(ATPTN)	IDegLira		3			1			
TRTP(ATPTN)	IGlar		3			-1			
TRTP(ATPTN)	IDegLira		4				1		
TRTP(ATPTN)	IGlar		4				-1		
TRTP(ATPTN)	IDegLira		5					1	
TRTP(ATPTN)	IGlar		5					-1	
TRTP(ATPTN)	IDegLira		6						1
TRTP(ATPTN)	IGlar		6						-1
TRTP(ATPTN)	IDegLira		7						
TRTP(ATPTN)	IGlar		7						
TRTP(ATPTN)	IDegLira		8						
TRTP(ATPTN)	IGlar		8						
TRTP(ATPTN)	IDegLira		9						
TRTP(ATPTN)	IGlar		9						
REGION1(ATPTN)		Africa	1						
REGION1(ATPTN)		Asia	1						
REGION1(ATPTN)		Europe	1						
REGION1(ATPTN)		North America	1						
REGION1(ATPTN)		South America	1						
REGION1(ATPTN)		Africa	2						
REGION1(ATPTN)		Asia	2						
REGION1(ATPTN)		Europe	2						
REGION1(ATPTN)		North America	2						
REGION1(ATPTN)		South America	2						
REGION1(ATPTN)		Africa	3						
REGION1(ATPTN)		Asia	3						
REGION1(ATPTN)		Europe	3						
REGION1(ATPTN)		North America	3						
REGION1(ATPTN)		South America	3						
REGION1(ATPTN)		Africa	4						
REGION1(ATPTN)		Asia	4						
REGION1(ATPTN)		Europe	4						
REGION1(ATPTN)		North America	4						
REGION1(ATPTN)		South America	4						
REGION1(ATPTN)		Africa	5						
REGION1(ATPTN)		Asia	5						
REGION1(ATPTN)		Europe	5						
REGION1(ATPTN)		North America	5						
REGION1(ATPTN)		South America	5						
REGION1(ATPTN)		Africa	6						
REGION1(ATPTN)		Asia	6						
REGION1(ATPTN)		Europe	6						
REGION1(ATPTN)		North America	6						
REGION1(ATPTN)		South America	6						
REGION1(ATPTN)		Africa	7						
REGION1(ATPTN)		Asia	7						
REGION1(ATPTN)		Europe	7						
REGION1(ATPTN)		North America	7						
REGION1(ATPTN)		South America	7						
REGION1(ATPTN)		Africa	8						
REGION1(ATPTN)		Asia	8						
REGION1(ATPTN)		Europe	8						
REGION1(ATPTN)		North America	8						
REGION1(ATPTN)		South America	8						
REGION1(ATPTN)		Africa	9						
REGION1(ATPTN)		Asia	9						

9-point self-measured plasma glucose profile after 104 weeks - supportive statistical analysis - full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
TRTP(ATPTN)	IDegLira		1			
TRTP(ATPTN)	IGlar		1			
TRTP(ATPTN)	IDegLira		2			
TRTP(ATPTN)	IGlar		2			
TRTP(ATPTN)	IDegLira		3			
TRTP(ATPTN)	IGlar		3			
TRTP(ATPTN)	IDegLira		4			
TRTP(ATPTN)	IGlar		4			
TRTP(ATPTN)	IDegLira		5			
TRTP(ATPTN)	IGlar		5			
TRTP(ATPTN)	IDegLira		6			
TRTP(ATPTN)	IGlar		6			
TRTP(ATPTN)	IDegLira		7	1		
TRTP(ATPTN)	IGlar		7	-1		
TRTP(ATPTN)	IDegLira		8		1	
TRTP(ATPTN)	IGlar		8		-1	
TRTP(ATPTN)	IDegLira		9			1
TRTP(ATPTN)	IGlar		9			-1
REGION1(ATPTN)		Africa	1			
REGION1(ATPTN)		Asia	1			
REGION1(ATPTN)		Europe	1			
REGION1(ATPTN)		North America	1			
REGION1(ATPTN)		South America	1			
REGION1(ATPTN)		Africa	2			
REGION1(ATPTN)		Asia	2			
REGION1(ATPTN)		Europe	2			
REGION1(ATPTN)		North America	2			
REGION1(ATPTN)		South America	2			
REGION1(ATPTN)		Africa	3			
REGION1(ATPTN)		Asia	3			
REGION1(ATPTN)		Europe	3			
REGION1(ATPTN)		North America	3			
REGION1(ATPTN)		South America	3			
REGION1(ATPTN)		Africa	4			
REGION1(ATPTN)		Asia	4			
REGION1(ATPTN)		Europe	4			
REGION1(ATPTN)		North America	4			
REGION1(ATPTN)		South America	4			
REGION1(ATPTN)		Africa	5			
REGION1(ATPTN)		Asia	5			
REGION1(ATPTN)		Europe	5			
REGION1(ATPTN)		North America	5			
REGION1(ATPTN)		South America	5			
REGION1(ATPTN)		Africa	6			
REGION1(ATPTN)		Asia	6			
REGION1(ATPTN)		Europe	6			
REGION1(ATPTN)		North America	6			
REGION1(ATPTN)		South America	6			
REGION1(ATPTN)		Africa	7			
REGION1(ATPTN)		Asia	7			
REGION1(ATPTN)		Europe	7			
REGION1(ATPTN)		North America	7			
REGION1(ATPTN)		South America	7			
REGION1(ATPTN)		Africa	8			
REGION1(ATPTN)		Asia	8			
REGION1(ATPTN)		Europe	8			
REGION1(ATPTN)		North America	8			
REGION1(ATPTN)		South America	8			
REGION1(ATPTN)		Africa	9			
REGION1(ATPTN)		Asia	9			

9-point self-measured plasma glucose profile after 104 weeks – supportive statistical analysis – full analysis set

Parameter Code=SMPGCOL

The Mixed Procedure

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row1	Row2	Row3	Row4	Row5	Row6
REGION1(ATPTN)		Europe	9						
REGION1(ATPTN)		North America	9						
REGION1(ATPTN)		South America	9						

Coefficients for TRTP(ATPTN) Least Squares Means Estimates Using WORK.ADPROF3 Margins

Effect	Planned Treatment	Geographic Region 1	Analysis Timepoint (N)	Row7	Row8	Row9
REGION1(ATPTN)		Europe	9			
REGION1(ATPTN)		North America	9			
REGION1(ATPTN)		South America	9			

Least Squares Means Estimates

Effect	Label	Margins	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha
TRTP(ATPTN)	1Treatment contrast	WORK.ADPROF3	0.08982	3.4594	1918	0.03	0.9793	0.05
TRTP(ATPTN)	2Treatment contrast	WORK.ADPROF3	-11.8932	3.4997	1967	-3.40	0.0007	0.05
TRTP(ATPTN)	3Treatment contrast	WORK.ADPROF3	-5.6317	3.4905	1953	-1.61	0.1068	0.05
TRTP(ATPTN)	4Treatment contrast	WORK.ADPROF3	-19.2918	3.4906	1953	-5.53	<.0001	0.05
TRTP(ATPTN)	5Treatment contrast	WORK.ADPROF3	-7.9384	3.4824	1942	-2.28	0.0227	0.05
TRTP(ATPTN)	6Treatment contrast	WORK.ADPROF3	-15.8081	3.4906	1953	-4.53	<.0001	0.05
TRTP(ATPTN)	7Treatment contrast	WORK.ADPROF3	-7.6196	3.5099	1982	-2.17	0.0301	0.05
TRTP(ATPTN)	8Treatment contrast	WORK.ADPROF3	-5.7732	3.5176	1993	-1.64	0.1009	0.05
TRTP(ATPTN)	9Treatment contrast	WORK.ADPROF3	-0.5575	3.4764	1938	-0.16	0.8726	0.05

Least Squares Means Estimates

Effect	Label	Lower	Upper
TRTP(ATPTN)	1Treatment contrast	-6.6947	6.8743
TRTP(ATPTN)	2Treatment contrast	-18.7567	-5.0296
TRTP(ATPTN)	3Treatment contrast	-12.4773	1.2138
TRTP(ATPTN)	4Treatment contrast	-26.1374	-12.4461
TRTP(ATPTN)	5Treatment contrast	-14.7681	-1.1088
TRTP(ATPTN)	6Treatment contrast	-22.6537	-8.9625
TRTP(ATPTN)	7Treatment contrast	-14.5032	-0.7361
TRTP(ATPTN)	8Treatment contrast	-12.6717	1.1253
TRTP(ATPTN)	9Treatment contrast	-7.3755	6.2604

19: Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

```
topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

                  Model Information

Data Set                      WORK.M9PP_MMRM
Dependent Variable            AVAL
Covariance Structure          Unstructured
Subject Effect                USUBJID
Estimation Method             REML
Residual Variance Method      None
Fixed Effects SE Method       Kenward-Roger
Degrees of Freedom Method     Kenward-Roger


               Class Level Information

Class        Levels    Values

treatment         2    IDegLira IGlar
region            5    Africa Asia Europe North
                       America South America
avisitn           2    70 130
```

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	977	NN9068-4228 [redacted] NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure



Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

```
                       NN9068-4228 [redacted]
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
                       NN9068-4228
PREOAD            2    Non-SU users SU users
HBA1CG1           2    <8.5 >=8.5
```

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	977
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1257
Number of Observations Not Used	767

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	4424.44110914	
1	2	4388.77360478	0.00039615
2	1	4388.33473072	0.00000267
3	1	4388.33189566	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	1.9945
UN(2,1)	USUBJID	0.6861
UN(2,2)	USUBJID	1.9047

Fit Statistics

-2 Res Log Likelihood	4388.3
AIC (Smaller is Better)	4394.3
AICC (Smaller is Better)	4394.4
BIC (Smaller is Better)	4409.0

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	36.11	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	569	11.37	<.0001
region(avisitn)	8	813	1.93	0.0521
PREOAD(avisitn)	2	545	2.54	0.0796
HBA1CG1(avisitn)	2	564	0.91	0.4014
base(avisitn)	2	587	39.41	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.087
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4893
region(avisitn)		North America			70	0.1453
region(avisitn)		South America			70	0.1842
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3501
PREOAD(avisitn)			SU users		70	0.6499
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5302
HBA1CG1(avisitn)				>=8.5	70	0.4698
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	10.294
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.M9PP_MMRM	6.9081	0.06956	810.3	99.31

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	6.7716	7.0447

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.087
region(avisitn)		Asia			70	0.0942

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			70	0.4893
region(avisitn)		North America			70	0.1453
region(avisitn)		South America			70	0.1842
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3501
PREOAD(avisitn)			SU users		70	0.6499
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5302
HBA1CG1(avisitn)				>=8.5	70	0.4698
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	10.294
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PP_MMRM	7.2120	0.07198	808	100.20

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	7.0707	7.3533

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PP_MMRM	-0.3039	0.1000	809.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.04	0.0025	0.05	-0.5002	-0.1076

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.087
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4893
region(avisitn)		North America			130	0.1453
region(avisitn)		South America			130	0.1842

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3501
PREOAD(avisitn)			SU users		130	0.6499
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5302
HBA1CG1(avisitn)				>=8.5	130	0.4698
base(avisitn)					70	
base(avisitn)					130	10.294

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.M9PP_MMRM	6.8979	0.08354	442.3	82.57

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	6.7338	7.0621

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.087
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4893
region(avisitn)		North America			130	0.1453
region(avisitn)		South America			130	0.1842
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3501
PREOAD(avisitn)			SU users		130	0.6499

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5302
HBA1CG1(avisitn)				>=8.5	130	0.4698
base(avisitn)					70	
base(avisitn)					130	10.294

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PP_MMRM	7.4691	0.1070	454.1	69.84

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	7.2589	7.6793

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PP_MMRM	-0.5712	0.1327	450.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.31	<.0001	0.05	-0.8320	-0.3104

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Model Information

Data Set	WORK.M9PP_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	977	NN9068-4228 [redacted] NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	977
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1257
Number of Observations Not Used	767

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	11601.10014991	
1	2	11565.43302562	0.00009006
2	1	11564.99416458	0.00000061
3	1	11564.99132970	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	647.65
UN(2,1)	USUBJID	222.79
UN(2,2)	USUBJID	618.49

Fit Statistics

-2 Res Log Likelihood	11565.0
AIC (Smaller is Better)	11571.0
AICC (Smaller is Better)	11571.0
BIC (Smaller is Better)	11585.6

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	36.11	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	569	11.37	<.0001
region(avisitn)	8	813	1.93	0.0521
PREOAD(avisitn)	2	545	2.54	0.0796
HBA1CG1(avisitn)	2	564	0.91	0.4015
base(avisitn)	2	587	39.41	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.087
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4893
region(avisitn)		North America			70	0.1453
region(avisitn)		South America			70	0.1842
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3501
PREOAD(avisitn)			SU users		70	0.6499
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5302
HBA1CG1(avisitn)				>=8.5	70	0.4698
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	185.5
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.M9PP_MMRM	124.48	1.2536	810.3	99.31

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	122.02	126.95

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.087
region(avisitn)		Asia			70	0.0942

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			70	0.4893
region(avisitn)		North America			70	0.1453
region(avisitn)		South America			70	0.1842
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3501
PREOAD(avisitn)			SU users		70	0.6499
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5302
HBA1CG1(avisitn)				>=8.5	70	0.4698
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	185.5
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PP_MMRM	129.96	1.2970	808	100.20

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	127.41	132.51

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PP_MMRM	-5.4762	1.8021	809.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.04	0.0025	0.05	-9.0136	-1.9388

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.087
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4893
region(avisitn)		North America			130	0.1453
region(avisitn)		South America			130	0.1842

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3501
PREOAD(avisitn)			SU users		130	0.6499
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5302
HBA1CG1(avisitn)				>=8.5	130	0.4698
base(avisitn)					70	
base(avisitn)					130	185.5

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.M9PP_MMRM	124.30	1.5053	442.3	82.57

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	121.34	127.26

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.087
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4893
region(avisitn)		North America			130	0.1453
region(avisitn)		South America			130	0.1842
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3501
PREOAD(avisitn)			SU users		130	0.6499

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5302
HBA1CG1(avisitn)				>=8.5	130	0.4698
base(avisitn)					70	
base(avisitn)					130	185.5

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PP_MMRM	134.59	1.9272	454.1	69.84

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	130.81	138.38

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PP_MMRM	-10.2931	2.3909	450.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.31	<.0001	0.05	-14.9918	-5.5943

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Model Information

Data Set	WORK.M9PP_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Class Level Information

```
Class        Levels    Values

USUBJID         977    NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
```

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure



Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228 [redacted]

```
Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change
from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

		NN9068-4228 [redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	977
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1257
Number of Observations Not Used	767

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	4424.44110915	
1	2	4388.77360478	0.00039615
2	1	4388.33473072	0.00000267
3	1	4388.33189566	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	1.9945
UN(2,1)	USUBJID	0.6861
UN(2,2)	USUBJID	1.9047

Fit Statistics

-2 Res Log Likelihood	4388.3
AIC (Smaller is Better)	4394.3
AICC (Smaller is Better)	4394.4
BIC (Smaller is Better)	4409.0

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	36.11	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	569	11.37	<.0001
region(avisitn)	8	813	1.93	0.0521
PREOAD(avisitn)	2	545	2.54	0.0796
HBA1CG1(avisitn)	2	564	0.91	0.4014
base(avisitn)	2	587	876.92	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.087
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4893
region(avisitn)		North America			70	0.1453
region(avisitn)		South America			70	0.1842
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3501
PREOAD(avisitn)			SU users		70	0.6499
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5302
HBA1CG1(avisitn)				>=8.5	70	0.4698
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	10.294
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.M9PP_MMRM	-3.3858	0.06956	810.3	-48.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	-3.5223	-3.2492

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.087
region(avisitn)		Asia			70	0.0942

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			70	0.4893
region(avisitn)		North America			70	0.1453
region(avisitn)		South America			70	0.1842
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3501
PREOAD(avisitn)			SU users		70	0.6499
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5302
HBA1CG1(avisitn)				>=8.5	70	0.4698
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	10.294
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PP_MMRM	-3.0819	0.07198	808	-42.82

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	-3.2231	-2.9406

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PP_MMRM	-0.3039	0.1000	809.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.04	0.0025	0.05	-0.5002	-0.1076

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.087
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4893
region(avisitn)		North America			130	0.1453
region(avisitn)		South America			130	0.1842

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3501
PREOAD(avisitn)			SU users		130	0.6499
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5302
HBA1CG1(avisitn)				>=8.5	130	0.4698
base(avisitn)					70	
base(avisitn)					130	10.294

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.M9PP_MMRM	-3.3960	0.08354	442.3	-40.65

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	-3.5601	-3.2318

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.087
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4893
region(avisitn)		North America			130	0.1453
region(avisitn)		South America			130	0.1842
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3501
PREOAD(avisitn)			SU users		130	0.6499

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5302
HBA1CG1(avisitn)				>=8.5	130	0.4698
base(avisitn)					70	
base(avisitn)					130	10.294

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PP_MMRM	-2.8248	0.1070	454.1	-26.41

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	-3.0349	-2.6146

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PP_MMRM	-0.5712	0.1327	450.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.31	<.0001	0.05	-0.8320	-0.3104

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Model Information

Data Set	WORK.M9PP_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

```
Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change
from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

                Class Level Information

Class         Levels    Values

USUBJID          977    NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
```

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change
from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change
from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change
from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	977
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1257
Number of Observations Not Used	767

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	11601.10014991	
1	2	11565.43302562	0.00009006
2	1	11564.99416458	0.00000061
3	1	11564.99132970	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	647.65
UN(2,1)	USUBJID	222.79
UN(2,2)	USUBJID	618.49

Fit Statistics

-2 Res Log Likelihood	11565.0
AIC (Smaller is Better)	11571.0
AICC (Smaller is Better)	11571.0
BIC (Smaller is Better)	11585.6

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	36.11	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	569	11.37	<.0001
region(avisitn)	8	813	1.93	0.0521
PREOAD(avisitn)	2	545	2.54	0.0796
HBA1CG1(avisitn)	2	564	0.91	0.4015
base(avisitn)	2	587	876.92	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.087
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4893
region(avisitn)		North America			70	0.1453
region(avisitn)		South America			70	0.1842
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3501
PREOAD(avisitn)			SU users		70	0.6499
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5302
HBA1CG1(avisitn)				>=8.5	70	0.4698
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	185.5
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.M9PP_MMRM	-61.0113	1.2536	810.3	-48.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	-63.4719	-58.5507

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.087
region(avisitn)		Asia			70	0.0942

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			70	0.4893
region(avisitn)		North America			70	0.1453
region(avisitn)		South America			70	0.1842
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3501
PREOAD(avisitn)			SU users		70	0.6499
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5302
HBA1CG1(avisitn)				>=8.5	70	0.4698
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	185.5
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PP_MMRM	-55.5351	1.2970	808	-42.82

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	-58.0810	-52.9892

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PP_MMRM	-5.4762	1.8021	809.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.04	0.0025	0.05	-9.0136	-1.9388

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.087
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4893
region(avisitn)		North America			130	0.1453
region(avisitn)		South America			130	0.1842

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3501
PREOAD(avisitn)			SU users		130	0.6499
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5302
HBA1CG1(avisitn)				>=8.5	130	0.4698
base(avisitn)					70	
base(avisitn)					130	185.5

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.M9PP_MMRM	-61.1952	1.5053	442.3	-40.65

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	-64.1536	-58.2367

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.087
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4893
region(avisitn)		North America			130	0.1453
region(avisitn)		South America			130	0.1842
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3501
PREOAD(avisitn)			SU users		130	0.6499

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5302
HBA1CG1(avisitn)				>=8.5	130	0.4698
base(avisitn)					70	
base(avisitn)					130	185.5

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PP_MMRM	-50.9021	1.9272	454.1	-26.41

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	-54.6895	-47.1146

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	

Mean of 9-point self-measured plasma glucose profile after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_MEAN_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PP_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PP_MMRM	-10.2931	2.3909	450.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.31	<.0001	0.05	-14.9918	-5.5943

20: Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	977	NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	977
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1254
Number of Observations Not Used	770

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	5675.81068419	
1	2	5643.24022773	0.00000604
2	1	5643.22995781	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	5.4553
UN(2,1)	USUBJID	1.6229
UN(2,2)	USUBJID	5.2744

Fit Statistics

-2 Res Log Likelihood	5643.2
AIC (Smaller is Better)	5649.2
AICC (Smaller is Better)	5649.2
BIC (Smaller is Better)	5663.9

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	32.58	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	601	7.37	0.0007
region(avisitn)	8	838	1.07	0.3820
PREOAD(avisitn)	2	584	3.30	0.0375
HBA1CG1(avisitn)	2	602	0.05	0.9495
base(avisitn)	2	601	29.36	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4923
region(avisitn)		North America			70	0.1402
region(avisitn)		South America			70	0.1853
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5343
HBA1CG1(avisitn)				>=8.5	70	0.4657
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	3.3623
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	2.7062	0.1165	806.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	23.24	<.0001	0.05	2.4776	2.9348

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4923

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1402
region(avisitn)		South America			70	0.1853
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5343
HBA1CG1(avisitn)				>=8.5	70	0.4657
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	3.3623
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	3.1379	0.1175	803.3	26.71

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	2.9073	3.3685

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.4317	0.1658	805.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-2.60	0.0094	0.05	-0.7571	-0.1063

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4923
region(avisitn)		North America			130	0.1402
region(avisitn)		South America			130	0.1853
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5343
HBA1CG1(avisitn)				>=8.5	130	0.4657
base(avisitn)					70	
base(avisitn)					130	3.3623

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	2.4327	0.1402	449.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	17.35	<.0001	0.05	2.1571	2.7083

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4923
region(avisitn)		North America			130	0.1402
region(avisitn)		South America			130	0.1853
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5343
HBA1CG1(avisitn)				>=8.5	130	0.4657
base(avisitn)					70	
base(avisitn)					130	3.3623

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	3.1657	0.1788	451.1	17.71

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	2.8144	3.5170

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.7330	0.2222	451.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.30	0.0010	0.05	-1.1698	-0.2963

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	977	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	977
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1254
Number of Observations Not Used	770

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12835.12060343	
1	2	12802.55032088	0.00000194
2	1	12802.54005092	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	1771.45
UN(2,1)	USUBJID	526.99
UN(2,2)	USUBJID	1712.69

Fit Statistics

-2 Res Log Likelihood	12802.5
AIC (Smaller is Better)	12808.5
AICC (Smaller is Better)	12808.6
BIC (Smaller is Better)	12823.2

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	32.58	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	601	7.37	0.0007
region(avisitn)	8	838	1.07	0.3820
PREOAD(avisitn)	2	584	3.30	0.0375
HBA1CG1(avisitn)	2	602	0.05	0.9495
base(avisitn)	2	601	29.36	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4923
region(avisitn)		North America			70	0.1402
region(avisitn)		South America			70	0.1853
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5343
HBA1CG1(avisitn)				>=8.5	70	0.4657
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	60.589
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	48.7661	2.0986	806.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	23.24	<.0001	0.05	44.6468	52.8855

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4923

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1402
region(avisitn)		South America			70	0.1853
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5343
HBA1CG1(avisitn)				>=8.5	70	0.4657
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	60.589
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	56.5450	2.1168	803.3	26.71

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	52.3899	60.7001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-7.7788	2.9873	805.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-2.60	0.0094	0.05	-13.6426	-1.9151

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4923
region(avisitn)		North America			130	0.1402
region(avisitn)		South America			130	0.1853
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5343
HBA1CG1(avisitn)				>=8.5	130	0.4657
base(avisitn)					70	
base(avisitn)					130	60.589

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	43.8369	2.5271	449.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	17.35	<.0001	0.05	38.8704	48.8034

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4923
region(avisitn)		North America			130	0.1402
region(avisitn)		South America			130	0.1853
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5343
HBA1CG1(avisitn)				>=8.5	130	0.4657
base(avisitn)					70	
base(avisitn)					130	60.589

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	57.0460	3.2213	451.1	17.71

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	50.7155	63.3765

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-13.2091	4.0046	451.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.30	0.0010	0.05	-21.0791	-5.3391

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	974	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/ [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	974
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1251
Number of Observations Not Used	773

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	5733.09215388	
1	2	5723.42336531	0.00000009
2	1	5723.42320685	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	5.9442
UN(2,1)	USUBJID	0.8053
UN(2,2)	USUBJID	5.2197

Fit Statistics

-2 Res Log Likelihood	5723.4
AIC (Smaller is Better)	5729.4
AICC (Smaller is Better)	5729.4
BIC (Smaller is Better)	5744.1

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	9.67	0.0080

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	605	6.93	0.0011
region(avisitn)	8	840	2.13	0.0310
PREOAD(avisitn)	2	585	0.95	0.3869
HBA1CG1(avisitn)	2	606	0.16	0.8529
base(avisitn)	2	618	20.02	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0883
region(avisitn)		Asia			70	0.0945
region(avisitn)		Europe			70	0.4918
region(avisitn)		North America			70	0.1448
region(avisitn)		South America			70	0.1807
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3532
PREOAD(avisitn)			SU users		70	0.6468
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5298
HBA1CG1(avisitn)				>=8.5	70	0.4702
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	1.9501
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	1.5962	0.1210	799.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	13.19	<.0001	0.05	1.3586	1.8337

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0883
region(avisitn)		Asia			70	0.0945
region(avisitn)		Europe			70	0.4918

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1448
region(avisitn)		South America			70	0.1807
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3532
PREOAD(avisitn)			SU users		70	0.6468
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5298
HBA1CG1(avisitn)				>=8.5	70	0.4702
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	1.9501
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	2.1836	0.1237	798.8	17.66

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	1.9408	2.4263

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.5874	0.1735	799.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.39	0.0007	0.05	-0.9279	-0.2469

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0883
region(avisitn)		Asia			130	0.0945
region(avisitn)		Europe			130	0.4918
region(avisitn)		North America			130	0.1448
region(avisitn)		South America			130	0.1807
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3532
PREOAD(avisitn)			SU users		130	0.6468
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5298
HBA1CG1(avisitn)				>=8.5	130	0.4702
base(avisitn)					70	
base(avisitn)					130	1.9501

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	1.5518	0.1419	437.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	10.94	<.0001	0.05	1.2729	1.8306

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0883
region(avisitn)		Asia			130	0.0945
region(avisitn)		Europe			130	0.4918
region(avisitn)		North America			130	0.1448
region(avisitn)		South America			130	0.1807
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3532
PREOAD(avisitn)			SU users		130	0.6468
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5298
HBA1CG1(avisitn)				>=8.5	130	0.4702
base(avisitn)					70	
base(avisitn)					130	1.9501

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	1.9734	0.1827	437.3	10.80

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	1.6143	2.3326

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.4217	0.2256	437.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.87	0.0622	0.05	-0.8650	0.02163

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	974	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

```
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
```

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile –
change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
```

[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	974
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1251
Number of Observations Not Used	773

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12875.05302355	
1	2	12865.38422896	0.00000003
2	1	12865.38407050	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	1930.20
UN(2,1)	USUBJID	261.51
UN(2,2)	USUBJID	1694.94

Fit Statistics

-2 Res Log Likelihood	12865.4
AIC (Smaller is Better)	12871.4
AICC (Smaller is Better)	12871.4
BIC (Smaller is Better)	12886.0

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	9.67	0.0080

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	605	6.93	0.0011
region(avisitn)	8	840	2.13	0.0310
PREOAD(avisitn)	2	585	0.95	0.3869
HBA1CG1(avisitn)	2	606	0.16	0.8529
base(avisitn)	2	618	20.02	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0883
region(avisitn)		Asia			70	0.0945
region(avisitn)		Europe			70	0.4918
region(avisitn)		North America			70	0.1448
region(avisitn)		South America			70	0.1807
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3532
PREOAD(avisitn)			SU users		70	0.6468
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5298
HBA1CG1(avisitn)				>=8.5	70	0.4702
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	35.141
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	28.7632	2.1809	799.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	13.19	<.0001	0.05	24.4822	33.0441

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0883
region(avisitn)		Asia			70	0.0945
region(avisitn)		Europe			70	0.4918

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1448
region(avisitn)		South America			70	0.1807
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3532
PREOAD(avisitn)			SU users		70	0.6468
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5298
HBA1CG1(avisitn)				>=8.5	70	0.4702
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	35.141
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	39.3481	2.2284	798.8	17.66

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	34.9740	43.7222

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-10.5849	3.1260	799.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.39	0.0007	0.05	-16.7210	-4.4488

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0883
region(avisitn)		Asia			130	0.0945
region(avisitn)		Europe			130	0.4918
region(avisitn)		North America			130	0.1448
region(avisitn)		South America			130	0.1807
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3532
PREOAD(avisitn)			SU users		130	0.6468
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5298
HBA1CG1(avisitn)				>=8.5	130	0.4702
base(avisitn)					70	
base(avisitn)					130	35.141

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	27.9629	2.5565	437.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	10.94	<.0001	0.05	22.9383	32.9874

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0883
region(avisitn)		Asia			130	0.0945
region(avisitn)		Europe			130	0.4918
region(avisitn)		North America			130	0.1448
region(avisitn)		South America			130	0.1807
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3532
PREOAD(avisitn)			SU users		130	0.6468
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5298
HBA1CG1(avisitn)				>=8.5	130	0.4702
base(avisitn)					70	
base(avisitn)					130	35.141

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	35.5615	3.2927	437.3	10.80

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	29.0900	42.0329

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-7.5986	4.0645	437.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.87	0.0622	0.05	-15.5870	0.3897

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	980	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/ [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/ [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users ers
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	980
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1260
Number of Observations Not Used	764

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	5778.26902244	
1	2	5760.48501029	0.00000400
2	1	5760.47801767	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	5.9383
UN(2,1)	USUBJID	1.2502
UN(2,2)	USUBJID	5.3160

Fit Statistics

-2 Res Log Likelihood	5760.5
AIC (Smaller is Better)	5766.5
AICC (Smaller is Better)	5766.5
BIC (Smaller is Better)	5781.1

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	17.79	0.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	598	6.48	0.0016
region(avisitn)	8	835	4.13	<.0001
PREOAD(avisitn)	2	576	1.11	0.3288
HBA1CG1(avisitn)	2	598	0.74	0.4752
base(avisitn)	2	606	5.12	0.0063

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0939
region(avisitn)		Europe			70	0.4888
region(avisitn)		North America			70	0.1459
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5327
HBA1CG1(avisitn)				>=8.5	70	0.4673
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	1.8953
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	1.9406	0.1204	807.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	16.11	<.0001	0.05	1.7042	2.1770

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0939
region(avisitn)		Europe			70	0.4888

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1459
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5327
HBA1CG1(avisitn)				>=8.5	70	0.4673
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	1.8953
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	2.3236	0.1231	806.6	18.87

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	2.0819	2.5654

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.3830	0.1727	807.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-2.22	0.0268	0.05	-0.7219	-0.04409

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0939
region(avisitn)		Europe			130	0.4888
region(avisitn)		North America			130	0.1459
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5327
HBA1CG1(avisitn)				>=8.5	130	0.4673
base(avisitn)					70	
base(avisitn)					130	1.8953

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	1.6966	0.1421	443.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	11.94	<.0001	0.05	1.4174	1.9757

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0939
region(avisitn)		Europe			130	0.4888
region(avisitn)		North America			130	0.1459
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5327
HBA1CG1(avisitn)				>=8.5	130	0.4673
base(avisitn)					70	
base(avisitn)					130	1.8953

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	2.4021	0.1812	444.9	13.26

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	2.0460	2.7583

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.7056	0.2250	444.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.14	0.0018	0.05	-1.1478	-0.2634

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	980	NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
```

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	980
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1260
Number of Observations Not Used	764

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12972.27615346	
1	2	12954.49218651	0.00000130
2	1	12954.48519394	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	1928.28
UN(2,1)	USUBJID	405.96
UN(2,2)	USUBJID	1726.22

Fit Statistics

-2 Res Log Likelihood	12954.5
AIC (Smaller is Better)	12960.5
AICC (Smaller is Better)	12960.5
BIC (Smaller is Better)	12975.1

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	17.79	0.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	598	6.48	0.0016
region(avisitn)	8	835	4.13	<.0001
PREOAD(avisitn)	2	576	1.11	0.3288
HBA1CG1(avisitn)	2	598	0.74	0.4752
base(avisitn)	2	606	5.12	0.0063

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0939
region(avisitn)		Europe			70	0.4888
region(avisitn)		North America			70	0.1459
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5327
HBA1CG1(avisitn)				>=8.5	70	0.4673
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	34.153
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	34.9701	2.1702	807.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	16.11	<.0001	0.05	30.7103	39.2300

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0939
region(avisitn)		Europe			70	0.4888

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1459
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5327
HBA1CG1(avisitn)				>=8.5	70	0.4673
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	34.153
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	41.8720	2.2191	806.6	18.87

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	37.5162	46.2278

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-6.9018	3.1113	807.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-2.22	0.0268	0.05	-13.0091	-0.7946

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0939
region(avisitn)		Europe			130	0.4888
region(avisitn)		North America			130	0.1459
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5327
HBA1CG1(avisitn)				>=8.5	130	0.4673
base(avisitn)					70	
base(avisitn)					130	34.153

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	30.5719	2.5598	443.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	11.94	<.0001	0.05	25.5410	35.6028

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0939
region(avisitn)		Europe			130	0.4888
region(avisitn)		North America			130	0.1459
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5327
HBA1CG1(avisitn)				>=8.5	130	0.4673
base(avisitn)					70	
base(avisitn)					130	34.153

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	43.2866	3.2654	444.9	13.26

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	36.8691	49.7040

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-12.7146	4.0548	444.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.14	0.0018	0.05	-20.6835	-4.7457

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	991	NN9068-4228/[redacted] NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/ [redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/ [redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Dimensions

Columns in Z	0
Subjects	991
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1283
Number of Observations Not Used	741

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	4717.42152716	
1	2	4678.12715481	0.00001379
2	1	4678.11076910	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	2.3649
UN(2,1)	USUBJID	0.7215
UN(2,2)	USUBJID	2.1289

Fit Statistics

-2 Res Log Likelihood	4678.1
AIC (Smaller is Better)	4684.1
AICC (Smaller is Better)	4684.1
BIC (Smaller is Better)	4698.8

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	39.31	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	613	14.96	<.0001
region(avisitn)	8	853	3.36	0.0009
PREOAD(avisitn)	2	595	1.67	0.1887
HBA1CG1(avisitn)	2	613	0.17	0.8441

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
base(avisitn)	2	621	33.97	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0928
region(avisitn)		Europe			70	0.4884
region(avisitn)		North America			70	0.1473
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3542
PREOAD(avisitn)			SU users		70	0.6458
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	2.3923
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	2.1089	0.07509	827.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	28.09	<.0001	0.05	1.9615	2.2563

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0928
region(avisitn)		Europe			70	0.4884
region(avisitn)		North America			70	0.1473
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3542
PREOAD(avisitn)			SU users		70	0.6458
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	2.3923
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	2.5449	0.07667	825.2	33.19

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	2.3944	2.6954

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.4360	0.1076	826.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-4.05	<.0001	0.05	-0.6472	-0.2248

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0928
region(avisitn)		Europe			130	0.4884
region(avisitn)		North America			130	0.1473
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3542
PREOAD(avisitn)			SU users		130	0.6458
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
base(avisitn)					70	
base(avisitn)					130	2.3923

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	1.8943	0.08836	458.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	21.44	<.0001	0.05	1.7207	2.0680

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0928

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4884
region(avisitn)		North America			130	0.1473
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3542
PREOAD(avisitn)			SU users		130	0.6458
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
base(avisitn)					70	
base(avisitn)					130	2.3923

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	2.5207	0.1127	459.4	22.36

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	2.2992	2.7423

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.6264	0.1399	460.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.48	<.0001	0.05	-0.9014	-0.3514

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	991	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Dimensions

Columns in Z	0
Subjects	991
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1283
Number of Observations Not Used	741

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12044.43734290	
1	2	12005.14313644	0.00000335
2	1	12005.12675005	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	767.94
UN(2,1)	USUBJID	234.28
UN(2,2)	USUBJID	691.31

Fit Statistics

-2 Res Log Likelihood	12005.1
AIC (Smaller is Better)	12011.1
AICC (Smaller is Better)	12011.1
BIC (Smaller is Better)	12025.8

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	39.31	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	613	14.96	<.0001
region(avisitn)	8	853	3.36	0.0009
PREOAD(avisitn)	2	595	1.67	0.1887
HBA1CG1(avisitn)	2	613	0.17	0.8442

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
base(avisitn)	2	621	33.97	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0928
region(avisitn)		Europe			70	0.4884
region(avisitn)		North America			70	0.1473
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3542
PREOAD(avisitn)			SU users		70	0.6458
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	43.109
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	38.0025	1.3531	827.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	28.09	<.0001	0.05	35.3466	40.6584

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0928
region(avisitn)		Europe			70	0.4884
region(avisitn)		North America			70	0.1473
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3542
PREOAD(avisitn)			SU users		70	0.6458
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	43.109
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	45.8592	1.3816	825.2	33.19

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	43.1473	48.5711

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-7.8567	1.9389	826.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-4.05	<.0001	0.05	-11.6624	-4.0509

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0928
region(avisitn)		Europe			130	0.4884
region(avisitn)		North America			130	0.1473
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3542
PREOAD(avisitn)			SU users		130	0.6458
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
base(avisitn)					70	
base(avisitn)					130	43.109

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	34.1362	1.5923	458.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	21.44	<.0001	0.05	31.0071	37.2652

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0928

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4884
region(avisitn)		North America			130	0.1473
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3542
PREOAD(avisitn)			SU users		130	0.6458
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
base(avisitn)					70	
base(avisitn)					130	43.109

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	45.4236	2.0316	459.4	22.36

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	41.4311	49.4160

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-11.2874	2.5216	460.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.48	<.0001	0.05	-16.2426	-6.3321

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	977	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
```

[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228	[redacted]
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	977
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1254
Number of Observations Not Used	770

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	5675.81068419	
1	2	5643.24022773	0.00000604
2	1	5643.22995781	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	5.4553
UN(2,1)	USUBJID	1.6229
UN(2,2)	USUBJID	5.2744

Fit Statistics

-2 Res Log Likelihood	5643.2
AIC (Smaller is Better)	5649.2
AICC (Smaller is Better)	5649.2
BIC (Smaller is Better)	5663.9

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	32.58	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	601	7.37	0.0007
region(avisitn)	8	838	1.07	0.3820
PREOAD(avisitn)	2	584	3.30	0.0375
HBA1CG1(avisitn)	2	602	0.05	0.9495
base(avisitn)	2	601	570.75	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4923
region(avisitn)		North America			70	0.1402
region(avisitn)		South America			70	0.1853
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5343
HBA1CG1(avisitn)				>=8.5	70	0.4657
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	3.3623
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	-0.6561	0.1165	806.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	-5.63	<.0001	0.05	-0.8847	-0.4275

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4923

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1402
region(avisitn)		South America			70	0.1853
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5343
HBA1CG1(avisitn)				>=8.5	70	0.4657
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	3.3623
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	-0.2244	0.1175	803.3	-1.91

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0564	0.05	-0.4550	0.006142

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.4317	0.1658	805.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-2.60	0.0094	0.05	-0.7571	-0.1063

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4923
region(avisitn)		North America			130	0.1402
region(avisitn)		South America			130	0.1853
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5343
HBA1CG1(avisitn)				>=8.5	130	0.4657
base(avisitn)					70	
base(avisitn)					130	3.3623

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	-0.9297	0.1402	449.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-6.63	<.0001	0.05	-1.2053	-0.6540

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4923
region(avisitn)		North America			130	0.1402
region(avisitn)		South America			130	0.1853
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5343
HBA1CG1(avisitn)				>=8.5	130	0.4657
base(avisitn)					70	
base(avisitn)					130	3.3623

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	-0.1966	0.1788	451.1	-1.10

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.2719	0.05	-0.5479	0.1547

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.7330	0.2222	451.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.30	0.0010	0.05	-1.1698	-0.2963

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

               Class Level Information

Class        Levels    Values

USUBJID         977    NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
```

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile –
change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users ers
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	977
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1254
Number of Observations Not Used	770

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12835.12060343	
1	2	12802.55032088	0.00000194
2	1	12802.54005092	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	1771.45
UN(2,1)	USUBJID	526.99
UN(2,2)	USUBJID	1712.69

Fit Statistics

-2 Res Log Likelihood	12802.5
AIC (Smaller is Better)	12808.5
AICC (Smaller is Better)	12808.6
BIC (Smaller is Better)	12823.2

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	32.58	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	601	7.37	0.0007
region(avisitn)	8	838	1.07	0.3820
PREOAD(avisitn)	2	584	3.30	0.0375
HBA1CG1(avisitn)	2	602	0.05	0.9495
base(avisitn)	2	601	570.75	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4923
region(avisitn)		North America			70	0.1402
region(avisitn)		South America			70	0.1853
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5343
HBA1CG1(avisitn)				>=8.5	70	0.4657
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	60.589
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	-11.8232	2.0986	806.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	-5.63	<.0001	0.05	-15.9426	-7.7038

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.0942
region(avisitn)		Europe			70	0.4923

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1402
region(avisitn)		South America			70	0.1853
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5343
HBA1CG1(avisitn)				>=8.5	70	0.4657
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	60.589
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	-4.0444	2.1168	803.3	-1.91

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0564	0.05	-8.1994	0.1107

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-7.7788	2.9873	805.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-2.60	0.0094	0.05	-13.6426	-1.9151

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4923
region(avisitn)		North America			130	0.1402
region(avisitn)		South America			130	0.1853
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5343
HBA1CG1(avisitn)				>=8.5	130	0.4657
base(avisitn)					70	
base(avisitn)					130	60.589

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	-16.7524	2.5271	449.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-6.63	<.0001	0.05	-21.7189	-11.7860

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.0942
region(avisitn)		Europe			130	0.4923
region(avisitn)		North America			130	0.1402
region(avisitn)		South America			130	0.1853
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5343
HBA1CG1(avisitn)				>=8.5	130	0.4657
base(avisitn)					70	
base(avisitn)					130	60.589

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	-3.5433	3.2213	451.1	-1.10

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.2719	0.05	-9.8739	2.7872

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_B_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-13.2091	4.0046	451.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.30	0.0010	0.05	-21.0791	-5.3391

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	974	NN9068-4228/[redacted] NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	974
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1251
Number of Observations Not Used	773

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	5733.09215388	
1	2	5723.42336531	0.00000009
2	1	5723.42320685	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	5.9442
UN(2,1)	USUBJID	0.8053
UN(2,2)	USUBJID	5.2197

Fit Statistics

-2 Res Log Likelihood	5723.4
AIC (Smaller is Better)	5729.4
AICC (Smaller is Better)	5729.4
BIC (Smaller is Better)	5744.1

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	9.67	0.0080

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	605	6.93	0.0011
region(avisitn)	8	840	2.13	0.0310
PREOAD(avisitn)	2	585	0.95	0.3869
HBA1CG1(avisitn)	2	606	0.16	0.8529
base(avisitn)	2	618	590.05	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0883
region(avisitn)		Asia			70	0.0945
region(avisitn)		Europe			70	0.4918
region(avisitn)		North America			70	0.1448
region(avisitn)		South America			70	0.1807
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3532
PREOAD(avisitn)			SU users		70	0.6468
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5298
HBA1CG1(avisitn)				>=8.5	70	0.4702
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	1.9501
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	-0.3539	0.1210	799.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	-2.92	0.0035	0.05	-0.5915	-0.1164

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0883
region(avisitn)		Asia			70	0.0945
region(avisitn)		Europe			70	0.4918

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1448
region(avisitn)		South America			70	0.1807
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3532
PREOAD(avisitn)			SU users		70	0.6468
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5298
HBA1CG1(avisitn)				>=8.5	70	0.4702
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	1.9501
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	0.2335	0.1237	798.8	1.89

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0594	0.05	-0.00928	0.4762

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.5874	0.1735	799.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.39	0.0007	0.05	-0.9279	-0.2469

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0883
region(avisitn)		Asia			130	0.0945
region(avisitn)		Europe			130	0.4918
region(avisitn)		North America			130	0.1448
region(avisitn)		South America			130	0.1807
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3532
PREOAD(avisitn)			SU users		130	0.6468
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5298
HBA1CG1(avisitn)				>=8.5	130	0.4702
base(avisitn)					70	
base(avisitn)					130	1.9501

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	-0.3984	0.1419	437.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-2.81	0.0052	0.05	-0.6772	-0.1195

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0883
region(avisitn)		Asia			130	0.0945
region(avisitn)		Europe			130	0.4918
region(avisitn)		North America			130	0.1448
region(avisitn)		South America			130	0.1807
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3532
PREOAD(avisitn)			SU users		130	0.6468
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5298
HBA1CG1(avisitn)				>=8.5	130	0.4702
base(avisitn)					70	
base(avisitn)					130	1.9501

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	0.02332	0.1827	437.3	0.13

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.8985	0.05	-0.3358	0.3824

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.4217	0.2256	437.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.87	0.0622	0.05	-0.8650	0.02163

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	974	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	974
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1251
Number of Observations Not Used	773

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12875.05302355	
1	2	12865.38422896	0.00000003
2	1	12865.38407050	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	1930.20
UN(2,1)	USUBJID	261.51
UN(2,2)	USUBJID	1694.94

Fit Statistics

-2 Res Log Likelihood	12865.4
AIC (Smaller is Better)	12871.4
AICC (Smaller is Better)	12871.4
BIC (Smaller is Better)	12886.0

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	9.67	0.0080

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	605	6.93	0.0011
region(avisitn)	8	840	2.13	0.0310
PREOAD(avisitn)	2	585	0.95	0.3869
HBA1CG1(avisitn)	2	606	0.16	0.8529
base(avisitn)	2	618	590.05	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0883
region(avisitn)		Asia			70	0.0945
region(avisitn)		Europe			70	0.4918
region(avisitn)		North America			70	0.1448
region(avisitn)		South America			70	0.1807
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3532
PREOAD(avisitn)			SU users		70	0.6468
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5298
HBA1CG1(avisitn)				>=8.5	70	0.4702
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	35.141
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	-6.3781	2.1809	799.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	-2.92	0.0035	0.05	-10.6591	-2.0972

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0883
region(avisitn)		Asia			70	0.0945
region(avisitn)		Europe			70	0.4918

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1448
region(avisitn)		South America			70	0.1807
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3532
PREOAD(avisitn)			SU users		70	0.6468
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5298
HBA1CG1(avisitn)				>=8.5	70	0.4702
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	35.141
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	4.2068	2.2284	798.8	1.89

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0594	0.05	-0.1673	8.5809

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-10.5849	3.1260	799.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.39	0.0007	0.05	-16.7210	-4.4488

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0883
region(avisitn)		Asia			130	0.0945
region(avisitn)		Europe			130	0.4918
region(avisitn)		North America			130	0.1448
region(avisitn)		South America			130	0.1807
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3532
PREOAD(avisitn)			SU users		130	0.6468
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5298
HBA1CG1(avisitn)				>=8.5	130	0.4702
base(avisitn)					70	
base(avisitn)					130	35.141

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	-7.1785	2.5565	437.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-2.81	0.0052	0.05	-12.2030	-2.1539

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0883
region(avisitn)		Asia			130	0.0945
region(avisitn)		Europe			130	0.4918
region(avisitn)		North America			130	0.1448
region(avisitn)		South America			130	0.1807
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3532
PREOAD(avisitn)			SU users		130	0.6468
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5298
HBA1CG1(avisitn)				>=8.5	130	0.4702
base(avisitn)					70	
base(avisitn)					130	35.141

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	0.4202	3.2927	437.3	0.13

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.8985	0.05	-6.0513	6.8916

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_EV_MEAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-7.5986	4.0645	437.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.87	0.0622	0.05	-15.5870	0.3897

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	980	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	980
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1260
Number of Observations Not Used	764

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	5778.26902244	
1	2	5760.48501029	0.00000400
2	1	5760.47801767	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	5.9383
UN(2,1)	USUBJID	1.2502
UN(2,2)	USUBJID	5.3160

Fit Statistics

-2 Res Log Likelihood	5760.5
AIC (Smaller is Better)	5766.5
AICC (Smaller is Better)	5766.5
BIC (Smaller is Better)	5781.1

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	17.79	0.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	598	6.48	0.0016
region(avisitn)	8	835	4.13	<.0001
PREOAD(avisitn)	2	576	1.11	0.3288
HBA1CG1(avisitn)	2	598	0.74	0.4752
base(avisitn)	2	606	775.54	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0939
region(avisitn)		Europe			70	0.4888
region(avisitn)		North America			70	0.1459
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5327
HBA1CG1(avisitn)				>=8.5	70	0.4673
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	1.8953
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	0.04533	0.1204	807.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	0.38	0.7067	0.05	-0.1911	0.2817

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0939
region(avisitn)		Europe			70	0.4888

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1459
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5327
HBA1CG1(avisitn)				>=8.5	70	0.4673
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	1.8953
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	0.4283	0.1231	806.6	3.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0005	0.05	0.1866	0.6701

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.3830	0.1727	807.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-2.22	0.0268	0.05	-0.7219	-0.04409

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0939
region(avisitn)		Europe			130	0.4888
region(avisitn)		North America			130	0.1459
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5327
HBA1CG1(avisitn)				>=8.5	130	0.4673
base(avisitn)					70	
base(avisitn)					130	1.8953

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	-0.1988	0.1421	443.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-1.40	0.1625	0.05	-0.4779	0.08043

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0939
region(avisitn)		Europe			130	0.4888
region(avisitn)		North America			130	0.1459
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5327
HBA1CG1(avisitn)				>=8.5	130	0.4673
base(avisitn)					70	
base(avisitn)					130	1.8953

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	0.5068	0.1812	444.9	2.80

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.0054	0.05	0.1507	0.8630

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.7056	0.2250	444.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.14	0.0018	0.05	-1.1478	-0.2634

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

```
Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile –
change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

              Class Level Information

Class         Levels    Values

USUBJID          980    NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
                        NN9068-4228[redacted]
```

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure



Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure



Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure



Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure



Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure



Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure



Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure



Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure



Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	980
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1260
Number of Observations Not Used	764

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12972.27615346	
1	2	12954.49218651	0.00000130
2	1	12954.48519394	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	1928.28
UN(2,1)	USUBJID	405.96
UN(2,2)	USUBJID	1726.22

Fit Statistics

-2 Res Log Likelihood	12954.5
AIC (Smaller is Better)	12960.5
AICC (Smaller is Better)	12960.5
BIC (Smaller is Better)	12975.1

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	17.79	0.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	598	6.48	0.0016
region(avisitn)	8	835	4.13	<.0001
PREOAD(avisitn)	2	576	1.11	0.3288
HBA1CG1(avisitn)	2	598	0.74	0.4752
base(avisitn)	2	606	775.54	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0939
region(avisitn)		Europe			70	0.4888
region(avisitn)		North America			70	0.1459
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5327
HBA1CG1(avisitn)				>=8.5	70	0.4673
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	34.153
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	0.8168	2.1702	807.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	0.38	0.7067	0.05	-3.4431	5.0767

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0939
region(avisitn)		Europe			70	0.4888

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	0.1459
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5327
HBA1CG1(avisitn)				>=8.5	70	0.4673
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	34.153
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	7.7186	2.2191	806.6	3.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0005	0.05	3.3628	12.0745

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-6.9018	3.1113	807.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-2.22	0.0268	0.05	-13.0091	-0.7946

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0939
region(avisitn)		Europe			130	0.4888
region(avisitn)		North America			130	0.1459
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5327
HBA1CG1(avisitn)				>=8.5	130	0.4673
base(avisitn)					70	
base(avisitn)					130	34.153

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	-3.5814	2.5598	443.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-1.40	0.1625	0.05	-8.6123	1.4495

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0939
region(avisitn)		Europe			130	0.4888
region(avisitn)		North America			130	0.1459
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5327
HBA1CG1(avisitn)				>=8.5	130	0.4673
base(avisitn)					70	
base(avisitn)					130	34.153

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	9.1332	3.2654	444.9	2.80

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.0054	0.05	2.7158	15.5506

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_L_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-12.7146	4.0548	444.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-3.14	0.0018	0.05	-20.6835	-4.7457

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	991	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

		NN9068-4228 [redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Dimensions

Columns in Z	0
Subjects	991
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1283
Number of Observations Not Used	741

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	4717.42152716	
1	2	4678.12715481	0.00001379
2	1	4678.11076910	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	2.3649
UN(2,1)	USUBJID	0.7215
UN(2,2)	USUBJID	2.1289

Fit Statistics

-2 Res Log Likelihood	4678.1
AIC (Smaller is Better)	4684.1
AICC (Smaller is Better)	4684.1
BIC (Smaller is Better)	4698.8

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	39.31	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	613	14.96	<.0001
region(avisitn)	8	853	3.36	0.0009
PREOAD(avisitn)	2	595	1.67	0.1887
HBA1CG1(avisitn)	2	613	0.17	0.8441

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
base(avisitn)	2	621	527.33	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0928
region(avisitn)		Europe			70	0.4884
region(avisitn)		North America			70	0.1473
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3542
PREOAD(avisitn)			SU users		70	0.6458
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	2.3923
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	-0.2834	0.07509	827.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	-3.77	0.0002	0.05	-0.4308	-0.1360

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0928
region(avisitn)		Europe			70	0.4884
region(avisitn)		North America			70	0.1473
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3542
PREOAD(avisitn)			SU users		70	0.6458
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	2.3923
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	0.1526	0.07667	825.2	1.99

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0469	0.05	0.002100	0.3031

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.4360	0.1076	826.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-4.05	<.0001	0.05	-0.6472	-0.2248

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0928
region(avisitn)		Europe			130	0.4884
region(avisitn)		North America			130	0.1473
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3542
PREOAD(avisitn)			SU users		130	0.6458
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
base(avisitn)					70	
base(avisitn)					130	2.3923

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	-0.4980	0.08836	458.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-5.64	<.0001	0.05	-0.6716	-0.3243

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0928

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4884
region(avisitn)		North America			130	0.1473
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3542
PREOAD(avisitn)			SU users		130	0.6458
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
base(avisitn)					70	
base(avisitn)					130	2.3923

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	0.1284	0.1127	459.4	1.14

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.2553	0.05	-0.09314	0.3500

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-0.6264	0.1399	460.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.48	<.0001	0.05	-0.9014	-0.3514

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Model Information

Data Set	WORK.M9PRAND_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	991	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Dimensions

Columns in Z	0
Subjects	991
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1283
Number of Observations Not Used	741

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12044.43734290	
1	2	12005.14313644	0.00000335
2	1	12005.12675005	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	767.94
UN(2,1)	USUBJID	234.28
UN(2,2)	USUBJID	691.31

Fit Statistics

-2 Res Log Likelihood	12005.1
AIC (Smaller is Better)	12011.1
AICC (Smaller is Better)	12011.1
BIC (Smaller is Better)	12025.8

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	39.31	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	613	14.96	<.0001
region(avisitn)	8	853	3.36	0.0009
PREOAD(avisitn)	2	595	1.67	0.1887
HBA1CG1(avisitn)	2	613	0.17	0.8442

Prandial increment after 104 weeks - 9-point self-measured plasma glucose profile - change from baseline - supportive statistical analysis - full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
base(avisitn)	2	621	527.33	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0928
region(avisitn)		Europe			70	0.4884
region(avisitn)		North America			70	0.1473
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3542
PREOAD(avisitn)			SU users		70	0.6458
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	43.109
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.M9PRAND_MMRM	-5.1069	1.3531	827.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	-3.77	0.0002	0.05	-7.7628	-2.4511

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0878
region(avisitn)		Asia			70	0.0928
region(avisitn)		Europe			70	0.4884
region(avisitn)		North America			70	0.1473
region(avisitn)		South America			70	0.1837
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3542
PREOAD(avisitn)			SU users		70	0.6458
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	43.109
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.M9PRAND_MMRM	2.7497	1.3816	825.2	1.99

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0469	0.05	0.03782	5.4617

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.M9PRAND_MMRM	-7.8567	1.9389	826.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-4.05	<.0001	0.05	-11.6624	-4.0509

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0928
region(avisitn)		Europe			130	0.4884
region(avisitn)		North America			130	0.1473
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3542
PREOAD(avisitn)			SU users		130	0.6458
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
base(avisitn)					70	
base(avisitn)					130	43.109

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.M9PRAND_MMRM	-8.9733	1.5923	458.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-5.64	<.0001	0.05	-12.1023	-5.8442

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0878
region(avisitn)		Asia			130	0.0928

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4884
region(avisitn)		North America			130	0.1473
region(avisitn)		South America			130	0.1837
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3542
PREOAD(avisitn)			SU users		130	0.6458
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
base(avisitn)					70	
base(avisitn)					130	43.109

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.M9PRAND_MMRM	2.3141	2.0316	459.4	1.14

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.2553	0.05	-1.6783	6.3066

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Prandial increment after 104 weeks – 9-point self-measured plasma glucose profile – change from baseline – supportive statistical analysis – full analysis set

topic_cd=9PP_SMPG_INC_PRANDIAL_CONV

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.M9PRAND_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.M9PRAND_MMRM	-11.2874	2.5216	460.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-4.48	<.0001	0.05	-16.2426	-6.3321

21: Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.FSI_MMRM
Dependent Variable	log_aval
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1005	NN9068-4228/ [redacted] NN9068-4228/

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Fasting insulin after 26 and 104 weeks - supportive statistical analysis - full analysis
set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Fasting insulin after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/ [redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/ [redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users ers
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1005
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1450
Number of Observations Not Used	574

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	3260.56530661	
1	2	3179.34598312	0.00000007
2	1	3179.34596311	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.5285
UN(2,1)	USUBJID	0.2102
UN(2,2)	USUBJID	0.5525

Fit Statistics

-2 Res Log Likelihood	3179.3
AIC (Smaller is Better)	3185.3
AICC (Smaller is Better)	3185.4
BIC (Smaller is Better)	3200.1

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	81.22	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	711	0.15	0.8641
region(avisitn)	8	979	4.48	<.0001
PREOAD(avisitn)	2	690	10.28	<.0001
HBA1CG1(avisitn)	2	712	0.30	0.7402
log_base(avisitn)	2	714	301.66	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0886
region(avisitn)		Asia			70	0.0915
region(avisitn)		Europe			70	0.4905
region(avisitn)		North America			70	0.1493
region(avisitn)		South America			70	0.1801
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3512
PREOAD(avisitn)			SU users		70	0.6488
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5303
HBA1CG1(avisitn)				>=8.5	70	0.4697
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	3.9404
log_base(avisitn)					130	

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.FSI_MMRM	3.5485	0.03346	925.1	106.05

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	3.4829	3.6142	34.7620

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	32.5526	37.1213

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0886
region(avisitn)		Asia			70	0.0915
region(avisitn)		Europe			70	0.4905
region(avisitn)		North America			70	0.1493
region(avisitn)		South America			70	0.1801
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3512
PREOAD(avisitn)			SU users		70	0.6488
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5303
HBA1CG1(avisitn)				>=8.5	70	0.4697
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	3.9404
log_base(avisitn)					130	

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.FSI_MMRM	3.5465	0.03415	925.4	103.84

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	3.4794	3.6135	34.6905

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	32.4415	37.0954

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.FSI_MMRM	0.002058	0.04801	925.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.04	0.9658	0.05	-0.09217	0.09629

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.0021	0.9119	1.1011

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0886
region(avisitn)		Asia			130	0.0915
region(avisitn)		Europe			130	0.4905
region(avisitn)		North America			130	0.1493
region(avisitn)		South America			130	0.1801
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3512
PREOAD(avisitn)			SU users		130	0.6488
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5303
HBA1CG1(avisitn)				>=8.5	130	0.4697
log_base(avisitn)					70	
log_base(avisitn)					130	3.9404

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.FSI_MMRM	3.4568	0.04111	543.3	84.08

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	3.3760	3.5376	31.7150

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	29.2543	34.3827

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0886
region(avisitn)		Asia			130	0.0915
region(avisitn)		Europe			130	0.4905
region(avisitn)		North America			130	0.1493
region(avisitn)		South America			130	0.1801
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3512
PREOAD(avisitn)			SU users		130	0.6488
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5303
HBA1CG1(avisitn)				>=8.5	130	0.4697
log_base(avisitn)					70	
log_base(avisitn)					130	3.9404

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.FSI_MMRM	3.4900	0.05287	548	66.01

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	3.3861	3.5938	32.7856

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	29.5517	36.3734

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.FSI_MMRM	-0.03320	0.06587	548.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.50	0.6145	0.05	-0.1626	0.09619

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9673	0.8499	1.1010

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.FSI_MMRM
Dependent Variable	log_r2base
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1005	NN9068-4228[redacted] NN9068-4228[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis
set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting insulin after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis
set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
```

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting insulin after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

Fasting insulin after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1005
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1450
Number of Observations Not Used	574

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	3260.56530661	
1	2	3179.34598312	0.00000007
2	1	3179.34596311	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.5285
UN(2,1)	USUBJID	0.2102
UN(2,2)	USUBJID	0.5525

Fit Statistics

-2 Res Log Likelihood	3179.3
AIC (Smaller is Better)	3185.3
AICC (Smaller is Better)	3185.4
BIC (Smaller is Better)	3200.1

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	81.22	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	711	0.15	0.8641
region(avisitn)	8	979	4.48	<.0001
PREOAD(avisitn)	2	690	10.28	<.0001
HBA1CG1(avisitn)	2	712	0.30	0.7402
log_base(avisitn)	2	714	45.37	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0886
region(avisitn)		Asia			70	0.0915
region(avisitn)		Europe			70	0.4905
region(avisitn)		North America			70	0.1493
region(avisitn)		South America			70	0.1801
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3512
PREOAD(avisitn)			SU users		70	0.6488
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5303
HBA1CG1(avisitn)				>=8.5	70	0.4697
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	3.9404
log_base(avisitn)					130	

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.FSI_MMRM	-0.3919	0.03346	925.1	-11.71

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	-0.4576	-0.3262	0.6758

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	0.6328	0.7216

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0886
region(avisitn)		Asia			70	0.0915
region(avisitn)		Europe			70	0.4905
region(avisitn)		North America			70	0.1493
region(avisitn)		South America			70	0.1801
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3512
PREOAD(avisitn)			SU users		70	0.6488
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5303
HBA1CG1(avisitn)				>=8.5	70	0.4697
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	3.9404
log_base(avisitn)					130	

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.FSI_MMRM	-0.3940	0.03415	925.4	-11.53

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	-0.4610	-0.3269	0.6744

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	0.6307	0.7211

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.FSI_MMRM	0.002058	0.04801	925.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.04	0.9658	0.05	-0.09217	0.09629

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.0021	0.9119	1.1011

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0886
region(avisitn)		Asia			130	0.0915
region(avisitn)		Europe			130	0.4905
region(avisitn)		North America			130	0.1493
region(avisitn)		South America			130	0.1801
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3512
PREOAD(avisitn)			SU users		130	0.6488
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5303
HBA1CG1(avisitn)				>=8.5	130	0.4697
log_base(avisitn)					70	
log_base(avisitn)					130	3.9404

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.FSI_MMRM	-0.4836	0.04111	543.3	-11.76

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	-0.5644	-0.4029	0.6165

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.5687	0.6684

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0886
region(avisitn)		Asia			130	0.0915
region(avisitn)		Europe			130	0.4905
region(avisitn)		North America			130	0.1493
region(avisitn)		South America			130	0.1801
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3512
PREOAD(avisitn)			SU users		130	0.6488
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5303
HBA1CG1(avisitn)				>=8.5	130	0.4697
log_base(avisitn)					70	
log_base(avisitn)					130	3.9404

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.FSI_MMRM	-0.4504	0.05287	548	-8.52

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	-0.5543	-0.3466	0.6374

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.5745	0.7071

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.FSI_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting insulin after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=INSULIN_TOTAL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.FSI_MMRM	-0.03320	0.06587	548.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.50	0.6145	0.05	-0.1626	0.09619

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9673	0.8499	1.1010

22: Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.METABOL_MMRM
Dependent Variable	log_aval
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1003	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU user rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1003
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1449
Number of Observations Not Used	575

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	2526.60105220	
1	2	2430.11964976	0.00027397
2	1	2430.09192250	0.00000011
3	1	2430.09191191	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.3101
UN(2,1)	USUBJID	0.1431
UN(2,2)	USUBJID	0.3506

Fit Statistics

-2 Res Log Likelihood	2430.1
AIC (Smaller is Better)	2436.1
AICC (Smaller is Better)	2436.1
BIC (Smaller is Better)	2450.8

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	96.51	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	698	4.51	0.0113
region(avisitn)	8	968	2.15	0.0288
PREOAD(avisitn)	2	675	12.75	<.0001
HBA1CG1(avisitn)	2	697	0.15	0.8601
log_base(avisitn)	2	709	350.30	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0857
region(avisitn)		Asia			70	0.0917
region(avisitn)		Europe			70	0.4935
region(avisitn)		North America			70	0.1476
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3519
PREOAD(avisitn)			SU users		70	0.6481
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5314
HBA1CG1(avisitn)				>=8.5	70	0.4686
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.301
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.METABOL_MMRM	-0.7622	0.02572	916.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	-29.63	<.0001	0.05	-0.8127	-0.7117

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	0.4667	0.4437	0.4908

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0857
region(avisitn)		Asia			70	0.0917
region(avisitn)		Europe			70	0.4935
region(avisitn)		North America			70	0.1476
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3519
PREOAD(avisitn)			SU users		70	0.6481
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5314
HBA1CG1(avisitn)				>=8.5	70	0.4686
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.301
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.METABOL_MMRM	-0.8711	0.02616	914.2	-33.30

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	-0.9225	-0.8198	0.4185

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	0.3975	0.4405

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.METABOL_MMRM	0.1090	0.03688	915.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.95	0.0032	0.05	0.03659	0.1814

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.1151	1.0373	1.1988

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0857
region(avisitn)		Asia			130	0.0917
region(avisitn)		Europe			130	0.4935
region(avisitn)		North America			130	0.1476
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3519
PREOAD(avisitn)			SU users		130	0.6481
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5314
HBA1CG1(avisitn)				>=8.5	130	0.4686
log_base(avisitn)					70	
log_base(avisitn)					130	-0.301

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.METABOL_MMRM	-0.8203	0.03245	549.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-25.28	<.0001	0.05	-0.8840	-0.7565

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.4403	0.4131	0.4693

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0857
region(avisitn)		Asia			130	0.0917
region(avisitn)		Europe			130	0.4935
region(avisitn)		North America			130	0.1476
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3519
PREOAD(avisitn)			SU users		130	0.6481
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5314
HBA1CG1(avisitn)				>=8.5	130	0.4686
log_base(avisitn)					70	
log_base(avisitn)					130	-0.301

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.METABOL_MMRM	-0.8975	0.04185	555.5	-21.45

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	-0.9797	-0.8153	0.4076

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.3754	0.4425

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.METABOL_MMRM	0.07723	0.05219	556.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.48	0.1395	0.05	-0.02528	0.1797

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.0803	0.9750	1.1969

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Model Information

Data Set	WORK.METABOL_MMRM
Dependent Variable	log_aval
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

```
Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full
analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

               Class Level Information

Class         Levels    Values

USUBJID         1003    NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
```

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/ [redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1003
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1449
Number of Observations Not Used	575

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	2521.23039185	
1	2	2424.72836201	0.00022370
2	1	2424.70513549	0.00000007
3	1	2424.70512804	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.3083
UN(2,1)	USUBJID	0.1422
UN(2,2)	USUBJID	0.3500

Fit Statistics

-2 Res Log Likelihood	2424.7
AIC (Smaller is Better)	2430.7
AICC (Smaller is Better)	2430.7
BIC (Smaller is Better)	2445.4

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	96.53	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	698	4.69	0.0095
region(avisitn)	8	968	2.20	0.0255
PREOAD(avisitn)	2	676	12.55	<.0001
HBA1CG1(avisitn)	2	698	0.13	0.8786
log_base(avisitn)	2	708	323.31	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0857
region(avisitn)		Asia			70	0.0917
region(avisitn)		Europe			70	0.4935
region(avisitn)		North America			70	0.1476
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3519
PREOAD(avisitn)			SU users		70	0.6481
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5314
HBA1CG1(avisitn)				>=8.5	70	0.4686
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.806
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.METABOL_MMRM	0.3466	0.02565	916.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	13.52	<.0001	0.05	0.2963	0.3970

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	1.4143	1.3449	1.4873

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0857
region(avisitn)		Asia			70	0.0917
region(avisitn)		Europe			70	0.4935
region(avisitn)		North America			70	0.1476
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3519
PREOAD(avisitn)			SU users		70	0.6481
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5314
HBA1CG1(avisitn)				>=8.5	70	0.4686
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.806
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.METABOL_MMRM	0.2358	0.02609	914.2	9.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	0.1846	0.2870	1.2659

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	1.2028	1.3324

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.METABOL_MMRM	0.1108	0.03677	915.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	3.01	0.0026	0.05	0.03866	0.1830

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.1172	1.0394	1.2008

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0857
region(avisitn)		Asia			130	0.0917
region(avisitn)		Europe			130	0.4935
region(avisitn)		North America			130	0.1476
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3519
PREOAD(avisitn)			SU users		130	0.6481
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5314
HBA1CG1(avisitn)				>=8.5	130	0.4686
log_base(avisitn)					70	
log_base(avisitn)					130	0.806

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.METABOL_MMRM	0.2876	0.03243	549.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	8.87	<.0001	0.05	0.2239	0.3513

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	1.3332	1.2509	1.4209

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0857
region(avisitn)		Asia			130	0.0917
region(avisitn)		Europe			130	0.4935
region(avisitn)		North America			130	0.1476
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3519
PREOAD(avisitn)			SU users		130	0.6481
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5314
HBA1CG1(avisitn)				>=8.5	130	0.4686
log_base(avisitn)					70	
log_base(avisitn)					130	0.806

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.METABOL_MMRM	0.2096	0.04183	555.3	5.01

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	0.1274	0.2918	1.2332

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	1.1359	1.3388

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.METABOL_MMRM	0.07798	0.05216	556.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.50	0.1355	0.05	-0.02447	0.1804

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.0811	0.9758	1.1977

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.METABOL_MMRM
Dependent Variable	log_r2base
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1003	NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full
analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users[redacted]rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1003
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1449
Number of Observations Not Used	575

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	2526.60105220	
1	2	2430.11964976	0.00027397
2	1	2430.09192250	0.00000011
3	1	2430.09191191	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.3101
UN(2,1)	USUBJID	0.1431
UN(2,2)	USUBJID	0.3506

Fit Statistics

-2 Res Log Likelihood	2430.1
AIC (Smaller is Better)	2436.1
AICC (Smaller is Better)	2436.1
BIC (Smaller is Better)	2450.8

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	96.51	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	698	4.51	0.0113
region(avisitn)	8	968	2.15	0.0288
PREOAD(avisitn)	2	675	12.75	<.0001
HBA1CG1(avisitn)	2	697	0.15	0.8601
log_base(avisitn)	2	709	13.15	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0857
region(avisitn)		Asia			70	0.0917
region(avisitn)		Europe			70	0.4935
region(avisitn)		North America			70	0.1476
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3519
PREOAD(avisitn)			SU users		70	0.6481
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5314
HBA1CG1(avisitn)				>=8.5	70	0.4686
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.301
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.METABOL_MMRM	-0.4610	0.02572	916.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	-17.92	<.0001	0.05	-0.5115	-0.4105

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	0.6306	0.5996	0.6633

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0857
region(avisitn)		Asia			70	0.0917
region(avisitn)		Europe			70	0.4935
region(avisitn)		North America			70	0.1476
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3519
PREOAD(avisitn)			SU users		70	0.6481
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5314
HBA1CG1(avisitn)				>=8.5	70	0.4686
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.301
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.METABOL_MMRM	-0.5700	0.02616	914.2	-21.79

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	-0.6213	-0.5186	0.5655

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	0.5372	0.5953

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.METABOL_MMRM	0.1090	0.03688	915.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.95	0.0032	0.05	0.03659	0.1814

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.1151	1.0373	1.1988

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0857
region(avisitn)		Asia			130	0.0917
region(avisitn)		Europe			130	0.4935
region(avisitn)		North America			130	0.1476
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3519
PREOAD(avisitn)			SU users		130	0.6481
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5314
HBA1CG1(avisitn)				>=8.5	130	0.4686
log_base(avisitn)					70	
log_base(avisitn)					130	-0.301

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.METABOL_MMRM	-0.5191	0.03245	549.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-16.00	<.0001	0.05	-0.5829	-0.4554

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.5950	0.5583	0.6342

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0857
region(avisitn)		Asia			130	0.0917
region(avisitn)		Europe			130	0.4935
region(avisitn)		North America			130	0.1476
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3519
PREOAD(avisitn)			SU users		130	0.6481
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5314
HBA1CG1(avisitn)				>=8.5	130	0.4686
log_base(avisitn)					70	
log_base(avisitn)					130	-0.301

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.METABOL_MMRM	-0.5964	0.04185	555.5	-14.25

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	-0.6786	-0.5142	0.5508

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.5073	0.5980

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.METABOL_MMRM	0.07723	0.05219	556.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.48	0.1395	0.05	-0.02528	0.1797

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.0803	0.9750	1.1969

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Model Information

Data Set	WORK.METABOL_MMRM
Dependent Variable	log_r2base
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1003	NN9068-4228 [redacted] NN9068-4228

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full
analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure
```

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

NN9068-4228 [redacted]

Fasting C-peptide after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1003
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1449
Number of Observations Not Used	575

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	2521.23039185	
1	2	2424.72836201	0.00022370
2	1	2424.70513549	0.00000007
3	1	2424.70512804	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.3083
UN(2,1)	USUBJID	0.1422
UN(2,2)	USUBJID	0.3500

Fit Statistics

-2 Res Log Likelihood	2424.7
AIC (Smaller is Better)	2430.7
AICC (Smaller is Better)	2430.7
BIC (Smaller is Better)	2445.4

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	96.53	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	698	4.69	0.0095
region(avisitn)	8	968	2.20	0.0255
PREOAD(avisitn)	2	676	12.55	<.0001
HBA1CG1(avisitn)	2	698	0.13	0.8786
log_base(avisitn)	2	708	14.18	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0857
region(avisitn)		Asia			70	0.0917
region(avisitn)		Europe			70	0.4935
region(avisitn)		North America			70	0.1476
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3519
PREOAD(avisitn)			SU users		70	0.6481
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5314
HBA1CG1(avisitn)				>=8.5	70	0.4686
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.806
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira	WORK.METABOL_MMRM	-0.4594	0.02565	916.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	-17.91	<.0001	0.05	-0.5097	-0.4090

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	0.6317	0.6007	0.6643

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0857
region(avisitn)		Asia			70	0.0917
region(avisitn)		Europe			70	0.4935
region(avisitn)		North America			70	0.1476
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3519
PREOAD(avisitn)			SU users		70	0.6481
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5314
HBA1CG1(avisitn)				>=8.5	70	0.4686
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.806
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.METABOL_MMRM	-0.5702	0.02609	914.2	-21.86

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	-0.6214	-0.5190	0.5654

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	0.5372	0.5951

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.METABOL_MMRM	0.1108	0.03677	915.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	3.01	0.0026	0.05	0.03866	0.1830

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.1172	1.0394	1.2008

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0857
region(avisitn)		Asia			130	0.0917
region(avisitn)		Europe			130	0.4935
region(avisitn)		North America			130	0.1476
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3519
PREOAD(avisitn)			SU users		130	0.6481
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5314
HBA1CG1(avisitn)				>=8.5	130	0.4686
log_base(avisitn)					70	
log_base(avisitn)					130	0.806

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira	WORK.METABOL_MMRM	-0.5184	0.03243	549.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	-15.98	<.0001	0.05	-0.5821	-0.4547

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.5955	0.5587	0.6346

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0857
region(avisitn)		Asia			130	0.0917
region(avisitn)		Europe			130	0.4935
region(avisitn)		North America			130	0.1476
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3519
PREOAD(avisitn)			SU users		130	0.6481
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5314
HBA1CG1(avisitn)				>=8.5	130	0.4686
log_base(avisitn)					70	
log_base(avisitn)					130	0.806

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.METABOL_MMRM	-0.5964	0.04183	555.3	-14.26

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	-0.6786	-0.5143	0.5508

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.5073	0.5979

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.METABOL_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					130	

Fasting C-peptide after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=C_PEPTIDE_SERUM_CONV

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.METABOL_MMRM	0.07798	0.05216	556.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.50	0.1355	0.05	-0.02447	0.1804

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.0811	0.9758	1.1977

23: Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Model Information

Data Set	WORK.SPB_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	5	60 70 90 110 130

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	15
Columns in X	61
Columns in Z	0
Subjects	1012
Max Obs per Subject	5

Number of Observations

Number of Observations Read	5060
Number of Observations Used	3719
Number of Observations Not Used	1341

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	28865.36540248	
1	2	28272.21100747	0.00000030
2	1	28272.20772995	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	130.72
UN(2,1)	USUBJID	49.1973
UN(2,2)	USUBJID	144.13
UN(3,1)	USUBJID	43.0903
UN(3,2)	USUBJID	53.5762
UN(3,3)	USUBJID	141.70
UN(4,1)	USUBJID	37.3133
UN(4,2)	USUBJID	63.4711
UN(4,3)	USUBJID	62.6067
UN(4,4)	USUBJID	140.79

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(5,1)	USUBJID	32.1600
UN(5,2)	USUBJID	54.5354
UN(5,3)	USUBJID	53.3699
UN(5,4)	USUBJID	59.9334
UN(5,5)	USUBJID	157.45

Fit Statistics

-2 Res Log Likelihood	28272.2
AIC (Smaller is Better)	28302.2
AICC (Smaller is Better)	28302.3
BIC (Smaller is Better)	28376.0

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
14	593.16	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	5	758	2.45	0.0322
region(avisitn)	20	1615	2.76	<.0001
PREOAD(avisitn)	5	726	1.10	0.3595
HBA1CG1(avisitn)	5	759	0.80	0.5477
base(avisitn)	5	752	119.34	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	130.49
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.SPB_MMRM	129.11	0.5192	963.8	248.68

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	<.0001	0.05	128.09	130.13

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	130.49
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.SPB_MMRM	130.23	0.5230	963.3	248.99

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	129.21	131.26

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.SPB_MMRM	-1.1223	0.7403	963.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	-1.52	0.1299	0.05	-2.5751	0.3306

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	130.49
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SPB_MMRM	129.11	0.5494	944.4	235.02

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	128.03	130.19

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	130.49
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SPB_MMRM	131.03	0.5572	947	235.17

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	129.93	132.12

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SPB_MMRM	-1.9137	0.7859	945.6

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-2.44	0.0151	0.05	-3.4559	-0.3715

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	130.49
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.SPB_MMRM	129.50	0.5943	712.6	217.90

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	128.34	130.67

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	130.49
base(avisitn)					110	
base(avisitn)					130	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.SPB_MMRM	132.36	0.6827	737.5	193.88

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	131.02	133.70

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.SPB_MMRM	-2.8570	0.9027	727.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-3.17	0.0016	0.05	-4.6291	-1.0848

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	130.49
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.SPB_MMRM	129.89	0.6202	639.8	209.44

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	128.68	131.11

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	130.49
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.SPB_MMRM	131.48	0.7441	665.7	176.70

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	130.02	132.94

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.SPB_MMRM	-1.5895	0.9606	656.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	-1.65	0.0985	0.05	-3.4758	0.2968

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	130.49

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SPB_MMRM	130.83	0.6867	561.8	190.52

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	129.48	132.17

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	130.49

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SPB_MMRM	132.25	0.8755	575.5	151.06

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	130.53	133.97

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SPB_MMRM	-1.4243	1.0974	572.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.30	0.1948	0.05	-3.5797	0.7311

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Model Information

Data Set	WORK.SPB_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	5	60 70 90 110 130

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Systolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users[redacted]rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	15
Columns in X	61
Columns in Z	0
Subjects	1012
Max Obs per Subject	5

Number of Observations

Number of Observations Read	5060
Number of Observations Used	3719
Number of Observations Not Used	1341

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	28865.36540248	
1	2	28272.21100747	0.00000030
2	1	28272.20772995	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	130.72
UN(2,1)	USUBJID	49.1973
UN(2,2)	USUBJID	144.13
UN(3,1)	USUBJID	43.0903
UN(3,2)	USUBJID	53.5762
UN(3,3)	USUBJID	141.70
UN(4,1)	USUBJID	37.3133
UN(4,2)	USUBJID	63.4711
UN(4,3)	USUBJID	62.6067
UN(4,4)	USUBJID	140.79

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(5,1)	USUBJID	32.1600
UN(5,2)	USUBJID	54.5354
UN(5,3)	USUBJID	53.3699
UN(5,4)	USUBJID	59.9334
UN(5,5)	USUBJID	157.45

Fit Statistics

-2 Res Log Likelihood	28272.2
AIC (Smaller is Better)	28302.2
AICC (Smaller is Better)	28302.3
BIC (Smaller is Better)	28376.0

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
14	593.16	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	5	758	2.45	0.0322
region(avisitn)	20	1615	2.76	<.0001
PREOAD(avisitn)	5	726	1.10	0.3595
HBA1CG1(avisitn)	5	759	0.80	0.5477
base(avisitn)	5	752	108.08	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	130.49
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.SPB_MMRM	-1.3755	0.5192	963.8	-2.65

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	0.0082	0.05	-2.3944	-0.3567

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	130.49
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.SPB_MMRM	-0.2533	0.5230	963.3	-0.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	0.6283	0.05	-1.2797	0.7732

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.SPB_MMRM	-1.1223	0.7403	963.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	-1.52	0.1299	0.05	-2.5751	0.3306

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	130.49
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SPB_MMRM	-1.3728	0.5494	944.4	-2.50

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	0.0126	0.05	-2.4509	-0.2947

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	130.49
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SPB_MMRM	0.5409	0.5572	947	0.97

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.3319	0.05	-0.5525	1.6343

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SPB_MMRM	-1.9137	0.7859	945.6

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-2.44	0.0151	0.05	-3.4559	-0.3715

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	130.49
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.SPB_MMRM	-0.9802	0.5943	712.6	-1.65

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	0.0995	0.05	-2.1470	0.1866

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	130.49
base(avisitn)					110	
base(avisitn)					130	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.SPB_MMRM	1.8768	0.6827	737.5	2.75

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	0.0061	0.05	0.5365	3.2171

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.SPB_MMRM	-2.8570	0.9027	727.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-3.17	0.0016	0.05	-4.6291	-1.0848

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	130.49
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.SPB_MMRM	-0.5910	0.6202	639.8	-0.95

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	0.3410	0.05	-1.8089	0.6268

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	130.49
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.SPB_MMRM	0.9985	0.7441	665.7	1.34

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	0.1801	0.05	-0.4626	2.4595

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.SPB_MMRM	-1.5895	0.9606	656.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	-1.65	0.0985	0.05	-3.4758	0.2968

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	130.49

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SPB_MMRM	0.3400	0.6867	561.8	0.50

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	0.6207	0.05	-1.0087	1.6888

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	130.49

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SPB_MMRM	1.7643	0.8755	575.5	2.02

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.0443	0.05	0.04478	3.4838

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Systolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_SYSTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SPB_MMRM	-1.4243	1.0974	572.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.30	0.1948	0.05	-3.5797	0.7311

24: Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Model Information

Data Set	WORK.DPB_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	5	60 70 90 110 130

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228/[redacted] NN9068-4228/[redacted]

```
Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full
analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full
analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
```

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

```
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
```

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU user [redacted]rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	15
Columns in X	61
Columns in Z	0
Subjects	1012
Max Obs per Subject	5

Number of Observations

Number of Observations Read	5060
Number of Observations Used	3719
Number of Observations Not Used	1341

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	25593.26639581	
1	2	25067.24541929	0.00000032
2	1	25067.24245220	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	55.5868
UN(2,1)	USUBJID	19.8289
UN(2,2)	USUBJID	57.7283
UN(3,1)	USUBJID	17.4079
UN(3,2)	USUBJID	23.4613
UN(3,3)	USUBJID	58.7142
UN(4,1)	USUBJID	15.4759
UN(4,2)	USUBJID	18.2181
UN(4,3)	USUBJID	20.6766
UN(4,4)	USUBJID	60.6684

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(5,1)	USUBJID	21.0042
UN(5,2)	USUBJID	20.7713
UN(5,3)	USUBJID	22.6276
UN(5,4)	USUBJID	22.0409
UN(5,5)	USUBJID	60.5201

Fit Statistics

-2 Res Log Likelihood	25067.2
AIC (Smaller is Better)	25097.2
AICC (Smaller is Better)	25097.4
BIC (Smaller is Better)	25171.0

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
14	526.02	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	5	754	0.54	0.7468
region(avisitn)	20	1612	2.11	0.0029
PREOAD(avisitn)	5	722	0.90	0.4825
HBA1CG1(avisitn)	5	756	0.15	0.9811
base(avisitn)	5	735	105.12	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	79.004
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.DPB_MMRM	79.0199	0.3386	963.9	233.39

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	<.0001	0.05	78.3555	79.6844

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	79.004
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.DPB_MMRM	78.4902	0.3411	963.4	230.10

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	77.8208	79.1596

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.DPB_MMRM	0.5298	0.4829	963.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	1.10	0.2728	0.05	-0.4178	1.4773

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	79.004
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.DPB_MMRM	78.9498	0.3477	945.5	227.05

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	78.2674	79.6321

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	79.004
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.DPB_MMRM	78.7349	0.3527	948	223.27

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	78.0429	79.4270

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.DPB_MMRM	0.2148	0.4974	946.6

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.43	0.6659	0.05	-0.7614	1.1910

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	79.004
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.DPB_MMRM	79.1495	0.3820	713.7	207.20

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	78.3995	79.8994

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	79.004
base(avisitn)					110	
base(avisitn)					130	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.DPB_MMRM	79.3773	0.4382	741.8	181.15

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	78.5171	80.2375

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.DPB_MMRM	-0.2278	0.5797	730.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-0.39	0.6944	0.05	-1.3659	0.9102

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	79.004
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.DPB_MMRM	78.9517	0.4133	613	191.02

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	78.1400	79.7634

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	79.004
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.DPB_MMRM	78.7059	0.5030	625.6	156.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	77.7181	79.6936

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.DPB_MMRM	0.2458	0.6443	621.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	0.38	0.7030	0.05	-1.0195	1.5111

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	79.004

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.DPB_MMRM	79.1504	0.4215	571.3	187.77

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	78.3225	79.9784

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	79.004

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.DPB_MMRM	79.5610	0.5337	588.9	149.06

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	78.5128	80.6093

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.DPB_MMRM	-0.4106	0.6702	584.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.61	0.5404	0.05	-1.7270	0.9058

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Model Information

Data Set	WORK.DPB_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	5	60 70 90 110 130

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

```
               Class Level Information

Class        Levels    Values

USUBJID        1012    NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
                       NN9068-4228[redacted]
```

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Diastolic blood pressure after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/ [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/ [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/ [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/[redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/ [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/ [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/ [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

NN9068-4228/ [redacted]

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	15
Columns in X	61
Columns in Z	0
Subjects	1012
Max Obs per Subject	5

Number of Observations

Number of Observations Read	5060
Number of Observations Used	3719
Number of Observations Not Used	1341

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	25593.26639581	
1	2	25067.24541929	0.00000032
2	1	25067.24245220	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	55.5868
UN(2,1)	USUBJID	19.8289
UN(2,2)	USUBJID	57.7283
UN(3,1)	USUBJID	17.4079
UN(3,2)	USUBJID	23.4613
UN(3,3)	USUBJID	58.7142
UN(4,1)	USUBJID	15.4759
UN(4,2)	USUBJID	18.2181
UN(4,3)	USUBJID	20.6766
UN(4,4)	USUBJID	60.6684

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(5,1)	USUBJID	21.0042
UN(5,2)	USUBJID	20.7713
UN(5,3)	USUBJID	22.6276
UN(5,4)	USUBJID	22.0409
UN(5,5)	USUBJID	60.5201

Fit Statistics

-2 Res Log Likelihood	25067.2
AIC (Smaller is Better)	25097.2
AICC (Smaller is Better)	25097.4
BIC (Smaller is Better)	25171.0

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
14	526.02	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	5	754	0.54	0.7468
region(avisitn)	20	1612	2.11	0.0029
PREOAD(avisitn)	5	722	0.90	0.4825
HBA1CG1(avisitn)	5	756	0.15	0.9811
base(avisitn)	5	735	105.12	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	79.004
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.DPB_MMRM	0.01616	0.3386	963.9	0.05

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	0.9619	0.05	-0.6483	0.6806

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	79.004
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.DPB_MMRM	-0.5136	0.3411	963.4	-1.51

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	0.1325	0.05	-1.1830	0.1558

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.DPB_MMRM	0.5298	0.4829	963.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	1.10	0.2728	0.05	-0.4178	1.4773

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	79.004
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.DPB_MMRM	-0.05400	0.3477	945.5	-0.16

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	0.8766	0.05	-0.7364	0.6284

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	79.004
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.DPB_MMRM	-0.2688	0.3527	948	-0.76

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.4461	0.05	-0.9609	0.4232

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.DPB_MMRM	0.2148	0.4974	946.6

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.43	0.6659	0.05	-0.7614	1.1910

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	79.004
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.DPB_MMRM	0.1457	0.3820	713.7	0.38

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	0.7030	0.05	-0.6042	0.8957

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	79.004
base(avisitn)					110	
base(avisitn)					130	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.DPB_MMRM	0.3735	0.4382	741.8	0.85

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	0.3942	0.05	-0.4867	1.2338

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.DPB_MMRM	-0.2278	0.5797	730.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-0.39	0.6944	0.05	-1.3659	0.9102

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	79.004
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.DPB_MMRM	-0.05210	0.4133	613	-0.13

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	0.8997	0.05	-0.8638	0.7596

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	79.004
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.DPB_MMRM	-0.2979	0.5030	625.6	-0.59

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	0.5539	0.05	-1.2856	0.6898

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.DPB_MMRM	0.2458	0.6443	621.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	0.38	0.7030	0.05	-1.0195	1.5111

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	79.004

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.DPB_MMRM	0.1467	0.4215	571.3	0.35

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	0.7280	0.05	-0.6813	0.9746

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	79.004

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.DPB_MMRM	0.5573	0.5337	588.9	1.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.2969	0.05	-0.4910	1.6055

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.DPB_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Diastolic blood pressure after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=BP_DIASTOLIC_MEAN

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.DPB_MMRM	-0.4106	0.6702	584.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.61	0.5404	0.05	-1.7270	0.9058

25: HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_aval
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1006	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

```
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	1006
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2125
Number of Observations Not Used	911

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	2946.12503940	
1	2	2849.47706523	0.00000618
2	1	2849.47394412	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.2131
UN(2,1)	USUBJID	0.06204
UN(2,2)	USUBJID	0.2438
UN(3,1)	USUBJID	0.04777
UN(3,2)	USUBJID	0.05617
UN(3,3)	USUBJID	0.2196

Fit Statistics

-2 Res Log Likelihood	2849.5
AIC (Smaller is Better)	2861.5
AICC (Smaller is Better)	2861.5
BIC (Smaller is Better)	2891.0

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	96.65	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	721	6.00	0.0005
region(avisitn)	12	1215	2.36	0.0054
PREOAD(avisitn)	3	696	4.80	0.0026
HBA1CG1(avisitn)	3	723	0.69	0.5570
log_base(avisitn)	3	714	31.00	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0885
region(avisitn)		Asia			70	0.0915
region(avisitn)		Europe			70	0.4901
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1809
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3509
PREOAD(avisitn)			SU users		70	0.6491
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.642
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	-1.0300	0.02133	926.1	-48.30

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	-1.0719	-0.9882	0.3570

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	0.3424	0.3723

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0885
region(avisitn)		Asia			70	0.0915
region(avisitn)		Europe			70	0.4901
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1809
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3509
PREOAD(avisitn)			SU users		70	0.6491
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.642
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	-0.9267	0.02161	925	-42.88

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	-0.9691	-0.8843	0.3959

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	0.3794	0.4130

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.1033	0.03050	925.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.39	0.0007	0.05	-0.1632	-0.04347

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.9018	0.8495	0.9575

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0885
region(avisitn)		Asia			90	0.0915
region(avisitn)		Europe			90	0.4901
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1809
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3509
PREOAD(avisitn)			SU users		90	0.6491
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5308
HBA1CG1(avisitn)				>=8.5	90	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	-0.642
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	-1.0235	0.02516	677.8	-40.68

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	<.0001	0.05	-1.0729	-0.9741	0.3593

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	0.3420	0.3775

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0885
region(avisitn)		Asia			90	0.0915
region(avisitn)		Europe			90	0.4901
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1809
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3509
PREOAD(avisitn)			SU users		90	0.6491
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5308

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	-0.642
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	-0.9118	0.02929	687	-31.13

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	<.0001	0.05	-0.9693	-0.8543	0.4018

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	0.3793	0.4256

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.1117	0.03849	683.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-2.90	0.0038	0.05	-0.1872	-0.03610

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.8943	0.8292	0.9645

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0885
region(avisitn)		Asia			130	0.0915
region(avisitn)		Europe			130	0.4901
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1809
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3509
PREOAD(avisitn)			SU users		130	0.6491
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	-0.642

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	-0.9814	0.02624	527.1	-37.40

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	-1.0329	-0.9298	0.3748

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.3560	0.3946

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0885
region(avisitn)		Asia			130	0.0915
region(avisitn)		Europe			130	0.4901
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1809
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3509
PREOAD(avisitn)			SU users		130	0.6491
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	-0.642

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	-0.8880	0.03411	531.4	-26.03

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	-0.9550	-0.8210	0.4115

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.3848	0.4400

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.09337	0.04233	530.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-2.21	0.0278	0.05	-0.1765	-0.01022

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9109	0.8382	0.9898

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_aval
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	998	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

```
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
                                 NN9068-4228/[redacted]
PREOAD               2           Non-SU users SU users
```

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	998
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2093
Number of Observations Not Used	943

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	-1732.62414205	
1	2	-2132.19908596	0.00000621
2	1	-2132.21766606	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.02249
UN(2,1)	USUBJID	0.01150
UN(2,2)	USUBJID	0.02417
UN(3,1)	USUBJID	0.009795
UN(3,2)	USUBJID	0.01364
UN(3,3)	USUBJID	0.02496

Fit Statistics

-2 Res Log Likelihood	-2132.2
AIC (Smaller is Better)	-2120.2
AICC (Smaller is Better)	-2120.2
BIC (Smaller is Better)	-2090.8

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	399.59	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	724	0.94	0.4194
region(avisitn)	12	1207	3.01	0.0004
PREOAD(avisitn)	3	699	1.12	0.3400
HBA1CG1(avisitn)	3	723	0.31	0.8208
log_base(avisitn)	3	722	805.03	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0872
region(avisitn)		Asia			70	0.0922
region(avisitn)		Europe			70	0.489
region(avisitn)		North America			70	0.1493
region(avisitn)		South America			70	0.1824
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3477
PREOAD(avisitn)			SU users		70	0.6523
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5311
HBA1CG1(avisitn)				>=8.5	70	0.4689
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.0973
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	0.1218	0.006973	919	17.46

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	0.1081	0.1355	1.1295

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	1.1142	1.1451

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0872
region(avisitn)		Asia			70	0.0922
region(avisitn)		Europe			70	0.489
region(avisitn)		North America			70	0.1493
region(avisitn)		South America			70	0.1824
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3477
PREOAD(avisitn)			SU users		70	0.6523
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5311
HBA1CG1(avisitn)				>=8.5	70	0.4689
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.0973
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	0.1227	0.007066	916.3	17.36

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	0.1088	0.1365	1.1305

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	1.1149	1.1463

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.00089	0.009975	917.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-0.09	0.9292	0.05	-0.02046	0.01869

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.9991	0.9797	1.0189

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0872
region(avisitn)		Asia			90	0.0922
region(avisitn)		Europe			90	0.489
region(avisitn)		North America			90	0.1493
region(avisitn)		South America			90	0.1824
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3477
PREOAD(avisitn)			SU users		90	0.6523
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5311
HBA1CG1(avisitn)				>=8.5	90	0.4689
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.0973
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	0.1052	0.007794	721.1	13.50

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	<.0001	0.05	0.08990	0.1205	1.1109

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	1.0941	1.1281

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0872
region(avisitn)		Asia			90	0.0922
region(avisitn)		Europe			90	0.489
region(avisitn)		North America			90	0.1493
region(avisitn)		South America			90	0.1824
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3477
PREOAD(avisitn)			SU users		90	0.6523
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5311

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	0.4689
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.0973
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	0.1226	0.008917	754.1	13.75

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	<.0001	0.05	0.1051	0.1401	1.1305

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	1.1108	1.1504

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01742	0.01181	740.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-1.47	0.1407	0.05	-0.04061	0.005768

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.9827	0.9602	1.0058

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0872
region(avisitn)		Asia			130	0.0922
region(avisitn)		Europe			130	0.489
region(avisitn)		North America			130	0.1493
region(avisitn)		South America			130	0.1824
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3477
PREOAD(avisitn)			SU users		130	0.6523
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5311
HBA1CG1(avisitn)				>=8.5	130	0.4689
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.0973

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	0.1124	0.008684	578.6	12.94

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	0.09532	0.1294	1.1189

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	1.1000	1.1382

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0872
region(avisitn)		Asia			130	0.0922
region(avisitn)		Europe			130	0.489
region(avisitn)		North America			130	0.1493
region(avisitn)		South America			130	0.1824
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3477
PREOAD(avisitn)			SU users		130	0.6523
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5311
HBA1CG1(avisitn)				>=8.5	130	0.4689
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.0973

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	0.1273	0.01093	596.1	11.65

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	0.1059	0.1488	1.1358

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	1.1117	1.1605

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01498	0.01377	591.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.09	0.2770	0.05	-0.04201	0.01206

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9851	0.9589	1.0121

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_aval
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

```
HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis
set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis
set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis
set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

```
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
                               NN9068-4228/[redacted]
PREOAD             2           Non-SU users SU users
HBA1CG1            2           <8.5 >=8.5
```

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	997
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2087
Number of Observations Not Used	949

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	979.39611101	
1	2	629.98363970	0.00008033
2	1	629.85351319	0.00000014
3	1	629.85329118	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.08276
UN(2,1)	USUBJID	0.03551
UN(2,2)	USUBJID	0.07714
UN(3,1)	USUBJID	0.03804
UN(3,2)	USUBJID	0.05145
UN(3,3)	USUBJID	0.1164

Fit Statistics

-2 Res Log Likelihood	629.9
AIC (Smaller is Better)	641.9
AICC (Smaller is Better)	641.9
BIC (Smaller is Better)	671.3

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	349.54	<.0001

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	707	1.15	0.3287
region(avisitn)	12	1188	2.85	0.0007
PREOAD(avisitn)	3	682	0.52	0.6686
HBA1CG1(avisitn)	3	706	0.56	0.6395
log_base(avisitn)	3	719	397.51	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0873
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1494
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.348
PREOAD(avisitn)			SU users		70	0.652
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5316
HBA1CG1(avisitn)				>=8.5	70	0.4684
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.7737
log_base(avisitn)					90	
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	0.8144	0.01338	913.6	60.86

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	0.7882	0.8407	2.2579

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	2.1994	2.3180

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0873
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1494
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.348
PREOAD(avisitn)			SU users		70	0.652
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5316
HBA1CG1(avisitn)				>=8.5	70	0.4684
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.7737
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	0.8029	0.01360	912	59.06

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	0.7762	0.8296	2.2321

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	2.1733	2.2924

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	0.01151	0.01918	913

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.60	0.5484	0.05	-0.02612	0.04915

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.0116	0.9742	1.0504

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0873
region(avisitn)		Asia			90	0.0923
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1494
region(avisitn)		South America			90	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.348
PREOAD(avisitn)			SU users		90	0.652
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5316
HBA1CG1(avisitn)				>=8.5	90	0.4684
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.7737
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	0.7767	0.01399	715.1	55.53

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	<.0001	0.05	0.7493	0.8042	2.1743

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	2.1154	2.2349

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0873
region(avisitn)		Asia			90	0.0923
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1494
region(avisitn)		South America			90	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.348
PREOAD(avisitn)			SU users		90	0.652
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5316
HBA1CG1(avisitn)				>=8.5	90	0.4684
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.7737
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	0.7994	0.01612	738.5	49.60

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	<.0001	0.05	0.7677	0.8310	2.2241

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	2.1548	2.2956

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.02264	0.02129	729.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-1.06	0.2879	0.05	-0.06443	0.01915

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.9776	0.9376	1.0193

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0873
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1494
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.348
PREOAD(avisitn)			SU users		130	0.652
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5316
HBA1CG1(avisitn)				>=8.5	130	0.4684
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.7737

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	0.7253	0.01885	545.3	38.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	0.6883	0.7623	2.0653

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	1.9902	2.1432

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0873
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1494
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.348
PREOAD(avisitn)			SU users		130	0.652
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5316
HBA1CG1(avisitn)				>=8.5	130	0.4684
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.7737

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	0.7638	0.02388	571	31.99

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	0.7169	0.8107	2.1464

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	2.0480	2.2494

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.03850	0.02997	561.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.28	0.1994	0.05	-0.09737	0.02036

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9622	0.9072	1.0206

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_aval
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	999	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	999
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2099
Number of Observations Not Used	937

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	1934.68974618	
1	2	1617.21492150	0.00000064
2	1	1617.21421597	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.1437
UN(2,1)	USUBJID	0.06315
UN(2,2)	USUBJID	0.1438
UN(3,1)	USUBJID	0.06202
UN(3,2)	USUBJID	0.06417
UN(3,3)	USUBJID	0.1278

Fit Statistics

-2 Res Log Likelihood	1617.2
AIC (Smaller is Better)	1629.2
AICC (Smaller is Better)	1629.3
BIC (Smaller is Better)	1658.7

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	317.48	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	708	0.44	0.7263
region(avisitn)	12	1194	2.64	0.0017
PREOAD(avisitn)	3	684	8.97	<.0001
HBA1CG1(avisitn)	3	710	1.31	0.2684
log_base(avisitn)	3	706	339.55	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0871
region(avisitn)		Asia			70	0.0921
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1822
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3483
PREOAD(avisitn)			SU users		70	0.6517
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5305
HBA1CG1(avisitn)				>=8.5	70	0.4695
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.5719
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	0.3983	0.01760	918.1	22.63

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	0.3637	0.4328	1.4893

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	1.4387	1.5416

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0871
region(avisitn)		Asia			70	0.0921
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1822
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3483
PREOAD(avisitn)			SU users		70	0.6517
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5305
HBA1CG1(avisitn)				>=8.5	70	0.4695
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.5719
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	0.4119	0.01784	916.7	23.08

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	0.3769	0.4469	1.5096

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	1.4577	1.5634

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01360	0.02519	917.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-0.54	0.5895	0.05	-0.06303	0.03584

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.9865	0.9389	1.0365

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0871
region(avisitn)		Asia			90	0.0921
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1822
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3483
PREOAD(avisitn)			SU users		90	0.6517
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5305
HBA1CG1(avisitn)				>=8.5	90	0.4695
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.5719
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	0.4662	0.01911	708.9	24.40

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	<.0001	0.05	0.4287	0.5037	1.5940

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	1.5353	1.6549

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0871
region(avisitn)		Asia			90	0.0921
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1822
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3483
PREOAD(avisitn)			SU users		90	0.6517
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5305

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	0.4695
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.5719
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	0.4503	0.02192	733.8	20.54

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	<.0001	0.05	0.4073	0.4934	1.5688

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	1.5027	1.6378

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	0.01592	0.02900	723.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.55	0.5833	0.05	-0.04101	0.07285

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	1.0160	0.9598	1.0756

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0871
region(avisitn)		Asia			130	0.0921
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1822
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3483
PREOAD(avisitn)			SU users		130	0.6517
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5305
HBA1CG1(avisitn)				>=8.5	130	0.4695
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.5719

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	0.4710	0.01967	561.1	23.95

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	0.4324	0.5097	1.6016

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	1.5410	1.6647

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0871
region(avisitn)		Asia			130	0.0921
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1822
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3483
PREOAD(avisitn)			SU users		130	0.6517
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5305
HBA1CG1(avisitn)				>=8.5	130	0.4695
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.5719

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	0.4867	0.02473	577.9	19.68

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	0.4381	0.5353	1.6269

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	1.5498	1.7079

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01567	0.03112	573.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.50	0.6148	0.05	-0.07680	0.04546

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9845	0.9261	1.0465

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_aval
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	999	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis
set

topic_cd=T_CHOL_SERUM

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	999
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2100
Number of Observations Not Used	936

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	-1352.93069415	
1	2	-1673.43082261	0.00000014
2	1	-1673.43121800	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.02681
UN(2,1)	USUBJID	0.01215
UN(2,2)	USUBJID	0.02848
UN(3,1)	USUBJID	0.01239
UN(3,2)	USUBJID	0.01505
UN(3,3)	USUBJID	0.03244

Fit Statistics

-2 Res Log Likelihood	-1673.4
AIC (Smaller is Better)	-1661.4
AICC (Smaller is Better)	-1661.4
BIC (Smaller is Better)	-1632.0

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	320.50	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	717	0.50	0.6841
region(avisitn)	12	1203	2.82	0.0008
PREOAD(avisitn)	3	693	2.55	0.0545
HBA1CG1(avisitn)	3	718	0.33	0.8049
log_base(avisitn)	3	721	467.37	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0871
region(avisitn)		Asia			70	0.0921
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1822
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3483
PREOAD(avisitn)			SU users		70	0.6517
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5305
HBA1CG1(avisitn)				>=8.5	70	0.4695
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	1.4517
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	1.4425	0.007596	915.9	189.90

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	1.4276	1.4574	4.2311

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	4.1685	4.2947

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0871
region(avisitn)		Asia			70	0.0921
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1822
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3483
PREOAD(avisitn)			SU users		70	0.6517
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5305
HBA1CG1(avisitn)				>=8.5	70	0.4695
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	1.4517
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	1.4415	0.007715	915.4	186.84

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	1.4264	1.4566	4.2270

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	4.1635	4.2915

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	0.000973	0.01088	915.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.09	0.9288	0.05	-0.02039	0.02233

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.0010	0.9798	1.0226

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0871
region(avisitn)		Asia			90	0.0921
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1822
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3483
PREOAD(avisitn)			SU users		90	0.6517
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5305
HBA1CG1(avisitn)				>=8.5	90	0.4695
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	1.4517
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	1.4328	0.008503	709.3	168.51

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	<.0001	0.05	1.4161	1.4495	4.1904

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	4.1210	4.2609

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0871
region(avisitn)		Asia			90	0.0921
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1822
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3483
PREOAD(avisitn)			SU users		90	0.6517
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5305

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	0.4695
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	1.4517
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	1.4412	0.009753	733.9	147.76

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	<.0001	0.05	1.4220	1.4603	4.2257

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	4.1455	4.3074

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.00839	0.01290	724

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-0.65	0.5157	0.05	-0.03373	0.01694

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.9916	0.9668	1.0171

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0871
region(avisitn)		Asia			130	0.0921
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1822
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3483
PREOAD(avisitn)			SU users		130	0.6517
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5305
HBA1CG1(avisitn)				>=8.5	130	0.4695
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	1.4517

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	1.4140	0.009960	559.4	141.96

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	1.3944	1.4336	4.1124

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	4.0327	4.1936

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0871
region(avisitn)		Asia			130	0.0921
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1822
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3483
PREOAD(avisitn)			SU users		130	0.6517
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5305
HBA1CG1(avisitn)				>=8.5	130	0.4695
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	1.4517

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	1.4309	0.01254	574.6	114.15

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	1.4062	1.4555	4.1823

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	4.0806	4.2866

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01687	0.01576	570.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.07	0.2847	0.05	-0.04782	0.01408

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9833	0.9533	1.0142

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_aval
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]

```
HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis
set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure
```

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure



HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	997
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2091
Number of Observations Not Used	945

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	1704.64116733	
1	2	1383.16263357	0.00000038
2	1	1383.16217037	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.1288
UN(2,1)	USUBJID	0.05590
UN(2,2)	USUBJID	0.1295
UN(3,1)	USUBJID	0.05798
UN(3,2)	USUBJID	0.05669
UN(3,3)	USUBJID	0.1139

Fit Statistics

-2 Res Log Likelihood	1383.2
AIC (Smaller is Better)	1395.2
AICC (Smaller is Better)	1395.2
BIC (Smaller is Better)	1424.6

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	321.48	<.0001

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	707	0.14	0.9371
region(avisitn)	12	1189	2.41	0.0043
PREOAD(avisitn)	3	682	7.98	<.0001
HBA1CG1(avisitn)	3	707	0.90	0.4395
log_base(avisitn)	3	699	329.30	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0873
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1494
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.348
PREOAD(avisitn)			SU users		70	0.652
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.229
log_base(avisitn)					90	
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	-0.3904	0.01668	914.7	-23.40

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	-0.4231	-0.3577	0.6768

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	0.6550	0.6993

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0873
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1494
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.348
PREOAD(avisitn)			SU users		70	0.652
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.229
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	-0.3862	0.01693	914.2	-22.82

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	-0.4195	-0.3530	0.6796

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	0.6574	0.7026

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.00417	0.02389	914.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-0.17	0.8616	0.05	-0.05104	0.04271

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.9958	0.9502	1.0436

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0873
region(avisitn)		Asia			90	0.0923
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1494
region(avisitn)		South America			90	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.348
PREOAD(avisitn)			SU users		90	0.652
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	-0.229
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	-0.3324	0.01816	706.4	-18.31

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	<.0001	0.05	-0.3680	-0.2968	0.7172

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	0.6921	0.7432

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0873
region(avisitn)		Asia			90	0.0923
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1494
region(avisitn)		South America			90	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.348
PREOAD(avisitn)			SU users		90	0.652
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	-0.229
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	-0.3409	0.02087	730	-16.33

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	<.0001	0.05	-0.3819	-0.2999	0.7111

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	0.6826	0.7409

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	0.008498	0.02758	720.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.31	0.7581	0.05	-0.04565	0.06265

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	1.0085	0.9554	1.0647

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0873
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1494
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.348
PREOAD(avisitn)			SU users		130	0.652
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	-0.229

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	-0.3301	0.01854	564.8	-17.80

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	-0.3665	-0.2937	0.7189

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.6932	0.7455

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0873
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1494
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.348
PREOAD(avisitn)			SU users		130	0.652
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	-0.229

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	-0.3189	0.02336	580.5	-13.65

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	-0.3648	-0.2730	0.7270

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.6944	0.7611

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01121	0.02937	577.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.38	0.7028	0.05	-0.06890	0.04648

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9889	0.9334	1.0476

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_r2base
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1006	NN9068-4228/[redacted] NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228	[redacted]
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	
NN9068-4228	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	1006
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2125
Number of Observations Not Used	911

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	2946.12503940	
1	2	2849.47706523	0.00000618
2	1	2849.47394412	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.2131
UN(2,1)	USUBJID	0.06204
UN(2,2)	USUBJID	0.2438
UN(3,1)	USUBJID	0.04777
UN(3,2)	USUBJID	0.05617
UN(3,3)	USUBJID	0.2196

Fit Statistics

-2 Res Log Likelihood	2849.5
AIC (Smaller is Better)	2861.5
AICC (Smaller is Better)	2861.5
BIC (Smaller is Better)	2891.0

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	96.65	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	721	6.00	0.0005
region(avisitn)	12	1215	2.36	0.0054
PREOAD(avisitn)	3	696	4.80	0.0026
HBA1CG1(avisitn)	3	723	0.69	0.5570
log_base(avisitn)	3	714	205.60	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0885
region(avisitn)		Asia			70	0.0915
region(avisitn)		Europe			70	0.4901
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1809
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3509
PREOAD(avisitn)			SU users		70	0.6491
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.642
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	-0.3881	0.02133	926.1	-18.20

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	-0.4300	-0.3462	0.6783

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	0.6505	0.7073

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0885
region(avisitn)		Asia			70	0.0915
region(avisitn)		Europe			70	0.4901
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1809
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3509
PREOAD(avisitn)			SU users		70	0.6491
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5308
HBA1CG1(avisitn)				>=8.5	70	0.4692
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.642
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	-0.2848	0.02161	925	-13.18

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	-0.3272	-0.2424	0.7522

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	0.7209	0.7848

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.1033	0.03050	925.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-3.39	0.0007	0.05	-0.1632	-0.04347

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.9018	0.8495	0.9575

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0885
region(avisitn)		Asia			90	0.0915
region(avisitn)		Europe			90	0.4901
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1809
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3509
PREOAD(avisitn)			SU users		90	0.6491
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5308
HBA1CG1(avisitn)				>=8.5	90	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	-0.642
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	-0.3815	0.02516	677.8	-15.17

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	<.0001	0.05	-0.4309	-0.3321	0.6828

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	0.6499	0.7174

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0885
region(avisitn)		Asia			90	0.0915
region(avisitn)		Europe			90	0.4901
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1809
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3509
PREOAD(avisitn)			SU users		90	0.6491
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5308

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	0.4692
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	-0.642
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	-0.2699	0.02929	687	-9.21

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	<.0001	0.05	-0.3274	-0.2124	0.7635

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	0.7208	0.8087

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.1117	0.03849	683.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-2.90	0.0038	0.05	-0.1872	-0.03610

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.8943	0.8292	0.9645

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0885
region(avisitn)		Asia			130	0.0915
region(avisitn)		Europe			130	0.4901
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1809
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3509
PREOAD(avisitn)			SU users		130	0.6491
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	-0.642

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	-0.3395	0.02624	527.1	-12.94

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	-0.3910	-0.2879	0.7122

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.6764	0.7498

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0885
region(avisitn)		Asia			130	0.0915
region(avisitn)		Europe			130	0.4901
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1809
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3509
PREOAD(avisitn)			SU users		130	0.6491
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5308
HBA1CG1(avisitn)				>=8.5	130	0.4692
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	-0.642

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	-0.2461	0.03411	531.4	-7.21

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	<.0001	0.05	-0.3131	-0.1791	0.7818

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.7312	0.8360

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=FFA_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.09337	0.04233	530.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-2.21	0.0278	0.05	-0.1765	-0.01022

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9109	0.8382	0.9898

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_r2base
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	998	NN9068-4228[redacted] NN9068-4228[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/ [redacted]
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

PREOAD 2 Non-SU users SU users

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	998
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2093
Number of Observations Not Used	943

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	-1732.62414205	
1	2	-2132.19908596	0.00000621
2	1	-2132.21766606	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.02249
UN(2,1)	USUBJID	0.01150
UN(2,2)	USUBJID	0.02417
UN(3,1)	USUBJID	0.009795
UN(3,2)	USUBJID	0.01364
UN(3,3)	USUBJID	0.02496

Fit Statistics

-2 Res Log Likelihood	-2132.2
AIC (Smaller is Better)	-2120.2
AICC (Smaller is Better)	-2120.2
BIC (Smaller is Better)	-2090.8

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	399.59	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	724	0.94	0.4194
region(avisitn)	12	1207	3.01	0.0004
PREOAD(avisitn)	3	699	1.12	0.3400
HBA1CG1(avisitn)	3	723	0.31	0.8208
log_base(avisitn)	3	722	46.32	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0872
region(avisitn)		Asia			70	0.0922
region(avisitn)		Europe			70	0.489
region(avisitn)		North America			70	0.1493
region(avisitn)		South America			70	0.1824
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3477
PREOAD(avisitn)			SU users		70	0.6523
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5311
HBA1CG1(avisitn)				>=8.5	70	0.4689
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.0973
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	0.02452	0.006973	919	3.52

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	0.0005	0.05	0.01083	0.03820	1.0248

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	1.0109	1.0389

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0872
region(avisitn)		Asia			70	0.0922
region(avisitn)		Europe			70	0.489
region(avisitn)		North America			70	0.1493
region(avisitn)		South America			70	0.1824
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3477
PREOAD(avisitn)			SU users		70	0.6523
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5311
HBA1CG1(avisitn)				>=8.5	70	0.4689
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.0973
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	0.02540	0.007066	916.3	3.60

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	0.0003	0.05	0.01154	0.03927	1.0257

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	1.0116	1.0401

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.00089	0.009975	917.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-0.09	0.9292	0.05	-0.02046	0.01869

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.9991	0.9797	1.0189

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0872
region(avisitn)		Asia			90	0.0922
region(avisitn)		Europe			90	0.489
region(avisitn)		North America			90	0.1493
region(avisitn)		South America			90	0.1824
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3477
PREOAD(avisitn)			SU users		90	0.6523
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5311
HBA1CG1(avisitn)				>=8.5	90	0.4689
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.0973
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	0.007937	0.007794	721.1	1.02

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	0.3089	0.05	-0.00737	0.02324	1.0080

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	0.9927	1.0235

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0872
region(avisitn)		Asia			90	0.0922
region(avisitn)		Europe			90	0.489
region(avisitn)		North America			90	0.1493
region(avisitn)		South America			90	0.1824
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3477
PREOAD(avisitn)			SU users		90	0.6523
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5311

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	0.4689
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.0973
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	0.02536	0.008917	754.1	2.84

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	0.0046	0.05	0.007853	0.04286	1.0257

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	1.0079	1.0438

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01742	0.01181	740.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-1.47	0.1407	0.05	-0.04061	0.005768

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.9827	0.9602	1.0058

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0872
region(avisitn)		Asia			130	0.0922
region(avisitn)		Europe			130	0.489
region(avisitn)		North America			130	0.1493
region(avisitn)		South America			130	0.1824
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3477
PREOAD(avisitn)			SU users		130	0.6523
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5311
HBA1CG1(avisitn)				>=8.5	130	0.4689
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.0973

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	0.01510	0.008684	578.6	1.74

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	0.0825	0.05	-0.00195	0.03216	1.0152

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.9981	1.0327

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0872
region(avisitn)		Asia			130	0.0922
region(avisitn)		Europe			130	0.489
region(avisitn)		North America			130	0.1493
region(avisitn)		South America			130	0.1824
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3477
PREOAD(avisitn)			SU users		130	0.6523
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5311
HBA1CG1(avisitn)				>=8.5	130	0.4689
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.0973

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	0.03008	0.01093	596.1	2.75

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	0.0061	0.05	0.008608	0.05156	1.0305

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	1.0086	1.0529

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=HDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01498	0.01377	591.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.09	0.2770	0.05	-0.04201	0.01206

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9851	0.9589	1.0121

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_r2base
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted] NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/ [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	997
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2087
Number of Observations Not Used	949

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	979.39611101	
1	2	629.98363970	0.00008033
2	1	629.85351319	0.00000014
3	1	629.85329118	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.08276
UN(2,1)	USUBJID	0.03551
UN(2,2)	USUBJID	0.07714
UN(3,1)	USUBJID	0.03804
UN(3,2)	USUBJID	0.05145
UN(3,3)	USUBJID	0.1164

Fit Statistics

-2 Res Log Likelihood	629.9
AIC (Smaller is Better)	641.9
AICC (Smaller is Better)	641.9
BIC (Smaller is Better)	671.3

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	349.54	<.0001

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	707	1.15	0.3287
region(avisitn)	12	1188	2.85	0.0007
PREOAD(avisitn)	3	682	0.52	0.6686
HBA1CG1(avisitn)	3	706	0.56	0.6395
log_base(avisitn)	3	719	109.90	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0873
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1494
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.348
PREOAD(avisitn)			SU users		70	0.652
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5316
HBA1CG1(avisitn)				>=8.5	70	0.4684
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.7737
log_base(avisitn)					90	
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	0.04069	0.01338	913.6	3.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	0.0024	0.05	0.01443	0.06695	1.0415

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	1.0145	1.0692

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0873
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1494
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.348
PREOAD(avisitn)			SU users		70	0.652
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5316
HBA1CG1(avisitn)				>=8.5	70	0.4684
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.7737
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	0.02918	0.01360	912	2.15

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	0.0321	0.05	0.002494	0.05586	1.0296

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	1.0025	1.0574

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	0.01151	0.01918	913

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.60	0.5484	0.05	-0.02612	0.04915

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.0116	0.9742	1.0504

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0873
region(avisitn)		Asia			90	0.0923
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1494
region(avisitn)		South America			90	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.348
PREOAD(avisitn)			SU users		90	0.652
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5316
HBA1CG1(avisitn)				>=8.5	90	0.4684
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.7737
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	0.002973	0.01399	715.1	0.21

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	0.8318	0.05	-0.02449	0.03043	1.0030

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	0.9758	1.0309

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0873
region(avisitn)		Asia			90	0.0923
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1494
region(avisitn)		South America			90	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.348
PREOAD(avisitn)			SU users		90	0.652
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5316
HBA1CG1(avisitn)				>=8.5	90	0.4684
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.7737
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	0.02561	0.01612	738.5	1.59

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	0.1124	0.05	-0.00602	0.05725	1.0259

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	0.9940	1.0589

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.02264	0.02129	729.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-1.06	0.2879	0.05	-0.06443	0.01915

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.9776	0.9376	1.0193

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0873
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1494
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.348
PREOAD(avisitn)			SU users		130	0.652
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5316
HBA1CG1(avisitn)				>=8.5	130	0.4684
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.7737

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	-0.04847	0.01885	545.3	-2.57

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	0.0104	0.05	-0.08549	-0.01144	0.9527

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.9181	0.9886

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0873
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1494
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.348
PREOAD(avisitn)			SU users		130	0.652
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5316
HBA1CG1(avisitn)				>=8.5	130	0.4684
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.7737

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	-0.00996	0.02388	571	-0.42

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	0.6767	0.05	-0.05686	0.03694	0.9901

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.9447	1.0376

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=LDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.03850	0.02997	561.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.28	0.1994	0.05	-0.09737	0.02036

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9622	0.9072	1.0206

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_r2base
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	999	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	999
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2099
Number of Observations Not Used	937

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	1934.68974618	
1	2	1617.21492150	0.00000064
2	1	1617.21421597	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.1437
UN(2,1)	USUBJID	0.06315
UN(2,2)	USUBJID	0.1438
UN(3,1)	USUBJID	0.06202
UN(3,2)	USUBJID	0.06417
UN(3,3)	USUBJID	0.1278

Fit Statistics

-2 Res Log Likelihood	1617.2
AIC (Smaller is Better)	1629.2
AICC (Smaller is Better)	1629.3
BIC (Smaller is Better)	1658.7

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	317.48	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	708	0.44	0.7263
region(avisitn)	12	1194	2.64	0.0017
PREOAD(avisitn)	3	684	8.97	<.0001
HBA1CG1(avisitn)	3	710	1.31	0.2684
log_base(avisitn)	3	706	99.23	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0871
region(avisitn)		Asia			70	0.0921
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1822
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3483
PREOAD(avisitn)			SU users		70	0.6517
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5305
HBA1CG1(avisitn)				>=8.5	70	0.4695
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.5719
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	-0.1736	0.01760	918.1	-9.86

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	-0.2082	-0.1391	0.8406

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	0.8121	0.8702

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0871
region(avisitn)		Asia			70	0.0921
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1822
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3483
PREOAD(avisitn)			SU users		70	0.6517
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5305
HBA1CG1(avisitn)				>=8.5	70	0.4695
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	0.5719
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	-0.1600	0.01784	916.7	-8.97

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	-0.1950	-0.1250	0.8521

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	0.8228	0.8825

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01360	0.02519	917.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-0.54	0.5895	0.05	-0.06303	0.03584

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.9865	0.9389	1.0365

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0871
region(avisitn)		Asia			90	0.0921
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1822
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3483
PREOAD(avisitn)			SU users		90	0.6517
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5305
HBA1CG1(avisitn)				>=8.5	90	0.4695
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.5719
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	-0.1056	0.01911	708.9	-5.53

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	<.0001	0.05	-0.1432	-0.06814	0.8997

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	0.8666	0.9341

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0871
region(avisitn)		Asia			90	0.0921
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1822
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3483
PREOAD(avisitn)			SU users		90	0.6517
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5305

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	0.4695
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	0.5719
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	-0.1216	0.02192	733.8	-5.54

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	<.0001	0.05	-0.1646	-0.07852	0.8855

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	0.8482	0.9245

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	0.01592	0.02900	723.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.55	0.5833	0.05	-0.04101	0.07285

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	1.0160	0.9598	1.0756

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0871
region(avisitn)		Asia			130	0.0921
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1822
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3483
PREOAD(avisitn)			SU users		130	0.6517
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5305
HBA1CG1(avisitn)				>=8.5	130	0.4695
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.5719

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	-0.1008	0.01967	561.1	-5.13

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	-0.1395	-0.06221	0.9041

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.8698	0.9397

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0871
region(avisitn)		Asia			130	0.0921
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1822
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3483
PREOAD(avisitn)			SU users		130	0.6517
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5305
HBA1CG1(avisitn)				>=8.5	130	0.4695
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	0.5719

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	-0.08518	0.02473	577.9	-3.44

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	0.0006	0.05	-0.1338	-0.03660	0.9183

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.8748	0.9641

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=TRIGLYCERIDES_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01567	0.03112	573.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.50	0.6148	0.05	-0.07680	0.04546

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9845	0.9261	1.0465

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_r2base
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

```
HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis
set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

               Class Level Information

Class         Levels    Values

USUBJID          999    NN9068-4228 [redacted]
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
                        NN9068-4228
```

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis
set

topic_cd=T_CHOL_SERUM

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	999
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2100
Number of Observations Not Used	936

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	-1352.93069415	
1	2	-1673.43082261	0.00000014
2	1	-1673.43121800	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.02681
UN(2,1)	USUBJID	0.01215
UN(2,2)	USUBJID	0.02848
UN(3,1)	USUBJID	0.01239
UN(3,2)	USUBJID	0.01505
UN(3,3)	USUBJID	0.03244

Fit Statistics

-2 Res Log Likelihood	-1673.4
AIC (Smaller is Better)	-1661.4
AICC (Smaller is Better)	-1661.4
BIC (Smaller is Better)	-1632.0

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	320.50	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	717	0.50	0.6841
region(avisitn)	12	1203	2.82	0.0008
PREOAD(avisitn)	3	693	2.55	0.0545
HBA1CG1(avisitn)	3	718	0.33	0.8049
log_base(avisitn)	3	721	56.93	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0871
region(avisitn)		Asia			70	0.0921
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1822
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3483
PREOAD(avisitn)			SU users		70	0.6517
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5305
HBA1CG1(avisitn)				>=8.5	70	0.4695
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	1.4517
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	-0.00923	0.007596	915.9	-1.22

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	0.2245	0.05	-0.02414	0.005676	0.9908

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	0.9761	1.0057

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0871
region(avisitn)		Asia			70	0.0921
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1491
region(avisitn)		South America			70	0.1822
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3483
PREOAD(avisitn)			SU users		70	0.6517
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5305
HBA1CG1(avisitn)				>=8.5	70	0.4695
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	1.4517
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	-0.01020	0.007715	915.4	-1.32

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	0.1863	0.05	-0.02535	0.004937	0.9898

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	0.9750	1.0049

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	0.000973	0.01088	915.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.09	0.9288	0.05	-0.02039	0.02233

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.0010	0.9798	1.0226

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0871
region(avisitn)		Asia			90	0.0921
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1822
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3483
PREOAD(avisitn)			SU users		90	0.6517
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5305
HBA1CG1(avisitn)				>=8.5	90	0.4695
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	1.4517
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	-0.01892	0.008503	709.3	-2.22

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	0.0264	0.05	-0.03561	-0.00222	0.9813

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	0.9650	0.9978

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0871
region(avisitn)		Asia			90	0.0921
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1491
region(avisitn)		South America			90	0.1822
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3483
PREOAD(avisitn)			SU users		90	0.6517
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5305

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	0.4695
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	1.4517
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	-0.01052	0.009753	733.9	-1.08

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	0.2809	0.05	-0.02967	0.008623	0.9895

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	0.9708	1.0087

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.00839	0.01290	724

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	-0.65	0.5157	0.05	-0.03373	0.01694

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.9916	0.9668	1.0171

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0871
region(avisitn)		Asia			130	0.0921
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1822
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3483
PREOAD(avisitn)			SU users		130	0.6517
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5305
HBA1CG1(avisitn)				>=8.5	130	0.4695
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	1.4517

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	-0.03771	0.009960	559.4	-3.79

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	0.0002	0.05	-0.05727	-0.01814	0.9630

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.9443	0.9820

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0871
region(avisitn)		Asia			130	0.0921
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1491
region(avisitn)		South America			130	0.1822
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.3483
PREOAD(avisitn)			SU users		130	0.6517
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5305
HBA1CG1(avisitn)				>=8.5	130	0.4695
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	1.4517

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	-0.02083	0.01254	574.6	-1.66

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	0.0970	0.05	-0.04545	0.003785	0.9794

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.9556	1.0038

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=T_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01687	0.01576	570.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.07	0.2847	0.05	-0.04782	0.01408

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9833	0.9533	1.0142

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Model Information

Data Set	WORK.LIPIDS_MMRM
Dependent Variable	log_r2base
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	3	70 90 130

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis
set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

HDL cholesterol after 26 and 104 weeks - supportive statistical analysis - full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Dimensions

Covariance Parameters	6
Columns in X	37
Columns in Z	0
Subjects	997
Max Obs per Subject	3

Number of Observations

Number of Observations Read	3036
Number of Observations Used	2091
Number of Observations Not Used	945

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	1704.64116733	
1	2	1383.16263357	0.00000038
2	1	1383.16217037	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	0.1288
UN(2,1)	USUBJID	0.05590
UN(2,2)	USUBJID	0.1295
UN(3,1)	USUBJID	0.05798
UN(3,2)	USUBJID	0.05669
UN(3,3)	USUBJID	0.1139

Fit Statistics

-2 Res Log Likelihood	1383.2
AIC (Smaller is Better)	1395.2
AICC (Smaller is Better)	1395.2
BIC (Smaller is Better)	1424.6

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
5	321.48	<.0001

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	3	707	0.14	0.9371
region(avisitn)	12	1189	2.41	0.0043
PREOAD(avisitn)	3	682	7.98	<.0001
HBA1CG1(avisitn)	3	707	0.90	0.4395
log_base(avisitn)	3	699	86.74	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0873
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1494
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.348
PREOAD(avisitn)			SU users		70	0.652
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.229
log_base(avisitn)					90	
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.LIPIDS_MMRM	-0.1614	0.01668	914.7	-9.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IDegLira	<.0001	0.05	-0.1941	-0.1286	0.8510

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira	0.8236	0.8793

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0873
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4895
region(avisitn)		North America			70	0.1494
region(avisitn)		South America			70	0.1815
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.348
PREOAD(avisitn)			SU users		70	0.652
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	-0.229
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.LIPIDS_MMRM	-0.1572	0.01693	914.2	-9.29

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V070 IGlar	<.0001	0.05	-0.1904	-0.1240	0.8545

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IGlar	0.8266	0.8834

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.00417	0.02389	914.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	-0.17	0.8616	0.05	-0.05104	0.04271

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.9958	0.9502	1.0436

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0873
region(avisitn)		Asia			90	0.0923
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1494
region(avisitn)		South America			90	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.348
PREOAD(avisitn)			SU users		90	0.652
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	-0.229
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.LIPIDS_MMRM	-0.1034	0.01816	706.4	-5.69

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IDegLira	<.0001	0.05	-0.1390	-0.06771	0.9018

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira	0.8702	0.9345

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0873
region(avisitn)		Asia			90	0.0923
region(avisitn)		Europe			90	0.4895
region(avisitn)		North America			90	0.1494
region(avisitn)		South America			90	0.1815
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.348
PREOAD(avisitn)			SU users		90	0.652
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	-0.229
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.LIPIDS_MMRM	-0.1119	0.02087	730	-5.36

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V090 IGlar	<.0001	0.05	-0.1528	-0.07088	0.8942

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IGlar	0.8583	0.9316

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.LIPIDS_MMRM	0.008498	0.02758	720.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	0.31	0.7581	0.05	-0.04565	0.06265

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V090 IDegLira - IGlar	1.0085	0.9554	1.0647

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0873
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1494
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.348
PREOAD(avisitn)			SU users		130	0.652
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	-0.229

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.LIPIDS_MMRM	-0.1010	0.01854	564.8	-5.45

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IDegLira	<.0001	0.05	-0.1375	-0.06463	0.9039

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira	0.8716	0.9374

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	0.0873
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4895
region(avisitn)		North America			130	0.1494
region(avisitn)		South America			130	0.1815
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	0.348
PREOAD(avisitn)			SU users		130	0.652
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	-0.229

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.LIPIDS_MMRM	-0.08983	0.02336	580.5	-3.85

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper	Exponentiated
treatment(avisitn)	V130 IGlar	0.0001	0.05	-0.1357	-0.04396	0.9141

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IGlar	0.8731	0.9570

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.LIPIDS_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
log_base(avisitn)					70	
log_base(avisitn)					90	
log_base(avisitn)					130	

HDL cholesterol after 26 and 104 weeks – supportive statistical analysis – full analysis set

topic_cd=VLDL_CHOL_SERUM

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.LIPIDS_MMRM	-0.01121	0.02937	577.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.38	0.7028	0.05	-0.06890	0.04648

Least Squares Means Estimate

Effect	Label	Exponentiated	Exponentiated Lower	Exponentiated Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.9889	0.9334	1.0476

26: Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Class Level Information

```
Class        Levels    Values

USUBJID        1011    NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
                       NN9068-4228 [redacted]
```

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	10435.08860535	
1	2	10373.83331522	0.00000002
2	1	10373.83325253	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	68.8723
UN(2,1)	USUBJID	23.4874
UN(2,2)	USUBJID	76.1179

Fit Statistics

-2 Res Log Likelihood	10373.8
AIC (Smaller is Better)	10379.8
AICC (Smaller is Better)	10379.8
BIC (Smaller is Better)	10394.6

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	61.26	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	731	1.72	0.1800
region(avisitn)	8	1000	4.78	<.0001
PREOAD(avisitn)	2	709	0.84	0.4338
HBA1CG1(avisitn)	2	731	1.50	0.2246
base(avisitn)	2	719	189.46	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	50.583
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	51.9815	0.3801	938	136.75

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	51.2355	52.7274

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	50.583
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	50.9830	0.3863	938	131.97

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	50.2248	51.7411

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.9985	0.5443	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.83	0.0669	0.05	-0.06963	2.0666

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	50.583

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	51.5702	0.4829	543.7	106.79

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	50.6216	52.5189

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	50.583

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	51.4388	0.6238	545.2	82.46

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	50.2134	52.6642

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	0.1314	0.7773	546.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.17	0.8658	0.05	-1.3955	1.6584

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Class Level Information

Class Levels Values

USUBJID 1011 NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9903.96927451	
1	2	9799.89154231	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	46.8863
UN(2,1)	USUBJID	21.3377
UN(2,2)	USUBJID	54.8143

Fit Statistics

-2 Res Log Likelihood	9799.9
AIC (Smaller is Better)	9805.9
AICC (Smaller is Better)	9805.9
BIC (Smaller is Better)	9820.6

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	104.08	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	724	0.75	0.4730
region(avisitn)	8	995	6.44	<.0001
PREOAD(avisitn)	2	704	1.32	0.2681
HBA1CG1(avisitn)	2	725	0.12	0.8840
base(avisitn)	2	725	265.11	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	47.683
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	50.1170	0.3136	938	159.79

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	49.5015	50.7325

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	47.683
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	49.7493	0.3188	938	156.08

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	49.1237	50.3749

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.3677	0.4491	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.82	0.4131	0.05	-0.5136	1.2490

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	47.683

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	49.7606	0.4043	560.8	123.07

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	48.9665	50.5548

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	47.683

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	50.1513	0.5157	567.1	97.24

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	49.1383	51.1643

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	-0.3906	0.6455	567.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.61	0.5453	0.05	-1.6584	0.8772

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users[redacted]rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9857.01505876	
1	2	9801.08887601	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	45.2294
UN(2,1)	USUBJID	15.2384
UN(2,2)	USUBJID	53.3717

Fit Statistics

-2 Res Log Likelihood	9801.1
AIC (Smaller is Better)	9807.1
AICC (Smaller is Better)	9807.1
BIC (Smaller is Better)	9821.8

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	55.93	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	723	0.26	0.7677
region(avisitn)	8	995	4.35	<.0001
PREOAD(avisitn)	2	702	0.22	0.7998
HBA1CG1(avisitn)	2	723	1.46	0.2328
base(avisitn)	2	719	291.16	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.795
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	51.1124	0.3080	938.1	165.93

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	50.5079	51.7169

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.795
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	50.8421	0.3131	938.1	162.40

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	50.2277	51.4565

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.2703	0.4411	938.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.61	0.5402	0.05	-0.5953	1.1358

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.795

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	51.6082	0.4048	538.8	127.49

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	50.8130	52.4034

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.795

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	51.2688	0.5223	541.6	98.15

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	50.2427	52.2949

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	0.3395	0.6502	542.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.52	0.6018	0.05	-0.9377	1.6166

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	10074.59254513	
1	2	10005.06763351	0.00000003
2	1	10005.06751655	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	51.7917
UN(2,1)	USUBJID	19.7855
UN(2,2)	USUBJID	63.5428

Fit Statistics

-2 Res Log Likelihood	10005.1
AIC (Smaller is Better)	10011.1
AICC (Smaller is Better)	10011.1
BIC (Smaller is Better)	10025.8

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	69.53	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	720	1.30	0.2730
region(avisitn)	8	992	4.05	<.0001
PREOAD(avisitn)	2	698	0.29	0.7459
HBA1CG1(avisitn)	2	719	0.89	0.4095
base(avisitn)	2	713	254.68	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.311
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	50.9354	0.3297	938	154.47

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	50.2883	51.5825

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.311
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	50.7017	0.3351	938	151.30

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	50.0440	51.3593

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.2338	0.4723	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.49	0.6207	0.05	-0.6930	1.1606

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.311

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	51.5161	0.4402	542.9	117.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	50.6515	52.3808

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.311

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	50.3766	0.5669	547.6	88.86

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	49.2630	51.4903

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	1.1395	0.7071	547.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.61	0.1077	0.05	-0.2495	2.5285

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU user [redacted] rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9349.44780984	
1	2	9223.64748847	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	32.4357
UN(2,1)	USUBJID	15.9110
UN(2,2)	USUBJID	36.6793

Fit Statistics

-2 Res Log Likelihood	9223.6
AIC (Smaller is Better)	9229.6
AICC (Smaller is Better)	9229.7
BIC (Smaller is Better)	9244.4

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	125.80	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	725	2.41	0.0908
region(avisitn)	8	996	5.92	<.0001
PREOAD(avisitn)	2	704	0.21	0.8069
HBA1CG1(avisitn)	2	725	2.06	0.1282
base(avisitn)	2	726	417.98	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.009
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	50.6017	0.2609	938	193.98

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	50.0897	51.1136

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.009
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	49.8792	0.2651	938	188.13

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	49.3588	50.3995

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.7225	0.3735	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.93	0.0534	0.05	-0.01049	1.4555

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.009

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	49.7357	0.3286	571.5	151.37

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	49.0904	50.3811

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.009

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	49.8903	0.4172	579.6	119.60

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	49.0710	50.7096

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	-0.1546	0.5232	580.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.30	0.7677	0.05	-1.1823	0.8731

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/251009
NN9068-4228/253001
NN9068-4228/253002
NN9068-4228/253003
NN9068-4228/253005
NN9068-4228/253006
NN9068-4228/254001
NN9068-4228/254002
NN9068-4228/254003
NN9068-4228/254004
NN9068-4228/254005
NN9068-4228/254006
NN9068-4228/254007
NN9068-4228/254008
NN9068-4228/254009
NN9068-4228/255001
NN9068-4228/255002
NN9068-4228/255003
NN9068-4228/255004
NN9068-4228/255005
NN9068-4228/255006
NN9068-4228/256001
NN9068-4228/256002
NN9068-4228/256004
NN9068-4228/256005
NN9068-4228/256006
NN9068-4228/256007
NN9068-4228/256008
NN9068-4228/301001
NN9068-4228/301002
NN9068-4228/301003
NN9068-4228/301005
NN9068-4228/301006
NN9068-4228/301008
NN9068-4228/301010
NN9068-4228/301011
NN9068-4228/301014
NN9068-4228/301018
NN9068-4228/301021
NN9068-4228/301022
NN9068-4228/301023
NN9068-4228/301026
NN9068-4228/301027
NN9068-4228/302001
NN9068-4228/302003
NN9068-4228/302005
NN9068-4228/302006
NN9068-4228/302008
NN9068-4228/302009
NN9068-4228/302010
NN9068-4228/303001
NN9068-4228/303002
NN9068-4228/303003
NN9068-4228/303004
NN9068-4228/303005
NN9068-4228/303006
NN9068-4228/303007
NN9068-4228/303008
NN9068-4228/303010

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9626.54094000	
1	2	9500.89642614	0.00000908
2	1	9500.86500893	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	38.3905
UN(2,1)	USUBJID	20.2420
UN(2,2)	USUBJID	47.0142

Fit Statistics

-2 Res Log Likelihood	9500.9
AIC (Smaller is Better)	9506.9
AICC (Smaller is Better)	9506.9
BIC (Smaller is Better)	9521.6

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	125.68	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	709	0.24	0.7888
region(avisitn)	8	985	3.89	0.0002
PREOAD(avisitn)	2	687	0.76	0.4676
HBA1CG1(avisitn)	2	710	2.74	0.0655
base(avisitn)	2	718	376.87	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.557
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	49.8131	0.2838	938.1	175.53

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	49.2562	50.3700

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.557
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	49.5366	0.2885	938.1	171.69

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	48.9704	50.1029

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.2765	0.4064	938.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.68	0.4965	0.05	-0.5211	1.0740

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.557

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	49.1767	0.3710	562.6	132.54

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	48.4479	49.9055

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.557

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	48.9694	0.4694	579.3	104.31

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	48.0474	49.8915

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	0.2073	0.5894	576.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.35	0.7253	0.05	-0.9505	1.3650

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	10127.14291973	
1	2	10078.49956175	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	58.0707
UN(2,1)	USUBJID	17.2339
UN(2,2)	USUBJID	57.5441

Fit Statistics

-2 Res Log Likelihood	10078.5
AIC (Smaller is Better)	10084.5
AICC (Smaller is Better)	10084.5
BIC (Smaller is Better)	10099.3

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	48.64	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	726	0.28	0.7591
region(avisitn)	8	998	4.84	<.0001
PREOAD(avisitn)	2	706	2.03	0.1324
HBA1CG1(avisitn)	2	727	3.24	0.0398
base(avisitn)	2	726	216.74	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.188
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	48.9863	0.3492	938	140.30

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	48.3011	49.6715

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.188
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	48.6177	0.3550	938	136.94

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	47.9209	49.3145

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.3686	0.5004	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.74	0.4615	0.05	-0.6133	1.3505

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.188

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	49.6333	0.4207	538.2	117.97

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	48.8068	50.4598

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.188

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	49.5876	0.5435	540	91.24

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	48.5200	50.6552

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	0.04566	0.6759	540.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.07	0.9462	0.05	-1.2821	1.3734

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

               Class Level Information

Class         Levels    Values

USUBJID         1011    NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
                        NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU user [redacted]rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9741.51928749	
1	2	9686.77427064	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	43.0567
UN(2,1)	USUBJID	14.2056
UN(2,2)	USUBJID	46.9835

Fit Statistics

-2 Res Log Likelihood	9686.8
AIC (Smaller is Better)	9692.8
AICC (Smaller is Better)	9692.8
BIC (Smaller is Better)	9707.5

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	54.75	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	723	2.26	0.1056
region(avisitn)	8	995	6.17	<.0001
PREOAD(avisitn)	2	702	1.75	0.1740
HBA1CG1(avisitn)	2	724	2.68	0.0690
base(avisitn)	2	718	279.92	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.462
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	49.8323	0.3006	938	165.80

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	49.2425	50.4221

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.462
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	48.9319	0.3055	938	160.19

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	48.3324	49.5313

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.9004	0.4303	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.09	0.0367	0.05	0.05591	1.7450

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.462

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	49.5458	0.3795	539.8	130.57

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	48.8004	50.2911

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.462

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	49.4686	0.4901	542.7	100.93

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	48.5059	50.4314

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	0.07712	0.6098	543.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.13	0.8994	0.05	-1.1207	1.2750

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

              Class Level Information

Class        Levels    Values

USUBJID        1011    NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure



Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure



Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure



Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure



Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure



Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9817.25856655	
1	2	9779.43642860	0.00000001

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	44.7417
UN(2,1)	USUBJID	12.5073
UN(2,2)	USUBJID	50.6725

Fit Statistics

-2 Res Log Likelihood	9779.4
AIC (Smaller is Better)	9785.4
AICC (Smaller is Better)	9785.5
BIC (Smaller is Better)	9800.2

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	37.82	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	719	3.72	0.0246
region(avisitn)	8	992	3.74	0.0003
PREOAD(avisitn)	2	697	0.03	0.9673
HBA1CG1(avisitn)	2	721	0.86	0.4244
base(avisitn)	2	718	182.04	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.905
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	51.6632	0.3064	938.3	168.63

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	51.0620	52.2645

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.905
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	50.6227	0.3114	938.3	162.54

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	50.0115	51.2339

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	1.0405	0.4387	938.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.37	0.0179	0.05	0.1796	1.9015

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.905

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	50.7457	0.3962	531.4	128.08

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	49.9674	51.5240

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.905

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	51.3021	0.5135	533.9	99.90

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	50.2933	52.3109

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	-0.5564	0.6378	534

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.87	0.3834	0.05	-1.8094	0.6966

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9848.85627294	
1	2	9790.93512369	0.00000023
2	1	9790.93431454	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	46.5969
UN(2,1)	USUBJID	16.2101
UN(2,2)	USUBJID	50.4475

Fit Statistics

-2 Res Log Likelihood	9790.9
AIC (Smaller is Better)	9796.9
AICC (Smaller is Better)	9797.0
BIC (Smaller is Better)	9811.7

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	57.92	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	715	0.05	0.9491
region(avisitn)	8	989	7.83	<.0001
PREOAD(avisitn)	2	693	1.03	0.3562
HBA1CG1(avisitn)	2	716	1.02	0.3620
base(avisitn)	2	718	327.13	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	51.873
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	53.3101	0.3127	938	170.51

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	52.6965	53.9237

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	51.873
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	53.2902	0.3178	938	167.70

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	52.6665	53.9138

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.01990	0.4477	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.04	0.9646	0.05	-0.8587	0.8985

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	51.873

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	53.2036	0.3925	539.5	135.55

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	52.4326	53.9746

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	51.873

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	53.3919	0.5052	544.9	105.69

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	52.3996	54.3843

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	-0.1883	0.6293	544.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.30	0.7648	0.05	-1.4245	1.0478

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	10435.08860535	
1	2	10373.83331522	0.00000002
2	1	10373.83325253	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	68.8723
UN(2,1)	USUBJID	23.4874
UN(2,2)	USUBJID	76.1179

Fit Statistics

-2 Res Log Likelihood	10373.8
AIC (Smaller is Better)	10379.8
AICC (Smaller is Better)	10379.8
BIC (Smaller is Better)	10394.6

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	61.26	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	731	1.72	0.1800
region(avisitn)	8	1000	4.78	<.0001
PREOAD(avisitn)	2	709	0.84	0.4338
HBA1CG1(avisitn)	2	731	1.50	0.2246
base(avisitn)	2	719	227.42	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	50.583
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	1.3982	0.3801	938	3.68

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	0.0002	0.05	0.6522	2.1441

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	50.583
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	0.3997	0.3863	938	1.03

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.3011	0.05	-0.3585	1.1578

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.9985	0.5443	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.83	0.0669	0.05	-0.06963	2.0666

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	50.583

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	0.9870	0.4829	543.7	2.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	0.0415	0.05	0.03835	1.9356

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	50.583

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	0.8555	0.6238	545.2	1.37

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.1708	0.05	-0.3698	2.0809

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_BODILY_PAIN_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	0.1314	0.7773	546.5

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.17	0.8658	0.05	-1.3955	1.6584

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9903.96927451	
1	2	9799.89154231	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	46.8863
UN(2,1)	USUBJID	21.3377
UN(2,2)	USUBJID	54.8143

Fit Statistics

-2 Res Log Likelihood	9799.9
AIC (Smaller is Better)	9805.9
AICC (Smaller is Better)	9805.9
BIC (Smaller is Better)	9820.6

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	104.08	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	724	0.75	0.4730
region(avisitn)	8	995	6.44	<.0001
PREOAD(avisitn)	2	704	1.32	0.2681
HBA1CG1(avisitn)	2	725	0.12	0.8840
base(avisitn)	2	725	176.15	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	47.683
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	2.4344	0.3136	938	7.76

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	1.8189	3.0499

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	47.683
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	2.0667	0.3188	938	6.48

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	1.4412	2.6923

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.3677	0.4491	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.82	0.4131	0.05	-0.5136	1.2490

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	47.683

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	2.0781	0.4043	560.8	5.14

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	1.2839	2.8723

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	47.683

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	2.4687	0.5157	567.1	4.79

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	1.4557	3.4817

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_GENERAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	-0.3906	0.6455	567.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.61	0.5453	0.05	-1.6584	0.8772

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228/[redacted] NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9857.01505876	
1	2	9801.08887601	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	45.2294
UN(2,1)	USUBJID	15.2384
UN(2,2)	USUBJID	53.3717

Fit Statistics

-2 Res Log Likelihood	9801.1
AIC (Smaller is Better)	9807.1
AICC (Smaller is Better)	9807.1
BIC (Smaller is Better)	9821.8

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	55.93	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	723	0.26	0.7677
region(avisitn)	8	995	4.35	<.0001
PREOAD(avisitn)	2	702	0.22	0.7998
HBA1CG1(avisitn)	2	723	1.46	0.2328
base(avisitn)	2	719	237.44	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.795
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	1.3178	0.3080	938.1	4.28

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	0.7133	1.9223

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.795
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	1.0476	0.3131	938.1	3.35

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0009	0.05	0.4332	1.6620

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.2703	0.4411	938.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.61	0.5402	0.05	-0.5953	1.1358

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.795

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	1.8137	0.4048	538.8	4.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	1.0185	2.6089

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.795

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	1.4742	0.5223	541.6	2.82

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.0049	0.05	0.4482	2.5003

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	0.3395	0.6502	542.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.52	0.6018	0.05	-0.9377	1.6166

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	10074.59254513	
1	2	10005.06763351	0.00000003
2	1	10005.06751655	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	51.7917
UN(2,1)	USUBJID	19.7855
UN(2,2)	USUBJID	63.5428

Fit Statistics

-2 Res Log Likelihood	10005.1
AIC (Smaller is Better)	10011.1
AICC (Smaller is Better)	10011.1
BIC (Smaller is Better)	10025.8

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	69.53	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	720	1.30	0.2730
region(avisitn)	8	992	4.05	<.0001
PREOAD(avisitn)	2	698	0.29	0.7459
HBA1CG1(avisitn)	2	719	0.89	0.4095
base(avisitn)	2	713	216.20	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.311
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	1.6242	0.3297	938	4.93

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	0.9771	2.2713

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.311
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	1.3904	0.3351	938	4.15

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	0.7328	2.0481

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.2338	0.4723	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.49	0.6207	0.05	-0.6930	1.1606

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.311

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	2.2049	0.4402	542.9	5.01

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	1.3403	3.0696

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.311

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	1.0654	0.5669	547.6	1.88

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.0607	0.05	-0.04824	2.1791

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_MENTAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	1.1395	0.7071	547.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.61	0.1077	0.05	-0.2495	2.5285

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9349.44780984	
1	2	9223.64748847	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	32.4357
UN(2,1)	USUBJID	15.9110
UN(2,2)	USUBJID	36.6793

Fit Statistics

-2 Res Log Likelihood	9223.6
AIC (Smaller is Better)	9229.6
AICC (Smaller is Better)	9229.7
BIC (Smaller is Better)	9244.4

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	125.80	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	725	2.41	0.0908
region(avisitn)	8	996	5.92	<.0001
PREOAD(avisitn)	2	704	0.21	0.8069
HBA1CG1(avisitn)	2	725	2.06	0.1282
base(avisitn)	2	726	122.08	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.009
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	1.5924	0.2609	938	6.10

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	1.0804	2.1043

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.009
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	0.8698	0.2651	938	3.28

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0011	0.05	0.3495	1.3902

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.7225	0.3735	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.93	0.0534	0.05	-0.01049	1.4555

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.009

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	0.7264	0.3286	571.5	2.21

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	0.0274	0.05	0.08103	1.3718

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.009

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	0.8810	0.4172	579.6	2.11

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.0351	0.05	0.06167	1.7003

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_COMPONENT_SUMMARY

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	-0.1546	0.5232	580.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.30	0.7677	0.05	-1.1823	0.8731

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228 [redacted] NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
                                     NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9626.54094000	
1	2	9500.89642614	0.00000908
2	1	9500.86500893	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	38.3905
UN(2,1)	USUBJID	20.2420
UN(2,2)	USUBJID	47.0142

Fit Statistics

-2 Res Log Likelihood	9500.9
AIC (Smaller is Better)	9506.9
AICC (Smaller is Better)	9506.9
BIC (Smaller is Better)	9521.6

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	125.68	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	709	0.24	0.7888
region(avisitn)	8	985	3.89	0.0002
PREOAD(avisitn)	2	687	0.76	0.4676
HBA1CG1(avisitn)	2	710	2.74	0.0655
base(avisitn)	2	718	142.13	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.557
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	1.2559	0.2838	938.1	4.43

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	0.6990	1.8129

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.557
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	0.9795	0.2885	938.1	3.39

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0007	0.05	0.4132	1.5457

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.2765	0.4064	938.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.68	0.4965	0.05	-0.5211	1.0740

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.557

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	0.6195	0.3710	562.6	1.67

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	0.0955	0.05	-0.1093	1.3483

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.557

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	0.4123	0.4694	579.3	0.88

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.3802	0.05	-0.5097	1.3343

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_PHYSICAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	0.2073	0.5894	576.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.35	0.7253	0.05	-0.9505	1.3650

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure
```

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	10127.14291973	
1	2	10078.49956175	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	58.0707
UN(2,1)	USUBJID	17.2339
UN(2,2)	USUBJID	57.5441

Fit Statistics

-2 Res Log Likelihood	10078.5
AIC (Smaller is Better)	10084.5
AICC (Smaller is Better)	10084.5
BIC (Smaller is Better)	10099.3

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	48.64	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	726	0.28	0.7591
region(avisitn)	8	998	4.84	<.0001
PREOAD(avisitn)	2	706	2.03	0.1324
HBA1CG1(avisitn)	2	727	3.24	0.0398
base(avisitn)	2	726	233.52	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.188
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	0.7981	0.3492	938	2.29

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	0.0225	0.05	0.1128	1.4833

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.188
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	0.4295	0.3550	938	1.21

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.2267	0.05	-0.2673	1.1262

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.3686	0.5004	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.74	0.4615	0.05	-0.6133	1.3505

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.188

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	1.4451	0.4207	538.2	3.43

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	0.0006	0.05	0.6186	2.2716

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.188

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	1.3994	0.5435	540	2.57

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.0103	0.05	0.3318	2.4670

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_EMOTIONAL_PROBLEM_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	0.04566	0.6759	540.8

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.07	0.9462	0.05	-1.2821	1.3734

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9741.51928749	
1	2	9686.77427064	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	43.0567
UN(2,1)	USUBJID	14.2056
UN(2,2)	USUBJID	46.9835

Fit Statistics

-2 Res Log Likelihood	9686.8
AIC (Smaller is Better)	9692.8
AICC (Smaller is Better)	9692.8
BIC (Smaller is Better)	9707.5

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	54.75	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	723	2.26	0.1056
region(avisitn)	8	995	6.17	<.0001
PREOAD(avisitn)	2	702	1.75	0.1740
HBA1CG1(avisitn)	2	724	2.68	0.0690
base(avisitn)	2	718	209.64	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.462
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	1.3706	0.3006	938	4.56

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	0.7808	1.9604

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	48.462
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	0.4702	0.3055	938	1.54

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.1241	0.05	-0.1293	1.0697

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.9004	0.4303	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.09	0.0367	0.05	0.05591	1.7450

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.462

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	1.0841	0.3795	539.8	2.86

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	0.0044	0.05	0.3387	1.8295

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	48.462

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	1.0070	0.4901	542.7	2.05

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.0404	0.05	0.04419	1.9697

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_ROLE_PHYSICAL_HEALTH_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	0.07712	0.6098	543.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	0.13	0.8994	0.05	-1.1207	1.2750

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228/[redacted] NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9817.25856655	
1	2	9779.43642860	0.00000001

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	44.7417
UN(2,1)	USUBJID	12.5073
UN(2,2)	USUBJID	50.6725

Fit Statistics

-2 Res Log Likelihood	9779.4
AIC (Smaller is Better)	9785.4
AICC (Smaller is Better)	9785.5
BIC (Smaller is Better)	9800.2

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	37.82	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	719	3.72	0.0246
region(avisitn)	8	992	3.74	0.0003
PREOAD(avisitn)	2	697	0.03	0.9673
HBA1CG1(avisitn)	2	721	0.86	0.4244
base(avisitn)	2	718	324.12	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.905
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	1.7579	0.3064	938.3	5.74

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	1.1567	2.3592

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.905
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	0.7174	0.3114	938.3	2.30

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0215	0.05	0.1062	1.3286

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	1.0405	0.4387	938.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.37	0.0179	0.05	0.1796	1.9015

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.905

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	0.8404	0.3962	531.4	2.12

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	0.0344	0.05	0.06205	1.6187

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	49.905

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	1.3968	0.5135	533.9	2.72

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.0067	0.05	0.3880	2.4056

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_SOCIAL_FUNCTIONING_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	-0.5564	0.6378	534

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.87	0.3834	0.05	-1.8094	0.6966

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Model Information

Data Set	WORK.SF36_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1011	NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]
		NN9068-4228[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Health related quality of life (SF-36) scores after 26 and 104 weeks - change from
baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Health related quality of life (SF-36) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU user [redacted]rs
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	1011
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1472
Number of Observations Not Used	552

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	9848.85627294	
1	2	9790.93512369	0.00000023
2	1	9790.93431454	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	46.5969
UN(2,1)	USUBJID	16.2101
UN(2,2)	USUBJID	50.4475

Fit Statistics

-2 Res Log Likelihood	9790.9
AIC (Smaller is Better)	9796.9
AICC (Smaller is Better)	9797.0
BIC (Smaller is Better)	9811.7

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	57.92	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	715	0.05	0.9491
region(avisitn)	8	989	7.83	<.0001
PREOAD(avisitn)	2	693	1.03	0.3562
HBA1CG1(avisitn)	2	716	1.02	0.3620
base(avisitn)	2	718	209.93	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	51.873
base(avisitn)					130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.SF36_MMRM	1.4374	0.3127	938	4.60

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	0.8238	2.0509

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.088
region(avisitn)		Asia			70	0.091
region(avisitn)		Europe			70	0.4906
region(avisitn)		North America			70	0.1503
region(avisitn)		South America			70	0.18
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.3541
PREOAD(avisitn)			SU users		70	0.6459
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5312
HBA1CG1(avisitn)				>=8.5	70	0.4688
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	51.873
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.SF36_MMRM	1.4175	0.3178	938	4.46

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	0.7938	2.0411

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.SF36_MMRM	0.01990	0.4477	938

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	0.04	0.9646	0.05	-0.8587	0.8985

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	51.873

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.SF36_MMRM	1.3309	0.3925	539.5	3.39

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	0.0007	0.05	0.5599	2.1019

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.088
region(avisitn)		Asia			130	0.091
region(avisitn)		Europe			130	0.4906
region(avisitn)		North America			130	0.1503
region(avisitn)		South America			130	0.18
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.3541
PREOAD(avisitn)			SU users		130	0.6459
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5312
HBA1CG1(avisitn)				>=8.5	130	0.4688
base(avisitn)					70	
base(avisitn)					130	51.873

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.SF36_MMRM	1.5192	0.5052	544.9	3.01

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.0028	0.05	0.5269	2.5115

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Health related quality of life (SF-36) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=SF36V2_STD_SCORE_VITALITY_NBS

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.SF36_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.SF36_MMRM	-0.1883	0.6293	544.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.30	0.7648	0.05	-1.4245	1.0478

27: Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

```
topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

                  Model Information

Data Set                      WORK.TRIMD_MMRM
Dependent Variable            AVAL
Covariance Structure          Unstructured
Subject Effect                USUBJID
Estimation Method             REML
Residual Variance Method      None
Fixed Effects SE Method       Kenward-Roger
Degrees of Freedom Method     Kenward-Roger


               Class Level Information

Class        Levels    Values

treatment         2    IDegLira IGlar
region            5    Africa Asia Europe North
                       America South America
avisitn           2    70 130
```

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

```
                 Class Level Information

Class          Levels    Values

USUBJID           997    NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
                         NN9068-4228 [redacted]
```

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
                       NN9068-4228/[redacted]
```

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1448
Number of Observations Not Used	576

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	11618.25843043	
1	2	11571.89040621	0.00000002
2	1	11571.89030896	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	180.08
UN(2,1)	USUBJID	55.9488
UN(2,2)	USUBJID	192.34

Fit Statistics

-2 Res Log Likelihood	11571.9
AIC (Smaller is Better)	11577.9
AICC (Smaller is Better)	11577.9
BIC (Smaller is Better)	11592.6

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	46.37	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	707	3.63	0.0270
region(avisitn)	8	973	2.33	0.0178

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
PREOAD(avisitn)	2	685	1.61	0.2005
HBA1CG1(avisitn)	2	706	0.23	0.7970
base(avisitn)	2	702	79.66	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	76.977
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	87.8519	0.6183	924	142.08

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	86.6384	89.0654

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	76.977
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	85.8737	0.6313	924	136.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	84.6349	87.1126

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	1.9782	0.8877	924

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.23	0.0261	0.05	0.2360	3.7204

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	76.977

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	87.2443	0.7738	525.5	112.75

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	85.7242	88.7644

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	76.977

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	88.4848	1.0111	528.8	87.52

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	86.4986	90.4710

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	-1.2405	1.2531	529.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.99	0.3227	0.05	-3.7022	1.2212

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted] NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure



Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure



Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
```

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1448
Number of Observations Not Used	576

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	11699.29415927	
1	2	11653.77710382	0.00000007
2	1	11653.77677361	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	198.46
UN(2,1)	USUBJID	58.3804
UN(2,2)	USUBJID	189.53

Fit Statistics

-2 Res Log Likelihood	11653.8
AIC (Smaller is Better)	11659.8
AICC (Smaller is Better)	11659.8
BIC (Smaller is Better)	11674.5

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	45.52	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	704	1.45	0.2353
region(avisitn)	8	971	10.57	<.0001

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
PREOAD(avisitn)	2	682	5.24	0.0055
HBA1CG1(avisitn)	2	704	2.10	0.1235
base(avisitn)	2	711	115.57	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	80.761
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	84.1359	0.6490	924	129.65

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	82.8623	85.4095

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	80.761
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	83.1087	0.6631	924	125.33

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	81.8074	84.4101

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	1.0271	0.9322	924

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.10	0.2708	0.05	-0.8023	2.8565

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	80.761

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	84.8706	0.7691	524.8	110.35

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	83.3596	86.3815

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	80.761

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	86.1457	1.0027	528.6	85.91

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	84.1759	88.1155

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	-1.2751	1.2442	528.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.02	0.3059	0.05	-3.7192	1.1690

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

```
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
                          NN9068-4228[redacted]
PREOAD            2       Non-SU users SU users
HBA1CG1           2       <8.5 >=8.5
```

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1448
Number of Observations Not Used	576

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12368.40976159	
1	2	12246.48705036	0.00000053
2	1	12246.48451027	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	305.94
UN(2,1)	USUBJID	148.99
UN(2,2)	USUBJID	324.37

Fit Statistics

-2 Res Log Likelihood	12246.5
AIC (Smaller is Better)	12252.5
AICC (Smaller is Better)	12252.5
BIC (Smaller is Better)	12267.2

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	121.93	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	705	10.79	<.0001
region(avisitn)	8	972	1.83	0.0677

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
PREOAD(avisitn)	2	684	0.25	0.7768
HBA1CG1(avisitn)	2	706	0.25	0.7752
base(avisitn)	2	698	29.91	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.801
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	68.8408	0.8057	924	85.44

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	67.2595	70.4221

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.801
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	64.0075	0.8227	924	77.80

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	62.3928	65.6221

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	4.8334	1.1571	924

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	4.18	<.0001	0.05	2.5626	7.1042

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	49.801

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	71.5992	0.9814	557.2	72.96

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	69.6715	73.5269

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	49.801

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	66.2543	1.2546	569.4	52.81

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	63.7900	68.7186

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	5.3449	1.5698	568.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	3.40	0.0007	0.05	2.2616	8.4282

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]
NN9068-4228	[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1448
Number of Observations Not Used	576

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	11393.31582349	
1	2	11317.70552672	0.00000170
2	1	11317.69810181	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	163.02
UN(2,1)	USUBJID	60.2377
UN(2,2)	USUBJID	149.31

Fit Statistics

-2 Res Log Likelihood	11317.7
AIC (Smaller is Better)	11323.7
AICC (Smaller is Better)	11323.7
BIC (Smaller is Better)	11338.4

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	75.62	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	699	4.82	0.0084
region(avisitn)	8	967	4.00	0.0001

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
PREOAD(avisitn)	2	676	1.80	0.1657
HBA1CG1(avisitn)	2	699	2.86	0.0581
base(avisitn)	2	688	136.94	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	79.424
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	87.5306	0.5882	924	148.81

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	86.3762	88.6850

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	79.424
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	85.0185	0.6006	924	141.55

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	83.8398	86.1973

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	2.5120	0.8446	924

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.97	0.0030	0.05	0.8544	4.1696

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	79.424

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	89.2054	0.6750	534.8	132.15

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	87.8793	90.5314

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	79.424

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	87.3446	0.8735	543.9	99.99

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	85.6287	89.0604

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	1.8608	1.0876	542.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.71	0.0877	0.05	-0.2757	3.9973

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure



Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure



Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure



```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure



Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure



Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure



Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure



Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure



Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure



Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1448
Number of Observations Not Used	576

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	10754.63186588	
1	2	10640.22858972	0.00000055
2	1	10640.22638493	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	102.76
UN(2,1)	USUBJID	46.2106
UN(2,2)	USUBJID	98.3344

Fit Statistics

-2 Res Log Likelihood	10640.2
AIC (Smaller is Better)	10646.2
AICC (Smaller is Better)	10646.2
BIC (Smaller is Better)	10660.9

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	114.41	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	705	7.53	0.0006
region(avisitn)	8	972	4.29	<.0001

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
PREOAD(avisitn)	2	684	4.41	0.0125
HBA1CG1(avisitn)	2	705	1.29	0.2746
base(avisitn)	2	697	125.62	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	71.108
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	80.6677	0.4670	924	172.74

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	79.7512	81.5842

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	71.108
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	78.1346	0.4769	924	163.84

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	77.1987	79.0705

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	2.5331	0.6706	924

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	3.78	0.0002	0.05	1.2171	3.8491

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	71.108

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	82.3096	0.5414	553.8	152.02

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	81.2460	83.3731

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	71.108

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	80.4363	0.6937	565.2	115.96

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	79.0738	81.7988

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	1.8733	0.8673	564.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	2.16	0.0312	0.05	0.1697	3.5769

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	AVAL
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228
NN9068-4228

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure
```

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]
NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1449
Number of Observations Not Used	575

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12208.41965381	
1	2	12125.89988366	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	269.12
UN(2,1)	USUBJID	106.63
UN(2,2)	USUBJID	289.10

Fit Statistics

-2 Res Log Likelihood	12125.9
AIC (Smaller is Better)	12131.9
AICC (Smaller is Better)	12131.9
BIC (Smaller is Better)	12146.6

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	82.52	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	716	3.47	0.0316
region(avisitn)	8	982	3.23	0.0012
PREOAD(avisitn)	2	696	3.77	0.0236

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
HBA1CG1(avisitn)	2	717	0.62	0.5359
base(avisitn)	2	706	67.87	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	65.793
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	73.6407	0.7557	924.2	97.45

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	72.1576	75.1238

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	65.793
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	71.3885	0.7716	924.2	92.51

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	69.8741	72.9028

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	2.2522	1.0852	924.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.08	0.0382	0.05	0.1225	4.3820

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	65.793

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	76.6492	0.9392	544.7	81.61

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	74.8042	78.4941

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	65.793

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	73.4017	1.2136	548.1	60.48

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	71.0179	75.7855

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	3.2475	1.5105	549.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	2.15	0.0320	0.05	0.2804	6.2147

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1448
Number of Observations Not Used	576

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	11618.25843043	
1	2	11571.89040621	0.00000002
2	1	11571.89030896	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	180.08
UN(2,1)	USUBJID	55.9488
UN(2,2)	USUBJID	192.34

Fit Statistics

-2 Res Log Likelihood	11571.9
AIC (Smaller is Better)	11577.9
AICC (Smaller is Better)	11577.9
BIC (Smaller is Better)	11592.6

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	46.37	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	707	3.63	0.0270
region(avisitn)	8	973	2.33	0.0178

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
PREOAD(avisitn)	2	685	1.61	0.2005
HBA1CG1(avisitn)	2	706	0.23	0.7970
base(avisitn)	2	702	604.72	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	76.977
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	10.8751	0.6183	924	17.59

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	9.6616	12.0886

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	76.977
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	8.8968	0.6313	924	14.09

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	7.6580	10.1357

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	1.9782	0.8877	924

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.23	0.0261	0.05	0.2360	3.7204

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	76.977

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	10.2674	0.7738	525.5	13.27

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	8.7474	11.7875

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	76.977

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	11.5079	1.0111	528.8	11.38

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	9.5217	13.4942

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_COMPLIANCE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	-1.2405	1.2531	529.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-0.99	0.3227	0.05	-3.7022	1.2212

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1448
Number of Observations Not Used	576

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	11699.29415927	
1	2	11653.77710382	0.00000007
2	1	11653.77677361	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	198.46
UN(2,1)	USUBJID	58.3804
UN(2,2)	USUBJID	189.53

Fit Statistics

-2 Res Log Likelihood	11653.8
AIC (Smaller is Better)	11659.8
AICC (Smaller is Better)	11659.8
BIC (Smaller is Better)	11674.5

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	45.52	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	704	1.45	0.2353
region(avisitn)	8	971	10.57	<.0001

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
PREOAD(avisitn)	2	682	5.24	0.0055
HBA1CG1(avisitn)	2	704	2.10	0.1235
base(avisitn)	2	711	366.71	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	80.761
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	3.3754	0.6490	924	5.20

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	2.1017	4.6490

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	80.761
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	2.3482	0.6631	924	3.54

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.0004	0.05	1.0468	3.6496

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	1.0271	0.9322	924

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	1.10	0.2708	0.05	-0.8023	2.8565

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	80.761

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	4.1100	0.7691	524.8	5.34

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	2.5991	5.6210

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	80.761

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	5.3852	1.0027	528.6	5.37

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	3.4154	7.3549

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DAILY_LIFE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	-1.2751	1.2442	528.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	-1.02	0.3059	0.05	-3.7192	1.1690

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

```
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228 [redacted]
                                   NN9068-4228/[redacted]
PREOAD                  2          Non-SU users SU users
HBA1CG1                 2          <8.5 >=8.5
```

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1448
Number of Observations Not Used	576

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12368.40976159	
1	2	12246.48705036	0.00000053
2	1	12246.48451027	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	305.94
UN(2,1)	USUBJID	148.99
UN(2,2)	USUBJID	324.37

Fit Statistics

-2 Res Log Likelihood	12246.5
AIC (Smaller is Better)	12252.5
AICC (Smaller is Better)	12252.5
BIC (Smaller is Better)	12267.2

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	121.93	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	705	10.79	<.0001
region(avisitn)	8	972	1.83	0.0677

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
PREOAD(avisitn)	2	684	0.25	0.7768
HBA1CG1(avisitn)	2	706	0.25	0.7752
base(avisitn)	2	698	536.14	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.801
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	19.0394	0.8057	924	23.63

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	17.4581	20.6207

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	49.801
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	14.2060	0.8227	924	17.27

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	12.5914	15.8207

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	4.8334	1.1571	924

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	4.18	<.0001	0.05	2.5626	7.1042

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	49.801

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	21.7978	0.9814	557.2	22.21

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	19.8701	23.7255

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	49.801

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	16.4528	1.2546	569.4	13.11

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	13.9886	18.9171

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_DIAB_MAN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	5.3449	1.5698	568.4

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	3.40	0.0007	0.05	2.2616	8.4282

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

NN9068-4228/[redacted]

PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1448
Number of Observations Not Used	576

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	11393.31582349	
1	2	11317.70552672	0.00000170
2	1	11317.69810181	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	163.02
UN(2,1)	USUBJID	60.2377
UN(2,2)	USUBJID	149.31

Fit Statistics

-2 Res Log Likelihood	11317.7
AIC (Smaller is Better)	11323.7
AICC (Smaller is Better)	11323.7
BIC (Smaller is Better)	11338.4

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	75.62	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	699	4.82	0.0084
region(avisitn)	8	967	4.00	0.0001

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
PREOAD(avisitn)	2	676	1.80	0.1657
HBA1CG1(avisitn)	2	699	2.86	0.0581
base(avisitn)	2	688	436.23	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	79.424
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	8.1070	0.5882	924	13.78

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	6.9526	9.2614

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	79.424
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	5.5950	0.6006	924	9.32

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	4.4162	6.7737

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	2.5120	0.8446	924

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.97	0.0030	0.05	0.8544	4.1696

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	79.424

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	9.7818	0.6750	534.8	14.49

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	8.4557	11.1078

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	79.424

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	7.9210	0.8735	543.9	9.07

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	6.2052	9.6369

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_PSYCH_HEALTH

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	1.8608	1.0876	542.9

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	1.71	0.0877	0.05	-0.2757	3.9973

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]
		NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1448
Number of Observations Not Used	576

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	10754.63186588	
1	2	10640.22858972	0.00000055
2	1	10640.22638493	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	102.76
UN(2,1)	USUBJID	46.2106
UN(2,2)	USUBJID	98.3344

Fit Statistics

-2 Res Log Likelihood	10640.2
AIC (Smaller is Better)	10646.2
AICC (Smaller is Better)	10646.2
BIC (Smaller is Better)	10660.9

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	114.41	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	705	7.53	0.0006
region(avisitn)	8	972	4.29	<.0001

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
PREOAD(avisitn)	2	684	4.41	0.0125
HBA1CG1(avisitn)	2	705	1.29	0.2746
base(avisitn)	2	697	315.23	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	71.108
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	9.5595	0.4670	924	20.47

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	8.6430	10.4760

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	71.108
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	7.0264	0.4769	924	14.73

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	6.0905	7.9623

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	2.5331	0.6706	924

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	3.78	0.0002	0.05	1.2171	3.8491

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	71.108

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	11.2014	0.5414	553.8	20.69

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	10.1378	12.2649

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	71.108

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	9.3281	0.6937	565.2	13.45

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	7.9656	10.6906

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TOTAL

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	1.8733	0.8673	564.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	2.16	0.0312	0.05	0.1697	3.5769

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Model Information

Data Set	WORK.TRIMD_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	2	70 130

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	997	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks -
change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Treatment related impact measures - diabetes (TRIM-D) scores after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/
NN9068-4228/

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

		NN9068-4228/[redacted]
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Dimensions

Covariance Parameters	3
Columns in X	25
Columns in Z	0
Subjects	997
Max Obs per Subject	2

Number of Observations

Number of Observations Read	2024
Number of Observations Used	1449
Number of Observations Not Used	575

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	12208.41965381	
1	2	12125.89988366	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	269.12
UN(2,1)	USUBJID	106.63
UN(2,2)	USUBJID	289.10

Fit Statistics

-2 Res Log Likelihood	12125.9
AIC (Smaller is Better)	12131.9
AICC (Smaller is Better)	12131.9
BIC (Smaller is Better)	12146.6

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	82.52	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	2	716	3.47	0.0316
region(avisitn)	8	982	3.23	0.0012
PREOAD(avisitn)	2	696	3.77	0.0236

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
HBA1CG1(avisitn)	2	717	0.62	0.5359
base(avisitn)	2	706	352.51	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	65.793
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.TRIMD_MMRM	7.8482	0.7557	924.2	10.39

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	6.3651	9.3313

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	0.0853
region(avisitn)		Asia			70	0.0923
region(avisitn)		Europe			70	0.4875
region(avisitn)		North America			70	0.1525
region(avisitn)		South America			70	0.1825
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	0.349
PREOAD(avisitn)			SU users		70	0.651
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	0.5296
HBA1CG1(avisitn)				>=8.5	70	0.4704
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	65.793
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.TRIMD_MMRM	5.5960	0.7716	924.2	7.25

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	4.0816	7.1103

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				130	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.TRIMD_MMRM	2.2522	1.0852	924.2

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	2.08	0.0382	0.05	0.1225	4.3820

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	65.793

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.TRIMD_MMRM	10.8567	0.9392	544.7	11.56

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	9.0117	12.7016

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	0.0853
region(avisitn)		Asia			130	0.0923

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			130	0.4875
region(avisitn)		North America			130	0.1525
region(avisitn)		South America			130	0.1825
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	0.349
PREOAD(avisitn)			SU users		130	0.651
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	0.5296
HBA1CG1(avisitn)				>=8.5	130	0.4704
base(avisitn)					70	
base(avisitn)					130	65.793

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.TRIMD_MMRM	7.6092	1.2136	548.1	6.27

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	5.2254	9.9930

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		70	

Treatment related impact measures – diabetes (TRIM-D) scores after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=TRIM_D_TREAT_BURDEN

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.TRIMD_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					70	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.TRIMD_MMRM	3.2475	1.5105	549.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	2.15	0.0320	0.05	0.2804	6.2147

28: Hypoglycaemic episodes during 26 weeks of treatment – treatment emergent – supportive statistical analysis – full analysis set

The GENMOD Procedure

Model Information

Data Set	WORK.HYPODATA
Distribution	Negative Binomial
Link Function	Log
Dependent Variable	tot_hypos Analysis Value
Offset Variable	log_offset

Number of Observations Read	1012
Number of Observations Used	1010
Missing Values	2

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
HBA1CG1	2	<8.5 >=8.5
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America

Parameter Information

Parameter	Effect	ARM	HBA1CG1	PREOAD	REGION1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1		<8.5		
Prm5	HBA1CG1		>=8.5		
Prm6	PREOAD			Non-SU users	
Prm7	PREOAD			SU users	
Prm8	REGION1				Africa
Prm9	REGION1				Asia
Prm10	REGION1				Europe
Prm11	REGION1				North America
Prm12	REGION1				South America

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Deviance	1002	473.4429	0.4725
Scaled Deviance	1002	473.4429	0.4725
Pearson Chi-Square	1002	1230.6943	1.2282
Scaled Pearson X2	1002	1230.6943	1.2282
Log Likelihood		-452.2800	
Full Log Likelihood		-733.8413	
AIC (smaller is better)		1485.6826	
AICC (smaller is better)		1485.8626	
BIC (smaller is better)		1529.9419	

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	4.9207	0.2334	4.4632	5.3782	444.33	<.0001
ARM	IDegLira	1	-0.5720	0.1880	-0.9404	-0.2036	9.26	0.0023
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	0.0814	0.2001	-0.3108	0.4737	0.17	0.6840

Hypoglycaemic episodes during 26 weeks of treatment – treatment emergent – supportive statistical analysis – full analysis set

The GENMOD Procedure

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	-0.3766	0.2097	-0.7876	0.0345	3.22	0.0726
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	-0.7164	0.4037	-1.5075	0.0748	3.15	0.0760
REGION1	Asia	1	0.0161	0.3713	-0.7116	0.7438	0.00	0.9654
REGION1	Europe	1	-0.2607	0.2543	-0.7592	0.2377	1.05	0.3053
REGION1	North America	1	-0.1210	0.3130	-0.7345	0.4926	0.15	0.6992
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
Dispersion		1	5.7721	0.7018	4.5483	7.3252		

NOTE: The negative binomial dispersion parameter was estimated by maximum likelihood.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	3.9847	0.1612	24.73	<.0001	0.05	3.6689	4.3006	53.7699
IGlar	4.5567	0.1490	30.59	<.0001	0.05	4.2648	4.8487	95.2722

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	39.2072	73.7418
IGlar	71.1506	127.57

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	-0.5720	0.1880	-3.04	0.0023	0.05	-0.9404	-0.2036

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	0.5644	0.3905	0.8158

29: Hypoglycaemic episodes during 104 weeks of treatment – treatment emergent – supportive statistical analysis – full analysis set

The GENMOD Procedure

Model Information

Data Set	WORK.HYPODATA
Distribution	Negative Binomial
Link Function	Log
Dependent Variable	tot_hypos Analysis Value
Offset Variable	log_offset

Number of Observations Read	1012
Number of Observations Used	1010
Missing Values	2

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
HBA1CG1	2	<8.5 >=8.5
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America

Parameter Information

Parameter	Effect	ARM	HBA1CG1	PREOAD	REGION1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1		<8.5		
Prm5	HBA1CG1		>=8.5		
Prm6	PREOAD			Non-SU users	
Prm7	PREOAD			SU users	
Prm8	REGION1				Africa
Prm9	REGION1				Asia
Prm10	REGION1				Europe
Prm11	REGION1				North America
Prm12	REGION1				South America

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Deviance	1002	646.9615	0.6457
Scaled Deviance	1002	646.9615	0.6457
Pearson Chi-Square	1002	1529.2830	1.5262
Scaled Pearson X2	1002	1529.2830	1.5262
Log Likelihood		-9.5523	
Full Log Likelihood		-1115.2797	
AIC (smaller is better)		2248.5593	
AICC (smaller is better)		2248.7393	
BIC (smaller is better)		2292.8187	

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	4.9349	0.1916	4.5594	5.3104	663.55	<.0001
ARM	IDegLira	1	-0.8139	0.1530	-1.1138	-0.5140	28.29	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.1565	0.1600	-0.4701	0.1572	0.96	0.3282

Hypoglycaemic episodes during 104 weeks of treatment - treatment emergent - supportive statistical analysis - full analysis set

The GENMOD Procedure

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	-0.3177	0.1679	-0.6468	0.0115	3.58	0.0585
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	-0.4941	0.3174	-1.1163	0.1281	2.42	0.1196
REGION1	Asia	1	-0.3781	0.3190	-1.0034	0.2473	1.40	0.2360
REGION1	Europe	1	-0.3501	0.2103	-0.7623	0.0621	2.77	0.0960
REGION1	North America	1	0.0266	0.2575	-0.4782	0.5313	0.01	0.9179
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
Dispersion		1	4.2167	0.3839	3.5276	5.0406		

NOTE: The negative binomial dispersion parameter was estimated by maximum likelihood.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	3.6448	0.1334	27.32	<.0001	0.05	3.3833	3.9062	38.2746
IGlar	4.4587	0.1191	37.43	<.0001	0.05	4.2252	4.6921	86.3722

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	29.4688	49.7117
IGlar	68.3875	109.09

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	-0.8139	0.1530	-5.32	<.0001	0.05	-1.1138	-0.5140

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	0.4431	0.3283	0.5981

30: Nocturnal hypoglycaemic episodes during 26 weeks of treatment – treatment emergent – supportive statistical analysis – full analysis set

The GENMOD Procedure

Model Information

Data Set	WORK.HYPODATA
Distribution	Negative Binomial
Link Function	Log
Dependent Variable	tot_hypos
Offset Variable	log_offset

Analysis Value

Number of Observations Read	1012
Number of Observations Used	1010
Missing Values	2

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
HBA1CG1	2	<8.5 >=8.5
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America

Parameter Information

Parameter	Effect	ARM	HBA1CG1	PREOAD	REGION1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1		<8.5		
Prm5	HBA1CG1		>=8.5		
Prm6	PREOAD			Non-SU users	
Prm7	PREOAD			SU users	
Prm8	REGION1				Africa
Prm9	REGION1				Asia
Prm10	REGION1				Europe
Prm11	REGION1				North America
Prm12	REGION1				South America

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Deviance	1002	212.1280	0.2117
Scaled Deviance	1002	212.1280	0.2117
Pearson Chi-Square	1002	1061.0464	1.0589
Scaled Pearson X2	1002	1061.0464	1.0589
Log Likelihood		-242.2136	
Full Log Likelihood		-269.7583	
AIC (smaller is better)		557.5165	
AICC (smaller is better)		557.6965	
BIC (smaller is better)		601.7759	

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	3.4413	0.3517	2.7519	4.1307	95.72	<.0001
ARM	IDegLira	1	-0.8015	0.3119	-1.4129	-0.1902	6.60	0.0102
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	0.0999	0.3161	-0.5198	0.7195	0.10	0.7521

Nocturnal hypoglycaemic episodes during 26 weeks of treatment - treatment emergent - supportive statistical analysis - full analysis set

The GENMOD Procedure

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	-0.6730	0.3468	-1.3528	0.0068	3.77	0.0523
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	-0.2702	0.6268	-1.4986	0.9583	0.19	0.6664
REGION1	Asia	1	-0.6659	0.6450	-1.9300	0.5982	1.07	0.3018
REGION1	Europe	1	-0.1320	0.4025	-0.9209	0.6568	0.11	0.7429
REGION1	North America	1	0.1497	0.4800	-0.7911	1.0904	0.10	0.7552
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
Dispersion		1	8.7385	2.3679	5.1379	14.8626		

NOTE: The negative binomial dispersion parameter was estimated by maximum likelihood.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	2.1695	0.2883	7.53	<.0001	0.05	1.6045	2.7345	8.7538
IGlar	2.9710	0.2345	12.67	<.0001	0.05	2.5114	3.4306	19.5121

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	4.9752	15.4022
IGlar	12.3228	30.8957

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	-0.8015	0.3119	-2.57	0.0102	0.05	-1.4129	-0.1902

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	0.4486	0.2434	0.8268

31: Nocturnal hypoglycaemic episodes during 104 weeks of treatment – treatment emergent – supportive statistical analysis – full analysis set

The GENMOD Procedure

Model Information

Data Set	WORK.HYPODATA
Distribution	Negative Binomial
Link Function	Log
Dependent Variable	tot_hypos
Offset Variable	log_offset

Analysis Value

Number of Observations Read	1012
Number of Observations Used	1010
Missing Values	2

Class Level Information

Class	Levels	Values
ARM	2	IDegLira IGlar
HBA1CG1	2	<8.5 >=8.5
PREOAD	2	Non-SU users SU users
REGION1	5	Africa Asia Europe North America South America

Parameter Information

Parameter	Effect	ARM	HBA1CG1	PREOAD	REGION1
Prm1	Intercept				
Prm2	ARM	IDegLira			
Prm3	ARM	IGlar			
Prm4	HBA1CG1		<8.5		
Prm5	HBA1CG1		>=8.5		
Prm6	PREOAD			Non-SU users	
Prm7	PREOAD			SU users	
Prm8	REGION1				Africa
Prm9	REGION1				Asia
Prm10	REGION1				Europe
Prm11	REGION1				North America
Prm12	REGION1				South America

Criteria For Assessing Goodness Of Fit

Criterion	DF	Value	Value/DF
Deviance	1002	326.4340	0.3258
Scaled Deviance	1002	326.4340	0.3258
Pearson Chi-Square	1002	1388.2990	1.3855
Scaled Pearson X2	1002	1388.2990	1.3855
Log Likelihood		-321.4784	
Full Log Likelihood		-471.2374	
AIC (smaller is better)		960.4749	
AICC (smaller is better)		960.6549	
BIC (smaller is better)		1004.7342	

Algorithm converged.

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
Intercept		1	3.2191	0.2936	2.6435	3.7946	120.18	<.0001
ARM	IDegLira	1	-1.1412	0.2388	-1.6092	-0.6732	22.84	<.0001
ARM	IGlar	0	0.0000	0.0000	0.0000	0.0000		
HBA1CG1	<8.5	1	-0.0275	0.2444	-0.5066	0.4516	0.01	0.9104

Nocturnal hypoglycaemic episodes during 104 weeks of treatment - treatment emergent - supportive statistical analysis - full analysis set

The GENMOD Procedure

Analysis Of Maximum Likelihood Parameter Estimates

Parameter		DF	Estimate	Standard Error	Wald 95% Confidence Limits		Wald Chi-Square	Pr > ChiSq
HBA1CG1	>=8.5	0	0.0000	0.0000	0.0000	0.0000		
PREOAD	Non-SU users	1	-0.2472	0.2541	-0.7452	0.2508	0.95	0.3306
PREOAD	SU users	0	0.0000	0.0000	0.0000	0.0000		
REGION1	Africa	1	0.0119	0.4871	-0.9428	0.9665	0.00	0.9806
REGION1	Asia	1	-0.5515	0.5300	-1.5902	0.4873	1.08	0.2981
REGION1	Europe	1	0.0139	0.3361	-0.6448	0.6726	0.00	0.9670
REGION1	North America	1	0.5127	0.3897	-0.2510	1.2765	1.73	0.1883
REGION1	South America	0	0.0000	0.0000	0.0000	0.0000		
Dispersion		1	7.1026	1.1771	5.1327	9.8284		

NOTE: The negative binomial dispersion parameter was estimated by maximum likelihood.

ARM Least Squares Means

Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper	Exponentiated
IDegLira	1.9379	0.2179	8.89	<.0001	0.05	1.5109	2.3649	6.9441
IGlar	3.0791	0.1776	17.34	<.0001	0.05	2.7310	3.4272	21.7395

ARM Least Squares Means

Description of Planned Arm	Exponentiated Lower	Exponentiated Upper
IDegLira	4.5307	10.6431
IGlar	15.3489	30.7909

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Estimate	Standard Error	z Value	Pr > |z|	Alpha	Lower	Upper
IDegLira	IGlar	-1.1412	0.2388	-4.78	<.0001	0.05	-1.6092	-0.6732

Differences of ARM Least Squares Means

Description of Planned Arm	Description of Planned Arm	Exponentiated	Exponentiated Lower	Exponentiated Upper
IDegLira	IGlar	0.3194	0.2000	0.5101

32: Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

```
topic_cd=PULSE

The Mixed Procedure

                  Model Information

Data Set                      WORK.PULSE_MMRM
Dependent Variable            AVAL
Covariance Structure          Unstructured
Subject Effect                USUBJID
Estimation Method             REML
Residual Variance Method      None
Fixed Effects SE Method       Kenward-Roger
Degrees of Freedom Method     Kenward-Roger


               Class Level Information

Class        Levels    Values

treatment         2    IDegLira IGlar
region            5    Africa Asia Europe North
                       America South America
avisitn           5    60 70 90 110 130
```

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228 [redacted] NN9068-4228 [redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis -
full analysis set

topic_cd=PULSE

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis -
full analysis set

topic_cd=PULSE

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

```
Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis -
full analysis set

topic_cd=PULSE

The Mixed Procedure
```

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

		NN9068-4228/[redacted]
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
		NN9068-4228/
PREOAD	2	Non-SU users SU users
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	15
Columns in X	61
Columns in Z	0
Subjects	1012
Max Obs per Subject	5

Number of Observations

Number of Observations Read	5060
Number of Observations Used	3717
Number of Observations Not Used	1343

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	25595.68790525	
1	2	24931.69396180	0.00000051
2	1	24931.68931398	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	56.4694
UN(2,1)	USUBJID	23.4306
UN(2,2)	USUBJID	54.8776
UN(3,1)	USUBJID	20.8954
UN(3,2)	USUBJID	26.4917
UN(3,3)	USUBJID	61.0101
UN(4,1)	USUBJID	20.0978
UN(4,2)	USUBJID	22.4397
UN(4,3)	USUBJID	27.2562
UN(4,4)	USUBJID	58.8778

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(5,1)	USUBJID	17.3142
UN(5,2)	USUBJID	19.0147
UN(5,3)	USUBJID	22.5999
UN(5,4)	USUBJID	22.2357
UN(5,5)	USUBJID	64.5636

Fit Statistics

-2 Res Log Likelihood	24931.7
AIC (Smaller is Better)	24961.7
AICC (Smaller is Better)	24961.8
BIC (Smaller is Better)	25035.5

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
14	664.00	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	5	766	10.07	<.0001
region(avisitn)	20	1626	2.12	0.0027
PREOAD(avisitn)	5	733	1.35	0.2418
HBA1CG1(avisitn)	5	766	1.57	0.1674
base(avisitn)	5	745	155.98	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	75.418
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.PULSE_MMRM	77.4802	0.3414	963.7	226.97

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	<.0001	0.05	76.8103	78.1501

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	75.418
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.PULSE_MMRM	74.9480	0.3438	963	218.00

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	<.0001	0.05	74.2733	75.6227

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.PULSE_MMRM	2.5322	0.4868	963.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	5.20	<.0001	0.05	1.5769	3.4874

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	75.418
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.PULSE_MMRM	77.6207	0.3390	942.2	228.96

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	76.9553	78.2860

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	75.418
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.PULSE_MMRM	74.9151	0.3436	945.8	218.02

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	<.0001	0.05	74.2408	75.5895

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.PULSE_MMRM	2.7055	0.4850	944

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	5.58	<.0001	0.05	1.7537	3.6574

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	75.418
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.PULSE_MMRM	78.5291	0.3876	724.3	202.58

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	77.7681	79.2902

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	75.418
base(avisitn)					110	
base(avisitn)					130	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.PULSE_MMRM	75.5909	0.4425	760.4	170.82

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	<.0001	0.05	74.7222	76.4595

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.PULSE_MMRM	2.9383	0.5872	745.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	5.00	<.0001	0.05	1.7856	4.0909

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	75.418
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.PULSE_MMRM	77.0730	0.4019	639.2	191.75

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	76.2837	77.8623

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	75.418
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.PULSE_MMRM	75.1118	0.4842	662.1	155.12

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	<.0001	0.05	74.1610	76.0625

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.PULSE_MMRM	1.9612	0.6239	654.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	3.14	0.0017	0.05	0.7361	3.1863

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	75.418

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.PULSE_MMRM	77.5168	0.4407	555	175.90

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	76.6512	78.3825

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	75.418

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.PULSE_MMRM	74.8166	0.5640	566.1	132.64

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	<.0001	0.05	73.7087	75.9245

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.PULSE_MMRM	2.7002	0.7054	563.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	3.83	0.0001	0.05	1.3146	4.0858

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Model Information

Data Set	WORK.PULSE_MMRM
Dependent Variable	CHG
Covariance Structure	Unstructured
Subject Effect	USUBJID
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Kenward-Roger
Degrees of Freedom Method	Kenward-Roger

Class Level Information

Class	Levels	Values
treatment	2	IDegLira IGlar
region	5	Africa Asia Europe North America South America
avisitn	5	60 70 90 110 130

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Class Level Information

Class	Levels	Values
USUBJID	1012	NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]
		NN9068-4228 [redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

```
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
```

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]

```
Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis -
full analysis set

topic_cd=PULSE

The Mixed Procedure

                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
                  NN9068-4228/[redacted]
```

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]
NN9068-4228/[redacted]

Pulse after 26 and 104 weeks - change from baseline - supportive statistical analysis - full analysis set

topic_cd=PULSE

The Mixed Procedure

		NN9068-4228 [redacted]
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
		NN9068-4228
PREOAD	2	Non-SU users ers
HBA1CG1	2	<8.5 >=8.5

Dimensions

Covariance Parameters	15
Columns in X	61
Columns in Z	0
Subjects	1012
Max Obs per Subject	5

Number of Observations

Number of Observations Read	5060
Number of Observations Used	3717
Number of Observations Not Used	1343

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	25595.68790525	
1	2	24931.69396180	0.00000051
2	1	24931.68931398	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(1,1)	USUBJID	56.4694
UN(2,1)	USUBJID	23.4306
UN(2,2)	USUBJID	54.8776
UN(3,1)	USUBJID	20.8954
UN(3,2)	USUBJID	26.4917
UN(3,3)	USUBJID	61.0101
UN(4,1)	USUBJID	20.0978
UN(4,2)	USUBJID	22.4397
UN(4,3)	USUBJID	27.2562
UN(4,4)	USUBJID	58.8778

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Covariance Parameter Estimates

Cov Parm	Subject	Estimate
UN(5,1)	USUBJID	17.3142
UN(5,2)	USUBJID	19.0147
UN(5,3)	USUBJID	22.5999
UN(5,4)	USUBJID	22.2357
UN(5,5)	USUBJID	64.5636

Fit Statistics

-2 Res Log Likelihood	24931.7
AIC (Smaller is Better)	24961.7
AICC (Smaller is Better)	24961.8
BIC (Smaller is Better)	25035.5

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
14	664.00	<.0001

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
treatment(avisitn)	5	766	10.07	<.0001
region(avisitn)	20	1626	2.12	0.0027
PREOAD(avisitn)	5	733	1.35	0.2418
HBA1CG1(avisitn)	5	766	1.57	0.1674
base(avisitn)	5	745	130.40	<.0001

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	75.418
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IDegLira	WORK.PULSE_MMRM	2.0626	0.3414	963.7	6.04

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira	<.0001	0.05	1.3927	2.7325

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	0.0879
region(avisitn)		Asia			60	0.0909
region(avisitn)		Europe			60	0.4911
region(avisitn)		North America			60	0.1502
region(avisitn)		South America			60	0.1798
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	0.3538
PREOAD(avisitn)			SU users		60	0.6462

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	0.5306
HBA1CG1(avisitn)				>=8.5	60	0.4694
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	75.418
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V060 IGlar	WORK.PULSE_MMRM	-0.4695	0.3438	963	-1.37

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IGlar	0.1723	0.05	-1.1442	0.2051

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	1
treatment(avisitn)	IGlar				60	-1
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V060 IDegLira - IGlar	WORK.PULSE_MMRM	2.5322	0.4868	963.3

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V060 IDegLira - IGlar	5.20	<.0001	0.05	1.5769	3.4874

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	75.418
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IDegLira	WORK.PULSE_MMRM	2.2031	0.3390	942.2	6.50

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira	<.0001	0.05	1.5378	2.8684

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	0.0879
region(avisitn)		Asia			70	0.0909
region(avisitn)		Europe			70	0.4911
region(avisitn)		North America			70	0.1502
region(avisitn)		South America			70	0.1798
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	0.3538
PREOAD(avisitn)			SU users		70	0.6462
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	0.5306
HBA1CG1(avisitn)				>=8.5	70	0.4694
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	75.418
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V070 IGlar	WORK.PULSE_MMRM	-0.5024	0.3436	945.8	-1.46

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IGlar	0.1440	0.05	-1.1767	0.1719

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	1
treatment(avisitn)	IGlar				70	-1
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V070 IDegLira - IGlar	WORK.PULSE_MMRM	2.7055	0.4850	944

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V070 IDegLira - IGlar	5.58	<.0001	0.05	1.7537	3.6574

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	75.418
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IDegLira	WORK.PULSE_MMRM	3.1116	0.3876	724.3	8.03

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira	<.0001	0.05	2.3505	3.8726

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	0.0879
region(avisitn)		Asia			90	0.0909
region(avisitn)		Europe			90	0.4911
region(avisitn)		North America			90	0.1502
region(avisitn)		South America			90	0.1798
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	0.3538
PREOAD(avisitn)			SU users		90	0.6462
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	0.5306
HBA1CG1(avisitn)				>=8.5	90	0.4694
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	75.418
base(avisitn)					110	
base(avisitn)					130	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V090 IGlar	WORK.PULSE_MMRM	0.1733	0.4425	760.4	0.39

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IGlar	0.6954	0.05	-0.6954	1.0420

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	1
treatment(avisitn)	IGlar				90	-1
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V090 IDegLira - IGlar	WORK.PULSE_MMRM	2.9383	0.5872	745.6

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V090 IDegLira - IGlar	5.00	<.0001	0.05	1.7856	4.0909

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
base(avisitn)					90	
base(avisitn)					110	75.418
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IDegLira	WORK.PULSE_MMRM	1.6554	0.4019	639.2	4.12

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira	<.0001	0.05	0.8661	2.4447

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Africa			110	0.0879
region(avisitn)		Asia			110	0.0909
region(avisitn)		Europe			110	0.4911
region(avisitn)		North America			110	0.1502
region(avisitn)		South America			110	0.1798
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	0.3538
PREOAD(avisitn)			SU users		110	0.6462
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	0.5306
HBA1CG1(avisitn)				>=8.5	110	0.4694
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	75.418
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V110 IGlar	WORK.PULSE_MMRM	-0.3058	0.4842	662.1	-0.63

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IGlar	0.5279	0.05	-1.2566	0.6450

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	1
treatment(avisitn)	IGlar				110	-1
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V110 IDegLira - IGlar	WORK.PULSE_MMRM	1.9612	0.6239	654.1

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V110 IDegLira - IGlar	3.14	0.0017	0.05	0.7361	3.1863

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	75.418

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IDegLira	WORK.PULSE_MMRM	2.0993	0.4407	555	4.76

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira	<.0001	0.05	1.2337	2.9649

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						1
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	
treatment(avisitn)	IGlar				130	1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	0.0879
region(avisitn)		Asia			130	0.0909
region(avisitn)		Europe			130	0.4911
region(avisitn)		North America			130	0.1502
region(avisitn)		South America			130	0.1798
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	0.3538

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
PREOAD(avisitn)			SU users		130	0.6462
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	0.5306
HBA1CG1(avisitn)				>=8.5	130	0.4694
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	75.418

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF	t Value
treatment(avisitn)	V130 IGlar	WORK.PULSE_MMRM	-0.6009	0.5640	566.1	-1.07

Least Squares Means Estimate

Effect	Label	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IGlar	0.2872	0.05	-1.7088	0.5070

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
Intercept						
treatment(avisitn)	IDegLira				60	
treatment(avisitn)	IGlar				60	
treatment(avisitn)	IDegLira				70	
treatment(avisitn)	IGlar				70	
treatment(avisitn)	IDegLira				90	
treatment(avisitn)	IGlar				90	
treatment(avisitn)	IDegLira				110	
treatment(avisitn)	IGlar				110	
treatment(avisitn)	IDegLira				130	1
treatment(avisitn)	IGlar				130	-1
region(avisitn)		Africa			60	
region(avisitn)		Asia			60	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Coefficients for treatment(avisitn) Least Squares Means Estimates Using WORK.PULSE_MMRM Margins

Effect	treatment	Geographic Region 1	Pre Trial OAD	HbA1c at Baseline Group 1	avisitn	Row1
region(avisitn)		Europe			60	
region(avisitn)		North America			60	
region(avisitn)		South America			60	
region(avisitn)		Africa			70	
region(avisitn)		Asia			70	
region(avisitn)		Europe			70	
region(avisitn)		North America			70	
region(avisitn)		South America			70	
region(avisitn)		Africa			90	
region(avisitn)		Asia			90	
region(avisitn)		Europe			90	
region(avisitn)		North America			90	
region(avisitn)		South America			90	
region(avisitn)		Africa			110	
region(avisitn)		Asia			110	
region(avisitn)		Europe			110	
region(avisitn)		North America			110	
region(avisitn)		South America			110	
region(avisitn)		Africa			130	
region(avisitn)		Asia			130	
region(avisitn)		Europe			130	
region(avisitn)		North America			130	
region(avisitn)		South America			130	
PREOAD(avisitn)			Non-SU users		60	
PREOAD(avisitn)			SU users		60	
PREOAD(avisitn)			Non-SU users		70	
PREOAD(avisitn)			SU users		70	
PREOAD(avisitn)			Non-SU users		90	
PREOAD(avisitn)			SU users		90	
PREOAD(avisitn)			Non-SU users		110	
PREOAD(avisitn)			SU users		110	
PREOAD(avisitn)			Non-SU users		130	
PREOAD(avisitn)			SU users		130	
HBA1CG1(avisitn)				<8.5	60	
HBA1CG1(avisitn)				>=8.5	60	
HBA1CG1(avisitn)				<8.5	70	
HBA1CG1(avisitn)				>=8.5	70	
HBA1CG1(avisitn)				<8.5	90	
HBA1CG1(avisitn)				>=8.5	90	
HBA1CG1(avisitn)				<8.5	110	
HBA1CG1(avisitn)				>=8.5	110	
HBA1CG1(avisitn)				<8.5	130	
HBA1CG1(avisitn)				>=8.5	130	
base(avisitn)					60	
base(avisitn)					70	
base(avisitn)					90	
base(avisitn)					110	
base(avisitn)					130	

Pulse after 26 and 104 weeks – change from baseline – supportive statistical analysis – full analysis set

topic_cd=PULSE

The Mixed Procedure

Least Squares Means Estimate

Effect	Label	Margins	Estimate	Standard Error	DF
treatment(avisitn)	V130 IDegLira - IGlar	WORK.PULSE_MMRM	2.7002	0.7054	563.7

Least Squares Means Estimate

Effect	Label	t Value	Pr > |t|	Alpha	Lower	Upper
treatment(avisitn)	V130 IDegLira - IGlar	3.83	0.0001	0.05	1.3146	4.0858